0001124140-23-000044.txt : 20230509 0001124140-23-000044.hdr.sgml : 20230509 20230509170628 ACCESSION NUMBER: 0001124140-23-000044 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 96 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230509 DATE AS OF CHANGE: 20230509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EXACT SCIENCES CORP CENTRAL INDEX KEY: 0001124140 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 204782291 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35092 FILM NUMBER: 23903227 BUSINESS ADDRESS: STREET 1: 5505 ENDEAVOR LANE CITY: MADISON STATE: WI ZIP: 53719 BUSINESS PHONE: 608-284-5700 MAIL ADDRESS: STREET 1: 5505 ENDEAVOR LANE CITY: MADISON STATE: WI ZIP: 53719 FORMER COMPANY: FORMER CONFORMED NAME: EXACT CORP DATE OF NAME CHANGE: 20000919 10-Q 1 exas-20230331.htm 10-Q exas-20230331
2023Q10001124140false--12-31http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent100011241402023-01-012023-03-3100011241402023-05-08xbrli:shares00011241402023-03-31iso4217:USD00011241402022-12-31iso4217:USDxbrli:shares00011241402022-01-012022-03-310001124140us-gaap:CommonStockMember2022-12-310001124140us-gaap:AdditionalPaidInCapitalMember2022-12-310001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001124140us-gaap:RetainedEarningsMember2022-12-310001124140us-gaap:CommonStockMember2023-01-012023-03-310001124140us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001124140us-gaap:RetainedEarningsMember2023-01-012023-03-310001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001124140us-gaap:CommonStockMember2023-03-310001124140us-gaap:AdditionalPaidInCapitalMember2023-03-310001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001124140us-gaap:RetainedEarningsMember2023-03-3100011241402022-03-310001124140us-gaap:CommonStockMember2021-12-310001124140us-gaap:AdditionalPaidInCapitalMember2021-12-310001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001124140us-gaap:RetainedEarningsMember2021-12-3100011241402021-12-310001124140us-gaap:CommonStockMember2022-01-012022-03-310001124140us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001124140us-gaap:RetainedEarningsMember2022-01-012022-03-310001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001124140us-gaap:CommonStockMember2022-03-310001124140us-gaap:AdditionalPaidInCapitalMember2022-03-310001124140us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001124140us-gaap:RetainedEarningsMember2022-03-310001124140us-gaap:ConvertibleNotesPayableMember2023-01-012023-03-310001124140us-gaap:ConvertibleNotesPayableMember2022-01-012022-03-310001124140us-gaap:RestrictedStockMember2023-01-012023-03-310001124140us-gaap:RestrictedStockMember2022-01-012022-03-310001124140us-gaap:PerformanceSharesMember2023-01-012023-03-310001124140us-gaap:PerformanceSharesMember2022-01-012022-03-310001124140exas:EmployeeAndNonEmployeesStockOptionMember2023-01-012023-03-310001124140exas:EmployeeAndNonEmployeesStockOptionMember2022-01-012022-03-310001124140exas:SharesIssuedUponAcquisitionMember2023-01-012023-03-310001124140exas:SharesIssuedUponAcquisitionMember2022-01-012022-03-310001124140us-gaap:ProductMemberexas:ScreeningMember2023-01-012023-03-310001124140us-gaap:ProductMemberexas:ScreeningMember2022-01-012022-03-310001124140us-gaap:ServiceMemberexas:ScreeningMember2023-01-012023-03-310001124140us-gaap:ServiceMemberexas:ScreeningMember2022-01-012022-03-310001124140us-gaap:ProductAndServiceOtherMemberexas:ScreeningMember2023-01-012023-03-310001124140us-gaap:ProductAndServiceOtherMemberexas:ScreeningMember2022-01-012022-03-310001124140exas:ScreeningMember2023-01-012023-03-310001124140exas:ScreeningMember2022-01-012022-03-310001124140exas:PrecisionOncologyMemberus-gaap:ProductMember2023-01-012023-03-310001124140exas:PrecisionOncologyMemberus-gaap:ProductMember2022-01-012022-03-310001124140us-gaap:ServiceMemberexas:PrecisionOncologyMember2023-01-012023-03-310001124140us-gaap:ServiceMemberexas:PrecisionOncologyMember2022-01-012022-03-310001124140exas:InternationalSalesMemberexas:PrecisionOncologyMember2023-01-012023-03-310001124140exas:InternationalSalesMemberexas:PrecisionOncologyMember2022-01-012022-03-310001124140exas:PrecisionOncologyMemberus-gaap:ProductAndServiceOtherMember2023-01-012023-03-310001124140exas:PrecisionOncologyMemberus-gaap:ProductAndServiceOtherMember2022-01-012022-03-310001124140exas:PrecisionOncologyMember2023-01-012023-03-310001124140exas:PrecisionOncologyMember2022-01-012022-03-310001124140exas:COVID19TestingMember2023-01-012023-03-310001124140exas:COVID19TestingMember2022-01-012022-03-310001124140exas:VariablePriceContractMember2023-01-012023-03-310001124140exas:VariablePriceContractMember2022-01-012022-03-310001124140us-gaap:ShortTermInvestmentsMember2023-03-310001124140us-gaap:ShortTermInvestmentsMember2022-12-310001124140us-gaap:CashEquivalentsMemberus-gaap:CommercialPaperMember2023-03-310001124140us-gaap:CashEquivalentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-03-310001124140us-gaap:CashEquivalentsMember2023-03-310001124140us-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-03-310001124140us-gaap:CorporateBondSecuritiesMemberus-gaap:ShortTermInvestmentsMember2023-03-310001124140us-gaap:AssetBackedSecuritiesMemberus-gaap:ShortTermInvestmentsMember2023-03-310001124140us-gaap:CashEquivalentsMemberus-gaap:CommercialPaperMember2022-12-310001124140us-gaap:CashEquivalentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001124140us-gaap:CashEquivalentsMember2022-12-310001124140us-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001124140us-gaap:CorporateBondSecuritiesMemberus-gaap:ShortTermInvestmentsMember2022-12-310001124140us-gaap:AssetBackedSecuritiesMemberus-gaap:ShortTermInvestmentsMember2022-12-310001124140us-gaap:LandMember2023-03-310001124140us-gaap:LandMember2022-12-310001124140exas:BuildingsAndLeaseholdImprovementsMember2023-03-310001124140exas:BuildingsAndLeaseholdImprovementsMember2022-12-310001124140us-gaap:LandImprovementsMember2023-01-012023-03-310001124140us-gaap:LandImprovementsMember2023-03-310001124140us-gaap:LandImprovementsMember2022-12-310001124140us-gaap:BuildingMembersrt:MinimumMember2023-01-012023-03-310001124140us-gaap:BuildingMembersrt:MaximumMember2023-01-012023-03-310001124140us-gaap:BuildingMember2023-03-310001124140us-gaap:BuildingMember2022-12-310001124140exas:OfficeEquipmentAndComputerSoftwareMember2023-01-012023-03-310001124140exas:OfficeEquipmentAndComputerSoftwareMember2023-03-310001124140exas:OfficeEquipmentAndComputerSoftwareMember2022-12-310001124140srt:MinimumMemberus-gaap:EquipmentMember2023-01-012023-03-310001124140srt:MaximumMemberus-gaap:EquipmentMember2023-01-012023-03-310001124140us-gaap:EquipmentMember2023-03-310001124140us-gaap:EquipmentMember2022-12-310001124140srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2023-01-012023-03-310001124140srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2023-01-012023-03-310001124140us-gaap:FurnitureAndFixturesMember2023-03-310001124140us-gaap:FurnitureAndFixturesMember2022-12-310001124140us-gaap:AssetUnderConstructionMember2023-03-310001124140us-gaap:AssetUnderConstructionMember2022-12-310001124140us-gaap:ComputerSoftwareIntangibleAssetMember2023-03-310001124140us-gaap:TradeNamesMember2023-01-012023-03-310001124140us-gaap:TradeNamesMember2023-03-310001124140us-gaap:CustomerRelationshipsMember2023-01-012023-03-310001124140us-gaap:CustomerRelationshipsMember2023-03-310001124140us-gaap:PatentsMember2023-01-012023-03-310001124140us-gaap:PatentsMember2023-03-310001124140us-gaap:DevelopedTechnologyRightsMember2023-01-012023-03-310001124140us-gaap:DevelopedTechnologyRightsMember2023-03-310001124140us-gaap:TradeNamesMember2022-01-012022-12-310001124140us-gaap:TradeNamesMember2022-12-310001124140us-gaap:CustomerRelationshipsMember2022-01-012022-12-310001124140us-gaap:CustomerRelationshipsMember2022-12-310001124140us-gaap:PatentsMember2022-01-012022-12-310001124140us-gaap:PatentsMember2022-12-310001124140us-gaap:DevelopedTechnologyRightsMember2022-01-012022-12-310001124140us-gaap:DevelopedTechnologyRightsMember2022-12-310001124140exas:OmicEraMember2022-01-012022-12-310001124140exas:PreventionGeneticsLLCMember2022-01-012022-12-3100011241402022-01-012022-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-03-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-03-310001124140us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-03-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-03-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-03-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-03-310001124140us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-03-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-03-310001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310001124140us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310001124140us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2022-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2022-12-310001124140us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2022-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2022-12-310001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:FairValueInputsLevel1Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001124140us-gaap:EstimateOfFairValueFairValueDisclosureMemberexas:ThriveAndAshionMember2023-03-310001124140us-gaap:EstimateOfFairValueFairValueDisclosureMemberexas:ThriveAndAshionMember2022-12-310001124140exas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMembersrt:WeightedAverageMemberexas:MeasurementInputProbabilityOfSuccessMember2023-03-31xbrli:pure0001124140exas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMembersrt:WeightedAverageMemberexas:MeasurementInputProbabilityOfSuccessMember2022-12-310001124140exas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMembersrt:WeightedAverageMemberexas:MeasurementInputPresentValueFactorMember2023-03-310001124140exas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMembersrt:WeightedAverageMemberexas:MeasurementInputPresentValueFactorMember2022-12-310001124140exas:ThriveAndAshionMemberexas:RevenueAndOtherPerformanceBasedPaymentsMember2023-03-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2023-03-310001124140us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2022-12-310001124140exas:VentureCapitalInvestmentFundMember2023-01-012023-03-310001124140exas:VentureCapitalInvestmentFundMember2023-03-310001124140exas:VentureCapitalInvestmentFundMember2022-12-310001124140us-gaap:ForeignExchangeForwardMember2023-03-310001124140us-gaap:ForeignExchangeForwardMember2022-12-310001124140us-gaap:ForeignExchangeForwardMember2022-01-012022-03-310001124140us-gaap:ForeignExchangeForwardMember2023-01-012023-03-310001124140exas:SecuritizedReceivablesMember2022-06-290001124140srt:MinimumMemberexas:SecuritizedReceivablesMember2022-06-290001124140exas:SecuritizedReceivablesMember2023-03-310001124140us-gaap:RevolvingCreditFacilityMemberexas:RevolvingLoanAgreementMemberus-gaap:LineOfCreditMember2021-11-300001124140us-gaap:RevolvingCreditFacilityMemberexas:DailyBloombergShortTermBankYieldIndexRateMemberexas:RevolvingLoanAgreementMemberus-gaap:LineOfCreditMember2021-11-012021-11-300001124140us-gaap:LetterOfCreditMemberexas:RevolvingLoanAgreementMemberus-gaap:LineOfCreditMember2021-12-012021-12-310001124140us-gaap:LetterOfCreditMemberexas:RevolvingLoanAgreementMemberus-gaap:LineOfCreditMember2023-01-012023-01-310001124140us-gaap:RevolvingCreditFacilityMemberexas:RevolvingLoanAgreementMemberus-gaap:LineOfCreditMember2023-03-310001124140us-gaap:RevolvingCreditFacilityMemberexas:RevolvingLoanAgreementMemberus-gaap:LineOfCreditMember2022-12-310001124140exas:ConvertibleNotesPayable2030Member2023-03-310001124140us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberexas:ConvertibleNotesPayable2030Member2023-03-310001124140exas:ConvertibleNotesPayable2028Member2023-03-310001124140exas:ConvertibleNotesPayable2028Memberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001124140exas:ConvertibleNotesPayable2027Member2023-03-310001124140exas:ConvertibleNotesPayable2027Memberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001124140exas:ConvertibleNotesPayable2025Member2023-03-310001124140us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberexas:ConvertibleNotesPayable2025Member2023-03-310001124140exas:ConvertibleNotesPayable2028Member2022-12-310001124140exas:ConvertibleNotesPayable2028Memberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001124140exas:ConvertibleNotesPayable2027Member2022-12-310001124140exas:ConvertibleNotesPayable2027Memberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001124140exas:ConvertibleNotesPayable2025Member2022-12-310001124140us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberexas:ConvertibleNotesPayable2025Member2022-12-310001124140exas:ConvertibleNotesPayable2030Member2023-03-010001124140exas:ConvertibleNotesPayable2027Member2023-03-012023-03-310001124140exas:ConvertibleNotesPayable2028Member2023-03-012023-03-310001124140exas:ConvertibleNotesPayable2030Member2023-03-012023-03-3100011241402023-03-012023-03-310001124140exas:ConvertibleNotesPayable2025Memberexas:ConvertibleNotesPayable2030Member2023-03-060001124140exas:ConvertibleNotesPayable2025Member2023-03-012023-03-310001124140exas:ConvertibleNotesPayable2025Member2023-03-012023-03-310001124140exas:ConvertibleNotesPayable2025Member2023-01-012023-03-310001124140exas:ConvertibleNotesPayable2027Member2023-01-012023-03-310001124140exas:ConvertibleNotesPayable2028Member2023-01-012023-03-310001124140exas:ConvertibleNotesPayable2030Member2023-01-012023-03-310001124140exas:ConvertibleNotesPayable2030Member2022-01-012022-03-310001124140exas:ConvertibleNotesPayable2028Member2022-01-012022-03-310001124140exas:ConvertibleNotesPayable2027Member2022-01-012022-03-310001124140exas:ConvertibleNotesPayable2025Member2022-01-012022-03-310001124140us-gaap:LicensingAgreementsMemberexas:MAYOFoundationMember2020-09-30exas:installment0001124140us-gaap:LicensingAgreementsMemberexas:MAYOFoundationMember2023-01-012023-03-310001124140us-gaap:LicensingAgreementsMemberexas:MAYOFoundationMember2022-01-012022-03-310001124140exas:SalesMilestoneRangeOneMemberus-gaap:LicensingAgreementsMemberexas:ThriveEarlierDetectionCorporationMember2021-01-050001124140us-gaap:LicensingAgreementsMemberexas:SalesMilestoneRangeTwoMemberexas:ThriveEarlierDetectionCorporationMember2021-01-050001124140exas:SalesMilestoneRangeThreeMemberus-gaap:LicensingAgreementsMemberexas:ThriveEarlierDetectionCorporationMember2021-01-050001124140exas:SalesMilestoneRangeOneMemberus-gaap:LicensingAgreementsMemberexas:ThriveEarlierDetectionCorporationMember2021-01-052021-01-050001124140us-gaap:LicensingAgreementsMemberexas:SalesMilestoneRangeTwoMemberexas:ThriveEarlierDetectionCorporationMember2021-01-052021-01-050001124140exas:SalesMilestoneRangeThreeMemberus-gaap:LicensingAgreementsMemberexas:ThriveEarlierDetectionCorporationMember2021-01-052021-01-050001124140us-gaap:LicensingAgreementsMemberexas:TgenMemberexas:ProductRevenueRelatedToMRDDetectionPaymentOneMember2021-01-310001124140exas:ProductRevenueRelatedToMRDDetectionPaymentTwoMemberus-gaap:LicensingAgreementsMemberexas:TgenMember2021-01-310001124140exas:ProductRevenueRelatedToTreatmentPaymentOneMemberus-gaap:LicensingAgreementsMemberexas:TgenMember2021-01-310001124140us-gaap:LicensingAgreementsMemberexas:TgenMemberexas:ProductRevenueRelatedToTreatmentPaymentTwoMember2021-01-310001124140exas:PfizerIncMemberus-gaap:ManufacturedProductOtherMember2021-11-300001124140exas:PfizerIncMemberus-gaap:ManufacturedProductOtherMember2022-01-012022-03-310001124140exas:OmicEraDiagnosticsAcquisitionMember2022-05-012022-05-310001124140exas:OmicEraDiagnosticsAcquisitionMember2022-05-010001124140us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310001124140us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-03-310001124140us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-03-310001124140us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310001124140us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-03-310001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-03-310001124140us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310001124140us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-03-310001124140us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-03-310001124140us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-03-310001124140us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001124140us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001124140exas:StockBasedCompensationPlansMember2023-03-310001124140exas:StockBasedCompensationPlansMember2023-01-012023-03-310001124140exas:StockBasedCompensationPlansMember2022-12-310001124140exas:StockBasedCompensationPlansMember2022-12-312022-12-310001124140exas:StockBasedCompensationPlansMember2022-01-012022-03-310001124140exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember2022-12-310001124140exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember2023-01-012023-03-310001124140exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember2023-03-310001124140us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001124140exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember2022-01-012022-03-310001124140us-gaap:PerformanceSharesMember2022-12-310001124140us-gaap:PerformanceSharesMember2023-01-012023-03-310001124140us-gaap:PerformanceSharesMember2023-03-310001124140us-gaap:PerformanceSharesMember2022-01-012022-03-310001124140us-gaap:EmployeeStockMemberexas:EmployeeStockPurchasePlan2010Member2022-01-012022-03-310001124140us-gaap:EmployeeStockMemberexas:EmployeeStockPurchasePlan2010Member2023-01-012023-03-310001124140exas:DOSRuleInvestigationMember2021-12-310001124140exas:DOSRuleInvestigationMember2022-04-012022-06-300001124140exas:DOSRuleInvestigationMember2023-03-310001124140exas:WisconsinEconomicDevelopmentTaxCreditAgreementMember2015-02-280001124140exas:WisconsinEconomicDevelopmentTaxCreditAgreementMember2015-02-012015-02-28exas:position0001124140exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember2021-12-310001124140exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember2021-12-012021-12-310001124140exas:WisconsinEconomicDevelopmentTaxCreditAgreementMember2020-12-310001124140exas:WisconsinEconomicDevelopmentTaxCreditAgreementMember2022-12-310001124140exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember2023-03-310001124140us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberexas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember2023-03-310001124140exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMemberus-gaap:OtherNoncurrentAssetsMember2023-03-310001124140us-gaap:OperatingExpenseMemberexas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember2023-01-012023-03-310001124140us-gaap:OperatingExpenseMemberexas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember2022-01-012022-03-310001124140country:US2023-01-012023-03-310001124140country:US2022-01-012022-03-310001124140us-gaap:NonUsMember2023-01-012023-03-310001124140us-gaap:NonUsMember2022-01-012022-03-31exas:segment
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2023
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-35092
EXACT SCIENCES CORPORATION
(Exact name of registrant as specified in its charter)
Delaware02-0478229
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
5505 Endeavor Lane, Madison WI
53719
(Address of principal executive offices)(Zip Code)
(608) 535-8815 (Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par value per shareEXASThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer ☐
Non-accelerated filer☐Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of May 8, 2023, the registrant had 180,388,167 shares of common stock outstanding.


EXACT SCIENCES CORPORATION
INDEX
Page
Number

2
EXACT SCIENCES CORPORATION
Condensed Consolidated Balance Sheets
(Amounts in thousands, except share data - unaudited)
Part I — Financial Information
March 31, 2023December 31, 2022
ASSETS
Current assets:
Cash and cash equivalents$421,365 $242,493 
Marketable securities277,282 389,564 
Accounts receivable, net183,371 158,043 
Inventory124,092 118,259 
Prepaid expenses and other current assets85,274 73,898 
Total current assets1,091,384 982,257 
Long-term Assets:
Property, plant and equipment, net684,574 684,756 
Operating lease right-of-use assets156,782 167,003 
Goodwill2,346,235 2,346,040 
Intangible assets, net1,933,481 1,956,240 
Other long-term assets, net91,872 90,577 
Total assets$6,304,328 $6,226,873 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$86,713 $74,916 
Accrued liabilities241,844 299,216 
Operating lease liabilities, current portion30,014 28,366 
Other current liabilities8,783 10,249 
Total current liabilities367,354 412,747 
Long-term liabilities:
Convertible notes, net2,310,196 2,186,106 
Long-term debt50,000 50,000 
Other long-term liabilities344,380 352,459 
Operating lease liabilities, less current portion174,690 182,399 
Total liabilities3,246,620 3,183,711 
Commitments and contingencies (Note 14)
Stockholders’ equity:
Preferred stock, $0.01 par value Authorized—5,000,000; shares issued and outstanding—no shares at March 31, 2023 and December 31, 2022
— — 
Common stock, $0.01 par value Authorized—400,000,000; shares issued and outstanding—179,830,145 and 177,925,631 shares at March 31, 2023 and December 31, 2022
1,799 1,780 
Additional paid-in capital6,396,805 6,311,644 
Accumulated other comprehensive loss(1,719)(5,236)
Accumulated deficit(3,339,177)(3,265,026)
Total stockholders’ equity3,057,708 3,043,162 
Total liabilities and stockholders’ equity$6,304,328 $6,226,873 
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
EXACT SCIENCES CORPORATION
Condensed Consolidated Statements of Operations
(Amounts in thousands, except per share data - unaudited)
Three Months Ended March 31,
20232022
Revenue$602,450 $486,571 
Operating expenses
Cost of sales (exclusive of amortization of acquired intangible assets)156,866 134,705 
Research and development95,419 102,248 
Sales and marketing186,964 232,181 
General and administrative217,295 169,770 
Amortization of acquired intangible assets22,928 24,654 
Impairment of long-lived assets69 — 
Total operating expenses679,541 663,558 
Loss from operations(77,091)(176,987)
Other income (expense)
Investment income (loss), net490 (1,487)
Interest income (expense), net4,107 (4,478)
Total other income (expense)4,597 (5,965)
Net loss before tax(72,494)(182,952)
Income tax benefit (expense)(1,657)2,015 
Net loss$(74,151)$(180,937)
Net loss per share—basic and diluted$(0.42)$(1.04)
Weighted average common shares outstanding—basic and diluted178,574 174,417 
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
EXACT SCIENCES CORPORATION
Condensed Consolidated Statements of Comprehensive Loss
(Amounts in thousands - unaudited)
Three Months Ended March 31,
20232022
Net loss$(74,151)$(180,937)
Other comprehensive loss, net of tax:
Unrealized gain (loss) on available-for-sale investments2,967 (4,967)
Foreign currency translation adjustment550 (237)
Comprehensive loss$(70,634)$(186,141)
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
EXACT SCIENCES CORPORATION
Condensed Consolidated Statements of Stockholders’ Equity
(Amounts in thousands, except share data - unaudited)
Common StockAdditional Paid-In CapitalAccumulated Other Comprehensive LossAccumulated DeficitTotal Stockholders’ Equity
Number of Shares
$0.01
Par Value
Balance, January 1, 2023177,925,631 $1,780 $6,311,644 $(5,236)$(3,265,026)$3,043,162 
Exercise of common stock options88,228 1 963 — — 964 
Issuance of common stock to fund the Company’s 2022 401(k) match517,215 5 35,072 — — 35,077 
Compensation expense related to issuance of stock options and restricted stock awards1,299,071 13 49,126 — — 49,139 
Net loss— — — — (74,151)(74,151)
Other comprehensive income
— — — 3,517 — 3,517 
Balance, March 31, 2023179,830,145 $1,799 $6,396,805 $(1,719)$(3,339,177)$3,057,708 

Common StockAdditional Paid-In CapitalAccumulated Other Comprehensive LossAccumulated DeficitTotal Stockholders’ Equity
Number of Shares
$0.01
Par Value
Balance, January 1, 2022173,674,067 $1,738 $6,028,861 $(1,443)$(2,641,520)$3,387,636 
Exercise of common stock options485,537 5 4,277 — — 4,282 
Compensation expense related to issuance of stock options and restricted stock awards1,391,797 14 52,427 — — 52,441 
Other7 — (7)— — (7)
Net loss— — — — (180,937)(180,937)
Other comprehensive loss
— — — (5,204)— (5,204)
Balance, March 31, 2022175,551,408 $1,757 $6,085,558 $(6,647)$(2,822,457)$3,258,211 
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
EXACT SCIENCES CORPORATION
Condensed Consolidated Statements of Cash Flows
(Amounts in thousands - unaudited)
Three Months Ended March 31,
20232022
Cash flows from operating activities:
Net loss$(74,151)$(180,937)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation26,815 22,993 
Loss on disposal of property, plant and equipment284 321 
Unrealized loss on equity investments3,009 1,350 
Deferred tax expense (benefit)1,261 (1,912)
Stock-based compensation49,139 52,441 
Gain on settlements of convertible notes, net(10,324)— 
Amortization of deferred financing costs, convertible note debt discount and issuance costs, and other liabilities1,783 1,700 
Accretion (Amortization) of discount (premium) on short-term investments(54)956 
Amortization of acquired intangible assets22,928 24,654 
Impairment of long-lived assets69 — 
Remeasurement of contingent consideration(8,937)(26,680)
Non-cash lease expense6,806 7,363 
Changes in assets and liabilities:
Accounts receivable, net(25,434)11,020 
Inventory, net(5,827)(7,964)
Operating lease liabilities(5,982)(5,177)
Accounts payable and accrued liabilities(4,817)(66,048)
Other assets(13,622)(6,619)
Other liabilities(1,161)(1,215)
Net cash used in operating activities(38,215)(173,754)
Cash flows from investing activities:
Purchases of marketable securities(8,589)(70,267)
Maturities and sales of marketable securities121,332 150,630 
Purchases of property, plant and equipment(29,360)(33,623)
Investments in privately held companies(442)(1,172)
Other investing activities— (7)
Net cash provided by investing activities82,941 45,561 
Cash flows from financing activities:
Proceeds from exercise of common stock options964 4,282 
Proceeds from issuance of convertible notes137,976 — 
Other financing activities(5,344)(1,547)
Net cash provided by financing activities133,596 2,735 
Effects of exchange rate changes on cash and cash equivalents550 (237)
Net increase (decrease) in cash, cash equivalents and restricted cash178,872 (125,695)
Cash, cash equivalents and restricted cash, beginning of period242,790 315,768 
Cash, cash equivalents and restricted cash, end of period$421,662 $190,073 


7
EXACT SCIENCES CORPORATION
Condensed Consolidated Statements of Cash Flows
(Amounts in thousands - unaudited)
Three Months Ended March 31,
20232022
Supplemental disclosure of non-cash investing and financing activities
Property, plant and equipment acquired but not paid$10,548 $31,491 
Supplemental disclosure of cash flow information:
Interest paid$6,442 $5,133 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents$421,365 $189,776 
Restricted cash — included in prepaid expenses and other current assets as of March 31, 2023, and other long-term assets, net as of March 31, 2022
297 297 
Total cash, cash equivalents and restricted cash$421,662 $190,073 
The accompanying notes are an integral part of these condensed consolidated financial statements.
8
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)

(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Business
Exact Sciences Corporation (together with its subsidiaries, “Exact,” or the “Company”) was incorporated in February 1995. Exact is a leading global cancer diagnostics company. It has developed some of the most impactful tests in cancer screening and diagnostics, including Cologuard® and Oncotype DX®. Exact is currently working on the development of additional tests, with the goal of bringing new, innovative cancer tests to patients throughout the world.
Basis of Presentation and Principles of Consolidation
The accompanying condensed consolidated financial statements, which include the accounts of the Company and those of its wholly owned subsidiaries and variable interest entities, are unaudited and have been prepared on a basis substantially consistent with the Company’s audited financial statements and notes as of and for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K (the “2022 Form 10-K”). All intercompany transactions and balances have been eliminated upon consolidation. These condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted (“GAAP”) in the United States of America (“U.S.”) and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting only of adjustments of a normal and recurring nature) considered necessary for a fair statement of its financial position, operating results and cash flows for the periods presented. The condensed consolidated balance sheet at December 31, 2022 has been derived from audited financial statements, but does not contain all of the footnote disclosures from the 2022 Form 10-K. The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year. The statements should be read in conjunction with the audited financial statements and related notes included in the 2022 Form 10-K.
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that affect the Company’s financial statements materially and involve difficult, subjective or complex judgments by management, and actual results could differ from those estimates. These estimates include revenue recognition, valuation of intangible assets and goodwill, and accounting for income taxes among others. The Company’s critical accounting policies and estimates are explained further in the notes to the condensed consolidated financial statements in this Quarterly Report on Form 10-Q and the 2022 Form 10-K.
The spread of the coronavirus (“COVID-19”) and the macroeconomic conditions including inflation and fluctuations in foreign currency exchange rates has affected many segments of the global economy, including the cancer screening and diagnostics industry. The Company expects these matters to have an impact on operations, however, the ultimate impact presents uncertainty and depends on factors beyond the Company’s knowledge or control, including the duration and severity, as well as third-party actions taken. The Company continues to use the best information available to inform its accounting estimates in light of these uncertainties.
Significant Accounting Policies
During the three months ended March 31, 2023, there were no changes to the Company’s significant accounting policies as described in the Company’s 2022 Form 10-K.
Reclassifications
Certain prior year amounts have been reclassified to conform to the current year presentation in the condensed consolidated financial statements and accompanying notes to the condensed consolidated financial statements.
9
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Recent Accounting Pronouncements
The Company did not adopt any accounting standards updates (“ASU”) released by the Financial Accounting Standards Board (“FASB”) in the first quarter of 2023. In addition, there are no ASUs not yet adopted that are expected to impact the Company.
Net Loss Per Share
Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share is the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive as a result of the Company’s losses.
The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period:
March 31,
(In thousands)20232022
Shares issuable upon conversion of convertible notes23,231 20,309 
Shares issuable upon the release of restricted stock awards6,877 6,991 
Shares issuable upon the release of performance share units1,671 963 
Shares issuable upon exercise of stock options1,416 1,790 
Shares issuable in connection with acquisitions— 45 
33,195 30,098 

(2) REVENUE
The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard, Oncotype®, and COVID-19 tests. The services are completed upon release of a patient’s test result to the ordering healthcare provider.
The following table presents the Company’s revenues disaggregated by revenue source:
Three Months Ended March 31,
(In thousands)20232022
Screening
Medicare Parts B & C$171,730 $113,755 
Commercial233,033 161,680 
Other38,432 31,087 
Total Screening443,195 306,522 
Precision Oncology
Medicare Parts B & C$47,381 $52,565 
Commercial44,932 46,062 
International37,268 29,560 
Other25,851 24,433 
Total Precision Oncology155,432 152,620 
COVID-19 Testing$3,823 $27,429 
Total$602,450 $486,571 
Screening revenue primarily includes laboratory service revenue from Cologuard and PreventionGenetics LLC (“PreventionGenetics”) tests while Precision Oncology revenue includes laboratory service revenue from global Oncotype products and therapy selection products.
10
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. The Company recognized revenue from a change in transaction price of $11.7 million and $4.2 million for the three months ended March 31, 2023 and 2022, respectively.
The Company’s deferred revenue, which is reported in other current liabilities in the Company’s condensed consolidated balance sheets, was not material as of March 31, 2023 and December 31, 2022.
Revenue recognized for the three months ended March 31, 2023 and 2022, respectively, which was included in the deferred revenue balance at the beginning of the period, was not material.

(3) MARKETABLE SECURITIES
The following table sets forth the Company’s cash, cash equivalents, and marketable securities at March 31, 2023 and December 31, 2022:
(In thousands)March 31, 2023December 31, 2022
Cash and cash equivalents
Cash and money market$351,549 $178,168 
Cash equivalents69,816 64,325 
Total cash and cash equivalents421,365 242,493 
Marketable securities
Available-for-sale debt securities$274,694 $384,415 
Equity securities2,588 5,149 
Total marketable securities277,282 389,564 
Total cash, cash equivalents and marketable securities$698,647 $632,057 
Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at March 31, 2023, consisted of the following:
(In thousands)Amortized CostGains in Accumulated Other Comprehensive Income (Loss) (1)Losses in Accumulated Other Comprehensive Income (Loss) (1)Estimated Fair Value
Cash equivalents
Commercial paper$68,081 $— $— $68,081 
U.S. government agency securities1,735 — — 1,735 
Total cash equivalents69,816 — — 69,816 
Marketable securities
U.S. government agency securities$147,979 $16 $(909)$147,086 
Corporate bonds97,378 18 (948)96,448 
Asset backed securities31,659 106 (605)31,160 
Total marketable securities277,016 140 (2,462)274,694 
Total available-for-sale securities$346,832 $140 $(2,462)$344,510 
______________
(1)There was no tax impact from the gains and losses in accumulated other comprehensive income (loss) (“AOCI”).
11
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at December 31, 2022, consisted of the following:
(In thousands)Amortized CostGains in Accumulated Other Comprehensive Income (Loss) (1) Losses in Accumulated Other Comprehensive Income (Loss) (1)Estimated Fair Value
Cash equivalents
Commercial paper$63,021 $— $— $63,021 
U.S. government agency securities1,304 — — 1,304 
Total cash equivalents64,325 — — 64,325 
Marketable securities
U.S. government agency securities$228,012 $— $(2,789)$225,223 
Corporate bonds116,318 20 (1,667)114,671 
Asset backed securities45,374 2 (855)44,521 
Total marketable securities389,704 22 (5,311)384,415 
Total available-for-sale securities$454,029 $22 $(5,311)$448,740 
______________
(1)There was no tax impact from the gains and losses in AOCI.
The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at March 31, 2023:
Due one year or lessDue after one year through five years
(In thousands)CostFair ValueCostFair Value
Cash equivalents
Commercial paper$68,081 $68,081 $— $— 
U.S. government agency securities1,735 1,735 — — 
Total cash equivalents69,816 69,816 — — 
Marketable securities
U.S. government agency securities$138,322 $137,423 $9,657 $9,663 
Corporate bonds82,071 81,169 15,307 15,279 
Asset backed securities1,191 1,189 30,468 29,971 
Total marketable securities221,584 219,781 55,432 54,913 
Total available-for-sale securities$291,400 $289,597 $55,432 $54,913 
The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of March 31, 2023, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:
Less than one yearOne year or greaterTotal
(In thousands)Fair ValueGross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
Marketable securities
U.S. government agency securities$35,897 $(161)$103,474 $(748)$139,371 $(909)
Corporate bonds16,430 (61)71,885 (887)88,315 (948)
Asset backed securities10,767 (100)18,544 (505)29,311 (605)
Total available-for-sale securities$63,094 $(322)$193,903 $(2,140)$256,997 $(2,462)
12
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The Company evaluates investments that are in an unrealized loss position for impairment as a result of credit loss. It was determined that no credit losses exist as of March 31, 2023 and December 31, 2022, because the change in market value for those securities in an unrealized loss position has resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers.
The gains and losses recorded on available-for-sale debt securities and equity securities are included in investment income, net in the Company’s condensed consolidated statements of operations. The gains and losses recorded were not material for the three months ended March 31, 2023 and 2022.

(4) INVENTORY
Inventory consisted of the following:
(In thousands)March 31, 2023December 31, 2022
Raw materials$63,433 $61,207 
Semi-finished and finished goods60,659 57,052 
Total inventory$124,092 $118,259 

(5) PROPERTY, PLANT AND EQUIPMENT
The carrying value and estimated useful lives of property, plant and equipment are as follows:
(In thousands)Estimated Useful LifeMarch 31, 2023December 31, 2022
Property, plant and equipment
Landn/a$4,716 $4,716 
Leasehold and building improvements(1)200,314 200,588 
Land improvements15 years6,613 6,417 
Buildings
30 - 40 years
290,121 288,941 
Computer equipment and computer software3 years148,798 142,896 
Laboratory equipment
3 - 10 years
253,926 246,344 
Furniture and fixtures
3 - 10 years
34,601 34,047 
Assets under constructionn/a79,648 68,398 
Property, plant and equipment, at cost1,018,737 992,347 
Accumulated depreciation(334,163)(307,591)
Property, plant and equipment, net$684,574 $684,756 
______________
(1)Lesser of remaining lease term, building life, or estimated useful life.
Depreciation expense for the three months ended March 31, 2023 and 2022 was $26.8 million and $23.0 million, respectively.
At March 31, 2023, the Company had $79.6 million of assets under construction, which consisted of $51.9 million in laboratory equipment, $12.4 million in leasehold and building improvements, $10.1 million in capitalized costs related to software projects, and $5.2 million related to buildings. Depreciation will begin on these assets once they are placed into service upon completion.

13
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
(6) INTANGIBLE ASSETS AND GOODWILL
Intangible Assets
The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of March 31, 2023:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated Amortization
Net Balance at March 31, 2023
Finite-lived intangible assets
Trade name12.3$104,000 $(22,465)$81,535 
Customer relationships7.84,000 (556)3,444 
Patents and licenses4.111,542 (8,514)3,028 
Acquired developed technology (1)7.5861,644 (266,170)595,474 
Total finite-lived intangible assets981,186 (297,705)683,481 
In-process research and developmentn/a1,250,000 — 1,250,000 
Total intangible assets$2,231,186 $(297,705)$1,933,481 

The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2022:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated Amortization
Net balance at December 31, 2022
Finite-lived intangible assets
Trade name12.5$104,000 $(20,653)$83,347 
Customer relationships8.04,000 (444)3,556 
Patents and licenses4.211,542 (8,152)3,390 
Acquired developed technology (1)7.8861,474 (245,527)615,947 
Total finite-lived intangible assets981,016 (274,776)706,240 
In-process research and developmentn/a1,250,000 — 1,250,000 
Total intangible assets$2,231,016 $(274,776)$1,956,240 
______________
(1)The gross carrying amount includes an immaterial foreign currency translation adjustment related to the intangible asset acquired as a result of the acquisition of OmicEra Diagnostics GmbH (“OmicEra”), whose functional currency is also its local currency. Intangible asset balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.
14
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
As of March 31, 2023, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:
(In thousands)
2023 (remaining nine months)$68,786 
202491,378 
202590,331 
202689,271 
202789,271 
Thereafter254,444 
$683,481 
The Company’s acquired intangible assets are being amortized on a straight-line basis over their estimated useful lives.
Goodwill
The change in the carrying amount of goodwill for the periods ended March 31, 2023 and December 31, 2022 is as follows:
(In thousands)
Balance, January 1, 2022
$2,335,172 
OmicEra acquisition10,809 
PreventionGenetics acquisition adjustment(58)
Effects of changes in foreign currency exchange rates (1)117 
Balance, December 31, 2022
2,346,040 
Effects of changes in foreign currency exchange rates (1)195 
Balance March 31, 2023
$2,346,235 
______________
(1)Represents the impact of foreign currency translation related to the goodwill acquired as a result of the acquisition of OmicEra. Goodwill balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.
There were no impairment losses for the three months ended March 31, 2023 and 2022.

(7) FAIR VALUE MEASUREMENTS
The three levels of the fair value hierarchy established are as follows:
Level 1    Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2    Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
Level 3    Unobservable inputs that reflect the Company’s assumptions about the assumptions that market participants would use in pricing the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available.
15
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The following table presents the Company’s fair value measurements as of March 31, 2023 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands)Fair Value at March 31, 2023Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Cash, cash equivalents, and restricted cash
Cash and money market$351,549 $351,549 $— $— 
Commercial paper68,081 — 68,081 — 
U.S. government agency securities1,735 — 1,735 — 
Restricted cash297 297 — — 
Marketable securities
U.S. government agency securities$147,086 $— $147,086 $— 
Corporate bonds96,448 — 96,448 — 
Asset backed securities31,160 — 31,160 — 
Equity securities2,588 2,588 — — 
Non-marketable securities$10,190 $— $— $10,190 
Liabilities
Contingent consideration$(297,990)$— $— $(297,990)
Total$411,144 $354,434 $344,510 $(287,800)
The following table presents the Company’s fair value measurements as of December 31, 2022 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands)Fair Value at December 31, 2022Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Cash and cash equivalents
Cash and money market$178,168 $178,168 $— $— 
Commercial paper63,021 — 63,021 — 
U.S. government agency securities1,304 — 1,304 — 
Restricted cash297 297 — — 
Marketable securities
U.S. government agency securities$225,223 $— $225,223 $— 
Corporate bonds114,671 — 114,671 — 
Asset backed securities44,521 — 44,521 — 
Equity securities5,149 5,149 — — 
Non-marketable securities$10,065 $— $— $10,065 
Liabilities
Contingent consideration$(306,927)$— $— $(306,927)
Total$335,492 $183,614 $448,740 $(296,862)
There have been no changes in valuation techniques or transfers between fair value measurement levels during the three months ended March 31, 2023. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities are valued using a third-party pricing agency where the valuation is based on observable inputs including pricing for similar assets and other observable market factors.
16
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Contingent Consideration Liabilities
The fair value of the contingent consideration liabilities as of March 31, 2023 and December 31, 2022 was $298.0 million and $306.9 million, respectively, which was recorded in other long-term liabilities in the condensed consolidated balance sheets.
The following table provides a reconciliation of the beginning and ending balances of contingent consideration:
(In thousands)Contingent Consideration
Beginning balance, January 1, 2023$306,927 
Changes in fair value (1)(8,937)
Ending balance, March 31, 2023
$297,990 
______________
(1)The change in fair value of the contingent consideration liability for the three months ended March 31, 2022 was a reduction of $26.7 million.
This fair value measurement of contingent consideration is categorized as a Level 3 liability, as the measurement amount is based primarily on significant inputs not observable in the market.
The fair value of the contingent consideration liabilities recorded from the Company’s acquisitions of Thrive Earlier Detection Corporation (“Thrive”), Ashion Analytics, LLC (“Ashion”), and OmicEra related to regulatory and product development milestones was $297.9 million and $306.8 million as of March 31, 2023 and December 31, 2022, respectively. The Company evaluates the fair value of the expected contingent consideration and the corresponding liabilities related to the regulatory and product development milestones using the probability-weighted scenario based discounted cash flow model, which is consistent with the initial measurement of the expected contingent consideration liabilities. Probabilities of success are applied to each potential scenario and the resulting values are discounted using a present-value factor. The passage of time in addition to changes in projected milestone achievement timing, present-value factor, the degree of achievement, if applicable, and probabilities of success may result in adjustments to the fair value measurement. The fair value of the contingent consideration liability recorded related to regulatory and product development milestones was determined using a weighted average probability of success of 91% as of March 31, 2023 and December 31, 2022, and a weighted average present-value factor of 6.1% and 6.2% as of March 31, 2023 and December 31, 2022, respectively. The projected fiscal year of payment range is from 2024 to 2029. Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.
The fair value of the contingent consideration liability related to certain revenue milestones associated with the Biomatrica acquisition was not material as of March 31, 2023 and December 31, 2022. The revenue milestone associated with the Ashion acquisition is not expected to be achieved and therefore no liability has been recorded for this milestone.
Non-Marketable Equity Investments
As of March 31, 2023 and December 31, 2022, the aggregate carrying amounts of the Company’s non-marketable equity securities without readily determinable fair values were $39.4 million and $39.8 million, respectively, which are classified as a component of other long-term assets, net in the Company’s condensed consolidated balance sheets. Since initial recognition of these investments, there have been no upward or downward adjustments made on these investments since initial recognition.
The Company has committed capital to venture capital investment funds (the “Funds”) of $17.5 million, of which $13.3 million remained callable through 2033 as of March 31, 2023. The aggregate carrying amount of the Funds, which are classified as a component of other long-term assets, net in the Company’s condensed consolidated balance sheets, were $4.2 million and $3.9 million as of March 31, 2023 and December 31, 2022, respectively.
17
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Derivative Financial Instruments
The Company enters into foreign currency forward contracts on the last day of each month to mitigate the impact of adverse movements in foreign exchange rates related to the remeasurement of monetary assets and liabilities and hedge the Company’s foreign currency exchange rate exposure. As of March 31, 2023 and December 31, 2022, the Company had open foreign currency forward contracts with notional amounts of $29.2 million and $22.3 million, respectively. The Company's foreign exchange derivative instruments are classified as Level 2 within the fair value hierarchy as they are valued using inputs that are observable in the market or can be derived principally from or corroborated by observable market data. The fair value of the open foreign currency forward contracts was zero at March 31, 2023 and December 31, 2022, and there were no gains or losses recorded to adjust the fair value of the open foreign currency contract held as of March 31, 2023. The contracts are closed subsequent to each month-end, and the gains and losses recorded from the contracts were not material for the three months ended March 31, 2023 and 2022.

(8) LONG-TERM DEBT
Accounts Receivable Securitization Facility
On June 29, 2022, the Company, through a wholly-owned special purpose entity, Exact Receivables LLC (“Exact Receivables”) entered into an accounts receivable securitization program (the “Securitization Facility”) with PNC Bank, National Association (“PNC”), with a scheduled maturity date of June 29, 2024. The Securitization Facility provides Exact Receivables with a revolving line-of-credit of up to $150.0 million of borrowing capacity, subject to certain borrowing base requirements, by collateralizing a security interest in the domestic customer accounts receivable of certain wholly-owned subsidiaries of the Company. The amount available under the Securitization Facility fluctuates over time based on the total amount of eligible customer accounts receivable generated by the Company during the normal course of operations. The Securitization Facility requires the Company to maintain minimum borrowings under the facility of $50.0 million. The debt issuance costs incurred related to the Securitization Facility were not material and are being amortized over the life of the Securitization Facility through interest expense within the condensed consolidated statements of operations.
In connection with the Securitization Facility, the Company also entered into two Receivables Purchase Agreements (“Receivable Purchase Agreements”) on June 29, 2022. The Receivable Purchase Agreements are among the Company and certain wholly-owned subsidiaries of the Company, and between the Company and Exact Receivables. Under the agreements, the wholly-owned subsidiaries sell all of their right, title and interest in their accounts receivables to Exact Receivables. The receivables are used to collateralize borrowings made under the Securitization Facility. The Company retains the responsibility of servicing the accounts receivable balances pledged as collateral under the Securitization Facility and provides a performance guaranty.
As of March 31, 2023, the eligible borrowing base under the Securitization Facility was $111.1 million of which the Company elected to collateralize $50.0 million. As of March 31, 2023 and December 31, 2022, the Company had an outstanding balance of $50.0 million, which is recorded to long-term debt on the Company’s condensed consolidated balance sheets. The outstanding balance accrues interest at a rate equal to a daily secured overnight financing rate (“SOFR”) rate plus a SOFR adjustment and an applicable margin. The interest rate was 6.35% at March 31, 2023.
Revolving Loan Agreement
During November 2021, the Company entered into a revolving loan agreement (the “Revolving Loan Agreement”) with PNC. The Revolving Loan Agreement provides the Company with a revolving line of credit of up to $150.0 million (the “Revolver”). The Revolver is collateralized by the Company’s marketable securities held by PNC, which must continue to maintain a minimum market value of $150.0 million. The Revolver is available for general working capital purposes and all other lawful corporate purposes. In addition, the Company may request, in lieu of cash advances, letters of credit with an aggregate stated amount outstanding not to exceed $20.0 million. The availability of advances under the line of credit will be reduced by the stated amount of each letter of credit issued and outstanding.
Borrowings under the Revolving Loan Agreement accrue interest at an annual rate equal to the sum of the daily Bloomberg Short-Term Bank Yield Index Rate plus the applicable margin of 0.60%. Loans under the Revolving Loan Agreement may be prepaid at any time without penalty. In October 2022, the Revolving Loan Agreement was amended to extend the maturity date from November 5, 2023 to November 5, 2025. There were no other amendments to the Revolver.
18
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The Company has agreed to various financial covenants under the Revolving Loan Agreement, and as of March 31, 2023, the Company is in compliance with all covenants.
In December 2021 and January 2023, PNC issued a letters of credit of $2.9 million and $1.5 million, respectively, which, reduced the amount available for cash advances under the line of credit to $145.6 million and $147.1 million as of March 31, 2023 and December 31, 2022, respectively. As of March 31, 2023 and December 31, 2022, the Company has not drawn funds from, nor are any amounts outstanding under, the Revolving Loan Agreement.

(9) CONVERTIBLE NOTES
Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of March 31, 2023:
Fair Value (1)
(In thousands)Principal AmountUnamortized Debt Discount and Issuance CostsNet Carrying AmountAmountLeveling
2030 Convertible Notes - 2.000%
$572,993 $(4,912)$568,081 $635,489 2
2028 Convertible Notes - 0.375%
949,042 (12,396)936,646 832,784 2
2027 Convertible Notes - 0.375%
563,822 (6,705)557,117 523,526 2
2025 Convertible Notes - 1.000%
249,172 (820)248,352 284,709 2
Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of December 31, 2022:
Fair Value (1)
(In thousands)Principal AmountUnamortized Debt Discount and Issuance CostsNet Carrying AmountAmountLeveling
2028 Convertible Notes - 0.375%
$1,150,000 $(15,775)$1,134,225 $908,500 2
2027 Convertible Notes - 0.375%
747,500 (9,445)738,055 612,950 2
2025 Convertible Notes - 1.000%
315,005 (1,179)313,826 326,808 2
______________
(1)The fair values are based on observable market prices for this debt, which is traded in less active markets and therefore is classified as a Level 2 fair value measurement.
Issuances and Settlements
In February 2023, the Company entered into a privately negotiated exchange and purchase agreement with a single holder of certain of the Company’s convertible notes due in 2027 (the “2027 Notes”) and 2028 (the “2028 Notes”). The Company issued the holder $500.0 million aggregate principal amount of 2.0% Convertible Notes due in 2030 (collectively, the “2030 Notes”) in exchange for $183.7 million of aggregate principal of 2027 Notes, $201.0 million of aggregate principal of 2028 Notes, and $138.0 million of cash. The extinguishment resulted in a gain on settlement of convertible notes of $17.7 million, which is included in interest income (expense), net in the condensed consolidated statement of operations for the three months ended March 31, 2023. The gain represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of exchange.
In March 2023, the Company entered into a privately negotiated exchange agreement with two holders of certain of the Company’s convertible notes due in 2025 (the “2025 Notes”). The Company issued the holder $73.0 million aggregate principal amount of 2030 Notes in exchange for $65.8 million of aggregate principal of 2025 Notes. The extinguishment resulted in a loss on settlement of convertible notes of $7.4 million, which is included in interest income (expense), net in the condensed consolidated statement of operations for the three months ended March 31, 2023. The loss represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of exchange.
19
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The net proceeds from the issuance of the 2030 Notes were approximately $133.0 million, after deducting commissions and offering expenses payable by the Company.
The 2030 Notes will mature on March 1, 2030 and bear interest at a rate of 2.0% per year, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2023.
Summary of Conversion Features
Until the six-months immediately preceding the maturity date of the applicable series of the Company’s convertible notes (the “Notes”), each series of Notes is convertible only upon the occurrence of certain events and during certain periods, as set forth in the Indentures filed at the time of the original offerings. On or after the date that is six-months immediately preceding the maturity date of the applicable series of Notes until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert such Notes at any time. The Notes will be convertible into cash, shares of the Company’s common stock (plus, if applicable, cash in lieu of any fractional share), or a combination of cash and shares of the Company’s common stock, at the Company’s election.
It is the Company’s intent and policy to settle all conversions through combination settlement. The initial conversion rate is 13.26, 8.96, 8.21, and 12.37 shares of common stock per $1,000 principal amount for the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, respectively, which is equivalent to an initial conversion price of approximately $75.43, $111.66, $121.84, and $80.83 per share of the Company’s common stock for the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, respectively. The 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes are potentially convertible into up to 3.3 million, 5.0 million, 7.8 million, and 7.1 million shares, respectively. The conversion rate is subject to adjustment upon the occurrence of certain specified events as set forth in the Indentures filed at the time of the original offerings but will not be adjusted for accrued and unpaid interest. In addition, holders of the Notes who convert their Notes in connection with a “make-whole fundamental change” (as defined in the Indenture), will, under certain circumstances, be entitled to an increase in the conversion rate.
If the Company undergoes a “fundamental change” (as defined in the Indentures), holders of the Notes may require the Company to repurchase for cash all or part of their Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest.
Based on the closing price of the Company’s common stock of $67.81 on March 31, 2023, the if-converted values on the Notes do not exceed the principal amount.
The Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness, or the issuance or repurchase of securities by the Company.
Ranking of Convertible Notes
The Notes are the Company’s senior unsecured obligations and (i) rank senior in right of payment to all of its future indebtedness that is expressly subordinated in right of payment to the Notes; (ii) rank equal in right of payment to each outstanding series thereof and to all of the Company’s future liabilities that are not so subordinated, unsecured indebtedness; (iii) are effectively junior to all of the Company’s existing and future secured indebtedness and other secured obligations, to the extent of the value of the assets securing that indebtedness and other secured obligations; and (iv) are structurally subordinated to all indebtedness and other liabilities of the Company’s subsidiaries.
20
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Issuance Costs
Issuance costs are amortized to interest expense over the term of the Notes. The following table summarizes the original issuance costs at the time of issuance for each set of Notes:
(In thousands)
2030 Convertible Notes$4,970 
2028 Convertible Notes24,453 
2027 Convertible Notes14,285 
2025 Convertible Notes17,646 
Interest Expense
Interest expense on the Notes includes the following:
Three Months Ended March 31,
(In thousands)20232022
Debt issuance costs amortization$1,378 $1,412 
Debt discount amortization31 36 
Gain on settlements of convertible notes(10,324)— 
Coupon interest expense3,354 2,567 
Total interest expense (income) on convertible notes$(5,561)$4,015 
The following table summarizes the effective interest rates of the Notes:
Three Months Ended March 31,
20232022
2030 Convertible Notes2.12 %— %
2028 Convertible Notes0.64 %0.64 %
2027 Convertible Notes0.67 %0.67 %
2025 Convertible Notes1.18 %1.18 %
The remaining period over which the unamortized debt discount will be recognized as non-cash interest expense is 1.80, 3.96, 4.92, and 6.92 years for the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, respectively.

(10) LICENSE AND COLLABORATION AGREEMENTS
The Company licenses certain technologies that are, or may be, incorporated into its technology under several license agreements, as well as the rights to commercialize certain diagnostic tests through collaboration agreements. Generally, the license agreements require the Company to pay single-digit royalties based on net revenues received using the technologies and may require minimum royalty amounts, milestone payments, or maintenance fees.
Mayo
In June 2009, the Company entered into a license agreement with the Mayo Foundation for Medical Education and Research (“Mayo”). The Company’s license agreement with Mayo was most recently amended and restated in September 2020. Under the license agreement, Mayo granted the Company an exclusive, worldwide license to certain Mayo patents and patent applications, as well as a non-exclusive, worldwide license with regard to certain Mayo know-how. The scope of the license covers any screening, surveillance or diagnostic test or tool for use in connection with any type of cancer, pre-cancer, disease or condition.
21
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The licensed Mayo patents and patent applications contain both method and composition claims that relate to sample processing, analytical testing and data analysis associated with nucleic acid screening for cancers and other diseases. The jurisdictions covered by these patents and patent applications include the U.S., Australia, Canada, the European Union, China, Japan and Korea. Under the license agreement, the Company assumed the obligation and expense of prosecuting and maintaining the licensed Mayo patents and is obligated to make commercially reasonable efforts to bring to market products using the licensed Mayo intellectual property.
Pursuant to the Company’s agreement with Mayo, the Company is required to pay Mayo a low-single-digit royalty on the Company’s net sales of current and future products using the licensed Mayo intellectual property each year during the term of the Mayo agreement.
As part of the most recent amendment, the Company agreed to pay Mayo an additional $6.3 million, payable in five equal annual installments through 2024. The annual installments are recorded in research and development expenses in the Company’s condensed consolidated statements of operations.
The license agreement will remain in effect, unless earlier terminated by the parties in accordance with the agreement, until the last of the licensed patents expires in 2039 (or later, if certain licensed patent applications are issued). However, if the Company is still using the licensed Mayo know-how or certain Mayo-provided biological specimens or their derivatives on such expiration date, the term shall continue until the earlier of the date the Company stops using such know-how and materials and the date that is five years after the last licensed patent expires. The license agreement contains customary termination provisions and permits Mayo to terminate the license agreement if the Company sues Mayo or its affiliates, other than any such suit claiming an uncured material breach by Mayo of the license agreement.
In addition to granting the Company a license to the covered Mayo intellectual property, Mayo provides the Company with product development and research and development assistance pursuant to the license agreement and other collaborative arrangements. In September 2020, Mayo also agreed to make available certain personnel to provide such assistance through January 2025. In connection with this collaboration, the Company incurred charges of $1.3 million and $1.4 million for the three months ended March 31, 2023 and 2022, respectively. The charges incurred in connection with this collaboration are recorded in research and development expenses in the Company’s condensed consolidated statements of operations.
Johns Hopkins University
Through the acquisition of Thrive, the Company acquired a worldwide exclusive license agreement with Johns Hopkins University (“JHU”) for use of several JHU patents and licensed know-how. The license is designed to enable the Company to leverage JHU proprietary data in the development and commercialization of a blood-based, multi-cancer early detection test. The agreement terms include single-digit sales-based royalties and sales-based milestone payments of $10.0 million, $15.0 million, and $20.0 million upon achieving calendar year licensed product revenue using JHU proprietary data of $0.50 billion, $1.00 billion, and $1.50 billion, respectively.
Translational Genomics Research Institute (“TGen”)
In January 2021, the Company entered into a worldwide exclusive license to the proprietary Targeted Digital Sequencing (“TARDIS”) technology from TGen, an affiliate of City of Hope. Under the agreement, the Company acquired a royalty-free, worldwide exclusive license to proprietary TARDIS patents and know-how. Under the agreement, the Company is obligated to make milestone payments to TGen of $10.0 million and $35.0 million upon achieving cumulative product revenue related to MRD detection and/or treatment totaling $100.0 million and $250.0 million, respectively. These payments are contingent upon achievement of these cumulative revenues on or before December 31, 2030. The Company will record the sales milestones once achievement is deemed probable.

(11) PFIZER PROMOTION AGREEMENT
In August 2018, the Company entered into a Promotion Agreement (the “Original Promotion Agreement”) with Pfizer Inc. (“Pfizer”), which was amended and restated in October 2020 (the “Restated Promotion Agreement”). The Restated Promotion Agreement extended the relationship between the Company and Pfizer and restructured the manner in which the Company compensates Pfizer for promotion of the Cologuard test through a service fee, and provision of certain other sales and marketing services related to the Cologuard test. The Restated Promotion Agreement included fixed and performance-related fees, some of which retroactively went into effect on April 1, 2020. In November 2021, the Company and Pfizer entered into an
22
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
amendment to the Restated Promotion Agreement (the “November 2021 Amendment”), which provided that after November 30, 2021, Pfizer will no longer promote the Cologuard test to healthcare providers. The November 2021 Amendment provided that the Company pay Pfizer a total of $35.9 million in three installments, which occurred during the second, third, and fourth quarters of 2022. The November 2021 Amendment eliminated the Company's obligation to pay Pfizer royalties or other fees except for certain media fees, advertising fees, and any detail fees owed to Pfizer for promoting the Cologuard test prior to November 30, 2021. The $35.9 million fee incurred as a result of the November 2021 Amendment was recognized in full during the fourth quarter of 2021. All payments to Pfizer are recorded in sales and marketing expenses in the Company’s condensed consolidated statements of operations.
Under the Original Promotion Agreement, the service fee was calculated based on incremental gross profits over specified baselines during the term. Under the Restated Promotion Agreement (and prior to giving effect to the November 2021 Amendment), the service fee provided a fee-for-service model that included certain fixed fees and performance-related bonuses. The performance-related bonuses were contingent upon the achievement of certain annual performance criteria with any applicable expense being recognized ratably upon achievement of the payment becoming probable. The Company incurred a charge of $2.5 million for the service fee during the three months ended March 31, 2022. The Company incurred charges of $38.4 million for promotion, sales and marketing services performed by Pfizer on behalf of the Company during the three months ended March 31, 2022. All services provided by Pfizer under the November 2021 Amendment ended in the third quarter of 2022, and there were no payments made or charges incurred during the three months ended March 31, 2023.

(12) STOCKHOLDERS’ EQUITY
OmicEra Acquisition Stock Issuance
In May 2022, the Company completed its acquisition of OmicEra. In connection with the acquisition, which is further described in Note 16, the Company issued 0.3 million shares of the Company's common stock that had a fair value of $14.8 million.
Changes in Accumulated Other Comprehensive Income (Loss)
The amount recognized in AOCI for the three months ended March 31, 2023 were as follows:
(In thousands)Cumulative Translation AdjustmentUnrealized Gain (Loss) on Securities (1)Accumulated Other Comprehensive Income (Loss)
Balance at December 31, 2022$53 $(5,289)$(5,236)
Other comprehensive loss before reclassifications550 2,289 2,839 
Amounts reclassified from accumulated other comprehensive loss— 678 678 
Net current period change in accumulated other comprehensive loss550 2,967 3,517 
Balance at March 31, 2023$603 $(2,322)$(1,719)
______________
(1)There was no tax impact from the amounts recognized in AOCI for the three months ended March 31, 2023.
23
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The amounts recognized in AOCI for the three months ended March 31, 2022 were as follows:
(In thousands)Cumulative Translation AdjustmentUnrealized Gain (Loss) on Securities (1)Accumulated Other Comprehensive Income (Loss)
Balance at December 31, 2021$23 $(1,466)$(1,443)
Other comprehensive loss before reclassifications(237)(4,994)(5,231)
Amounts reclassified from accumulated other comprehensive income— 27 27 
Net current period change in accumulated other comprehensive loss(237)(4,967)(5,204)
Balance at March 31, 2022$(214)$(6,433)$(6,647)
______________
(1)There was no tax impact from the amounts recognized in AOCI for the three months ended March 31, 2022.
Amounts reclassified from AOCI for the three months ended March 31, 2023 and 2022 were as follows:
Affected Line Item in the
Statements of Operations		Three Months Ended March 31,
Details about AOCI Components (In thousands)20232022
Change in value of available-for-sale investments
Sales and maturities of available-for-sale investmentsInvestment income (loss), net$678 $27 
Total reclassifications$678 $27 

(13) STOCK-BASED COMPENSATION
Stock-Based Compensation Plans
The Company maintains the following plans for which awards were granted from or had awards outstanding in 2023: the 2010 Omnibus Long-Term Incentive Plan (As Amended and Restated Effective July 27, 2017), the 2019 Omnibus Long-Term Incentive Plan, and the 2010 Employee Stock Purchase Plan (collectively referred to as the “Stock Plans”).
In February 2023, the Company adopted the Equity Award Death, Disability and Retirement Policy (the “Policy”) as further described in Item 9B of the Company’s 2022 Form 10-K. The terms of the Policy will result in the recognition of expense on an accelerated basis for retirement-eligible participants for restricted stock units only. The Policy was considered a modification to outstanding awards with no impact to fair value. The accelerated stock-based compensation expense recorded as a result of the modification was not material for the three months ended March 31, 2023.
Stock-Based Compensation Expense
The Company records stock-based compensation expense in connection with the amortization of restricted stock and restricted stock unit awards, performance share units, stock purchase rights granted under the Company’s employee stock purchase plan and stock options granted to employees, non-employee consultants and non-employee directors. The Company recorded $49.1 million and $52.4 million in stock-based compensation expense during the three months ended March 31, 2023 and 2022, respectively.
As of March 31, 2023, there was approximately $503.4 million of expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted under all equity compensation plans. The Company expects to recognize that cost over a weighted average period of 2.9 years.
24
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Stock Options
A summary of stock option activity under the Stock Plans is as follows:
Option SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Aggregate Intrinsic Value (1)
(Aggregate intrinsic value in thousands)
Outstanding, January 1, 20231,517,876 $44.82 4.7
Exercised(88,260)10.93 
Forfeited(13,285)93.78 
Outstanding, March 31, 20231,416,331 $46.48 4.5$42,583 
Vested and expected to vest, March 31, 2023
1,416,331 $46.48 4.5$42,583 
Exercisable, March 31, 20231,351,469 $44.18 4.4$42,439 
______________
(1)The total intrinsic value of options exercised during the three months ended March 31, 2023 and 2022 was $4.8 million and $29.6 million, respectively, determined as of the date of exercise.
The Company received approximately $1.0 million and $4.3 million from stock option exercises during the three months ended March 31, 2023 and 2022, respectively.
Restricted Stock and Restricted Stock Units
The fair value of restricted stock and restricted stock units is determined on the date of grant using the closing stock price on that day.
A summary of restricted stock and restricted stock unit activity during the three months ended March 31, 2023 is as follows:
Restricted SharesWeighted Average Grant Date Fair Value (1)
Outstanding, January 1, 20235,254,709 $89.29 
Granted3,109,184 60.25 
Released (2)(1,279,999)95.01 
Forfeited(207,363)79.15 
Outstanding, March 31, 20236,876,531 $72.87 
______________
(1)The weighted average grant date fair value of the restricted stock units granted during the three months ended March 31, 2022 was $77.31.
(2)The fair value of restricted stock units vested and converted to shares of the Company’s common stock was $121.2 million and $110.8 million during the three months ended March 31, 2023 and 2022, respectively.
Performance Share Units
The Company has issued performance-based equity awards to certain employees which vest upon the achievement of certain performance goals, including financial performance targets and operational milestones. In addition, certain of the performance-based equity awards include a market condition.
25
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
A summary of performance share unit activity is as follows:
Performance Share Units (1)Weighted Average Grant Date Fair Value (2)
Outstanding, January 1, 2023967,846 $102.58 
Granted749,459 79.17 
Released (3)(12,284)78.32 
Forfeited(34,007)100.78 
Outstanding, March 31, 20231,671,014 $92.30 
______________
(1)The performance share units listed above assumes attainment of maximum payout rates as set forth in the performance criteria. Applying actual or expected payout rates, the number of outstanding performance share units as of March 31, 2023 was 575,702.
(2)The weighted average grant date fair value of the performance share units granted during the three months ended March 31, 2022 was $92.31.
(3)The fair value of performance share units vested and converted to shares of the Company’s common stock was $1.0 million and $27.2 million for the three months ended March 31, 2023 and 2022, respectively.
Employee Stock Purchase Plan
There were no shares issued under the 2010 Employee Stock Purchase Plan during the three months ended March 31, 2023 and 2022.

(14) COMMITMENTS AND CONTINGENCIES
Leases
Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows:
Three Months Ended March 31,
(In thousands)20232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$9,135$8,097
Operating cash flows from finance leases170211
Finance cash flows from finance leases7451,548
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for new operating lease liabilities (1)$(3,833)$4,259
Right-of-use assets obtained in exchange for new finance lease liabilities318878
Weighted-average remaining lease term - operating leases (in years)7.188.17
Weighted-average remaining lease term - finance leases (in years)3.072.80
Weighted-average discount rate - operating leases6.42 %6.09 %
Weighted-average discount rate - finance leases6.67 %5.32 %
______________
(1)For the three months ended March 31, 2023, this includes a reduction of $6.2 million on the carrying value of the right-of-use asset held related to a building lease due to a reduction of the expected lease term.
26
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
As of March 31, 2023 and December 31, 2022, the Company’s right-of-use assets from operating leases are $156.8 million and $167.0 million, respectively, which are reported in operating lease right-of-use assets in the Company’s condensed consolidated balance sheets. As of March 31, 2023, the Company has outstanding operating lease obligations of $204.7 million, of which $30.0 million is reported in operating lease liabilities, current portion and $174.7 million is reported in operating lease liabilities, less current portion in the Company’s condensed consolidated balance sheets. As of December 31, 2022, the Company had outstanding operating lease obligations of $210.8 million, of which $28.4 million is reported in operating lease liabilities, current portion and $182.4 million is reported in operating lease liabilities, less current portion in the Company’s condensed consolidated balance sheets.
As of March 31, 2023 and December 31, 2022, the Company’s right-of-use assets from finance leases are $9.5 million and $10.2 million, respectively, which are reported in other long-term assets, net in the Company’s condensed consolidated balance sheets. As of March 31, 2023, the Company has outstanding finance lease obligations of $10.0 million, of which $3.2 million is reported in other current liabilities and $6.8 million is reported in other long-term liabilities in the Company’s condensed consolidated balance sheets. As of December 31, 2022, the Company had outstanding finance lease obligations of $10.6 million, of which $3.2 million is reported in other current liabilities and $7.4 million is reported in other long-term liabilities in the Company’s condensed consolidated balance sheets.

Legal Matters
The Company records reserves and accrues costs for certain legal proceedings and regulatory matters to the extent that it determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. While such reserves and accrued costs reflect the Company’s best estimate of the probable loss for such matters, the recorded amounts may differ materially from the actual amount of any such losses. In some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal and regulatory proceedings, which may be exacerbated by various factors, including but not limited to, they may involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; involve a large number of parties, claimants or regulatory bodies; are in the early stages of the proceedings; involve a number of separate proceedings and/or a wide range of potential outcomes; or result in a change of business practices.
As of the date of this Quarterly Report on Form 10-Q, amounts accrued for legal proceedings and regulatory matters were not material except for the amounts accrued related to the Medicare Date of Service Rule Investigation discussed below. However, it is possible that in a particular quarter or annual period the Company’s financial condition, results of operations, cash flow and/or liquidity could be materially adversely affected by an ultimate unfavorable resolution of, or development in, legal and/or regulatory proceedings, including as described below. Except for the proceedings discussed below, the Company believes that the ultimate outcome of any of the regulatory and legal proceedings that are currently pending against it should not have a material adverse effect on financial condition, results of operations, cash flow or liquidity.
The Company is currently responding to civil investigative demands and administrative subpoenas issued pursuant to the Health Insurance Portability and Accountability Act of 1996 by the United States Department of Justice (“DOJ”) concerning Genomic Health’s compliance with the Medicare Date of Service billing regulations (the “DOS Rule Investigation”). The Company has been cooperating with these inquiries and has produced documents in response thereto.
During the second quarter of 2021, as part of ongoing discussions between the DOJ and the Company regarding the DOS Rule Investigation, the DOJ presented an initial estimate of civil damages in the amount of $48.2 million relating to alleged non-compliance with the Medicare Date of Service billing regulations from 2007 to 2020. The initial civil damages estimate did not include potential treble damages, civil or criminal penalties or other remedies that the DOJ could seek against the Company. In December 2021, the DOJ presented a total adjusted demand of $53.8 million for civil damages, which includes a multiplier and penalties. On January 19, 2023, the Company was informed that the DOJ has closed its criminal investigation without taking any action. Based on the Company’s review and analysis of the DOJ presentation, ongoing discussions held with the DOJ, the civil damages estimate, and range of potential exposure, the Company recorded an accrual of approximately $29 million as of March 31, 2023.
As noted above, litigation outcomes are difficult to predict, and the estimation of probable losses requires an analysis of multiple possible outcomes that often depend on judgments about potential actions by third parties. Accordingly, the recorded accrual of approximately $29 million as of March 31, 2023 is based on several factors, considerations, and judgments, and the ultimate resolution of this matter could result in a material loss in excess of the recorded accrual.
27
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
On June 24, 2019, Niles Rosen M.D. filed a sealed ex parte qui tam lawsuit against the Company in the United States District Court for the Middle District of Florida, that alleged a violation of the Federal Anti-Kickback Statute and False Claims Act for offering gift cards to patients in exchange for returning the Cologuard screening test (the “Qui Tam Suit”). Dr. Rosen seeks on behalf of the U.S. government and himself an award of civil penalties, treble damages and fees and costs. On February 25, 2020, the Company received a civil investigative demand by the DOJ related to the Company’s gift card program. The Company produced documents in response thereto. On March 25, 2021, the DOJ filed a notice of its election to decline intervention in the Qui Tam Suit. This election does not prevent Dr. Rosen from continuing the Qui Tam Suit. On April 12, 2021, Dr. Rosen filed an amended complaint against the Company, alleging violations of the Federal Anti-Kickback Statute and False Claims Act. The Company first learned of the Qui Tam Suit and the DOJ’s election to decline intervention in July 2021. The Company intends to vigorously defend itself against Dr. Rosen's claims and seek, among other things, the Company’s attorneys’ fees and costs incurred in defending this action. Although the Company denies Dr. Rosen's allegations and believes that it has meritorious defenses to his False Claims Act claims, neither the outcome of the litigation nor can a reasonable estimate or an estimated range of loss associated with the litigation be determined at this time.
Adverse outcomes from the DOS Rule Investigation and the Qui Tam Suit could include the Company being required to pay treble damages, incur civil and criminal penalties, paying attorneys’ fees, entering into a corporate integrity agreement, being excluded from participation in government healthcare programs, including Medicare and Medicaid, and other adverse actions that could materially affect the Company’s business, financial condition, and results of operation.

(15) WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS
During February 2015, the Company entered into an agreement with the Wisconsin Economic Development Corporation (“WEDC,” “Original WEDC Agreement”) to earn $9.0 million in refundable tax credits on the condition that the Company expends $26.3 million in capital investments and establishes and maintains 758 full-time positions over a seven-year period.
During December 2021, the Company amended its agreement with the WEDC (“Amended WEDC Agreement”) to earn an additional $18.5 million in refundable tax credits on the condition that the Company expends $350.0 million in capital investments and establishes and maintains 1,300 additional full-time positions over a five-year period. The capital investment credits are earned at a rate of 10% of eligible capital investments up to a maximum of $7.0 million, while the jobs creation credits are earned annually pursuant to the agreement.
The tax credits earned are first applied against the tax liability otherwise due, and if there is no such liability present, the claim for tax credits will be reimbursed in cash to the Company. The maximum amount of the refundable tax credit to be earned for each year is fixed, and the Company earns the credits by meeting certain capital investment and job creation thresholds over the term of the agreement. Should the Company earn and receive the job creation tax credits but not maintain those full-time positions through the end of the agreement, the Company may be required to pay those credits back to the WEDC.
Under the Original WEDC Agreement, the Company recorded the earned tax credits as job creation and capital investments occurred. The tax credits earned from capital investment are being recognized as an offset to depreciation expense over the expected life of the acquired capital assets. The tax credits earned related to job creation were recognized as an offset to operational expenses through December 31, 2020.
As of December 31, 2020, the Company had earned all $9.0 million of the refundable tax credits, and as of December 31, 2022, the Company had received payment of $9.0 million from the WEDC under the Original WEDC Agreement.
Under the Amended WEDC Agreement, the Company records the earned tax credits as job creation and capital investments occurs. The tax credits earned from capital investment are recognized as a reduction to capital expenditures at the time the costs are incurred, and then as an offset to depreciation expense over the expected life of the acquired capital assets. The tax credits earned related to job creation are recognized as an offset to operational expenses in the period in which the credits are earned. The credits recognized will be required to be repaid if the Company does not maintain minimum cumulative job requirements.
As of March 31, 2023, the Company has earned $10.2 million of the refundable tax credits under the Amended WEDC Agreement and received payment of $1.7 million from the WEDC. The unpaid portion is $8.5 million, of which $3.8 million is reported in prepaid expenses and other current assets and $4.7 million is reported in other long-term assets, net in the Company’s condensed consolidated balance sheets reflecting when collection of the refundable tax credits is expected to occur.
28
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
During the three months ended March 31, 2023 and 2022, the Company recorded $1.2 million and $1.0 million respectively, as a reduction to operational expenses for the credits earned for job creation.

(16) ACQUISITIONS AND DIVESTITURES
Business Combinations
OmicEra Diagnostics, GmbH
On May 2, 2022, the Company completed the acquisition (the “OmicEra Acquisition”) of all of the outstanding equity interests of OmicEra Diagnostics GmbH. The OmicEra Acquisition provided the Company a state-of-the-art proteomics lab based in Planegg, Germany. OmicEra combines its mass spectrometry-based proteome analysis technology with its in-house proteomics scientific expertise to discover more reliable and valuable protein biomarkers, which will expand the Company’s research and development capabilities.
Refer to the Company’s 2022 Form 10-K for detailed disclosures on the combination, including the fair value of the consideration transferred, purchase price allocation, and goodwill and intangible assets identified in the transaction. During the three months ended March 31, 2023, there were no changes to the purchase price and purchase price allocation. The measurement period remains open pending the completion of valuation procedures related to certain acquired assets and liabilities assumed, primarily in connection with the developed technology intangible asset.
Divestitures
Oncotype DX Genomic Prostate Score Test
On August 2, 2022, pursuant to an asset purchase agreement with MDxHealth SA, the Company completed the sale of the intellectual property and know-how related to the Company’s Oncotype DX Genomic Prostate Score test, which will allow the Company to focus on the highest impact projects core to the Company’s vision.
Refer to the Company’s 2022 Form 10-K for detailed disclosures on the divestiture, including the fair value of the consideration received, carrying value of the intangible asset sold, and terms of the revenue-based contingent consideration included in the asset purchase agreement. As of March 31, 2023, the contingent consideration remains fully constrained.

(17) SEGMENT INFORMATION
Management determined that the Company functions as a single operating segment, and thus reports as a single reportable segment. This operating segment is focused on the development and global commercialization of clinical laboratory services allowing healthcare providers and patients to make individualized treatment decisions. Management assessed the discrete financial information routinely reviewed by the Company's Chief Operating Decision Maker, its President and Chief Executive Officer, to monitor the Company's operating performance and support decisions regarding allocation of resources to its operations. Performance is continuously monitored at the consolidated level to timely identify deviations from expected results.
The following table summarizes total revenue from customers by geographic region. Product revenues are attributed to countries based on ship-to location.
Three Months Ended March 31,
(In thousands)20232022
United States$565,182 $457,011 
Outside of United States37,268 29,560 
Total revenues$602,450 $486,571 
Long-lived assets located in countries outside of the United States are not significant.

29
EXACT SCIENCES CORPORATION
Notes to Condensed Consolidated Financial Statements
(Unaudited)
(18) INCOME TAXES
The Company recorded income tax expense of $1.7 million for the three months ended March 31, 2023 and a benefit of $2.0 million for the three months ended March 31, 2022. The Company’s income tax expense recorded during the three months ended March 31, 2023 is primarily related to current foreign and state tax expense. A deferred tax liability of $20.1 million and $19.7 million was recorded as of March 31, 2023 and December 31, 2022, respectively, which is included in other long-term liabilities on the Company’s condensed consolidated balance sheet. The Company continues to maintain a full valuation allowance against its deferred tax assets based on management’s determination that it is more likely than not the benefit will not be realized.
The Company had $29.6 million and $28.3 million of unrecognized tax benefits at March 31, 2023 and December 31, 2022, respectively. These amounts have been recorded as a reduction to the Company’s deferred tax asset, if recognized they would not have an impact on the effective tax rate due to the existing valuation allowance. Certain of the Company's unrecognized tax benefits could change due to activities of various tax authorities, including possible settlement of audits, or through normal expiration of various statutes of limitations. The Company does not expect a material change in unrecognized tax benefits in the next twelve months.
As of March 31, 2023, due to the carryforward of unutilized net operating losses and research and development credits, the Company is subject to U.S. federal income tax examinations for the tax years 2000 through 2023, and to state income tax examinations for the tax years 2000 through 2023. No interest or penalties related to income taxes have been accrued or recognized as of March 31, 2023.

30

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Objective
The purpose of this Management's Discussion and Analysis is to better allow our investors to understand and view our Company from management's perspective. We are providing an overview of our business and strategy including a discussion of our financial condition and results of operations. The following discussion of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2022, which has been filed with the U.S. Securities and Exchange Commission (“SEC”) (the “2022 Form 10-K”).

Forward-Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate” or other comparable terms. All statements other than statements of historical facts included in this Quarterly Report on Form 10-Q regarding our strategies, prospects, expectations, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; our strategies, positioning, resources, capabilities and expectations for future events or performance; and the anticipated benefits of our acquisitions, including estimated synergies and other financial impacts. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; our reliance upon certain suppliers, including suppliers that are the sole source of certain products; the willingness of health insurance companies and other payers to cover our products and services and adequately reimburse us for such products and services; the amount and nature of competition for our products and services; the effects of any judicial, executive or legislative action affecting us or the healthcare system; recommendations, guidelines and quality metrics issued by various organizations regarding cancer screening or our products and services; our ability to successfully develop new products and services and assess potential market opportunities; our ability to effectively enter into and utilize strategic partnerships and acquisitions; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; the results of our validation studies and clinical trials, including the risks that the results of future studies and trials may differ materially from the results of previously completed studies and trials; our ability to manage an international business and our expectations regarding our international expansion and opportunities;our ability to raise the capital necessary to support our operations or meet our payment obligations under our indebtedness; the potential effects of changing macroeconomic conditions, including the effects of inflation and interest rate and foreign currency exchange rate fluctuations and any such efforts to hedge such effects; our ability to efficiently and flexibly manage our business amid uncertainties related to the coronavirus (“COVID-19”) pandemic; the possibility that the anticipated benefits from our business acquisitions will not be realized in full or at all or may take longer to realize than expected; the possibility that costs or difficulties related to the integration of acquired businesses’ operations or the divestiture of business operations will be greater than expected and the possibility that integration or divestiture efforts will disrupt our business and strain management time and resources; the outcome of any litigation, government investigations, enforcement actions or other legal proceedings; our ability to retain and hire key personnel; and the impact of labor shortages, turnover, and labor cost increases. The risks included above are not exhaustive. Other important risks and uncertainties are described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the 2022 Form 10-K and subsequently filed Quarterly Reports on Form 10-Q. You are further cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
31
Overview
Exact Sciences Corporation (together with its subsidiaries, “Exact,” “we,” “us,” “our” or the “Company”) is a leading, global, advanced cancer diagnostics company. We have developed some of the most impactful tests in cancer diagnostics, and we are currently working on the development of additional tests, with the goal of bringing new, innovative cancer tests to patients throughout the world.
During the first quarter of 2023, we achieved many critical milestones, including:
•delivering more than 1 million completed tests to patients globally, including a record number of Cologuard® results,
•growing core revenue, which excludes revenue from the Oncotype DX Genomic Prostate Score test (“GPS test”) and COVID-19 testing, by $146.4 million compared to the three months ended March 31, 2022,
•accelerating our path to profitability through prioritization efforts, leading to improved financial results including a decrease in cash used in operating activities of $135.5 million compared to the three months ended March 31, 2022,
•launching OncoExtra™, our enhanced therapy selection test,
•making progress towards completing BLUE-C, our pivotal study to support our next generation Cologuard and colon cancer blood tests, and
•generating high-quality evidence supporting our key research and development initiatives within multi-cancer early detection (“MCED”) and molecular residual disease and recurrence (“MRD”).

Our Screening Tests
Cologuard Test
Colorectal cancer is the second leading cause of cancer deaths in the United States (“U.S.”) and the leading cause of cancer deaths in the U.S. among non-smokers. Each year in the U.S., there are approximately 153,000 new cases of colorectal cancer and approximately 53,000 deaths. It is widely accepted that colorectal cancer is among the most preventable, yet least prevented cancers.
Our flagship screening product, the Cologuard test, is a patient-friendly, non-invasive stool-based DNA (“sDNA”) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Upon approval by the U.S. Food and Drug Administration (“FDA”) in August 2014, our Cologuard test became the first and only FDA-approved sDNA non-invasive colorectal cancer screening test. Our Cologuard test is now indicated for average risk adults 45 years of age and older.
Clinical Genetic Testing
We provide more than 5,000 predefined genetic tests for nearly all clinically relevant genes, additional custom panels, and comprehensive germline, whole exome (“PGxome®”), and whole genome (“PGnome®”) sequencing tests.
Our hereditary cancer test, RiskguardTM, helps people understand their inherited risk of cancer, arming them with critical information to make better treatment decisions.

Our Precision Oncology Tests
Our Oncotype® portfolio delivers actionable genomic insights to inform prognosis and cancer treatment after a diagnosis. In breast cancer, the Oncotype DX Breast Recurrence Score® test is the only test shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. The Oncotype DX® test is recognized as the standard of care and is included in all major breast cancer treatment guidelines. The OncoExTra test applies comprehensive tumor profiling, utilizing whole exome and whole transcriptome sequencing, to aid in therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. With an extensive panel of approximately 20,000 genes and 169 introns, the OncoExTra test is one of the most comprehensive genomic (DNA) and transcriptomic (RNA) panels available today. We enable patients to take a more active role in their cancer care and makes it easy for providers to order tests, interpret results, and personalize medicine by applying real-world evidence and guideline recommendations.

32
International Business Background and Products
We now commercialize or plan to commercialize our Oncotype tests internationally through employees in Canada, Japan and eight European countries, as well as through exclusive distribution agreements. We have provided our Oncotype tests in more than 90 countries outside of the U.S. We do not offer our Cologuard test or COVID-19 testing outside of the U.S.

Pipeline Research and Development
Our research and development efforts are focused on developing new products and enhancing existing products to address unmet cancer needs and expand the clinical utility and addressable patient populations for our existing tests. We expect to advance liquid biopsy through biomarker discovery and validation in tissue, blood, or other fluids and to leverage recent business development activities to accelerate our leadership in earlier cancer detection and treatment guidance. We are pursuing the following opportunities:
•Colorectal Cancer Screening. We are seeking to improve our Cologuard test’s performance characteristics, focusing on reducing the false positive rate of the test. In January 2022, we and Mayo Foundation for Medical Education and Research (“Mayo”) presented data at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium showing overall sensitivity of 95% for colorectal cancer at specificity of 92%. In December of 2022, we finished enrollment of our multi-center, prospective BLUE-C study, which we expect to support FDA approval of our enhanced Cologuard test. We are also working to develop a blood-based screening test for colorectal cancer as a second-line option for people who haven't been screened with more accurate methods.
•MCED Test Development. We are currently seeking to develop a MCED test to help detect many different types of cancer from a single blood draw. In September 2022, we presented data at the European Society for Medical Oncology (“ESMO”) Congress from a biomarker validation study, which demonstrated the ability to detect cancer signals from 15 organ sites with a mean sensitivity of 61% and mean specificity of 98.2%. The multi-biomarker approach detected stage I and stage II cancers with a combined sensitivity of 38.7%. A larger case-control study is underway to further validate the results shared at ESMO and to determine the final design of the MCED test. We will then begin recruiting patients for the FDA registrational Study of All comeRs (“SOAR”) trial, which we expect to be the largest prospective, interventional MCED trial ever conducted in the United States.
•MRD Test Development. We plan to offer a tumor-informed MRD test to help detect small amounts of tumor DNA that may remain in patients’ blood after they have undergone initial cancer treatment. This test will help patients and oncologists understand the success of initial treatment and monitor for cancer recurrence. Our goal is to support all patients in MRD and recurrence monitoring, whether there is access to tumor tissue to inform patient-specific biomarker targets or no access to tissue and a predefined biomarker panel is used. We are currently evaluating different technological approaches, including a tumor-agnostic platform, and have presented promising early data.
Research and development, which includes our clinical study programs, accounts for a material portion of our operating expenses. As we seek to enhance our product portfolio and advance our pipeline, we expect that our research and development expenditures will continue to increase.

COVID-19 Testing Business
In late March 2020, we began providing COVID-19 testing. We have partnered with various customers, including the State of Wisconsin Department of Health Services, to administer testing. Customers are responsible for employing trained personnel to collect specimens. Specimens are sent to our laboratory in Madison, Wisconsin, where we run the assay in our laboratories and provide test results to ordering providers. We expect revenue from our COVID-19 testing to decline as the pandemic abates and plan to discontinue COVID-19 testing later in the year.

2023 Priorities
Our top priorities for 2023 are to (1) provide outstanding experiences for patients and teams, (2) deliver on the future of cancer diagnostics, and (3) live our mission.
33
Provide Outstanding Experiences for Patients and Teams
We intend to continue to provide an exceptional experience for our patients and team members. We plan to improve customer relations by delivering simple and smooth workflows, providing communication that is clear and easy to understand, and providing results that are fast and accurate. We're working to deliver a common technology platform for our cancer tests and improve our digital tools for providers and patients. We will also strive to ensure that Exact Sciences remains a great place to work by taking care of our people.
Deliver on the Future of Cancer Diagnostics
In 2023, we will focus on advancing new tests in our highest priority programs including colorectal cancer screening, multi-cancer early detection, and molecular residual disease and recurrence testing. We plan to continue investing in ongoing and additional clinical trials to enhance existing products and bring new products to patients and providers.
Live our Mission
We are committed to improving lives through testing more people with our laboratory testing services in 2023. By testing more people, we will continue to expand our business in a cost-efficient manner allowing us to generate sustainable profits and increase shareholder value. Generating sustained profits will put us in a better position to continue investing in life-changing cancer diagnostics to help achieve our mission.

Recent Developments and Trends
Impacts of COVID-19 and Current Inflationary Environment
COVID-19 has affected many segments of the global economy, including the cancer screening and diagnostics industry. Our Screening and Precision Oncology businesses have been negatively impacted by the pandemic but have recovered. Future outbreaks of COVID-19 and its variants could diminish patients’ and our sales representatives’ access to healthcare provider offices. Pandemic-related supply chain disruptions, whether caused by restrictions or slowdowns in shipping or logistics, increases in demand for certain goods used in our operations, or otherwise, could impact our operations.
The inflationary environment has resulted in higher prices, which have impacted costs incurred to generate revenue from our laboratory testing services, costs to attract and retain personnel, and other operating costs. The severity and duration of the current inflationary environment remains uncertain and may continue to impact our financial condition and results of operations. Additionally, fluctuations in foreign currency exchange rates can affect our financial position and results of operations. While the impact has not been material to our financial position to date and we make efforts to hedge our foreign currency exchange rate exposure, we cannot predict the extent to which currency fluctuations may affect our business and financial position in the future.

Results of Operations
We have generated significant losses since inception and, as of March 31, 2023, we had an accumulated deficit of approximately $3.34 billion. We expect to continue to incur losses for the near future, and it is possible we may never achieve profitability.
Revenue. Our revenue is primarily generated by our laboratory testing services from our Cologuard, Oncotype, and COVID-19 tests.
Three Months Ended March 31,
Amounts in millions20232022Change
Screening$443.2 $306.5 $136.7 
Precision Oncology155.4 152.6 2.8 
COVID-19 Testing3.8 27.4 (23.6)
Total$602.5 $486.6 $115.9 
34
The increase in Screening revenue, which primarily includes laboratory service revenue from our Cologuard test, was mainly due to an increase in the number of completed Cologuard tests. The increase in completed Cologuard tests for the three months ended March 31, 2023 was due to improved sales team productivity, growth across all customer segments, and enhancements made to our patient compliance program in 2022. The increase in Precision Oncology revenue, which primarily includes laboratory service revenue from our global Oncotype products, was mainly due to an increase in the number of completed Oncotype DX breast cancer tests, both domestically and internationally. Continued adoption by providers and payers for node-positive breast cancer patients following the RxPONDER publication in the New England Journal of Medicine also contributed to the increase in completed Oncotype tests for the three months ended March 31, 2023. The increase in completed Oncotype tests was partially offset by a decrease in revenues from our GPS test, which was divested on August 2, 2022.
During the three months ended March 31, 2023 and March 31, 2022, revenue recognized from changes in transaction price was $11.7 million and $4.2 million, respectively. The increase to revenue from changes in transaction price is a result of improvements made in our order to cash operations, specifically within our billing systems and processes.
We expect continuing revenue growth for our Cologuard and Oncotype products subject to seasonal variability. We expect revenue from our COVID-19 testing to decline as the pandemic abates and plan to discontinue COVID-19 testing later in the year. Our revenues are affected by the test volume of our products, patient adherence rates, payer mix, the levels of reimbursement, our order to cash operations, and payment patterns of payers and patients.
Cost of sales (exclusive of amortization of acquired intangible assets). Cost of sales includes costs related to inventory production and usage, shipment of collection kits and tissue samples, royalties and the cost of services to process tests and provide results to healthcare providers. The increase in cost of sales for the three months ended March 31, 2023 is primarily due to an increase in production costs and personnel expenses, which is primarily due to an increase in completed Cologuard and Oncotype tests and the corresponding increase in headcount to support the increase in tests completed. In addition, our production costs and personnel expenses have risen as a result of the inflationary environment discussed above. The increase was partially offset by a reduction in the number of COVID-19 tests completed. We expect that cost of sales will generally continue to increase in future periods as a result of an increase in our existing laboratory testing services and as we launch our pipeline products. We also expect to see a corresponding increase in personnel and support services associated with this growth.
Three Months Ended March 31,
Amounts in millions20232022Change
Production costs$92.7 $73.3 $19.4 
Personnel expenses45.0 39.1 5.9 
Facility and support services13.6 17.3 (3.7)
Stock-based compensation4.9 4.3 0.6 
Other cost of sales expenses0.7 0.7 — 
Total cost of sales expense$156.9 $134.7 $22.2 
35
Research and development expenses. The decrease in research and development expenses for the three months ended March 31, 2023 is primarily due to a decrease in clinical trial related expenses related to our BLUE-C clinical trial after enrollment for the study was completed in December 2022. The decrease was offset by an increase in personnel expenses, stock-based compensation, and facility and support services due to an increase in headcount and other resources needed to support our ongoing clinical trials. We expect that research and development expenses will generally continue to increase in future periods as we continue to invest to advance new tests.
Three Months Ended March 31,
Amounts in millions20232022Change
Personnel expenses$43.7 $35.5 $8.2 
Direct research and development23.3 45.0 (21.7)
Facility and support services14.6 9.6 5.0 
Stock-based compensation9.7 9.6 0.1 
Other research and development2.5 1.2 1.3 
Professional fees1.6 1.3 0.3 
Total research and development expenses$95.4 $102.2 $(6.8)
Sales and marketing expenses. The decrease in sales and marketing expenses for the three months ended March 31, 2023 was primarily due to a decrease in personnel expenses as a result of a decrease in headcount and in direct marketing costs and professional fees. The decrease in personnel expenses was due to minor restructuring of the sales force to reduce overlap and increase productivity. The decrease in direct marketing costs and professional fees was related to our promotion agreement with Pfizer Inc. (“Pfizer”), which ended in the third quarter of 2022. In addition, there was a decrease in facility and support services due to fewer costs incurred on commercial related information technology projects. We expect sales and marketing expenses in 2023 to be remain below 2022 levels due to improved efficiency from our commercial organization. We expect sales and marketing expenses to continue decreasing as a percentage of revenue over time as our Cologuard and Oncotype testing services grow and we make new tests available.
Three Months Ended March 31,
Amounts in millions20232022Change
Personnel expenses$110.3 $122.9 $(12.6)
Direct marketing costs47.3 64.3 (17.0)
Stock-based compensation12.7 15.0 (2.3)
Professional and legal fees11.0 18.2 (7.2)
Facility and support services4.5 10.5 (6.0)
Other sales and marketing expenses1.2 1.3 (0.1)
Total sales and marketing expenses$187.0 $232.2 $(45.2)
36
General and administrative expenses. The increase in general and administrative expenses for the three months ended March 31, 2023 is primarily due to an increase in professional and legal fees as a result of our civil investigative demand with the U.S. Department of Justice (“DOJ”) as further described in Note 14 of our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. The increase in other general and administrative expenses is primarily due to a decrease in the gain recorded for the three months ended March 31, 2023 as a result of the change in fair value of our outstanding contingent consideration as further described in Note 7 of our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. In addition, facility and support services increased to support the growth in our operations. We expect significant leverage in general and administrative expenses going forward, but expenses will generally continue to increase in future periods due to an increase in headcount that will be necessary to support the growth in our existing and pipeline products.
Three Months Ended March 31,
Amounts in millions20232022Change
Personnel expenses$98.4 $100.5 $(2.1)
Professional and legal fees47.1 26.9 20.2 
Facility and support services42.8 31.7 11.1 
Stock-based compensation21.8 23.5 (1.7)
Other general and administrative7.2 (12.8)20.0 
Total general and administrative expenses$217.3 $169.8 $47.5 
Amortization of acquired intangible assets. Amortization of acquired intangible assets decreased to $22.9 million for the three months ended March 31, 2023 compared to $24.7 million for the three months ended March 31, 2022. The decrease is primarily due to reduced amortization on the intangible asset that was disposed of with the sale of the GPS test in August 2022. This was partially offset by amortization of the intangible asset acquired as part of our acquisition of OmicEra Diagnostics, GmbH in May 2022.
Impairment of long-lived assets. Impairment of long-lived assets increased to $0.1 million for the three months ended March 31, 2023 compared to zero for the three months ended March 31, 2022. The impairment charge recorded for the three months ended March 31, 2023 related to a building lease on a domestic facility.
Investment income (loss), net. For the three months ended March 31, 2023, we had net investment income of $0.5 million, compared to net investment loss of $1.5 million for the three months ended March 31, 2022. The net investment income for the three months ended March 31, 2023 was primarily due to gains on recorded on our marketable securities. Net investment loss for the three months ended March 31, 2022 was primarily due to losses recorded on our equity securities.
Interest income (expense), net. Net interest income was $4.1 million for the three months ended March 31, 2023 compared to interest expense of $4.5 million for the three months ended March 31, 2022. Net interest income for the three months ended March 31, 2023 was due to a net gain on settlement of convertible notes of $10.3 million, which was partially offset by interest expense recorded on our outstanding convertible notes of $4.8 million. Interest expense recorded from our outstanding convertible notes totaled $4.0 million during the three months ended March 31, 2022. The convertible notes are further described in Note 9 of our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.
Income tax benefit (expense). Income tax expense was $1.7 million for the three months ended March 31, 2023 compared to a benefit of $2.0 million for the three months ended March 31, 2022. Income tax expense for the three months ended March 31, 2023 is primarily related to current foreign and state tax expense.

37
Liquidity and Capital Resources
Overview
We have incurred losses and negative cash flows from operations since our inception, and have historically financed our operations primarily through public offerings of our common stock and convertible debt and through revenue generated by the sale of our laboratory testing services. We expect our operating expenditures to continue to increase to support future growth of our laboratory testing services, as well as an increase in research and development and clinical trial costs to support the advancement of our pipeline products and bringing new tests to market. We expect that cash, cash equivalents and marketable securities on hand at March 31, 2023, along with cash flows generated through our operations, will be sufficient to fund our current operations for at least the next twelve months based on current operating plans.
We have access to a revolving line-of-credit (the “Revolver”) of up to $150.0 million, which had its maturity date extended to November 2025 through an amended agreement in October 2022. The Revolver is collateralized by certain marketable securities which must continue to maintain a minimum market value of $150.0 million. PNC Bank, National Association has issued letters of credit totaling $4.4 million, which reduces the amount available for cash advances under the line of credit to $145.6 million. As of March 31, 2023, we had not drawn any funds under the Revolver. In addition to the Revolver, we have access to $150.0 million under an accounts receivable securitization facility (the “Securitization Facility”), which expires in June 2024. The amount that we may borrow is determined based on the amount of qualifying accounts receivable at a given point in time. The Securitization Facility is collateralized by our accounts receivables. As of March 31, 2023, we had $50.0 million outstanding under the Securitization Facility, which is the minimum amount that we must borrow under the terms of the Securitization Facility. The Revolver and Securitization Facility are further described in Note 8 of our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.
We may raise additional capital to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons. If we are unable to obtain sufficient additional funds to enable us to fund our business plans and strategic investments, our results of operations and financial condition could be materially adversely affected, and we may be required to delay the implementation of our plans or otherwise scale back our operations. There can be no certainty that we will ever be successful in generating sufficient cash flow from operations to achieve and maintain profitability and meet all of our obligations as they come due.
Cash, Cash Equivalents and Marketable Securities
As of March 31, 2023, we had approximately $421.4 million in unrestricted cash and cash equivalents and approximately $277.3 million in marketable securities.
The majority of our investments in marketable securities consist of fixed income investments, and all are deemed available-for-sale. The objectives of this portfolio are to provide liquidity and safety of principal while striving to achieve the highest rate of return. Our investment policy limits investments to certain types of instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer.
Cash Flows
Three Months Ended March 31,
Amounts In millions20232022
Net cash used in operating activities$(38.2)$(173.8)
Net cash provided by investing activities82.9 45.6 
Net cash provided by financing activities133.6 2.7 
38
Operating activities
The cash used in operating activities for the three months ended March 31, 2023 was primarily to fund our net loss. The decrease in our net loss was primarily due to an increase in revenue, which was primarily driven by an increase in the number of completed Cologuard and Oncotype tests. The decrease in cash used for the three months ended March 31, 2023 was also due to a decrease in certain of our operating expenses as a result of cost saving measures implemented in the second half of 2022 and timing of payments on our accounts payable and accrued expenses, which was partially offset by an increase in cost of sales to support the increase in completed Cologuard and Oncotype tests.
Investing activities
Cash provided by investing activities for the three months ended March 31, 2023 was primarily due to a net cash inflow from purchases, sales, maturities of marketable securities of $112.7 million which was partially offset by purchases of property and equipment of $29.4 million and investments in privately held companies of $0.4 million. Cash provided by investing activities for the three months ended March 31, 2022 was primarily due to a net cash inflow from purchases, sales, and maturities of marketable securities of $80.4 million, which was partially offset by purchases of property and equipment of $33.6 million, and investments in privately held companies of $1.2 million.
Financing activities
The cash provided by financing activities during the three months ended March 31, 2023 consisted of proceeds of $138.0 million from the issuance of convertible notes and $1.0 million from the exercise of stock options, which was partially offset by cash outflows of $5.3 million for other financing activities. The cash provided by financing activities for the three months ended March 31, 2022 consisted of proceeds of $4.3 million from the exercise of stock options, which was partially offset by $1.5 million for other financing activities.
Material Cash Requirements
A discussion of our material cash requirements as of December 31, 2022 was provided in the Management’s Discussion and Analysis of Financial Condition and Results of Operation of our 2022 Form 10-K.
In February 2023, we entered into a privately negotiated exchange and purchase agreement with a single holder of certain of our convertible notes due in 2027 (the “2027 Notes”) and 2028 (the “2028 Notes”). We issued the holder $500.0 million aggregate principal amount of 2.0% Convertible Notes due in 2030 in exchange for $183.7 million of aggregate principal of 2027 Notes, $201.0 million of aggregate principal of 2028 Notes, and $138.0 million of cash. In addition, in March 2023 we entered into a privately negotiated exchange agreement with two holders of certain of the our convertible notes due in 2025 (the “2025 Notes”). We issued the holder $73.0 million aggregate principal amount of 2.0% Convertible Notes due in 2030 (collectively, the “2030 Notes”) in exchange for $65.8 million of aggregate principal of 2025 Notes. The 2030 Notes will mature on March 1, 2030 and bear interest at a rate of 2.0% per year, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2023. The outstanding aggregate principal of all our convertible notes was $2.34 billion as of March 31, 2023. Refer to Note 9 of our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for further information.
As of the date of this Quarterly Report on Form 10-Q, amounts accrued for legal proceedings and regulatory matters were not material except for the amounts accrued related to the Medicare Date of Service Rule Investigation, discussed further in Note 14 to our condensed consolidated financial statements. Based on the our review and analysis of the DOJ presentation, ongoing discussions held with the DOJ, the civil damages estimate and range of potential exposure, we have recorded an accrual of approximately $29 million as of March 31, 2023. The recorded accrual of $29 million is based on several factors, considerations, and judgements, and the ultimate resolution of this matter could result in a material loss in excess of the recorded accrual.
Other than the matters described above, there were no material changes outside the ordinary course of our business in our specified material cash requirements during the three months ended March 31, 2023.
As of March 31, 2023, we had no off-balance sheet arrangements.

39
Critical Accounting Policies and Estimates
Management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience and on various other factors that are believed to be appropriate under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
For a discussion of our critical accounting policies and estimates, refer to our Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2022 Form 10-K. There have been no material changes to our critical accounting policies and estimates since our 2022 Form 10-K.
Recent Accounting Pronouncements
See Note 1 of our condensed consolidated financial statements for the discussion of Recent Accounting Pronouncements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk
Interest Rate Risk
Our exposure to market risk is principally confined to our cash, cash equivalents and marketable securities and our outstanding variable-rate debt. We invest our cash, cash equivalents, and marketable securities in securities of the U.S. governments and its agencies and in investment-grade, highly liquid investments consisting of commercial paper, bank certificates of deposit, and corporate bonds, which as of March 31, 2023 and December 31, 2022 were classified as available-for-sale. We place our cash, cash equivalents, restricted cash, and marketable securities with high-quality financial institutions, limit the amount of credit exposure to any one institution, and have established investment guidelines relative to diversification and maturities designed to maintain safety and liquidity.
Based on a hypothetical 100 basis point decrease in market interest rates, the potential losses in future earnings, fair value of risk-sensitive financial instruments, and cash flows are immaterial, although the actual effects may differ materially from the hypothetical analysis. While we believe our cash, cash equivalents, restricted cash, and marketable securities do not contain excessive risk, we cannot provide absolute assurance that, in the future, our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash, cash equivalents, restricted cash, and marketable securities at one or more financial institutions that are in excess of federally insured limits. Given the potential instability of financial institutions, we cannot provide assurance that we will not experience losses on these deposits. We do not utilize interest rate hedging agreements or other interest rate derivative instruments.
As of March 31, 2023, we had $50.0 million in outstanding variable rate debt. Based on a hypothetical 100 basis point increase in market interest rates, annual interest expense on variable rate debt as of March 31, 2023 would increase by approximately $0.5 million. If we were to draw down additional amounts under either our Revolving Loan or Securitization Facility, the impact of increases in prevailing market interest rates would be even greater. All of our other significant interest-bearing liabilities bear interest at fixed rates and therefore are not subject to fluctuations in market interest rates; however, because these interest rates are fixed, we may be paying a higher interest rate, relative to market, in the future if circumstances change.
Foreign Currency Risk
The functional currency for most of our international subsidiaries is the U.S. dollar, and as a result we are not subject to material gains and losses from foreign currency translation of the subsidiary financial statements. Substantially all of our revenues are recognized in U.S. dollars, although a small portion is denominated in foreign currency as we continue to expand into markets outside of the U.S. Certain expenses related to our international activities are payable in foreign currencies. As a result, factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets will affect our financial results.
40
We enter into forward contracts to mitigate the impact of adverse movements in foreign exchange rates related to the re-measurement of monetary assets and liabilities and hedge our foreign currency exchange rate exposure. As of March 31, 2023, we had open foreign currency forward contracts with notional amounts of $29.2 million. Although the impact of currency fluctuations on our financial results has been immaterial in the past, there can be no guarantee that the impact of currency fluctuations related to our international activities will not be material in the future.

Item 4. Controls and Procedures
As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, of the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based upon that evaluation, our principal executive officer and our principal financial officer concluded that, as of March 31, 2023, our disclosure controls and procedures were effective. Disclosure controls and procedures enable us to record, process, summarize and report information required to be included in our Exchange Act filings within the required time period. Our disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed by us in the periodic reports filed with the SEC is accumulated and communicated to our management, including our principal executive, financial and accounting officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
There have been no significant changes in internal control over financial reporting during the quarter ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
41
Part II - Other Information

Item 1. Legal Proceedings
From time to time we are a party to various legal proceedings arising in the ordinary course of our business. Legal proceedings, including litigation, government investigations and enforcement actions could result in material costs, occupy significant management resources and entail civil and criminal penalties. The information called for by this item is incorporated by reference to the information in Note 14 of our condensed consolidated financial statements included in Part I of this Quarterly Report on Form 10-Q.

Item 1A. Risk Factors
We operate in a rapidly changing environment that involves a number of risks that could materially affect our business, financial condition or future results, some of which are beyond our control. In addition to the other information set forth in this report, the risks and uncertainties that we believe are most important for you to consider are discussed in Part I, “Item 1A. Risk Factors” in the 2022 Form 10-K and in Part II, “Item 1A. Risk Factors” in our subsequently filed Quarterly Reports on Form 10-Q. Other than the factors set forth below, there have been no material changes to the risk factors described in the 2022 Form 10-K.
Our business is affected by macroeconomic conditions.
Various macroeconomic factors could adversely affect our business and the results of our operations and financial condition, including changes in inflation, interest rates, and foreign currency exchange rates and overall economic conditions and uncertainties, including those resulting from the current and future conditions in the global financial markets. For instance, we experienced inflationary pressures in 2022 and expect such pressures to continue in 2023. Cost inflation, including increases in raw material prices, labor rates, and transportation costs may impact our profitability. Our ability to recover these cost increases through price increases is significantly limited by the process by which we are reimbursed for our products and services by government and private payers. The volatility of the capital markets could also affect the value of our investments and our ability to liquidate our investments or access our cash and cash equivalents in order to fund our operations. For example, on March 10, 2023, Silicon Valley Bank was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation, or the FDIC, as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership followed by First Republic Bank on May 1, 2023. While we do not maintain deposits with these particular institutions, we do maintain deposits in excess of federally insured limits at other financial institutions as a part of doing business that could be at risk if another similar event were to occur. Our ongoing cash management strategy is to maintain diversity in our deposit accounts at multiple financial institutions, but there can be no assurance that this strategy will be successful. If other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, then our ability to access our cash and cash equivalents may be threatened which could have a material adverse effect on our business and financial condition.
Increasing interest rates, reduced access to capital markets, and the failure of financial institutions could also adversely affect the ability of our suppliers, distributors, licensors, collaborators, contract manufacturers and other commercial partners to remain effective business partners or to remain in business. The loss of a critical business partner, or a failure to perform by a critical business partner, could have a disruptive effect on our business and could adversely affect our results of operations.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Not applicable.

Item 3. Defaults Upon Senior Securities
Not applicable.

Item 4. Mine Safety Disclosures
Not applicable.

42
Item 5. Other Information
Given the Company’s rapid growth, focus on profitability, and expanded leadership team, beginning May 9, 2023, Jeffrey Elliott will focus on leadership of the Company’s finance, accounting and analytics functions, in addition to other responsibilities assigned to him from time to time. Mr. Elliott will continue as the Company’s principal financial officer and principal accounting officer and hold the title of Executive Vice President and Chief Financial Officer. His chief operating officer responsibilities will be distributed across our expanded leadership, as a natural step in the Company’s evolution.
43
Item 6. Exhibits
The following documents are filed as part of this Form 10-Q.
Exhibit
Number		Exhibit DescriptionFiled
with
This
Report		Incorporated
by Reference
herein from
Form or
Schedule		Filing
Date		SEC File /
Registration
Number
Sixth Amended and Restated Certificate of Incorporation of the RegistrantS-1 (Exhibit 3.3)12/4/2000333-48812
Amendment to Sixth Amended and Restated Certificate of Incorporation of the Registrant8-K (Exhibit 3.1)7/24/2020001-35092
Sixth Amended and Restated By-Laws of the Registrant8-K (Exhibit 3.1)1/28/2022001-35092
Fourth Supplemental Indenture, dated March 1, 2023, between the Company and U.S. Bank National Association, as Trustee (including the form of 2.00% Convertible Senior Notes due 2030).8-K (Exhibit 4.2)3/1/2023001-35092
The Registrant's Equity Award, Death, Disability and Retirement Policy10-K (Exhibit 10.32)2/21/2023001-35092
The Registrant's 2010 Employee Stock Purchase Plan (as amended and restated March 22, 2023)X
The Registrant's Non-Employee Director Compensation Policy dated January 24, 2023X
Certification Pursuant to Rule 13(a)-14(a) or Rule 15d-14(a) of Securities Exchange Act of 1934X
Certification Pursuant to Rule 13(a)-14(a) or Rule 15d-14(a) of Securities Exchange Act of 1934X
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X
101
The following materials from the Quarterly Report on Form 10-Q of Exact Sciences Corporation for the quarter ended March 31, 2023 filed on May 9, 2023, formatted in Inline eXtensible Business Reporting Language (“iXBRL”): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statement of Changes in Stockholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows and (v) related notes to these financial statements
X
104
The cover page from our Quarterly Report for the period ended March 31, 2023, filed with the Securities and Exchange Commission on May 9, 2023, is formatted in Inline Extensible Business Reporting Language (“iXBRL”)
X
(*) Indicates a management contract or any compensatory plan, contract or arrangement.

44
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
EXACT SCIENCES CORPORATION
Date: May 9, 2023
By:/s/ Kevin T. Conroy
Kevin T. Conroy
President and Chief Executive Officer
(Principal Executive Officer)
Date: May 9, 2023
By:/s/ Jeffrey T. Elliott
Jeffrey T. Elliott
Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)

45
 EX-10.2 2 exas-20230331xexx102.htm EX-10.2 Document
EXHIBIT 10.2
EXACT SCIENCES CORPORATION
2010 EMPLOYEE STOCK PURCHASE PLAN
(As amended and restated on March 22, 2023)
Article 1-Purpose.
This 2010 Employee Stock Purchase Plan, as amended and restated (the "Plan"), is intended to encourage stock ownership by all eligible employees of Exact Sciences Corporation (the "Company"), a Delaware corporation, and its Participating Subsidiaries (as defined in Article 17) so that they may share in the growth of the Company by acquiring or increasing their proprietary interest in the Company through the purchase of shares of the Company's common stock ("Common Stock"). The Plan is designed to encourage eligible employees to remain in the employ of the Company and its Participating Subsidiaries.
It is intended that a component of the Plan constitutes an “employee stock purchase plan” within the meaning of Section 423(b) of the U.S. Internal Revenue Code of 1986, as amended (the “Code” and such component, the “423 Component”) and the 423 Component shall be interpreted in accordance with that intent (although the Company makes no undertaking or representation to maintain such qualification).
In addition, this Plan authorizes the grant of Options (as defined in Article 5) under a component of the Plan that does not qualify as an “employee stock purchase plan” under Section 423 of the Code (such component, the “Non-423 Component”). Such Options granted under the Non-423 Component shall be granted pursuant to such sub-plans, appendices, rules or procedures as may be adopted by the Committee (as defined in Article 2) to achieve tax, securities laws or other objectives for the eligible employees and the Participating Subsidiaries designated for participation in the Non-423 Component. Except as otherwise provided herein or by the Committee, the Non-423 Component will operate and be administered in the same manner as the 423 Component.
For purposes of this Plan, the Committee may designate separate offerings under the Plan in which eligible employees will participate, the terms of which need not be identical even if the dates of the applicable Offering Periods of such offerings are identical, provided that the terms of participation are the same within each separate offering under the 423 Component as determined under Section 423 of the Code. Unless otherwise determined by the Committee, each offering under the Plan in which employee of one or more Participating Subsidiaries may participate shall be deemed a separate offering for purposes of Section 423 of the Code, even if the dates of the applicable Offering Periods of each such offering are identical, and the provisions of the Plan shall separately apply to each offering.
Article 2-Administration of the Plan.
The Plan may be administered by a committee appointed by the Board of Directors of the Company (the "Committee"). The Board of Directors may from time to time remove members from, or add members to, the Committee. Vacancies on the Committee, howsoever caused, shall be filled by the Board of Directors. The Committee may select one of its members as Chairman, and shall hold meetings at such times and places as it may determine. Acts by a majority of the Committee, or acts reduced to or approved in writing by a majority of the members of the Committee, shall be the valid acts of the Committee.
The Committee has authority at any time to: (i) adopt, alter and repeal such rules, guidelines and practices for the administration of the Plan and for its own acts and proceedings as it shall deem advisable; (ii) interpret the terms and provisions of the Plan; (iii) determine when and how Options shall be granted and the provisions and terms of each offering (which need not be identical between offerings); (iv) determine eligibility for participation in the Plan, including which subsidiaries of the Company will be Participating Subsidiaries and whether such
1


Participating Subsidiaries participate in the 423 Component or the Non-423 Component (within the limits of the Plan); (v) make all determinations it deems advisable for the administration of the Plan; (vi) decide all disputes arising in connection with the Plan; and (vii) otherwise supervise the administration of the Plan. Further, the Committee may adopt sub-plans, appendices, rules or procedures relating to the operation and administration of the Plan to accommodate the specific requirements of local laws and procedures, provided that the adoption and implementation of any such sub-plans, appendices rules and/or procedures would not cause the 423 Component to violate Section 423 of the Code.
All interpretations and decisions of the Committee shall be binding on all persons, including the Company and the participants. No member of the Board of Directors or individual exercising administrative authority with respect to the Plan shall be liable for any action or determination made in good faith with respect to the Plan or any Option granted hereunder.
In the event the Board of Directors fails to appoint or refrains from appointing a Committee, the Board of Directors or the Compensation Committee of the Board of Directors shall have all power and authority to administer the Plan. In such event, the word "Committee" wherever used herein shall be deemed to mean the Board of Directors or the Compensation Committee of the Board of Directors.
To the extent not prohibited by applicable law, the Committee may, from time to time, delegate some or all of its authority under the Plan to a subcommittee or subcommittees of the Committee, to one or more of the Company’s officers or management team, or to other persons or groups of persons as it deems necessary, appropriate or advisable under conditions or limitations that it may set at or after the time of the delegation. For purposes of the Plan, reference to the Committee will be deemed to include any subcommittee, subcommittees, or other persons or groups of persons to whom the Committee delegates authority pursuant to this provision.
Article 3-Eligible Employees.
All employees of the Company or any of its Participating Subsidiaries who are employed on or before the forty-fifth (45th) day (or such other period of time not to exceed two (2) years) prior to the beginning of an Offering Period and whose customary employment at such time is more than 20 hours per week and for more than five months in any calendar year shall be eligible to receive Options under the Plan to purchase shares of Common Stock, provided that the Committee may allow employees whose customary employment is below these thresholds to be considered as eligible employees, including where applicable law requires that such employees be considered as eligible employees, subject in all cases to the provisions of this Article 3 and the requirements set forth in Article 7 hereof.
An employee who works for a Participating Subsidiary and is a citizen or resident of a jurisdiction other than the United States (without regard to whether such individual also is a citizen or resident of the United States or is a resident alien (within the meaning of Section 7701(b)(1)(A) of the Code)) may be excluded from participation in the Plan or an offering if the participation of such employee is prohibited under the laws of the applicable jurisdiction or if complying with the laws of the applicable jurisdiction would cause the Plan or an offering under the 423 Component to violate Section 423 of the Code. In the case of the Non-423 Component, an employee (or group of employees) may be excluded from participation in the Plan if the Committee has determined, in its sole discretion, that participation of such employee(s) is not advisable or practicable for any reason.
2


In no event may an employee be granted an Option if such employee, immediately after the Option was granted, would be treated as owning stock possessing five percent or more of the total combined voting power or value of all classes of stock of the Company or of any parent corporation or subsidiary corporation, as the terms "parent corporation" and "subsidiary corporation" are defined in Section 424(e) and (f) of the Code. For purposes of determining stock ownership under this paragraph, the rules of Section 424(d) of the Code shall apply, and stock which the employee may purchase under outstanding Options shall be treated as stock owned by the employee.
Article 4-Stock Subject to the Plan.
The stock subject to the Options under the Plan shall be shares of the Company's authorized but unissued common stock, par value $.01 per share (the "Common Stock"), or shares of Common Stock reacquired by the Company, including shares purchased in the open market. The aggregate number of shares of Common Stock which may be issued pursuant to the Plan is 5,800,000 subject to adjustment as provided in Article 12. If any Option granted under the Plan shall expire or terminate for any reason without having been exercised in full or shall cease for any reason to be exercisable in whole or in part, the unpurchased shares subject thereto shall again be available under the Plan. For avoidance of doubt, up to the maximum number of Shares reserved under this Article 4 may be used to satisfy purchases of shares of Common Stock under the 423 Component and any remaining portion of such maximum number of shares of Common Stock may be used to satisfy purchases of shares of Common Stock under the Non-423 Component.
Article 5-Offering Period and Stock Options.
Offering Periods under the Plan shall consist of twenty-four month periods commencing on November 1 and May 1 of each calendar year ("Offering Periods"). The Company will designate one or more dates within each Offering Period on which shares of Common Stock may be purchased by participants in an Offering Period ("Exercise Date(s)"). Unless and until otherwise determined by the Committee, there shall be four Exercise Dates occurring on each April 30 and October 31 (or, if such date is not a business day, the first business day thereafter) within each such Offering Period. On the first business day at the beginning of each Offering Period, the Company will grant to each eligible employee who is then a participant in the Plan an Option to purchase shares on the Exercise Dates (the "Option"), at the Option Price hereinafter provided for, a maximum of 10,000 shares of Common Stock, on condition that such employee remains eligible to participate in the Plan on each Exercise Date. If the participant's accumulated payroll deductions on the last date of the Offering Period would enable the participant to purchase more than the maximum number of shares provided herein except for the share limitation set forth herein, the excess of the amount of the accumulated payroll deductions over the aggregate purchase price of the maximum number of Shares of Common Stock that may be purchased in accordance with this Article 5 shall be promptly refunded to the participant by the Company, without interest. The participant shall be entitled to exercise the Option so granted only to the extent of the participant's accumulated payroll deductions on the Exercise Date. The option price per share of Common Stock for each Exercise Date within an Offering Period shall be the lesser of (i) 85% of the average market price of the Common Stock on the first business day of the Offering Period and (ii) 85% of the average market price of the Common Stock on the applicable Exercise Date, in either event rounded up to the nearest cent (the "Option Price"). The foregoing limitation on the number of shares subject to Option and the Option Price shall be subject to adjustment as provided in Article 12.
3


Unless a participant files a new authorization or withdraws from the Plan, the deductions and purchases under the authorization the participant has on file under the Plan will continue from one Offering Period to succeeding (but not overlapping) Offering Periods as long as the Plan remains in effect. Notwithstanding any of the foregoing, if the average market price of the Common Stock on an Exercise Date is less than or equal to the average market price of the Common Stock on the first business day of the Offering Period to which such Exercise Date relates, all participants shall be automatically withdrawn from such Offering Period immediately after the acquisition of shares of Common Stock for such Exercise Date and automatically enrolled in the immediately following Offering Period as of the first day thereof.
For purposes of the Plan, the term "average market price" on any date means (i) the average (on that date) of the high and low prices of the Common Stock on the principal national securities exchange on which the Common Stock is traded, if the Common Stock is then traded on a national securities exchange; or (ii) the average of the closing bid and asked prices last quoted (on that date) by an established quotation service for over-the-counter securities, if the Common Stock is not reported on the NASDAQ; or (iii) if the Common Stock is not publicly traded, the fair market value of the Common Stock as determined by the Committee after taking into consideration all factors which it deems appropriate, including, without limitation, recent sale and offer prices of the Common Stock in private transactions negotiated at arm's length.
For purposes of the Plan, the term "business day" means a day on which there is trading on the NASDAQ Capital Market or the aforementioned national securities exchange, whichever is applicable pursuant to the preceding paragraph; and if neither is applicable, a day that is not a Saturday, Sunday or legal holiday in State of Wisconsin.
Notwithstanding the foregoing, no participant may be granted an Option which permits his or her rights to purchase shares under the Plan, and any other employee stock purchase plan of the Company or Subsidiaries, to accrue at a rate which exceeds $25,000 of the fair market value of such shares (determined on the Option grant date or dates) for each calendar year in which the Option is outstanding at any time. The purpose of the limitation in the preceding sentence is to comply with Section 423(b)(8) of the Code and shall be applied taking Options into account in the order in which they were granted. Solely with respect to the 423 Component, for Offering Periods beginning on or after May 1, 2023, once the participant's accumulated payroll deductions would enable the participant to purchase the maximum amount of Common Stock permitted under the Section 423(b)(8) limitation described in this paragraph, payroll deductions will cease until the first day after the last Exercise Date in the calendar year in which accumulated payroll deductions reached such maximum amount. For both the 423 Component and the Non-423 Component, on any Exercise Date, if the participant’s accumulated payroll deductions would otherwise enable the participant to purchase Common Stock in excess of the Section 423(b)(8) limitation described in this paragraph, the excess of the amount over the accumulated payroll deductions over the aggregate purchase price of the shares actually purchased shall be promptly refunded to the participant by the Company, without interest.
4


Article 6-Exercise of Option.
Each eligible employee who continues to be a participant in the Plan on an Exercise Date within an Offering Period shall be deemed to have exercised his or her Option on such date and shall be deemed to have purchased from the Company such number of full shares of Common Stock reserved for the purpose of the Plan as the participant's accumulated payroll deductions on such date will pay for at the Option Price, subject to the 10,000 maximum share limit of the Option and the Section 423(b)(8) limitation described in Article 5. Only full shares of Common Stock may be purchased under the Plan, unless the Committee determines, in its sole discretion, that fractional shares may be purchased under the Plan. Unless otherwise determined by the Committee in advance of any Offering Period, unused payroll deductions remaining in a participant's account at the end of either an Exercise Date or an Offering Period, by reason of the inability to purchase a fractional share, shall be promptly refunded to the participant by the Company, without interest.
Article 7-Authorization for Entering the Plan.
An employee may elect to enter the Plan by filling out, signing and delivering an authorization to the Company (in such form and according to such procedures determined by the Committee which may include by electronic or other delivery). Such authorization shall:
A.State the percentage to be deducted regularly from the employee's Compensation;
B.Authorize the purchase of stock for the employee in each Offering Period in accordance with the terms of the Plan;
C.Specify the exact name or names in which stock purchased for the employee is to be issued as provided under Article 11 hereof; and
D.Include the employee's agreement any other terms and conditions for participation in the Plan that the Committee determines to be advisable.
Such authorization must be received by the Company at least ten days before the first day of the next Offering Period, or within such other time frame as determined by the Company and communicated to eligible employees, and shall take effect only if the employee is an eligible employee on the first business day of such Offering Period.
An employee cannot participate in more than one Offering Period at any time.
Unless a participant files a new authorization or withdraws from the Plan, the deductions and purchases under the authorization the participant has on file under the Plan will continue from one Offering Period to succeeding (but not overlapping) Offering Periods as long as the Plan remains in effect. The terms and conditions applicable to participation in the Plan in such successive Offering Periods shall be those in effect at the commencement of such successive Offering Periods, as set forth in the Plan and the authorization documentation available to eligible employees at such time.
5


The Company will accumulate and hold for each participant's account the amounts deducted from his or her Compensation. No interest will be paid on these amounts, unless required by applicable law. For purposes of the Plan, the term “Compensation” means the amount of base pay or wages (including 13th/14th month payments or similar concepts under local law), prior to salary reduction pursuant to Sections 125, 132(f) or 401(k) of the Code, and overtime, commissions, incentive or bonus awards, but excluding allowances and reimbursements for expenses such as relocation allowances or travel expenses, income or gains related to other Company share-based awards, and similar items. The Committee shall have the discretion to determine the application of this definition to participants on payrolls outside of the United States.
Article 8-Maximum Amount of Payroll Deductions.
An employee may authorize payroll deductions in an amount (expressed as a whole percentage) not less than one percent (1%) but not more than fifteen percent (15%) of the employee's total Compensation.
Notwithstanding any other provisions of the Plan to the contrary, in non-U.S. jurisdictions where participation in the Plan through payroll deductions is prohibited or otherwise problematic under applicable laws (as determined by the Committee in its sole discretion), the Committee may provide that an eligible employee may elect to participate through other contributions in a form acceptable to the Committee in lieu of or in addition to payroll deductions, provided that, for any offering under the 423 Component, the Committee must determine that any alternative method of contribution is applied on an equal and uniform basis to all eligible employees in the offering. Any reference to “payroll deductions” in this Article 8 (or in any other section of the Plan) will similarly cover contributions by other means made pursuant to this Article 8.
Article 9-Change in Payroll Deductions.
Payroll deductions may not be increased or decreased during an Offering Period. However, a participant may withdraw in full from the Plan (as described in Article 10). The Committee may, in advance of any Offering Period, establish rules, procedures and deadlines permitting a participant to increase, decrease or terminate his or her payroll deductions during an Offering Period.
Article 10-Withdrawal from the Plan.
A participant may withdraw from the Plan (in whole but not in part), within such time prior to the Exercise Date for such Offering Period as may be established by the Committee, by delivering a withdrawal notice to the Company (in such form and according to such procedures determined by the Committee which may include by electronic or other delivery). In the event a participant elects to withdraw from the Plan, amounts then credited to such participant's account shall be returned to the participant as soon as practicable after such election is received by the Company (without any interest thereon except as may be required by applicable local laws), the participant shall cease to participate in the Plan and the participant’s Option for such Offering Period shall terminate. 
To re-enter the Plan, an employee who has previously withdrawn must file a new authorization at least ten days before the first day of the next Offering Period in which he or she wishes to participate, or within such other time frame as determined by the Company and communicated to eligible employees. The employee's re-entry into the Plan becomes effective at the beginning of such Offering Period, provided that he or she is an eligible employee on the first business day of the Offering Period.
Article 11-Issuance of Stock.
Certificates for stock issued to participants (or other indicia of ownership of such stock) shall be delivered as soon as practicable after each Exercise Date by the Company's transfer agent.
6


Stock purchased under the Plan shall be issued only in the name of the participant, or if the participant's authorization so specifies and if and to the extent permitted by the Company, in the name of the participant and another person of legal age as joint tenants with rights of survivorship.
Article 12-Adjustments.
Upon the happening of any of the following described events, a participant's rights under Options granted under the Plan shall be adjusted as hereinafter provided:
A.In the event that the shares of Common Stock shall be subdivided or combined into a greater or smaller number of shares or if, upon a reorganization, split-up, liquidation, recapitalization or the like of the Company, the shares of Common Stock shall be exchanged for other securities of the Company, each participant shall be entitled, subject to the conditions herein stated, to purchase such number of shares of Common Stock or amount of other securities of the Company as were exchangeable for the number of shares of Common Stock that such participant would have been entitled to purchase except for such action, and appropriate adjustments shall be made in the purchase price per share to reflect such subdivision, combination or exchange; and
B.In the event the Company shall issue any of its shares or other securities, including any of the shares of any of its subsidiaries, as a stock dividend upon or with respect to the shares of stock of the class which shall at the time be subject to Option hereunder, each participant upon exercising such an Option shall be entitled to receive (for the purchase price paid upon such exercise) the shares as to which the participant is exercising his or her Option and, in addition thereto (at no additional cost), such number of shares of the class or classes in which such stock dividend or dividends were declared or paid, and such amount of cash in lieu of fractional shares, as is equal to the number of shares thereof and the amount of cash in lieu of fractional shares, respectively, which the participant would have received if the participant had been the holder of the shares as to which the participant is exercising his or her Option at all times between the date of the granting of such Option and the date of its exercise.
Upon the happening of any of the foregoing events (or in the event of an extraordinary cash dividend or other distribution that affects the shares of Common Stock), the class and aggregate number of shares set forth in Article 4 hereof which are subject to Options which have been or may be granted under the Plan and the limitations set forth in the second paragraph of Article 5 shall also be appropriately adjusted to reflect the events specified in paragraphs A and B above. Notwithstanding the foregoing, any adjustments made pursuant to paragraphs A or B shall be made only after the Committee, based on advice of counsel for the Company, determines whether such adjustments would constitute a "modification" (as that term is defined in Section 424 of the Code). If the Committee determines that such adjustments would constitute a modification, it may refrain from making such adjustments.
If the Company is to be consolidated with or acquired by another entity in a merger, a sale of all or substantially all of the Company's assets or otherwise (an "Acquisition"), the Committee or the board of directors of any entity assuming the obligations of the Company hereunder (the "Successor Board") shall, with respect to Options then outstanding under the Plan, either (i) make appropriate provision for the continuation of such Options by arranging for the substitution on an equitable basis for the shares then subject to such Options either (a) the consideration payable with respect to the outstanding shares of the Common Stock in connection with the Acquisition, (b) shares of stock of the successor corporation, or a parent or subsidiary of such corporation, or (c) such other securities as the Successor Board deems appropriate, the fair market value of which shall not materially exceed the fair market value of the shares of Common Stock subject to such Options immediately preceding the Acquisition; (ii) shorten the Offering Period with respect to which such Options relate by setting a new Exercise Date on which such Offering Period will end, with such new Exercise Date occurring before the effective date of the
7


Acquisition, and provided that each participant shall be notified of the new Exercise Date on which the Options will be exercised as provided in Article 6 hereof, unless prior to such date the participant has withdrawn from the Offering Period as provided in Article 10 hereof or the participant has ceased to be an eligible employee as provided in Article 14 hereof; or (iii) terminate each participant's Option in exchange for a cash payment equal to the excess of (a) the fair market value, on the date of the Acquisition, of the number of shares of Common Stock that the participant's accumulated payroll deductions as of the date of the Acquisition could purchase, at an Option Price determined with reference only to the first business day of the applicable Offering Period and subject to the maximum share limitation set forth in Article 5 hereof, Code Section 423(b)(8) and fractional-share limitations on the amount of stock a participant would be entitled to purchase, over (b) the result of multiplying such number of shares by such Option Price.
The Committee or Successor Board, as applicable, shall determine the adjustments to be made under this Article 12, and its determination shall be conclusive.
Article 13-No Transfer or Assignment of Employee's Rights.
An Option granted under the Plan may not be transferred or assigned, except by will or the laws of descent and distribution, and shall be exercised, during the participant's lifetime, only by the participant.
Article 14-Termination of Employee's Rights; Transfer of Employment.
Whenever a participant ceases to be an eligible employee because of retirement, voluntary or involuntary termination, resignation, layoff, discharge, death or for any other reason, his or her rights under the Plan shall immediately terminate, and the Company shall promptly refund, without interest (except where otherwise required by applicable law), the entire balance of his or her payroll deduction account under the Plan.
A participant will be deemed to have terminated employment, for this purpose, if the corporation that employs him or her, having been a Participating Subsidiary, ceases to be a subsidiary or to be designated as a Participating Subsidiary, or if the employee is transferred to any corporation other than the Company or a Participating Subsidiary. A participant will not be deemed to have terminated employment for this purpose, if the participant is on an approved leave of absence for military service or sickness or for any other purpose approved by the Company for up to 90 days, or if the employee’s right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Committee otherwise provides in writing, if longer than 90 days.
If a participant transfers employment from the Company or any Participating Subsidiary participating in the 423 Component to any Participating Subsidiary participating in the Non-423 Component, such transfer shall not be treated as a termination of employment, but the participant shall immediately cease to participate in the 423 Component; however, any contributions made for the Offering Period in which such transfer occurs shall be transferred to the Non-423 Component, and such participant shall immediately join the then-current offering under the Non-423 Component upon the same terms and conditions in effect for the participant’s participation in the 423 Component, except for such modifications otherwise applicable for participants in such offering. A participant who transfers employment from any Participating Subsidiary participating in the Non-423 Component to the Company or any Participating Subsidiary participating in the 423 Component shall not be treated as terminating the participant’s employment and shall remain a participant in the Non-423 Component until the earlier of (i) the end of the current Offering Period under the Non-423 Component, or (ii) the Offering Date of the first Offering Period in which the participant is eligible to participate following such transfer. Notwithstanding the foregoing, the Committee may establish different rules to govern transfers of employment between companies participating in the 423 Component and the Non-423 Component, consistent with the applicable requirements of Section 423 of the Code.
8


Article 15-Termination and Amendments to Plan.
Unless terminated sooner as provided below, the Plan shall terminate on October 31, 2030. The Plan may be terminated at any time by the Company's Board of Directors but such termination shall not affect Options then outstanding under the Plan. It will terminate in any case when all or substantially all of the unissued shares of stock reserved for the purposes of the Plan have been purchased. If at any time shares of stock reserved for the purpose of the Plan remain available for purchase but not in sufficient number to satisfy all then unfilled purchase requirements, the available shares shall be apportioned among participants in proportion to the amount of payroll deductions accumulated on behalf of each participant that would otherwise be used to purchase stock, and the Plan shall terminate. Upon such termination or any other termination of the Plan, all payroll deductions not used to purchase stock will be refunded, without interest (unless otherwise required under applicable law).
The Committee or the Board of Directors may from time to time adopt amendments to the Plan, provided that, without the approval of the stockholders of the Company, no amendment may (i) increase the number of shares that may be issued under the Plan; (ii) change the class of employees eligible to receive Options under the Plan, if such action would be treated as the adoption of a new plan for purposes of Section 423(b) of the Code; or (iii) cause Rule 16b-3 under the Securities Exchange Act of 1934 to become inapplicable to the Plan; (iv) otherwise be made to the extent stockholder approval is required under applicable law.
Article 16-Limits on Sale of Stock Purchased under the Plan.
The Plan is intended to provide shares of Common Stock for investment and not for resale. The Company does not, however, intend to restrict or influence any employee in the conduct of his or her own affairs. An employee may, therefore, sell stock purchased under the Plan at any time the employee chooses, subject to compliance with any applicable federal or state securities laws or other applicable securities or other laws and subject to any restrictions imposed under Article 23 to ensure that tax withholding obligations are satisfied. THE EMPLOYEE ASSUMES THE RISK OF ANY MARKET FLUCTUATIONS IN THE PRICE OF THE STOCK.
Article 17-Participating Subsidiaries.
The term "Participating Subsidiary" shall mean any present or future “subsidiary” of the Company, as that term is defined in Section 424(f) of the Code, that has been designated by the Committee from time to time, in its sole discretion, as eligible to participate in the Plan, such designation to specify whether such participation is in the 423 Component or Non-423 Component. A Participating Subsidiary may participate in either the 423 Component or Non-423 Component, but not both. Notwithstanding the foregoing, if any subsidiary is disregarded for U.S. tax purposes in respect of the Company or any Participating Subsidiary participating in the 423 Component, then such disregarded subsidiary shall automatically be a Participating Subsidiary participating in the 423 Component. If any subsidiary is disregarded for U.S. tax purposes in respect of any Participating Subsidiary participating in the Non-423 Component, the Committee may exclude such subsidiary from participating in the Plan, notwithstanding that the Participating Subsidiary in respect of which such subsidiary is disregarded may participate in the Plan. The Committee may so designate any subsidiary, or revoke any such designation, at any time and from time to time, either before or after the Plan is approved by the stockholders.
Article 18-Optionees Not Stockholders.
Neither the granting of an Option to an employee nor the deductions from an employee's Compensation shall constitute such employee a stockholder of the shares covered by an Option until such shares have been actually purchased by the employee.
9



Article 19-Section 409A.
The 423 Component of the Plan and the Options granted pursuant to an Offering Period are intended to be exempt from the application of Section 409A of the Code. Neither the Non-423 Component nor any Option granted pursuant to an Offering Period thereunder is intended to constitute or provide for “nonqualified deferred compensation” within the meaning of Section 409A of the Code. Notwithstanding any provision of the Plan to the contrary, if the Committee determines that any Option granted under the Plan may be or become subject to Section 409A of the Code or that any provision of the Plan may cause an Option granted under the Plan to be or become subject to Section 409A of the Code, the Committee may adopt such amendments to the Plan and/or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions as the Committee determines are necessary or appropriate to avoid the imposition of taxes under Section 409A of the Code, either through compliance with the requirements of Section 409A of the Code or with an available exemption therefrom.

Article 20-Application of Funds.
The proceeds received by the Company from the sale of Common Stock pursuant to Options granted under the Plan will be used for general corporate purposes.
Article 21-Notice to Company of Disposition.
By electing to participate in the Plan, each participant agrees to notify the Company in writing immediately after the participant transfers Common Stock acquired under the Plan. Each participant further agrees to provide any information about such a transfer as may be requested by the Company or any subsidiary corporation in order to assist it in complying with the tax laws. Without limitation to the foregoing, the Company reserves the right to require participants to hold any shares of Common Stock acquired under the Plan with a designated broker or other third party to facilitate compliance with the applicable reporting and other compliance requirements.
Article 22-Withholding of Additional Income Taxes.
By electing to participate in the Plan, each participant acknowledges that the Company and its Participating Subsidiaries are required to withhold any Tax-Related Items with respect to the amounts deducted from the participant's Compensation and accumulated for the benefit of the participant under the Plan, and each participant agrees that the Company and Participating Subsidiaries may deduct additional amounts from the participant's Compensation, when amounts are added to the participant's account, used to purchase shares of Common Stock or refunded, in order to satisfy such withholding obligations.
At the time a participant’s Option is exercised, in whole or in part, or at the time a participant disposes of some or all of the shares of Common Stock acquired under the Plan (or any other time that a taxable event related to the Plan occurs), the participant will make adequate provision for the payment and/or withholding of any Tax-Related Items. In their sole discretion, and except as otherwise determined by the Committee, the Company or a Participating Subsidiary that employs the participant may satisfy their obligations to withhold Tax-Related Items by (a) withholding from the participant’s wages or other cash compensation, (b) withholding a number of shares of Common Stock otherwise issuable following the exercise of the Option, (c) withholding from proceeds from the sale of shares of Common Stock issued upon exercise, either through a voluntary sale or a mandatory sale arranged by the Company, or (d) withholding by any other means determined by the Committee, in its sole discretion, and in compliance with applicable law.
10


For purposes of this Article 23, “Tax-Related Items” means any U.S. and non-U.S. federal, provincial, state and/or local taxes (including, without limitation, income tax, social insurance contributions, fringe benefit tax, employment tax, stamp tax and any employer tax liability which has been transferred to a participant) for which a participant is liable in connection with participation in the Plan.
Article 23-Governmental Regulations.
The Company's obligation to sell and deliver shares of Common Stock under the Plan is subject to the approval of any governmental authority required in connection with the authorization, issuance or sale of such shares.
Government regulations may impose reporting or other obligations on the Company with respect to the Plan. For example, the Company may be required to identify shares of Common Stock issued under the Plan on its stock ownership records and send tax information statements to employees and former employees who transfer title to such shares.
Article 24-Rules Particular to Specific Jurisdictions.
Without limitation to and notwithstanding any other provision in this Plan, the Committee may adopt such sub-plans or rules relating to the operation and administration of the Plan to accommodate local laws, customs and procedures for jurisdictions outside of the United States, the terms of which may take precedence over other provisions of this Plan, with the exception of Article 4 hereof, but unless otherwise superseded by the terms of such sub-plan or rules, the provisions of this Plan will govern the operation of such sub-plan or rules. To the extent inconsistent with the requirements of Section 423, any such sub-plan or rules will be considered part of a Non-423 Offering, and Options granted thereunder will not be required by the terms of the Plan to comply with Section 423 of the Code. Without limiting the generality of the foregoing, the Committee is authorized to adopt sub-plans or rules for particular non-U.S. jurisdictions that modify the terms of the Plan to meet applicable local requirements, customs or procedures regarding, without limitation, (i) eligibility to participate, (ii) the definition of Compensation, (iii) the dates and duration of Offering Periods or other periods during which participants may contribute payroll deductions towards the purchase of shares of Common Stock, (iv) the method of determining the Option Price and the discount from fair market value at which shares may be purchased, (v) any minimum or maximum amount of payroll deductions a participant may contribute in an Offering Period or other specified period under the applicable sub-plan or rules, (vi) the treatment of Options upon an Acquisition or adjustment event described in Article 12, (vii) the handling of payroll deductions and the methods for contributing to the Plan by means other than payroll deductions, (viii) establishment of bank, building society or trust accounts to hold payroll deductions, (ix) payment of interest or waivers therefrom, (x) conversion of local currency, (xi) obligations to pay payroll tax, (xii) determination of beneficiary designation requirements, (xiii) withholding procedures, and (xiv) handling of share issuances.
Article 25-Governing Law.
The validity and construction of the Plan shall be governed by the laws of Delaware, without giving effect to the principles of conflict of laws thereof.
Article 26-Approval of Board of Directors and Stockholders of the Company.
The Plan was initially adopted by the Board of Directors on April 15, 2010 and was initially approved by the stockholders of the Company on July 16, 2010. The Plan, as amended and restated, was adopted by the Board of Directors on April 13, 2022 and was approved by the stockholders of the Company on June 9, 2022.
11

 EX-10.3 3 exas-20230331xexx103.htm EX-10.3 Document
EXHIBIT 10.3
Exact Sciences Corporation
Non-Employee Director Compensation Policy

The purpose of this Non-Employee Director Compensation Policy of Exact Sciences Corporation, a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high caliber directors who are not employees or officers of the Company or its subsidiaries.

In furtherance of the purpose stated above, all non-employee directors shall be paid compensation for services provided to the Company as non-employee directors as set forth below:

A.Initial Equity Compensation
Upon his or her initial election to the board, each new non-employee director shall be granted restricted stock or deferred stock units having a value equal to $375,000. A director shall elect whether such award is restricted stock or deferred stock units by delivering written or electronic notice of such election to the Chief Financial Officer before the director begins to serve on the board (or within 30 days after if it is not possible for the director to make his or her election prior to beginning service); provided, however, that if the Chief Financial Officer receives no such election during such period, such grant shall be made in restricted stock. Such restricted stock or deferred stock units shall vest annually over three years (1/3 on the first anniversary of the grant, 1/3 on the second anniversary of the grant and 1/3 on the third anniversary of the grant). If a director ceases to serve as a director before such restricted shares or deferred stock units are fully vested due to death, Disability or if there is a Change in Control prior to such vesting, then such restricted stock or deferred stock units shall become fully vested as of the date of such death, Disability or Change in Control, as applicable. If the director ceases to serve on the Board for any reason other than death or Disability, any restricted stock or deferred stock units granted under this Paragraph A that are not then vested shall be forfeited as of the date of such cessation of services.

B.Annual Compensation
1.    Annual Cash Compensation

a.    On the date of each annual meeting of the Company’s stockholders, each non-employee director who is continuing as a non-employee director following such annual meeting shall be paid an annual cash compensation amount as follows:

Board Member Cash Compensation
Annual retainer for each director (“Annual Board Retainer”):$60,000
Board chair (if independent chair) additional compensation:$40,000
Lead independent director (if no independent chair) add. compensation:$40,000



Committee Member Cash Compensation
Committee chair cash compensation
– Audit and Finance$25,000
– Human Capital$20,000
– Nominating & Governance$15,000
– Innovation, Technology & Pipeline$15,000
Committee member (other than committee chair) cash compensation
– Audit and Finance$12,500
– Human Capital$10,000
– Nominating & Governance$6,500
– Innovation, Technology & Pipeline$6,500

b.    In lieu of cash, a director may elect to receive restricted stock having an equivalent dollar value. To be effective, notice of such election must be delivered to the Company’s Chief Financial Officer in writing or electronically prior to the annual meeting at which such election shall first take effect, and such election shall be irrevocable and remain in effect until the later of (i) immediately prior to the second annual meeting following the date of delivery of such notice, or (ii) written or electronic notice from the director to the Chief Financial Officer terminating such election. No restricted stock received pursuant to this Paragraph B.1.b shall vest in a calendar year other than the calendar year in which the corresponding cash amount would have otherwise been paid.

2.    Annual Equity Compensation
a.    On the date of each annual meeting of the Company’s stockholders, each non-employee director who is continuing as a non-employee director following the date of such annual meeting shall be granted restricted stock or deferred stock units having a value of $275,000. A director shall elect whether such award is restricted stock or deferred stock units by delivering written or electronic notice of such election to the Chief Financial Officer prior to January 1 of the calendar year in which such award will be made (or within 30 days of the director’s commencement of service as a non-employee director if it is not possible for the director to make his or her election prior to January 1 of the calendar year in which such award will be made); provided, however, that if the Chief Financial Officer receives no such election during such period, such grant shall be made in restricted stock.
b.    On the date of each annual meeting of the Company’s stockholders, the board chair (if independent), provided such individual will continue as board chair following the date of the annual meeting, shall be granted an additional annual award having a value equal to $15,000. The chair may elect to receive such award in either restricted stock or deferred stock units by delivering written or electronic notice of such election to the Chief Financial Officer prior to January 1 of the calendar year in which such award will be made (or within 30 days of the director’s commencement of service as a non-employee director if it is not possible for the chair to make his or her election prior to January 1 of the calendar year in which such award will be made); provided, however, that if the Chief Financial Officer receives no such election during such period, such grant shall be made in restricted stock.

c.    Grants of annual equity compensation described in Section 2 or, if applicable, Section 3 of this Policy shall not become vested until the first anniversary of the grant date (or, if earlier, the date of the next annual meeting of the Company’s stockholders (the “Annual Award Vesting Date”)). If a director ceases to serve as a director before the Annual Award Vesting Date due to the director’s death or Disability, or if there is a Change in Control prior to the Annual Award Vesting Date, then the restricted stock or deferred stock units shall become fully vested as of the date of such death, Disability or Change in Control, as applicable. If a director ceases to serve as a director at any time for any reason other than death or Disability before the earlier of the Annual Award Vesting Date or a Change in Control, then the annual equity grant shall become vested pro rata (based on the number of days between the grant date and the date of cessation of services divided by (x) 365 days for awards made at an annual stockholders meeting or (y) the number of days from the date of commencement of services until the next annual
2


stockholders meeting for an award made pursuant to Section 3 of this Policy), and to the extent the restricted stock or deferred stock units are not thereby vested they shall be forfeited as of the date of such cessation of services. These vesting rules will apply whether an award is payable in shares or deferred stock units.

3.    Partial Year Compensation

If a director is elected or appointed to the board other than on the date of an annual meeting of stockholders, such director’s annual cash and equity compensation for the period between the date of such election or appointment and the date of the next following annual meeting of the Company’s stockholders shall be granted in accordance with subsection B of this Policy on the date of such meeting but adjusted pro rata to reflect the date of such director’s election or appointment and the date of such meeting and, provided, further, that the number of restricted stock or deferred stock units to be issued pursuant to this paragraph shall be fully-vested on grant.     

4.    Cash Compensation for Certain Innovation, Technology & Pipeline Committee Meetings

Members of the Innovation, Technology & Pipeline Committee shall receive a cash payment, in addition to that described in Section B.1.a above, of $5,000 per full-day, on-site, special working meeting. It is contemplated that the Innovation, Technology & Pipeline Committee will have up to one such meeting a year and that such meetings would take place at one the Company’s offices or at some other location as determined by the Committee. In lieu of cash for any such meeting, a member of the Innovation, Technology & Pipeline Committee may elect to receive restricted stock having an equivalent dollar value, granted on the date of such meeting. To be effective, notice of such election must be delivered to the Company’s Chief Financial Officer in writing or electronically prior to the date of such meeting. No restricted stock received pursuant to this Paragraph 4 shall vest in a calendar year other than the calendar year in which the corresponding cash amount would have otherwise been paid.
        
C.Additional Terms

1.    All equity and equity-based awards under this Policy (including stock options, restricted stock and deferred stock units) shall be made under and pursuant to the Company’s 2019 Omnibus Long-Term Incentive Plan, as may be amended, modified or replaced (the “Plan”). Capitalized terms used herein and not otherwise defined shall have the meanings given to them (or terms of similar import) in the Plan.

2.    For purposes of this Policy, the aggregate number of shares or units, respectively, that shall be covered by a grant of restricted stock or deferred stock units, respectively, is the quotient of (A) the applicable dollar value set forth in this Policy divided by (B) the average closing stock price of the Company’s common stock for the 30 trading days prior to the date of grant (or, with respect to grants made pursuant to Section B.3, the date of the relevant director’s appointment to the board), rounded down to the nearest whole share or unit, as applicable.

3.    For purposes of this Policy, “Disability” has the meaning set forth in Treasury Regulation Section 1.409A-1(e)(1).

4.    Deferred stock units are bookkeeping entries representing the equivalent of shares of the Company’s common stock. Deferred stock units are paid in shares of the Company’s common stock on the effective date of the director’s termination of service or removal from the board.

5.    All vesting under the equity grants described in this Policy immediately ceases upon cessation of service as a director for any reason.

6.    A director may not sell, transfer or otherwise dispose of any shares of restricted stock awarded under this Policy until they become vested; however, the director shall have the right to receive dividends with respect to such shares and to vote such shares prior to vesting. A director may not sell, transfer or otherwise dispose of any deferred stock units.

7.    The compensation described in this Policy is in addition to reimbursement of all out-of-pocket expenses incurred by directors in attending meetings of the board.

8.    The board may at any time amend, alter, suspend or terminate this Policy. No amendment, alteration, suspension or termination of this Policy shall impair the rights of a non-employee director, unless mutually agreed otherwise between such non-employee director and the board, which agreement must be in writing and signed by such non-employee director and the Company.

9.    Compensation under this Policy is intended to be either exempt from the application of or meet the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”), and shall be construed and interpreted in accordance with such intent. To the extent that compensation under this Policy is
3


subject to Section 409A, such compensation must be paid, settled or deferred, as applicable, in a manner that shall meet the requirements of Section 409A, such that such compensation shall not be subject to the additional tax or interest applicable under Section 409A.


Approved January 24, 2023

4

 EX-31.1 4 exas-20230331xexx311.htm EX-31.1 Document
EXHIBIT 31.1
Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Kevin T. Conroy, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Exact Sciences Corporation (the “registrant”);
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 9, 2023
By:/s/ Kevin T. Conroy
Kevin T. Conroy
President and Chief Executive Officer
(Principal Executive Officer)

 EX-31.2 5 exas-20230331xexx312.htm EX-31.2 Document
EXHIBIT 31.2
Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Jeffrey T. Elliott, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Exact Sciences Corporation (the “registrant”);
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 9, 2023
By:/s/ Jeffrey T. Elliott
Jeffrey T. Elliott
Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)

 EX-32.1 6 exas-20230331xexx321.htm EX-32.1 Document
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 
In connection with the Quarterly Report of Exact Sciences Corporation (the “Company”) on Form 10-Q for the quarter ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Kevin T. Conroy, President and Chief Executive Officer of the Company and Jeffrey T. Elliott, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to our knowledge, that:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. 
Dated: May 9, 2023
/s/ Kevin T. Conroy
Name:Kevin T. Conroy
Title:President and Chief Executive Officer
(Principal Executive Officer)
Dated: May 9, 2023
/s/ Jeffrey T. Elliott
Name:Jeffrey T. Elliott
Title:Executive Vice President and Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)


 EX-101.SCH 7 exas-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - MARKETABLE SECURITIES link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - INVENTORY link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - PROPERTY, PLANT AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - INTANGIBLE ASSETS AND GOODWILL link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - LONG-TERM DEBT link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - CONVERTIBLE NOTES link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - PFIZER PROMOTION AGREEMENT link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - ACQUISITIONS AND DIVESTITURES link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - MARKETABLE SECURITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - INVENTORY (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - CONVERTIBLE NOTES (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - REVENUE - Schedule of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - REVENUE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - MARKETABLE SECURITIES - Schedule of Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - MARKETABLE SECURITIES - Schedule of Available For Sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - MARKETABLE SECURITIES - Schedule of Underlying Maturities of AFS Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - MARKETABLE SECURITIES - Schedule of Gross Unrealized Losses and Fair Values of Investments in an Unrealized Loss Position (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - INVENTORY (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Estimated Useful Lives (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Finite Lived Intangible Assets Net Balances and Weighted Average Useful Lives (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Finite Lived Intangible Assets Net Balances and Weighted Average Useful Lives (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Changes in Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - LONG-TERM DEBT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - CONVERTIBLE NOTES - Schedule of Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - CONVERTIBLE NOTES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - CONVERTIBLE NOTES - Schedule of Transaction Costs (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - CONVERTIBLE NOTES - Summary of Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - CONVERTIBLE NOTES - Schedule of Effective Interest Rates Related to Convertible Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Mayo (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - John Hopkins University (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Translational Genomics Research Institute (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - PFIZER PROMOTION AGREEMENT (Details) link:presentationLink link:calculationLink link:definitionLink 0000067 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000068 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of OCI (Details) link:presentationLink link:calculationLink link:definitionLink 0000069 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Amounts Reclassified from AOCI (Details) link:presentationLink link:calculationLink link:definitionLink 0000070 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000071 - Disclosure - STOCK-BASED COMPENSATION - Fair Value and Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000072 - Disclosure - STOCK-BASED COMPENSATION - Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000073 - Disclosure - STOCK-BASED COMPENSATION - Share-based Payment Arrangement, Performance Shares, Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000074 - Disclosure - COMMITMENTS AND CONTINGENCIES - Supplemental Disclosure of Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000075 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000076 - Disclosure - WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS (Details) link:presentationLink link:calculationLink link:definitionLink 0000077 - Disclosure - SEGMENT INFORMATION (Details) link:presentationLink link:calculationLink link:definitionLink 0000078 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 exas-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 exas-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 exas-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Unrealized Gain (Loss) on Marketable Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] City letter of credit Letter of Credit [Member] Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Released (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net loss Net loss Net Income (Loss) Attributable to Parent Stock plans Stock Based Compensation Plans [Member] The Company maintains the 2010 Omnibus Long-Term Incentive Plan (As Amended and Restated Effective July 27, 2017), the 2010 Employee Stock Purchase Plan, the 2015 Inducement Award Plan, the 2016 Inducement Award Plan and the 2000 Stock Option and Incentive Plan (collectively, the "Stock Plans"). Wisconsin economic development tax credit agreement Wisconsin Economic Development Tax Credit Agreement [Member] Information relating to the agreement with the Wisconsin Economic Development Corporation. Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Income Statement Location [Axis] Income Statement Location [Axis] Amount of debt extinguished Debt instrument, Amount Settled In Extinguishment Debt instrument, Amount Settled In Extinguishment Accumulated Amortization Finite-lived intangible assets, accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Statistical Measurement [Domain] Statistical Measurement [Domain] LICENSE AND COLLABORATION AGREEMENTS Licensing Agreement Disclosure [Text Block] This element represents the entire disclosure related to licensing agreement entered by an entity during the period. Schedule of Subsidiary or Equity Method Investee [Table] Schedule of Subsidiary or Equity Method Investee [Table] Security Exchange Name Security Exchange Name Equity securities Equity Securities, FV-NI, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Minimum market value covenant Debt Instrument, Covenant, Minimum Market Value Debt Instrument, Covenant, Minimum Market Value Revenue from Contract with Customer [Abstract] Additional paid-in capital Additional Paid in Capital, Common Stock Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Weighted-average remaining lease term - operating leases (in years) Operating Lease, Weighted Average Remaining Lease Term DOS Rule Investigation DOS Rule Investigation [Member] DOS Rule Investigation Other long-term assets, net Other Assets, Noncurrent Net current period change in accumulated other comprehensive loss Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent Property, plant and equipment acquired but not paid Noncash or Part Noncash Acquisition, Fixed Assets Acquired Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Investment, Name [Axis] Investment, Name [Axis] Credit earning rate Capital Investment Expenditures, Credit Earning Rate Capital Investment Expenditures, Credit Earning Rate Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity File Number Entity File Number Total intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Goodwill, Purchase Accounting Adjustments Goodwill, Purchase Accounting Adjustments PreventionGenetics acquisition adjustment PreventionGenetics LLC [Member] PreventionGenetics LLC Schedule of amounts reclassified from accumulated other comprehensive income (loss) Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] ACQUISITIONS AND DIVESTITURES Business Combination, Divestiture, And Asset Acquisition [Text Block] Business Combination, Divestiture, And Asset Acquisition Amortization of acquired intangible assets Amortization of Intangible Assets Weighted-average discount rate - operating leases Operating Lease, Weighted Average Discount Rate, Percent Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of inventory Schedule of Inventory, Current [Table Text Block] Buildings Building [Member] Financing receivable, amount elected to collateralize Financing Receivable, Amount Elected to Collateralize Financing Receivable, Amount Elected to Collateralize Business Combination and Asset Acquisition [Abstract] Fair value of equity instruments other than options vested in period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Business Acquisition [Axis] Business Acquisition [Axis] Share-based Payment Arrangement, Performance Shares, Activity Share-based Payment Arrangement, Performance Shares, Activity [Table Text Block] Property, plant and equipment, at cost Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Disposal Group Name [Axis] Disposal Group Name [Axis] Semi-finished and finished goods Inventory, Finished and Semi Finished Goods Amount before valuation and LIFO reserves of completed merchandise/goods and merchandise/goods expected to be completed within one year of operating cycle that are expected to be sold within one year or operating cycle, if longer. Award Type [Domain] Award Type [Domain] Cologuard promotion agreement Manufactured Product, Other [Member] Schedule of convertible note obligations included in the condensed consolidated balance sheets Convertible Debt [Table Text Block] Local Phone Number Local Phone Number Credit Facility [Domain] Credit Facility [Domain] Schedule of fair value of contingent consideration Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] ASSETS Assets [Abstract] Computer equipment and computer software Office Equipment And Computer Software [Member] Information relating to office equipment and computer software. Schedule of available-for-sale securities Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Tgen Tgen [Member] Tgen Fair value, nonrecurring Fair Value, Nonrecurring [Member] Exercisable at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Land Land [Member] Right-of-use assets obtained in exchange for new finance lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Charges for promotion, sales and marketing Marketing Expense Schedule of contractual maturities of available-for-sale investments Investments Classified by Contractual Maturity Date [Table Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Cash equivalents Cash Equivalents [Member] INTANGIBLE ASSETS AND GOODWILL Goodwill and Intangible Assets Disclosure [Text Block] Preferred stock, $0.01 par value Authorized—5,000,000; shares issued and outstanding—no shares at March 31, 2023 and December 31, 2022 Preferred Stock, Value, Issued Proceeds from exercise of common stock options Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Finance lease, liability, noncurrent, statement of financial position, extensible list Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Trade name Trade Names [Member] Accumulated Deficit​ Retained Earnings [Member] Refundable tax credit receivable Refundable Tax Credit Receivable The amount of refundable tax credit receivable as of the end of the reporting period. Debt Instrument [Axis] Debt Instrument [Axis] Long-term liabilities: Liabilities, Noncurrent [Abstract] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of gross unrealized losses and fair values of investments in an unrealized loss position Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block] WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS [Abstract] Wisconsin Economic Development Tax Credit Disclosure [Abstract] Contingent consideration liability, measurement input Business Combination, Contingent Consideration, Liability, Measurement Input Non-marketable securities Security Owned Not Readily Marketable, Fair Value Investments, All Other Investments [Abstract] Accounts receivable, net Increase (Decrease) in Accounts Receivable Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Extinguishment of Debt [Axis] Extinguishment of Debt [Axis] Investment income (loss), net Investment Income, Nonoperating Property, plant and equipment Property, Plant and Equipment [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Finance cash flows from finance leases Finance Lease, Principal Payments Number of operating segments Number of Operating Segments Operating expense Operating Expense [Member] Remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity OmicEra acquisition Thrive Earlier Detection Corporation [Member] Thrive Earlier Detection Corporation Contingent consideration Business Combination, Contingent Consideration, Liability, Current Net loss per share—basic (in usd per share) Earnings Per Share, Basic Convertible Notes Payable2030 Convertible Notes Payable2030 [Member] Convertible Notes Payable2030 Non-cash lease expense Operating Lease, Expense REVENUE Revenue from Contract with Customer [Text Block] Measurement Input, Probability of Success Measurement Input, Probability of Success [Member] Measurement Input, Probability of Success Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Due after one year through five years, Cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five Schedule of disaggregation of revenue Disaggregation of Revenue [Table Text Block] Restricted Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Restricted cash Restricted Cash, Fair Value Disclosure Restricted Cash, Fair Value Disclosure Commercial paper Commercial Paper [Member] Deferred tax liabilities, net Deferred Tax Liabilities, Net Operating cash flows from operating leases Operating Lease, Payments Revenue recognized from changes in transaction prices Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS Wisconsin Economic Development Tax Credit Disclosure [Text Block] The entire disclosure relating to the Wisconsin Economic Development Tax Credit. Amortization of deferred financing costs, convertible note debt discount and issuance costs, and other liabilities Amortization (Deferred Amortization) of Deferred Financing Costs, Debt Discounts (Premiums) and Issuance Costs, Other Liabilities Amortization (Deferred Amortization) of Deferred Financing Costs, Debt Discounts (Premiums) and Issuance Costs, Other Liabilities Venture capital investment fund Venture Capital Investment Fund [Member] Venture Capital Investment Fund Recognized Goodwill Goodwill [Roll Forward] Principal Amount Convertible Notes Payable Gross The amount as of balance sheet date of convertible notes payable including debt issuance costs and debt discounts. Issuance of common stock to fund the Company's 401(k) match Stock Issued During Period, Value, Employee Benefit Plan Plan Name [Axis] Plan Name [Axis] Finance lease, right-of-use asset Finance Lease, Right-of-Use Asset, after Accumulated Amortization Product Revenue Related to Treatment, Payment Two Product Revenue Related to Treatment, Payment Two [Member] Product Revenue Related to Treatment, Payment Two Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Impairment losses Goodwill, Impairment Loss Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entity Small Business Entity Small Business Sales milestone range one Sales Milestone Range One [Member] Represents information related to the first sales milestone range. Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total liabilities and stockholders’ equity Liabilities and Equity Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Commercial Service [Member] Restricted cash — included in prepaid expenses and other current assets as of March 31, 2023, and other long-term assets, net as of March 31, 2022 Restricted Cash Period patent remains in effect Time Period After Last Licensed Patent Expires That License Agreement Remains In Effect Represents the time period after the last licensed patent expires that the license agreement will remain in effect. U.S. government agency securities US Government Agencies Debt Securities [Member] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Cash equivalents Cash Equivalents, at Carrying Value LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Operating expenses Operating Expenses [Abstract] Entity Interactive Data Current Entity Interactive Data Current Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Schedule of interest expense Interest Expense, Debt [Table Text Block] Tabular disclosure of the total debt interest expense. Exercise of common stock options Stock Issued During Period, Value, Stock Options Exercised Minimum Minimum [Member] Shares issuable upon exercise of stock options Stock option Employee And Non Employees Stock Option [Member] An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize individuals, in addition to their regular compensation and benefits. Remeasurement of contingent consideration Change in amount of contingent consideration liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Marketable securities Marketable securities Marketable Securities, Current Effects of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Conversion rate, number of shares to be issued per $1,000 of principal amount (in shares) Debt Instrument, Convertible, Conversion Ratio Balance Sheet Location [Domain] Balance Sheet Location [Domain] 2028 Convertible Notes Convertible Notes Payable2027 Convertible Notes Payable2027 [Member] Represents information pertaining to convertible notes, maturing on 2027. Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Unrecognized tax benefits Unrecognized Tax Benefits Variable consideration Variable Price Contract [Member] The Company estimates the amount of variable consideration using the expected value method, which represents the sum of probability-weighted amounts in a range of possible consideration amounts. When estimating the amount of variable consideration, the Company considers several factors, such as historical collections experience, patient insurance eligibility and payer reimbursement contracts. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Securitized receivables Securitized Receivables [Member] Securitized Receivables Gains in Accumulated Other Comprehensive Income (Loss) Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Total Fair Value, Net Asset (Liability) Entity Address, State or Province Entity Address, State or Province Shares issuable in connection with acquisitions Shares Issued Upon Acquisition [Member] Shares Issued Upon Acquisition Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer Civil damages Loss Contingency, Damages Sought, Value Total reclassifications Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Amortization of tax credits Amortization of Refundable Tax Credits Represents the amortization of the tax credits, representing a reduction of operating expenses. Refundable tax credit received Refundable Tax Credit Received Amount of refundable tax credit received during the reporting period. Current liabilities: Liabilities, Current [Abstract] Refundable tax credits available, contingent Refundable Tax Credits Available Contingent on Capital Investments and Creation of Full-time Positions Represents the refundable tax credits available, that is contingent on the Company expending a specified dollar amount on capital investments and the creation of a specified number of full-time positions. Thrive and Ashion Thrive and Ashion [Member] Thrive and Ashion General and administrative General and Administrative Expense Service or Product Type [Domain] Service or Product Type [Domain] Service or Product Type Cumulative Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Exercisable at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Line of credit Line of Credit [Member] STOCK-BASED COMPENSATION Share-based Payment Arrangement [Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Maximum credits available to earn Capital Investment Expenditures, Maximum Credits Available To Earn Capital Investment Expenditures, Maximum Credits Available To Earn INVENTORY Inventory Disclosure [Text Block] Accumulated depreciation Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Accounting Policies [Abstract] Accounting Policies [Abstract] Collaborative Arrangement Milestone [Axis] Collaborative Arrangement Milestone [Axis] Represents the ranges of sale milestones. Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Derivative Instrument [Axis] Derivative Instrument [Axis] MARKETABLE SECURITIES Cash, Cash Equivalents, and Marketable Securities [Text Block] Additional amount to be recognized at lease commencement for the lease liability Operating Lease, Liability Sales milestone range two Sales Milestone Range Two [Member] Represents information related to the second sales milestone range one. Sales milestone range three Sales Milestone Range Three [Member] Represents information related to the third sales milestone range one. Document Transition Report Document Transition Report Common stock, $0.01 par value Authorized—400,000,000; shares issued and outstanding—179,830,145 and 177,925,631 shares at March 31, 2023 and December 31, 2022 Common Stock, Value, Issued Weighted-average discount rate - finance leases Finance Lease, Weighted Average Discount Rate, Percent Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Total other income (expense) Nonoperating Income (Expense) Contract with Customer, Basis of Pricing [Axis] Contract with Customer, Basis of Pricing [Axis] Weighted Average Remaining Contractual Term Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] Revenue and Other Performance-based Payments Revenue and Other Performance-based Payments [Member] Revenue and Other Performance-based Payments Weighted average period for recognition of cost Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Outstanding at the beginning of the period (in dollars per share) Outstanding at the end of the period (in dollars per share) Outstanding (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value OmicEra acquisition Goodwill, Acquired During Period Shares issuable upon the release of performance share units Performance share units Performance Shares [Member] Commitments and contingencies (Note 14) Commitments and Contingencies Product development and other milestone-based payments Product Development and Other Milestone-based Payments [Member] Product Development and Other Milestone-based Payments Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Emerging Growth Company Entity Emerging Growth Company Proceeds from Debt, Net of Issuance Costs Proceeds from Debt, Net of Issuance Costs Investment owned, at fair value Investment Owned, at Fair Value Shares issuable upon the release of restricted stock awards Restricted Stock [Member] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Cover [Abstract] Goodwill [Line Items] Goodwill [Line Items] OmicEra acquisition OmicEra [Member] OmicEra Total operating expenses Costs and Expenses Schedule of Convertible notes [Line Items] Schedule of Convertible notes [Line Items] Schedule of Convertible notes [Line Items] Revenue from external customers by geographic areas Revenue from External Customers by Geographic Areas [Table Text Block] Finance lease, liability, current, statement of financial position, extensible list Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Product Revenue Related to Treatment, Payment One Product Revenue Related to Treatment, Payment One [Member] Product Revenue Related to Treatment, Payment One Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Interest income (expense), net Interest Income (Expense), Net Cash and money market Cash Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Financial Instrument [Axis] Financial Instrument [Axis] Business acquisition, equity interest issued or issuable (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Estimated Fair Value Debt Securities, Available-for-Sale, Excluding Accrued Interest Accrued liabilities Accrued Liabilities, Current Revenue Revenue recognized Revenue from Contract with Customer, Excluding Assessed Tax Operating Lease, Right-of-Use Asset Modification Operating Lease, Right-of-Use Asset Modification Operating Lease, Right-of-Use Asset Modification Service or Product Type [Axis] Service or Product Type [Axis] Service or Product Type International International Sales [Member] International Sales Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Equity [Abstract] Document Quarterly Report Document Quarterly Report Net Carrying Amount Convertible Notes Payable Accretion (Amortization) of discount (premium) on short-term investments Increase (Decrease) in Amortization of Premium on Short Term Investments The increase (decrease) during the period in the carrying amount of amortization of purchase premium on nonoperating securities. Measurement Input Type [Domain] Measurement Input Type [Domain] Shares issuable upon conversion of convertible notes Convertible Notes Payable [Member] Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months Common Stock Common Stock [Member] Variable Rate [Axis] Variable Rate [Axis] Weighted-average remaining lease term - finance leases (in years) Finance Lease, Weighted Average Remaining Lease Term SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Loss from operations Operating Income (Loss) Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Available-for-sale securities Debt Securities, Available-for-sale [Line Items] Operating lease liabilities, current portion Operating lease liability, current Operating Lease, Liability, Current Due after one year through five years, Fair Value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Losses in Accumulated Other Comprehensive Income (Loss) Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Restricted Shares and RSUs Restricted Stock Awards And Restricted Stock Units R S U [Member] Represents the details relating to the restricted stock awards and restricted stock units (RSUs) as awarded by the entity to their employees as a form of incentive compensation. 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two PFIZER PROMOTION AGREEMENT Collaborative Arrangement Disclosure [Text Block] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Property, Plant and Equipment [Abstract] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Repurchase price, as percentage of principal amount, if company undergoes change of control Debt Instrument Repurchase Price Due to Change in Control as Percentage of Principal Amount Represents the price at which the debt may be repurchased, as a percentage of the principal amount if the entity undergoes a change of control. Variable Rate [Domain] Variable Rate [Domain] Investments in privately held companies Payments to Acquire Other Investments AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Additional Paid-In Capital Additional Paid-in Capital [Member] Cash and cash equivalents Total cash, cash equivalents and restricted cash Cash and Cash Equivalents, at Carrying Value Depreciation Depreciation Reconciliation of cash, cash equivalents and restricted cash: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect [Abstract] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Gain (Loss) on derivative instruments, net, pretax Gain (Loss) on Derivative Instruments, Net, Pretax Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative arrangement sales milestone amount Collaborative Arrangements Sales Milestone Amount Represents the amount of net sales of a licensed product considered as a milestone under the collaborative arrangement. Proceeds from lines of credit Proceeds from Lines of Credit Coupon interest expense Coupon Interest Expense The amount of coupon interest expense. Derivative, notional amount Derivative, Notional Amount Other liabilities Increase (Decrease) in Other Operating Liabilities Other investing activities Payments for (Proceeds from) Other Investing Activities Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Other current liabilities Other Liabilities, Current Derivative, fair value Derivative, Fair Value, Net Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Line of credit facility, interest rate at period end Line of Credit Facility, Interest Rate at Period End Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Total liabilities Liabilities Segment Reporting, Revenue Reconciling Item [Line Items] Segment Reporting, Revenue Reconciling Item [Line Items] Award Type [Axis] Award Type [Axis] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Outstanding at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Vested and expected to vest at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Product Revenue Related to MRD Detection, Payment Two Product Revenue Related to MRD Detection, Payment Two [Member] Product Revenue Related to MRD Detection, Payment Two Measurement Input Type [Axis] Measurement Input Type [Axis] Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Common stock, issued (in shares) Common Stock, Shares, Issued Preferred stock, issued (in shares) Preferred Stock, Shares Issued City Area Code City Area Code Exercisable at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Supplemental disclosure of cash flow information related to our operating leases Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] MAYO LICENSE AGREEMENT LICENSE AGREEMENTS [Abstract] Employee Stock Purchase Plan2010 Employee Stock Purchase Plan2010 [Member] Represents information pertaining to the 2010 employee stock purchase plan. Goodwill and Intangible Assets Disclosure [Abstract] Entity Address, City or Town Entity Address, City or Town Period over which the capital investment expenditures must be incurred and the creation of full-time positions must be completed Period for Capital Investment Expenditures and Creation of Full-time Positions to Earn Refundable Tax Credits The period over which the capital investment expenditures must be incurred and the creation of full-time positions must be completed. Gain (Loss) on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt Estimated Useful Life Property, Plant and Equipment, Useful Life Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Schedule of amounts recognized in accumulated other comprehensive income (loss) (AOCI) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] OmicEra diagnostics acquisition OmicEra Diagnostics Acquisition [Member] OmicEra Diagnostics Acquisition Balance Sheet Location [Axis] Balance Sheet Location [Axis] Other (in shares) Stockholders' Equity, Other Shares Operating lease liabilities, less current portion Operating lease liability, noncurrent Operating Lease, Liability, Noncurrent Measurement Frequency [Domain] Measurement Frequency [Domain] Face amount Debt Instrument, Face Amount Long-term Assets: Assets, Noncurrent [Abstract] Licensing agreements Licensing Agreements [Member] Market price (in dollars per share) Share Price Accumulated deficit Retained Earnings (Accumulated Deficit) Product Revenue Related to MRD Detection, Payment One Product Revenue Related to MRD Detection, Payment One [Member] Product Revenue Related to MRD Detection, Payment One Litigation Case [Domain] Litigation Case [Domain] Restricted stock units Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Purchase of employee stock purchase plan shares (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Entity Filer Category Entity Filer Category Finance lease liability Finance Lease, Liability Income Statement [Abstract] Income Statement [Abstract] Fair value Estimate of Fair Value Measurement [Member] Entity Registrant Name Entity Registrant Name Inventory Disclosure [Abstract] Operating lease liabilities Increase (Decrease) in Operating Lease Liabilities Increase (Decrease) in Operating Lease Liabilities Schedule of Convertible notes [Table] Schedule of Convertible notes [Table] Table information pertaining to convertible notes. Other long-term assets Other Noncurrent Assets [Member] Interest expense amortization term Debt Instrument, Convertible, Remaining Discount Amortization Period Proceeds from stock options exercised Proceeds from Stock Options Exercised In-process research and development Indefinite-lived Intangible Assets (Excluding Goodwill) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Income tax benefit (expense) Tax expense (benefit) Income Tax Expense (Benefit) Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Amendment Flag Amendment Flag Equity Components [Axis] Equity Components [Axis] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Collaboration arrangement, milestones to be paid Collaboration Arrangement, Milestones To Be Paid Collaboration Arrangement, Milestones To Be Paid Cash, Cash Equivalents and Investments Cash, Cash Equivalents and Investments [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Inventory Total inventory Inventory, Net Fair value measurements Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax Unrecognized compensation cost Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Equity Component [Domain] Equity Component [Domain] Number of outstanding performance share units (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Other Stockholders' Equity, Other Sales and marketing Selling and Marketing Expense Committed capital Investment Company, Committed Capital Disposal Group Name [Domain] Disposal Group Name [Domain] Precision Oncology Precision Oncology [Member] Precision Oncology Service fee based on incremental gross profits over specified baselines and royalties Service Fee Based on Incremental Gross Profits Over Specified Baselines and Royalties Represents service fee based on incremental gross profits over specified baselines and royalties. Extinguishment of Debt, Type [Domain] Extinguishment of Debt, Type [Domain] Debt discount amortization Amortization of Debt Discount (Premium) Available-for-sale debt securities Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current Statement Statement [Line Items] Litigation Case [Axis] Litigation Case [Axis] Property, plant and equipment, net Property, plant and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Number of installments License Fees Commitment Number of Installments Represents the number of annual installments in which the license fee commitment is payable under the terms of the license agreement. Estimated Fair Value Debt Securities, Available-for-sale Marketable securities Short-term Investments [Member] Counterparty Name [Domain] Counterparty Name [Domain] Amount Convertible Debt, Fair Value Disclosures Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Four Finite-Lived Intangible Asset, Expected Amortization, after Year Four Finite-lived and indefinite-lived intangible assets, gross Intangible Assets, Gross (Excluding Goodwill) Debt Disclosure [Abstract] Debt Disclosure [Abstract] Weighted average Weighted Average [Member] Finance lease liability, current Finance Lease, Liability, Current Purchases of marketable securities Payments to Acquire Marketable Securities Issuance of common stock to fund the Company's 401(k) match (in shares) Stock Issued During Period, Shares, Employee Benefit Plan Net loss before tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Total fair value of available-for-sale securities in a continuous unrealized loss position Debt Securities, Available-for-sale, Unrealized Loss Position Segment Reporting [Abstract] Compensation expense related to issuance of stock options and restricted stock awards (in shares) Compensation Expense Related to Issuance of Stock Options and Restricted Stock Awards, Shares This element represents number of stock options and restricted stock awards issued as a compensation expense by an entity during the period. Weighted-average remaining useful life of finite-lived intangible asset (in years) Finite-Lived Intangible Asset, Useful Life Compensation expense related to issuance of stock options and restricted stock awards Compensation Expense Related to Issuance of Stock Options and Restricted Stock Awards, Values This element represents equity impact of the value of stock options and restricted stock awards issued as a compensation expense by an entity during the period. Long-term debt Loans Payable, Noncurrent Aggregate Intrinsic Value Share Based Compensation Arrangement by Share Based Payment Award, Options, Intrinsic Value [Abstract] Use of Estimates Use of Estimates, Policy [Policy Text Block] Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Title of 12(b) Security Title of 12(b) Security 2030 Convertible Notes Convertible Notes Payable2025 [Member] Represents information pertaining to convertible notes, maturing on 2025. Total assets Assets Investment, Name [Domain] Investment, Name [Domain] Capital investment expenditures over specified period, requirement to earn the refundable tax credits Capital Investment Expenditures, Requirement for Refundable Tax Credits The amount of expenditures in capital investments the Company is required to make over a specified period to earn the refundable tax credits. Plan Name [Domain] Plan Name [Domain] Common stock, authorized (in shares) Common Stock, Shares Authorized Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Geographical [Domain] Geographical [Domain] Document Type Document Type Full-time positions that must be created over a specified time period to earn the refundable tax credits Number of Full-time Positions Required to be Created to Earn Refundable Tax Credits Represents the number of full-time positions that must be created over a specified time period to earn the refundable tax credits. Product and Service [Domain] Product and Service [Domain] Research and development Research and development expense Research and Development Expense Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss 2027 Convertible Notes Convertible Notes Payable2028 Convertible Notes Payable2028 [Member] Convertible Notes Payable2028 Coupon interest rate Debt Instrument, Interest Rate, Stated Percentage Amended wisconsin economic development tax credit agreement Amended Wisconsin Economic Development Tax Credit Agreement [Member] Amended Wisconsin Economic Development Tax Credit Agreement Derivative Contract [Domain] Derivative Contract [Domain] Contract with Customer, Basis of Pricing [Domain] Contract with Customer, Basis of Pricing [Domain] Beginning balance Ending balance Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability Stock-based compensation Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Convertible notes, net Convertible Notes Payable, Noncurrent Revolving loan agreement Revolving Credit Facility [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Furniture and fixtures Furniture and Fixtures [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Investment income (loss), net Investment Income (Expense), Nonoperating Investment Income (Expense), Nonoperating Corporate bonds Corporate Bond Securities [Member] Comprehensive loss Comprehensive Income (loss), Before Tax Amount before tax, of comprehensive income (loss). Geographical [Axis] Geographical [Axis] Assets under construction Asset under Construction [Member] Revolving loan agreement Revolving Loan Agreement [Member] Revolving Loan Agreement Weighted average common shares outstanding—basic (in shares) Weighted Average Number of Shares Outstanding, Basic Net loss per share—diluted (in usd per share) Earnings Per Share, Diluted Medicare Parts B & C Product [Member] Daily bloomberg short-term bank yield index rate Daily Bloomberg Short-Term Bank Yield Index Rate [Member] Daily Bloomberg Short-Term Bank Yield Index Rate Committed capital callable Investment Company, Committed Capital, Amount Callable Investment Company, Committed Capital, Amount Callable Outside of United States Non-US [Member] Contract termination fee Contract Termination Fee Contract Termination Fee Intangible assets, net Finite-lived and indefinite-lived intangible assets, net Intangible Assets, Net (Excluding Goodwill) Cost of sales (exclusive of amortization of acquired intangible assets) Cost of Revenue Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Leasehold and building improvements Buildings And Leasehold Improvements [Member] Represents information pertaining to buildings and leasehold improvements. Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Summary of Restricted Stock and Restricted Stock Unit Activity Under the Stock Plans Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Schedule of allocation of transaction costs related to convertible debt Schedule of Allocation of Transaction Costs Related to Convertible Debt [Table Text Block] Schedule of Allocation of Transaction Costs Related to Convertible Debt FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Accounts payable Accounts Payable, Current Impairment of long-lived assets Impairment, Long-Lived Asset, Held-for-Use Potential shares issued from convertible instrument (in shares) Debt Conversion, Converted Instrument, Potential Shares Issued Debt Conversion, Converted Instrument, Potential Shares Issued 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three Schedule of fair value measurements along with the level within the fair value hierarchy in which the fair value measurements fall Fair Value, Assets Measured on Recurring Basis [Table Text Block] Net proceeds from issuance Proceeds from Convertible Debt Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Total interest expense (income) on convertible notes Interest Expense (Income), Debt Interest Expense (Income), Debt 2023 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Inventory, net Increase (Decrease) in Inventories Marketable Securities [Table] Marketable Securities [Table] Common stock, outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Financial Instruments [Domain] Financial Instruments [Domain] Fair value of stock issued in acquisition Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Raw materials Inventory, Raw Materials and Supplies, Gross Computer software Computer Software, Intangible Asset [Member] Document Period End Date Document Period End Date Entity Central Index Key Entity Central Index Key Common shares not included in the computation of diluted net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Other comprehensive loss before reclassifications OCI, before Reclassifications, before Tax, Attributable to Parent Other Product and Service, Other [Member] Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Schedule of property, plant and equipment, net Property, Plant and Equipment [Table Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Supplemental disclosure of non-cash investing and financing activities Non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] License agreement fees commitment License Agreement Fees Commitment License Agreement Fees Commitment Customer relationships Customer Relationships [Member] Due in one year or less, Cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One PROPERTY, PLANT AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Other long-term liabilities Other Liabilities, Noncurrent Schedule of estimated future amortization expense, intangible assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Long-term debt Debt Instrument [Line Items] Trading Symbol Trading Symbol Unrealized loss on equity investments Equity Securities, FV-NI, Unrealized Gain (Loss) Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss Other assets Increase (Decrease) in Other Operating Assets Laboratory equipment Equipment [Member] Line of credit facility, current borrowing capacity Line of Credit Facility, Current Borrowing Capacity COVID-19 Testing COVID-19 Testing [Member] COVID-19 Testing Vested and expected to vest at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Loss Contingency Accrual Loss Contingency Accrual Total transaction costs Debt Instrument Convertible Transaction Costs The transaction costs of the liability and equity component of convertible debt which may be settled upon conversion. Outstanding at the beginning of the period (in dollars per share) Outstanding at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Pfizer Inc Pfizer Inc [Member] This member represents information regarding Pfizer Inc. Long-term debt Long-term Debt, Excluding Current Maturities Patents and licenses Patents [Member] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Stock-based compensation expense Share-based Payment Arrangement, Expense Exercisable at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Entity Current Reporting Status Entity Current Reporting Status Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Debt issuance costs amortization Amortization of Debt Issuance Costs Counterparty Name [Axis] Counterparty Name [Axis] Maturities and sales of marketable securities Proceeds from Sale and Maturity of Marketable Securities CONVERTIBLE NOTES. CONVERTIBLE NOTES [Abstract] CONVERTIBLE NOTES Loss on disposal of property, plant and equipment Gain (Loss) on Disposition of Property Plant Equipment Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents United States UNITED STATES Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Land improvements Land Improvements [Member] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Current assets: Assets, Current [Abstract] Other financing activities Proceeds from (Payments for) Other Financing Activities Cost Gross value of intangible asset Finite-Lived Intangible Assets, Gross PFIZER PROMOTION AGREEMENT PFIZER PROMOTION AGREEMENT n/a Schedule of net-book value and estimated remaining life and finite lived intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Changes in Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) [Line Items] Unrealized gain (loss) on available-for-sale investments OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Amounts reclassified from accumulated other comprehensive income Reclassification from AOCI, Current Period, before Tax, Attributable to Parent Cash and cash equivalents, fair value Cash and Cash Equivalents, Fair Value Disclosure Disposal Group Classification [Domain] Disposal Group Classification [Domain] Entity Address, Postal Zip Code Entity Address, Postal Zip Code CONVERTIBLE NOTES Convertible Notes [Text Block] The entire disclosure of convertible notes. Exercise of common stock options (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Weighted average common shares outstanding—diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Fair Value, Recurring Fair Value, Recurring [Member] Estimated civil damages Estimated Litigation Liability Subsidiary or Equity Method Investee [Line Items] Subsidiary or Equity Method Investee [Line Items] INCOME TAXES Income Tax Disclosure [Text Block] Total cash, cash equivalents and marketable securities Cash, Cash Equivalents, and Short-term Investments Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Summary of Stock Option Activity Under the Stock Plans Share-based Payment Arrangement, Option, Activity [Table Text Block] Finance lease, right-of-use asset, statement of financial position, extensible list Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Variable rate Debt Instrument, Basis Spread on Variable Rate Reconciliation of Revenue from Segments to Consolidated [Table] Reconciliation of Revenue from Segments to Consolidated [Table] STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] Measurement Basis [Axis] Measurement Basis [Axis] Schedule of potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Other income (expense) Nonoperating Income (Expense) [Abstract] Collaborative Arrangement Milestone [Domain] Collaborative Arrangement Milestone [Domain] Information by range of sale milestones pertaining to the collaborative arrangement. Credit Facility [Axis] Credit Facility [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Other comprehensive loss, net of tax: Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract] Entity Address, Address Line One Entity Address, Address Line One Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Portion at fair value measurement Portion at Fair Value Measurement [Member] Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Marketable securities Marketable Securities [Line Items] Refundable tax credits earned Refundable Tax Credit Earned to Date The amount of refundable tax credits earned, relating to capital investments and job creation, as of the end of the reporting period. Measurement Input, Present-value Factor Measurement Input, Present-value Factor [Member] Measurement Input, Present-value Factor Released (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Effective interest rate (as a percent) Debt Instrument, Interest Rate During Period Basis of Presentation and Principles of Consolidation Consolidation, Policy [Policy Text Block] Entity Shell Company Entity Shell Company Screening Screening [Member] Screening Total current liabilities Liabilities, Current Employee stock Employee Stock [Member] Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Operating Activities, Lessee [Abstract] Foreign exchange forward Foreign Exchange Forward [Member] Operating cash flows from finance leases Finance Lease, Interest Payment on Liability Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Cash and money market Money Market Funds [Member] Goodwill, foreign currency translation gain (loss) Goodwill, Foreign Currency Translation Gain (Loss) Reclassification out of accumulated other comprehensive income Reclassification out of Accumulated Other Comprehensive Income [Member] Vested and expected to vest at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Maximum outstanding cash advances threshold Debt Instrument, Covenant, Maximum Outstanding Cash Advances Threshold Debt Instrument, Covenant, Maximum Outstanding Cash Advances Threshold Current Fiscal Year End Date Current Fiscal Year End Date Unamortized Debt Discount and Issuance Costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Statement [Table] Statement [Table] Gain on settlements of convertible notes, net Gain on settlements of convertible notes, net Gain on Settlement of Convertible Notes Gain on Settlement of Convertible Notes Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Asset backed securities Asset-backed Securities [Member] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Principal amount, convertible note Principal Amount, Convertible Note Principal Amount, Convertible Note Mayo M A Y O Foundation [Member] Represents the pertinent information about MAYO Foundation for Medical Education and Research (MAYO). Finance lease liability, noncurrent Finance Lease, Liability, Noncurrent Intangibles, net Intangibles, net Finite-Lived Intangible Assets, Net Goodwill Beginning balance Ending balance Goodwill Assets under construction Construction in Progress, Gross Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Schedule of effective interest rates related to convertible debt Schedule of effective interest rates related to convertible debt [Table Text Block] Schedule of effective interest rates related to convertible debt Schedule of carrying amount of goodwill Schedule of Goodwill [Table Text Block] Acquired developed technology (1) Developed Technology Rights [Member] Due in one year or less, Fair Value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer, accumulated loss Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Agreements Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] LONG-TERM DEBT Long-term Debt [Text Block] Deferred tax expense (benefit) Deferred Income Tax Expense (Benefit) Adjustments to reconcile net loss to net cash used in operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Vested and expected to vest at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term EX-101.PRE 11 exas-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover Page - shares
 3 Months Ended
Mar. 31, 2023
May 08, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2023  
Document Transition Report false  
Entity File Number 001-35092  
Entity Registrant Name EXACT SCIENCES CORPORATION  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 02-0478229  
Entity Address, Address Line One 5505 Endeavor Lane  
Entity Address, City or Town Madison  
Entity Address, State or Province WI  
Entity Address, Postal Zip Code 53719  
City Area Code 608  
Local Phone Number 535-8815  
Title of 12(b) Security Common Stock, $0.01 par value per share  
Trading Symbol EXAS  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   180,388,167
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0001124140  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 421,365 $ 242,493
Marketable securities 277,282 389,564
Accounts receivable, net 183,371 158,043
Inventory 124,092 118,259
Prepaid expenses and other current assets 85,274 73,898
Total current assets 1,091,384 982,257
Long-term Assets:    
Property, plant and equipment, net 684,574 684,756
Operating lease right-of-use assets 156,782 167,003
Goodwill 2,346,235 2,346,040
Intangible assets, net 1,933,481 1,956,240
Other long-term assets, net 91,872 90,577
Total assets 6,304,328 6,226,873
Current liabilities:    
Accounts payable 86,713 74,916
Accrued liabilities 241,844 299,216
Operating lease liabilities, current portion 30,014 28,366
Other current liabilities 8,783 10,249
Total current liabilities 367,354 412,747
Long-term liabilities:    
Convertible notes, net 2,310,196 2,186,106
Long-term debt 50,000 50,000
Other long-term liabilities 344,380 352,459
Operating lease liabilities, less current portion 174,690 182,399
Total liabilities 3,246,620 3,183,711
Commitments and contingencies (Note 14)
Stockholders’ equity:    
Preferred stock, $0.01 par value Authorized—5,000,000; shares issued and outstanding—no shares at March 31, 2023 and December 31, 2022 0 0
Common stock, $0.01 par value Authorized—400,000,000; shares issued and outstanding—179,830,145 and 177,925,631 shares at March 31, 2023 and December 31, 2022 1,799 1,780
Additional paid-in capital 6,396,805 6,311,644
Accumulated other comprehensive loss (1,719) (5,236)
Accumulated deficit (3,339,177) (3,265,026)
Total stockholders’ equity 3,057,708 3,043,162
Total liabilities and stockholders’ equity $ 6,304,328 $ 6,226,873
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 5,000,000 5,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized (in shares) 400,000,000 400,000,000
Common stock, issued (in shares) 179,830,145 177,925,631
Common stock, outstanding (in shares) 179,830,145 177,925,631
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Revenue $ 602,450 $ 486,571
Operating expenses    
Cost of sales (exclusive of amortization of acquired intangible assets) 156,866 134,705
Research and development 95,419 102,248
Sales and marketing 186,964 232,181
General and administrative 217,295 169,770
Amortization of acquired intangible assets 22,928 24,654
Impairment of long-lived assets 69 0
Total operating expenses 679,541 663,558
Loss from operations (77,091) (176,987)
Other income (expense)    
Investment income (loss), net 490 (1,487)
Interest income (expense), net 4,107 (4,478)
Total other income (expense) 4,597 (5,965)
Net loss before tax (72,494) (182,952)
Income tax benefit (expense) (1,657) 2,015
Net loss $ (74,151) $ (180,937)
Net loss per share—basic (in usd per share) $ (0.42) $ (1.04)
Net loss per share—diluted (in usd per share) $ (0.42) $ (1.04)
Weighted average common shares outstanding—basic (in shares) 178,574 174,417
Weighted average common shares outstanding—diluted (in shares) 178,574 174,417
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Statement of Comprehensive Income [Abstract]    
Net loss $ (74,151) $ (180,937)
Other comprehensive loss, net of tax:    
Unrealized gain (loss) on available-for-sale investments 2,967 (4,967)
Foreign currency translation adjustment 550 (237)
Comprehensive loss $ (70,634) $ (186,141)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit​
Beginning balance (in shares) at Dec. 31, 2021   173,674,067      
Beginning balance at Dec. 31, 2021 $ 3,387,636 $ 1,738 $ 6,028,861 $ (1,443) $ (2,641,520)
Increase (Decrease) in Stockholders' Equity          
Exercise of common stock options (in shares)   485,537      
Exercise of common stock options 4,282 $ 5 4,277    
Compensation expense related to issuance of stock options and restricted stock awards (in shares)   1,391,797      
Compensation expense related to issuance of stock options and restricted stock awards 52,441 $ 14 52,427    
Other (7)   (7)    
Other (in shares)   7      
Net loss (180,937)       (180,937)
Other comprehensive income (loss) (5,204)     (5,204)  
Ending balance (in shares) at Mar. 31, 2022   175,551,408      
Ending balance at Mar. 31, 2022 $ 3,258,211 $ 1,757 6,085,558 (6,647) (2,822,457)
Beginning balance (in shares) at Dec. 31, 2022 177,925,631 177,925,631      
Beginning balance at Dec. 31, 2022 $ 3,043,162 $ 1,780 6,311,644 (5,236) (3,265,026)
Increase (Decrease) in Stockholders' Equity          
Exercise of common stock options (in shares)   88,228      
Exercise of common stock options 964 $ 1 963    
Issuance of common stock to fund the Company's 401(k) match (in shares)   517,215      
Compensation expense related to issuance of stock options and restricted stock awards (in shares)   1,299,071      
Compensation expense related to issuance of stock options and restricted stock awards 49,139 $ 13 49,126    
Issuance of common stock to fund the Company's 401(k) match 35,077 $ 5 35,072    
Net loss (74,151)       (74,151)
Other comprehensive income (loss) $ 3,517     3,517  
Ending balance (in shares) at Mar. 31, 2023 179,830,145 179,830,145      
Ending balance at Mar. 31, 2023 $ 3,057,708 $ 1,799 $ 6,396,805 $ (1,719) $ (3,339,177)
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Statement of Financial Position [Abstract]      
Common stock, par value (in dollars per share) $ 0.01 $ 0.01 $ 0.01
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows
$ in Thousands
 3 Months Ended
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Cash flows from operating activities:    
Net loss $ (74,151) $ (180,937)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 26,815 22,993
Loss on disposal of property, plant and equipment 284 321
Unrealized loss on equity investments 3,009 1,350
Deferred tax expense (benefit) 1,261 (1,912)
Stock-based compensation 49,139 52,441
Gain on settlements of convertible notes, net 10,324 0
Amortization of deferred financing costs, convertible note debt discount and issuance costs, and other liabilities 1,783 1,700
Accretion (Amortization) of discount (premium) on short-term investments (54) 956
Amortization of acquired intangible assets 22,928 24,654
Impairment of long-lived assets 69 0
Remeasurement of contingent consideration (8,937) (26,680)
Non-cash lease expense 6,806 7,363
Changes in assets and liabilities:    
Accounts receivable, net (25,434) 11,020
Inventory, net (5,827) (7,964)
Operating lease liabilities (5,982) (5,177)
Accounts payable and accrued liabilities (4,817) (66,048)
Other assets 13,622 6,619
Other liabilities (1,161) (1,215)
Net cash used in operating activities (38,215) (173,754)
Cash flows from investing activities:    
Purchases of marketable securities (8,589) (70,267)
Maturities and sales of marketable securities 121,332 150,630
Purchases of property, plant and equipment (29,360) (33,623)
Investments in privately held companies (442) (1,172)
Other investing activities 0 (7)
Net cash provided by investing activities 82,941 45,561
Cash flows from financing activities:    
Proceeds from exercise of common stock options 964 4,282
Net proceeds from issuance 137,976 0
Other financing activities (5,344) (1,547)
Net cash provided by financing activities 133,596 2,735
Effects of exchange rate changes on cash and cash equivalents 550 (237)
Net increase (decrease) in cash, cash equivalents and restricted cash 178,872 (125,695)
Cash, cash equivalents and restricted cash, beginning of period 242,790 315,768
Cash, cash equivalents and restricted cash, end of period 421,662 190,073
Supplemental disclosure of non-cash investing and financing activities    
Property, plant and equipment acquired but not paid 10,548 31,491
Supplemental disclosure of cash flow information:    
Interest paid 6,442 5,133
Reconciliation of cash, cash equivalents and restricted cash:    
Cash and cash equivalents 421,365 189,776
Restricted cash — included in prepaid expenses and other current assets as of March 31, 2023, and other long-term assets, net as of March 31, 2022 297 297
Total cash, cash equivalents and restricted cash $ 421,662 $ 190,073
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Business
Exact Sciences Corporation (together with its subsidiaries, “Exact,” or the “Company”) was incorporated in February 1995. Exact is a leading global cancer diagnostics company. It has developed some of the most impactful tests in cancer screening and diagnostics, including Cologuard® and Oncotype DX®. Exact is currently working on the development of additional tests, with the goal of bringing new, innovative cancer tests to patients throughout the world.
Basis of Presentation and Principles of Consolidation
The accompanying condensed consolidated financial statements, which include the accounts of the Company and those of its wholly owned subsidiaries and variable interest entities, are unaudited and have been prepared on a basis substantially consistent with the Company’s audited financial statements and notes as of and for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K (the “2022 Form 10-K”). All intercompany transactions and balances have been eliminated upon consolidation. These condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted (“GAAP”) in the United States of America (“U.S.”) and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting only of adjustments of a normal and recurring nature) considered necessary for a fair statement of its financial position, operating results and cash flows for the periods presented. The condensed consolidated balance sheet at December 31, 2022 has been derived from audited financial statements, but does not contain all of the footnote disclosures from the 2022 Form 10-K. The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year. The statements should be read in conjunction with the audited financial statements and related notes included in the 2022 Form 10-K.
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that affect the Company’s financial statements materially and involve difficult, subjective or complex judgments by management, and actual results could differ from those estimates. These estimates include revenue recognition, valuation of intangible assets and goodwill, and accounting for income taxes among others. The Company’s critical accounting policies and estimates are explained further in the notes to the condensed consolidated financial statements in this Quarterly Report on Form 10-Q and the 2022 Form 10-K.
The spread of the coronavirus (“COVID-19”) and the macroeconomic conditions including inflation and fluctuations in foreign currency exchange rates has affected many segments of the global economy, including the cancer screening and diagnostics industry. The Company expects these matters to have an impact on operations, however, the ultimate impact presents uncertainty and depends on factors beyond the Company’s knowledge or control, including the duration and severity, as well as third-party actions taken. The Company continues to use the best information available to inform its accounting estimates in light of these uncertainties.
Significant Accounting Policies
During the three months ended March 31, 2023, there were no changes to the Company’s significant accounting policies as described in the Company’s 2022 Form 10-K.
Reclassifications
Certain prior year amounts have been reclassified to conform to the current year presentation in the condensed consolidated financial statements and accompanying notes to the condensed consolidated financial statements.
Recent Accounting Pronouncements
The Company did not adopt any accounting standards updates (“ASU”) released by the Financial Accounting Standards Board (“FASB”) in the first quarter of 2023. In addition, there are no ASUs not yet adopted that are expected to impact the Company.
Net Loss Per Share
Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share is the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive as a result of the Company’s losses.
The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period:
March 31,
(In thousands)20232022
Shares issuable upon conversion of convertible notes23,231 20,309 
Shares issuable upon the release of restricted stock awards6,877 6,991 
Shares issuable upon the release of performance share units1,671 963 
Shares issuable upon exercise of stock options1,416 1,790 
Shares issuable in connection with acquisitions— 45 
33,195 30,098 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.1
REVENUE
 3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard, Oncotype®, and COVID-19 tests. The services are completed upon release of a patient’s test result to the ordering healthcare provider.
The following table presents the Company’s revenues disaggregated by revenue source:
Three Months Ended March 31,
(In thousands)20232022
Screening
Medicare Parts B & C$171,730 $113,755 
Commercial233,033 161,680 
Other38,432 31,087 
Total Screening443,195 306,522 
Precision Oncology
Medicare Parts B & C$47,381 $52,565 
Commercial44,932 46,062 
International37,268 29,560 
Other25,851 24,433 
Total Precision Oncology155,432 152,620 
COVID-19 Testing$3,823 $27,429 
Total$602,450 $486,571 
Screening revenue primarily includes laboratory service revenue from Cologuard and PreventionGenetics LLC (“PreventionGenetics”) tests while Precision Oncology revenue includes laboratory service revenue from global Oncotype products and therapy selection products.
At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. The Company recognized revenue from a change in transaction price of $11.7 million and $4.2 million for the three months ended March 31, 2023 and 2022, respectively.
The Company’s deferred revenue, which is reported in other current liabilities in the Company’s condensed consolidated balance sheets, was not material as of March 31, 2023 and December 31, 2022.
Revenue recognized for the three months ended March 31, 2023 and 2022, respectively, which was included in the deferred revenue balance at the beginning of the period, was not material.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.1
MARKETABLE SECURITIES
 3 Months Ended
Mar. 31, 2023
Cash and Cash Equivalents [Abstract]  
MARKETABLE SECURITIES MARKETABLE SECURITIES
The following table sets forth the Company’s cash, cash equivalents, and marketable securities at March 31, 2023 and December 31, 2022:
(In thousands)March 31, 2023December 31, 2022
Cash and cash equivalents
Cash and money market$351,549 $178,168 
Cash equivalents69,816 64,325 
Total cash and cash equivalents421,365 242,493 
Marketable securities
Available-for-sale debt securities$274,694 $384,415 
Equity securities2,588 5,149 
Total marketable securities277,282 389,564 
Total cash, cash equivalents and marketable securities$698,647 $632,057 
Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at March 31, 2023, consisted of the following:
(In thousands)Amortized CostGains in Accumulated Other Comprehensive Income (Loss) (1)Losses in Accumulated Other Comprehensive Income (Loss) (1)Estimated Fair Value
Cash equivalents
Commercial paper$68,081 $— $— $68,081 
U.S. government agency securities1,735 — — 1,735 
Total cash equivalents69,816 — — 69,816 
Marketable securities
U.S. government agency securities$147,979 $16 $(909)$147,086 
Corporate bonds97,378 18 (948)96,448 
Asset backed securities31,659 106 (605)31,160 
Total marketable securities277,016 140 (2,462)274,694 
Total available-for-sale securities$346,832 $140 $(2,462)$344,510 
______________
(1)There was no tax impact from the gains and losses in accumulated other comprehensive income (loss) (“AOCI”).
Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at December 31, 2022, consisted of the following:
(In thousands)Amortized CostGains in Accumulated Other Comprehensive Income (Loss) (1) Losses in Accumulated Other Comprehensive Income (Loss) (1)Estimated Fair Value
Cash equivalents
Commercial paper$63,021 $— $— $63,021 
U.S. government agency securities1,304 — — 1,304 
Total cash equivalents64,325 — — 64,325 
Marketable securities
U.S. government agency securities$228,012 $— $(2,789)$225,223 
Corporate bonds116,318 20 (1,667)114,671 
Asset backed securities45,374 2 (855)44,521 
Total marketable securities389,704 22 (5,311)384,415 
Total available-for-sale securities$454,029 $22 $(5,311)$448,740 
______________
(1)There was no tax impact from the gains and losses in AOCI.
The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at March 31, 2023:
Due one year or lessDue after one year through five years
(In thousands)CostFair ValueCostFair Value
Cash equivalents
Commercial paper$68,081 $68,081 $— $— 
U.S. government agency securities1,735 1,735 — — 
Total cash equivalents69,816 69,816 — — 
Marketable securities
U.S. government agency securities$138,322 $137,423 $9,657 $9,663 
Corporate bonds82,071 81,169 15,307 15,279 
Asset backed securities1,191 1,189 30,468 29,971 
Total marketable securities221,584 219,781 55,432 54,913 
Total available-for-sale securities$291,400 $289,597 $55,432 $54,913 
The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of March 31, 2023, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:
Less than one yearOne year or greaterTotal
(In thousands)Fair ValueGross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
Marketable securities
U.S. government agency securities$35,897 $(161)$103,474 $(748)$139,371 $(909)
Corporate bonds16,430 (61)71,885 (887)88,315 (948)
Asset backed securities10,767 (100)18,544 (505)29,311 (605)
Total available-for-sale securities$63,094 $(322)$193,903 $(2,140)$256,997 $(2,462)
The Company evaluates investments that are in an unrealized loss position for impairment as a result of credit loss. It was determined that no credit losses exist as of March 31, 2023 and December 31, 2022, because the change in market value for those securities in an unrealized loss position has resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers. The gains and losses recorded on available-for-sale debt securities and equity securities are included in investment income, net in the Company’s condensed consolidated statements of operations. The gains and losses recorded were not material for the three months ended March 31, 2023 and 2022.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.1
INVENTORY
 3 Months Ended
Mar. 31, 2023
Inventory Disclosure [Abstract]  
INVENTORY INVENTORY
Inventory consisted of the following:
(In thousands)March 31, 2023December 31, 2022
Raw materials$63,433 $61,207 
Semi-finished and finished goods60,659 57,052 
Total inventory$124,092 $118,259 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY, PLANT AND EQUIPMENT
 3 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY, PLANT AND EQUIPMENT PROPERTY, PLANT AND EQUIPMENT
The carrying value and estimated useful lives of property, plant and equipment are as follows:
(In thousands)Estimated Useful LifeMarch 31, 2023December 31, 2022
Property, plant and equipment
Landn/a$4,716 $4,716 
Leasehold and building improvements(1)200,314 200,588 
Land improvements15 years6,613 6,417 
Buildings
30 - 40 years
290,121 288,941 
Computer equipment and computer software3 years148,798 142,896 
Laboratory equipment
3 - 10 years
253,926 246,344 
Furniture and fixtures
3 - 10 years
34,601 34,047 
Assets under constructionn/a79,648 68,398 
Property, plant and equipment, at cost1,018,737 992,347 
Accumulated depreciation(334,163)(307,591)
Property, plant and equipment, net$684,574 $684,756 
______________
(1)Lesser of remaining lease term, building life, or estimated useful life.
Depreciation expense for the three months ended March 31, 2023 and 2022 was $26.8 million and $23.0 million, respectively.
At March 31, 2023, the Company had $79.6 million of assets under construction, which consisted of $51.9 million in laboratory equipment, $12.4 million in leasehold and building improvements, $10.1 million in capitalized costs related to software projects, and $5.2 million related to buildings. Depreciation will begin on these assets once they are placed into service upon completion.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.1
INTANGIBLE ASSETS AND GOODWILL
 3 Months Ended
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS AND GOODWILL INTANGIBLE ASSETS AND GOODWILL
Intangible Assets
The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of March 31, 2023:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated Amortization
Net Balance at March 31, 2023
Finite-lived intangible assets
Trade name12.3$104,000 $(22,465)$81,535 
Customer relationships7.84,000 (556)3,444 
Patents and licenses4.111,542 (8,514)3,028 
Acquired developed technology (1)7.5861,644 (266,170)595,474 
Total finite-lived intangible assets981,186 (297,705)683,481 
In-process research and developmentn/a1,250,000 — 1,250,000 
Total intangible assets$2,231,186 $(297,705)$1,933,481 

The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2022:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated Amortization
Net balance at December 31, 2022
Finite-lived intangible assets
Trade name12.5$104,000 $(20,653)$83,347 
Customer relationships8.04,000 (444)3,556 
Patents and licenses4.211,542 (8,152)3,390 
Acquired developed technology (1)7.8861,474 (245,527)615,947 
Total finite-lived intangible assets981,016 (274,776)706,240 
In-process research and developmentn/a1,250,000 — 1,250,000 
Total intangible assets$2,231,016 $(274,776)$1,956,240 
______________
(1)The gross carrying amount includes an immaterial foreign currency translation adjustment related to the intangible asset acquired as a result of the acquisition of OmicEra Diagnostics GmbH (“OmicEra”), whose functional currency is also its local currency. Intangible asset balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.
As of March 31, 2023, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:
(In thousands)
2023 (remaining nine months)$68,786 
202491,378 
202590,331 
202689,271 
202789,271 
Thereafter254,444 
$683,481 
The Company’s acquired intangible assets are being amortized on a straight-line basis over their estimated useful lives.
Goodwill
The change in the carrying amount of goodwill for the periods ended March 31, 2023 and December 31, 2022 is as follows:
(In thousands)
Balance, January 1, 2022
$2,335,172 
OmicEra acquisition10,809 
PreventionGenetics acquisition adjustment(58)
Effects of changes in foreign currency exchange rates (1)117 
Balance, December 31, 2022
2,346,040 
Effects of changes in foreign currency exchange rates (1)195 
Balance March 31, 2023
$2,346,235 
______________
(1)Represents the impact of foreign currency translation related to the goodwill acquired as a result of the acquisition of OmicEra. Goodwill balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.
There were no impairment losses for the three months ended March 31, 2023 and 2022.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.1
FAIR VALUE MEASUREMENTS
 3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
The three levels of the fair value hierarchy established are as follows:
Level 1    Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2    Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
Level 3    Unobservable inputs that reflect the Company’s assumptions about the assumptions that market participants would use in pricing the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available.
The following table presents the Company’s fair value measurements as of March 31, 2023 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands)Fair Value at March 31, 2023Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Cash, cash equivalents, and restricted cash
Cash and money market$351,549 $351,549 $— $— 
Commercial paper68,081 — 68,081 — 
U.S. government agency securities1,735 — 1,735 — 
Restricted cash297 297 — — 
Marketable securities
U.S. government agency securities$147,086 $— $147,086 $— 
Corporate bonds96,448 — 96,448 — 
Asset backed securities31,160 — 31,160 — 
Equity securities2,588 2,588 — — 
Non-marketable securities$10,190 $— $— $10,190 
Liabilities
Contingent consideration$(297,990)$— $— $(297,990)
Total$411,144 $354,434 $344,510 $(287,800)
The following table presents the Company’s fair value measurements as of December 31, 2022 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands)Fair Value at December 31, 2022Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Cash and cash equivalents
Cash and money market$178,168 $178,168 $— $— 
Commercial paper63,021 — 63,021 — 
U.S. government agency securities1,304 — 1,304 — 
Restricted cash297 297 — — 
Marketable securities
U.S. government agency securities$225,223 $— $225,223 $— 
Corporate bonds114,671 — 114,671 — 
Asset backed securities44,521 — 44,521 — 
Equity securities5,149 5,149 — — 
Non-marketable securities$10,065 $— $— $10,065 
Liabilities
Contingent consideration$(306,927)$— $— $(306,927)
Total$335,492 $183,614 $448,740 $(296,862)
There have been no changes in valuation techniques or transfers between fair value measurement levels during the three months ended March 31, 2023. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities are valued using a third-party pricing agency where the valuation is based on observable inputs including pricing for similar assets and other observable market factors.
Contingent Consideration Liabilities
The fair value of the contingent consideration liabilities as of March 31, 2023 and December 31, 2022 was $298.0 million and $306.9 million, respectively, which was recorded in other long-term liabilities in the condensed consolidated balance sheets.
The following table provides a reconciliation of the beginning and ending balances of contingent consideration:
(In thousands)Contingent Consideration
Beginning balance, January 1, 2023$306,927 
Changes in fair value (1)(8,937)
Ending balance, March 31, 2023
$297,990 
______________
(1)The change in fair value of the contingent consideration liability for the three months ended March 31, 2022 was a reduction of $26.7 million.
This fair value measurement of contingent consideration is categorized as a Level 3 liability, as the measurement amount is based primarily on significant inputs not observable in the market.
The fair value of the contingent consideration liabilities recorded from the Company’s acquisitions of Thrive Earlier Detection Corporation (“Thrive”), Ashion Analytics, LLC (“Ashion”), and OmicEra related to regulatory and product development milestones was $297.9 million and $306.8 million as of March 31, 2023 and December 31, 2022, respectively. The Company evaluates the fair value of the expected contingent consideration and the corresponding liabilities related to the regulatory and product development milestones using the probability-weighted scenario based discounted cash flow model, which is consistent with the initial measurement of the expected contingent consideration liabilities. Probabilities of success are applied to each potential scenario and the resulting values are discounted using a present-value factor. The passage of time in addition to changes in projected milestone achievement timing, present-value factor, the degree of achievement, if applicable, and probabilities of success may result in adjustments to the fair value measurement. The fair value of the contingent consideration liability recorded related to regulatory and product development milestones was determined using a weighted average probability of success of 91% as of March 31, 2023 and December 31, 2022, and a weighted average present-value factor of 6.1% and 6.2% as of March 31, 2023 and December 31, 2022, respectively. The projected fiscal year of payment range is from 2024 to 2029. Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.
The fair value of the contingent consideration liability related to certain revenue milestones associated with the Biomatrica acquisition was not material as of March 31, 2023 and December 31, 2022. The revenue milestone associated with the Ashion acquisition is not expected to be achieved and therefore no liability has been recorded for this milestone.
Non-Marketable Equity Investments
As of March 31, 2023 and December 31, 2022, the aggregate carrying amounts of the Company’s non-marketable equity securities without readily determinable fair values were $39.4 million and $39.8 million, respectively, which are classified as a component of other long-term assets, net in the Company’s condensed consolidated balance sheets. Since initial recognition of these investments, there have been no upward or downward adjustments made on these investments since initial recognition.
The Company has committed capital to venture capital investment funds (the “Funds”) of $17.5 million, of which $13.3 million remained callable through 2033 as of March 31, 2023. The aggregate carrying amount of the Funds, which are classified as a component of other long-term assets, net in the Company’s condensed consolidated balance sheets, were $4.2 million and $3.9 million as of March 31, 2023 and December 31, 2022, respectively.
Derivative Financial Instruments
The Company enters into foreign currency forward contracts on the last day of each month to mitigate the impact of adverse movements in foreign exchange rates related to the remeasurement of monetary assets and liabilities and hedge the Company’s foreign currency exchange rate exposure. As of March 31, 2023 and December 31, 2022, the Company had open foreign currency forward contracts with notional amounts of $29.2 million and $22.3 million, respectively. The Company's foreign exchange derivative instruments are classified as Level 2 within the fair value hierarchy as they are valued using inputs that are observable in the market or can be derived principally from or corroborated by observable market data. The fair value of the open foreign currency forward contracts was zero at March 31, 2023 and December 31, 2022, and there were no gains or losses recorded to adjust the fair value of the open foreign currency contract held as of March 31, 2023. The contracts are closed subsequent to each month-end, and the gains and losses recorded from the contracts were not material for the three months ended March 31, 2023 and 2022.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.1
LONG-TERM DEBT
 3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
LONG-TERM DEBT LONG-TERM DEBT
Accounts Receivable Securitization Facility
On June 29, 2022, the Company, through a wholly-owned special purpose entity, Exact Receivables LLC (“Exact Receivables”) entered into an accounts receivable securitization program (the “Securitization Facility”) with PNC Bank, National Association (“PNC”), with a scheduled maturity date of June 29, 2024. The Securitization Facility provides Exact Receivables with a revolving line-of-credit of up to $150.0 million of borrowing capacity, subject to certain borrowing base requirements, by collateralizing a security interest in the domestic customer accounts receivable of certain wholly-owned subsidiaries of the Company. The amount available under the Securitization Facility fluctuates over time based on the total amount of eligible customer accounts receivable generated by the Company during the normal course of operations. The Securitization Facility requires the Company to maintain minimum borrowings under the facility of $50.0 million. The debt issuance costs incurred related to the Securitization Facility were not material and are being amortized over the life of the Securitization Facility through interest expense within the condensed consolidated statements of operations.
In connection with the Securitization Facility, the Company also entered into two Receivables Purchase Agreements (“Receivable Purchase Agreements”) on June 29, 2022. The Receivable Purchase Agreements are among the Company and certain wholly-owned subsidiaries of the Company, and between the Company and Exact Receivables. Under the agreements, the wholly-owned subsidiaries sell all of their right, title and interest in their accounts receivables to Exact Receivables. The receivables are used to collateralize borrowings made under the Securitization Facility. The Company retains the responsibility of servicing the accounts receivable balances pledged as collateral under the Securitization Facility and provides a performance guaranty.
As of March 31, 2023, the eligible borrowing base under the Securitization Facility was $111.1 million of which the Company elected to collateralize $50.0 million. As of March 31, 2023 and December 31, 2022, the Company had an outstanding balance of $50.0 million, which is recorded to long-term debt on the Company’s condensed consolidated balance sheets. The outstanding balance accrues interest at a rate equal to a daily secured overnight financing rate (“SOFR”) rate plus a SOFR adjustment and an applicable margin. The interest rate was 6.35% at March 31, 2023.
Revolving Loan Agreement
During November 2021, the Company entered into a revolving loan agreement (the “Revolving Loan Agreement”) with PNC. The Revolving Loan Agreement provides the Company with a revolving line of credit of up to $150.0 million (the “Revolver”). The Revolver is collateralized by the Company’s marketable securities held by PNC, which must continue to maintain a minimum market value of $150.0 million. The Revolver is available for general working capital purposes and all other lawful corporate purposes. In addition, the Company may request, in lieu of cash advances, letters of credit with an aggregate stated amount outstanding not to exceed $20.0 million. The availability of advances under the line of credit will be reduced by the stated amount of each letter of credit issued and outstanding.
Borrowings under the Revolving Loan Agreement accrue interest at an annual rate equal to the sum of the daily Bloomberg Short-Term Bank Yield Index Rate plus the applicable margin of 0.60%. Loans under the Revolving Loan Agreement may be prepaid at any time without penalty. In October 2022, the Revolving Loan Agreement was amended to extend the maturity date from November 5, 2023 to November 5, 2025. There were no other amendments to the Revolver.
The Company has agreed to various financial covenants under the Revolving Loan Agreement, and as of March 31, 2023, the Company is in compliance with all covenants.
In December 2021 and January 2023, PNC issued a letters of credit of $2.9 million and $1.5 million, respectively, which, reduced the amount available for cash advances under the line of credit to $145.6 million and $147.1 million as of March 31, 2023 and December 31, 2022, respectively. As of March 31, 2023 and December 31, 2022, the Company has not drawn funds from, nor are any amounts outstanding under, the Revolving Loan Agreement.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE NOTES
 3 Months Ended
Mar. 31, 2023
CONVERTIBLE NOTES [Abstract]  
CONVERTIBLE NOTES CONVERTIBLE NOTES
Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of March 31, 2023:
Fair Value (1)
(In thousands)Principal AmountUnamortized Debt Discount and Issuance CostsNet Carrying AmountAmountLeveling
2030 Convertible Notes - 2.000%
$572,993 $(4,912)$568,081 $635,489 2
2028 Convertible Notes - 0.375%
949,042 (12,396)936,646 832,784 2
2027 Convertible Notes - 0.375%
563,822 (6,705)557,117 523,526 2
2025 Convertible Notes - 1.000%
249,172 (820)248,352 284,709 2
Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of December 31, 2022:
Fair Value (1)
(In thousands)Principal AmountUnamortized Debt Discount and Issuance CostsNet Carrying AmountAmountLeveling
2028 Convertible Notes - 0.375%
$1,150,000 $(15,775)$1,134,225 $908,500 2
2027 Convertible Notes - 0.375%
747,500 (9,445)738,055 612,950 2
2025 Convertible Notes - 1.000%
315,005 (1,179)313,826 326,808 2
______________
(1)The fair values are based on observable market prices for this debt, which is traded in less active markets and therefore is classified as a Level 2 fair value measurement.
Issuances and Settlements
In February 2023, the Company entered into a privately negotiated exchange and purchase agreement with a single holder of certain of the Company’s convertible notes due in 2027 (the “2027 Notes”) and 2028 (the “2028 Notes”). The Company issued the holder $500.0 million aggregate principal amount of 2.0% Convertible Notes due in 2030 (collectively, the “2030 Notes”) in exchange for $183.7 million of aggregate principal of 2027 Notes, $201.0 million of aggregate principal of 2028 Notes, and $138.0 million of cash. The extinguishment resulted in a gain on settlement of convertible notes of $17.7 million, which is included in interest income (expense), net in the condensed consolidated statement of operations for the three months ended March 31, 2023. The gain represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of exchange.
In March 2023, the Company entered into a privately negotiated exchange agreement with two holders of certain of the Company’s convertible notes due in 2025 (the “2025 Notes”). The Company issued the holder $73.0 million aggregate principal amount of 2030 Notes in exchange for $65.8 million of aggregate principal of 2025 Notes. The extinguishment resulted in a loss on settlement of convertible notes of $7.4 million, which is included in interest income (expense), net in the condensed consolidated statement of operations for the three months ended March 31, 2023. The loss represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of exchange.
The net proceeds from the issuance of the 2030 Notes were approximately $133.0 million, after deducting commissions and offering expenses payable by the Company.
The 2030 Notes will mature on March 1, 2030 and bear interest at a rate of 2.0% per year, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2023.
Summary of Conversion Features
Until the six-months immediately preceding the maturity date of the applicable series of the Company’s convertible notes (the “Notes”), each series of Notes is convertible only upon the occurrence of certain events and during certain periods, as set forth in the Indentures filed at the time of the original offerings. On or after the date that is six-months immediately preceding the maturity date of the applicable series of Notes until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert such Notes at any time. The Notes will be convertible into cash, shares of the Company’s common stock (plus, if applicable, cash in lieu of any fractional share), or a combination of cash and shares of the Company’s common stock, at the Company’s election.
It is the Company’s intent and policy to settle all conversions through combination settlement. The initial conversion rate is 13.26, 8.96, 8.21, and 12.37 shares of common stock per $1,000 principal amount for the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, respectively, which is equivalent to an initial conversion price of approximately $75.43, $111.66, $121.84, and $80.83 per share of the Company’s common stock for the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, respectively. The 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes are potentially convertible into up to 3.3 million, 5.0 million, 7.8 million, and 7.1 million shares, respectively. The conversion rate is subject to adjustment upon the occurrence of certain specified events as set forth in the Indentures filed at the time of the original offerings but will not be adjusted for accrued and unpaid interest. In addition, holders of the Notes who convert their Notes in connection with a “make-whole fundamental change” (as defined in the Indenture), will, under certain circumstances, be entitled to an increase in the conversion rate.
If the Company undergoes a “fundamental change” (as defined in the Indentures), holders of the Notes may require the Company to repurchase for cash all or part of their Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest.
Based on the closing price of the Company’s common stock of $67.81 on March 31, 2023, the if-converted values on the Notes do not exceed the principal amount.
The Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness, or the issuance or repurchase of securities by the Company.
Ranking of Convertible Notes
The Notes are the Company’s senior unsecured obligations and (i) rank senior in right of payment to all of its future indebtedness that is expressly subordinated in right of payment to the Notes; (ii) rank equal in right of payment to each outstanding series thereof and to all of the Company’s future liabilities that are not so subordinated, unsecured indebtedness; (iii) are effectively junior to all of the Company’s existing and future secured indebtedness and other secured obligations, to the extent of the value of the assets securing that indebtedness and other secured obligations; and (iv) are structurally subordinated to all indebtedness and other liabilities of the Company’s subsidiaries.
Issuance Costs
Issuance costs are amortized to interest expense over the term of the Notes. The following table summarizes the original issuance costs at the time of issuance for each set of Notes:
(In thousands)
2030 Convertible Notes$4,970 
2028 Convertible Notes24,453 
2027 Convertible Notes14,285 
2025 Convertible Notes17,646 
Interest Expense
Interest expense on the Notes includes the following:
Three Months Ended March 31,
(In thousands)20232022
Debt issuance costs amortization$1,378 $1,412 
Debt discount amortization31 36 
Gain on settlements of convertible notes(10,324)— 
Coupon interest expense3,354 2,567 
Total interest expense (income) on convertible notes$(5,561)$4,015 
The following table summarizes the effective interest rates of the Notes:
Three Months Ended March 31,
20232022
2030 Convertible Notes2.12 %— %
2028 Convertible Notes0.64 %0.64 %
2027 Convertible Notes0.67 %0.67 %
2025 Convertible Notes1.18 %1.18 %
The remaining period over which the unamortized debt discount will be recognized as non-cash interest expense is 1.80, 3.96, 4.92, and 6.92 years for the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, respectively.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.1
LICENSE AND COLLABORATION AGREEMENTS
 3 Months Ended
Mar. 31, 2023
LICENSE AGREEMENTS [Abstract]  
LICENSE AND COLLABORATION AGREEMENTS LICENSE AND COLLABORATION AGREEMENTS
The Company licenses certain technologies that are, or may be, incorporated into its technology under several license agreements, as well as the rights to commercialize certain diagnostic tests through collaboration agreements. Generally, the license agreements require the Company to pay single-digit royalties based on net revenues received using the technologies and may require minimum royalty amounts, milestone payments, or maintenance fees.
Mayo
In June 2009, the Company entered into a license agreement with the Mayo Foundation for Medical Education and Research (“Mayo”). The Company’s license agreement with Mayo was most recently amended and restated in September 2020. Under the license agreement, Mayo granted the Company an exclusive, worldwide license to certain Mayo patents and patent applications, as well as a non-exclusive, worldwide license with regard to certain Mayo know-how. The scope of the license covers any screening, surveillance or diagnostic test or tool for use in connection with any type of cancer, pre-cancer, disease or condition.
The licensed Mayo patents and patent applications contain both method and composition claims that relate to sample processing, analytical testing and data analysis associated with nucleic acid screening for cancers and other diseases. The jurisdictions covered by these patents and patent applications include the U.S., Australia, Canada, the European Union, China, Japan and Korea. Under the license agreement, the Company assumed the obligation and expense of prosecuting and maintaining the licensed Mayo patents and is obligated to make commercially reasonable efforts to bring to market products using the licensed Mayo intellectual property.
Pursuant to the Company’s agreement with Mayo, the Company is required to pay Mayo a low-single-digit royalty on the Company’s net sales of current and future products using the licensed Mayo intellectual property each year during the term of the Mayo agreement.
As part of the most recent amendment, the Company agreed to pay Mayo an additional $6.3 million, payable in five equal annual installments through 2024. The annual installments are recorded in research and development expenses in the Company’s condensed consolidated statements of operations.
The license agreement will remain in effect, unless earlier terminated by the parties in accordance with the agreement, until the last of the licensed patents expires in 2039 (or later, if certain licensed patent applications are issued). However, if the Company is still using the licensed Mayo know-how or certain Mayo-provided biological specimens or their derivatives on such expiration date, the term shall continue until the earlier of the date the Company stops using such know-how and materials and the date that is five years after the last licensed patent expires. The license agreement contains customary termination provisions and permits Mayo to terminate the license agreement if the Company sues Mayo or its affiliates, other than any such suit claiming an uncured material breach by Mayo of the license agreement.
In addition to granting the Company a license to the covered Mayo intellectual property, Mayo provides the Company with product development and research and development assistance pursuant to the license agreement and other collaborative arrangements. In September 2020, Mayo also agreed to make available certain personnel to provide such assistance through January 2025. In connection with this collaboration, the Company incurred charges of $1.3 million and $1.4 million for the three months ended March 31, 2023 and 2022, respectively. The charges incurred in connection with this collaboration are recorded in research and development expenses in the Company’s condensed consolidated statements of operations.
Johns Hopkins University
Through the acquisition of Thrive, the Company acquired a worldwide exclusive license agreement with Johns Hopkins University (“JHU”) for use of several JHU patents and licensed know-how. The license is designed to enable the Company to leverage JHU proprietary data in the development and commercialization of a blood-based, multi-cancer early detection test. The agreement terms include single-digit sales-based royalties and sales-based milestone payments of $10.0 million, $15.0 million, and $20.0 million upon achieving calendar year licensed product revenue using JHU proprietary data of $0.50 billion, $1.00 billion, and $1.50 billion, respectively.
Translational Genomics Research Institute (“TGen”)
In January 2021, the Company entered into a worldwide exclusive license to the proprietary Targeted Digital Sequencing (“TARDIS”) technology from TGen, an affiliate of City of Hope. Under the agreement, the Company acquired a royalty-free, worldwide exclusive license to proprietary TARDIS patents and know-how. Under the agreement, the Company is obligated to make milestone payments to TGen of $10.0 million and $35.0 million upon achieving cumulative product revenue related to MRD detection and/or treatment totaling $100.0 million and $250.0 million, respectively. These payments are contingent upon achievement of these cumulative revenues on or before December 31, 2030. The Company will record the sales milestones once achievement is deemed probable.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.1
PFIZER PROMOTION AGREEMENT
 3 Months Ended
Mar. 31, 2023
PFIZER PROMOTION AGREEMENT  
PFIZER PROMOTION AGREEMENT PFIZER PROMOTION AGREEMENTIn August 2018, the Company entered into a Promotion Agreement (the “Original Promotion Agreement”) with Pfizer Inc. (“Pfizer”), which was amended and restated in October 2020 (the “Restated Promotion Agreement”). The Restated Promotion Agreement extended the relationship between the Company and Pfizer and restructured the manner in which the Company compensates Pfizer for promotion of the Cologuard test through a service fee, and provision of certain other sales and marketing services related to the Cologuard test. The Restated Promotion Agreement included fixed and performance-related fees, some of which retroactively went into effect on April 1, 2020. In November 2021, the Company and Pfizer entered into an
amendment to the Restated Promotion Agreement (the “November 2021 Amendment”), which provided that after November 30, 2021, Pfizer will no longer promote the Cologuard test to healthcare providers. The November 2021 Amendment provided that the Company pay Pfizer a total of $35.9 million in three installments, which occurred during the second, third, and fourth quarters of 2022. The November 2021 Amendment eliminated the Company's obligation to pay Pfizer royalties or other fees except for certain media fees, advertising fees, and any detail fees owed to Pfizer for promoting the Cologuard test prior to November 30, 2021. The $35.9 million fee incurred as a result of the November 2021 Amendment was recognized in full during the fourth quarter of 2021. All payments to Pfizer are recorded in sales and marketing expenses in the Company’s condensed consolidated statements of operations.
Under the Original Promotion Agreement, the service fee was calculated based on incremental gross profits over specified baselines during the term. Under the Restated Promotion Agreement (and prior to giving effect to the November 2021 Amendment), the service fee provided a fee-for-service model that included certain fixed fees and performance-related bonuses. The performance-related bonuses were contingent upon the achievement of certain annual performance criteria with any applicable expense being recognized ratably upon achievement of the payment becoming probable. The Company incurred a charge of $2.5 million for the service fee during the three months ended March 31, 2022. The Company incurred charges of $38.4 million for promotion, sales and marketing services performed by Pfizer on behalf of the Company during the three months ended March 31, 2022. All services provided by Pfizer under the November 2021 Amendment ended in the third quarter of 2022, and there were no payments made or charges incurred during the three months ended March 31, 2023.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS' EQUITY
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
OmicEra Acquisition Stock Issuance
In May 2022, the Company completed its acquisition of OmicEra. In connection with the acquisition, which is further described in Note 16, the Company issued 0.3 million shares of the Company's common stock that had a fair value of $14.8 million.
Changes in Accumulated Other Comprehensive Income (Loss)
The amount recognized in AOCI for the three months ended March 31, 2023 were as follows:
(In thousands)Cumulative Translation AdjustmentUnrealized Gain (Loss) on Securities (1)Accumulated Other Comprehensive Income (Loss)
Balance at December 31, 2022$53 $(5,289)$(5,236)
Other comprehensive loss before reclassifications550 2,289 2,839 
Amounts reclassified from accumulated other comprehensive loss— 678 678 
Net current period change in accumulated other comprehensive loss550 2,967 3,517 
Balance at March 31, 2023$603 $(2,322)$(1,719)
______________
(1)There was no tax impact from the amounts recognized in AOCI for the three months ended March 31, 2023.
The amounts recognized in AOCI for the three months ended March 31, 2022 were as follows:
(In thousands)Cumulative Translation AdjustmentUnrealized Gain (Loss) on Securities (1)Accumulated Other Comprehensive Income (Loss)
Balance at December 31, 2021$23 $(1,466)$(1,443)
Other comprehensive loss before reclassifications(237)(4,994)(5,231)
Amounts reclassified from accumulated other comprehensive income— 27 27 
Net current period change in accumulated other comprehensive loss(237)(4,967)(5,204)
Balance at March 31, 2022$(214)$(6,433)$(6,647)
______________
(1)There was no tax impact from the amounts recognized in AOCI for the three months ended March 31, 2022.
Amounts reclassified from AOCI for the three months ended March 31, 2023 and 2022 were as follows:
Affected Line Item in the
Statements of Operations		Three Months Ended March 31,
Details about AOCI Components (In thousands)20232022
Change in value of available-for-sale investments
Sales and maturities of available-for-sale investmentsInvestment income (loss), net$678 $27 
Total reclassifications$678 $27 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK-BASED COMPENSATION
 3 Months Ended
Mar. 31, 2023
Share-based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
Stock-Based Compensation Plans
The Company maintains the following plans for which awards were granted from or had awards outstanding in 2023: the 2010 Omnibus Long-Term Incentive Plan (As Amended and Restated Effective July 27, 2017), the 2019 Omnibus Long-Term Incentive Plan, and the 2010 Employee Stock Purchase Plan (collectively referred to as the “Stock Plans”).
In February 2023, the Company adopted the Equity Award Death, Disability and Retirement Policy (the “Policy”) as further described in Item 9B of the Company’s 2022 Form 10-K. The terms of the Policy will result in the recognition of expense on an accelerated basis for retirement-eligible participants for restricted stock units only. The Policy was considered a modification to outstanding awards with no impact to fair value. The accelerated stock-based compensation expense recorded as a result of the modification was not material for the three months ended March 31, 2023.
Stock-Based Compensation Expense
The Company records stock-based compensation expense in connection with the amortization of restricted stock and restricted stock unit awards, performance share units, stock purchase rights granted under the Company’s employee stock purchase plan and stock options granted to employees, non-employee consultants and non-employee directors. The Company recorded $49.1 million and $52.4 million in stock-based compensation expense during the three months ended March 31, 2023 and 2022, respectively.
As of March 31, 2023, there was approximately $503.4 million of expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted under all equity compensation plans. The Company expects to recognize that cost over a weighted average period of 2.9 years.
Stock Options
A summary of stock option activity under the Stock Plans is as follows:
Option SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Aggregate Intrinsic Value (1)
(Aggregate intrinsic value in thousands)
Outstanding, January 1, 20231,517,876 $44.82 4.7
Exercised(88,260)10.93 
Forfeited(13,285)93.78 
Outstanding, March 31, 20231,416,331 $46.48 4.5$42,583 
Vested and expected to vest, March 31, 2023
1,416,331 $46.48 4.5$42,583 
Exercisable, March 31, 20231,351,469 $44.18 4.4$42,439 
______________
(1)The total intrinsic value of options exercised during the three months ended March 31, 2023 and 2022 was $4.8 million and $29.6 million, respectively, determined as of the date of exercise.
The Company received approximately $1.0 million and $4.3 million from stock option exercises during the three months ended March 31, 2023 and 2022, respectively.
Restricted Stock and Restricted Stock Units
The fair value of restricted stock and restricted stock units is determined on the date of grant using the closing stock price on that day.
A summary of restricted stock and restricted stock unit activity during the three months ended March 31, 2023 is as follows:
Restricted SharesWeighted Average Grant Date Fair Value (1)
Outstanding, January 1, 20235,254,709 $89.29 
Granted3,109,184 60.25 
Released (2)(1,279,999)95.01 
Forfeited(207,363)79.15 
Outstanding, March 31, 20236,876,531 $72.87 
______________
(1)The weighted average grant date fair value of the restricted stock units granted during the three months ended March 31, 2022 was $77.31.
(2)The fair value of restricted stock units vested and converted to shares of the Company’s common stock was $121.2 million and $110.8 million during the three months ended March 31, 2023 and 2022, respectively.
Performance Share Units
The Company has issued performance-based equity awards to certain employees which vest upon the achievement of certain performance goals, including financial performance targets and operational milestones. In addition, certain of the performance-based equity awards include a market condition.
A summary of performance share unit activity is as follows:
Performance Share Units (1)Weighted Average Grant Date Fair Value (2)
Outstanding, January 1, 2023967,846 $102.58 
Granted749,459 79.17 
Released (3)(12,284)78.32 
Forfeited(34,007)100.78 
Outstanding, March 31, 20231,671,014 $92.30 
______________
(1)The performance share units listed above assumes attainment of maximum payout rates as set forth in the performance criteria. Applying actual or expected payout rates, the number of outstanding performance share units as of March 31, 2023 was 575,702.
(2)The weighted average grant date fair value of the performance share units granted during the three months ended March 31, 2022 was $92.31.
(3)The fair value of performance share units vested and converted to shares of the Company’s common stock was $1.0 million and $27.2 million for the three months ended March 31, 2023 and 2022, respectively.
Employee Stock Purchase Plan
There were no shares issued under the 2010 Employee Stock Purchase Plan during the three months ended March 31, 2023 and 2022.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES
 3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Leases
Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows:
Three Months Ended March 31,
(In thousands)20232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$9,135$8,097
Operating cash flows from finance leases170211
Finance cash flows from finance leases7451,548
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for new operating lease liabilities (1)$(3,833)$4,259
Right-of-use assets obtained in exchange for new finance lease liabilities318878
Weighted-average remaining lease term - operating leases (in years)7.188.17
Weighted-average remaining lease term - finance leases (in years)3.072.80
Weighted-average discount rate - operating leases6.42 %6.09 %
Weighted-average discount rate - finance leases6.67 %5.32 %
______________
(1)For the three months ended March 31, 2023, this includes a reduction of $6.2 million on the carrying value of the right-of-use asset held related to a building lease due to a reduction of the expected lease term.
As of March 31, 2023 and December 31, 2022, the Company’s right-of-use assets from operating leases are $156.8 million and $167.0 million, respectively, which are reported in operating lease right-of-use assets in the Company’s condensed consolidated balance sheets. As of March 31, 2023, the Company has outstanding operating lease obligations of $204.7 million, of which $30.0 million is reported in operating lease liabilities, current portion and $174.7 million is reported in operating lease liabilities, less current portion in the Company’s condensed consolidated balance sheets. As of December 31, 2022, the Company had outstanding operating lease obligations of $210.8 million, of which $28.4 million is reported in operating lease liabilities, current portion and $182.4 million is reported in operating lease liabilities, less current portion in the Company’s condensed consolidated balance sheets.
As of March 31, 2023 and December 31, 2022, the Company’s right-of-use assets from finance leases are $9.5 million and $10.2 million, respectively, which are reported in other long-term assets, net in the Company’s condensed consolidated balance sheets. As of March 31, 2023, the Company has outstanding finance lease obligations of $10.0 million, of which $3.2 million is reported in other current liabilities and $6.8 million is reported in other long-term liabilities in the Company’s condensed consolidated balance sheets. As of December 31, 2022, the Company had outstanding finance lease obligations of $10.6 million, of which $3.2 million is reported in other current liabilities and $7.4 million is reported in other long-term liabilities in the Company’s condensed consolidated balance sheets.
Legal Matters
The Company records reserves and accrues costs for certain legal proceedings and regulatory matters to the extent that it determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. While such reserves and accrued costs reflect the Company’s best estimate of the probable loss for such matters, the recorded amounts may differ materially from the actual amount of any such losses. In some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal and regulatory proceedings, which may be exacerbated by various factors, including but not limited to, they may involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; involve a large number of parties, claimants or regulatory bodies; are in the early stages of the proceedings; involve a number of separate proceedings and/or a wide range of potential outcomes; or result in a change of business practices.
As of the date of this Quarterly Report on Form 10-Q, amounts accrued for legal proceedings and regulatory matters were not material except for the amounts accrued related to the Medicare Date of Service Rule Investigation discussed below. However, it is possible that in a particular quarter or annual period the Company’s financial condition, results of operations, cash flow and/or liquidity could be materially adversely affected by an ultimate unfavorable resolution of, or development in, legal and/or regulatory proceedings, including as described below. Except for the proceedings discussed below, the Company believes that the ultimate outcome of any of the regulatory and legal proceedings that are currently pending against it should not have a material adverse effect on financial condition, results of operations, cash flow or liquidity.
The Company is currently responding to civil investigative demands and administrative subpoenas issued pursuant to the Health Insurance Portability and Accountability Act of 1996 by the United States Department of Justice (“DOJ”) concerning Genomic Health’s compliance with the Medicare Date of Service billing regulations (the “DOS Rule Investigation”). The Company has been cooperating with these inquiries and has produced documents in response thereto.
During the second quarter of 2021, as part of ongoing discussions between the DOJ and the Company regarding the DOS Rule Investigation, the DOJ presented an initial estimate of civil damages in the amount of $48.2 million relating to alleged non-compliance with the Medicare Date of Service billing regulations from 2007 to 2020. The initial civil damages estimate did not include potential treble damages, civil or criminal penalties or other remedies that the DOJ could seek against the Company. In December 2021, the DOJ presented a total adjusted demand of $53.8 million for civil damages, which includes a multiplier and penalties. On January 19, 2023, the Company was informed that the DOJ has closed its criminal investigation without taking any action. Based on the Company’s review and analysis of the DOJ presentation, ongoing discussions held with the DOJ, the civil damages estimate, and range of potential exposure, the Company recorded an accrual of approximately $29 million as of March 31, 2023.
As noted above, litigation outcomes are difficult to predict, and the estimation of probable losses requires an analysis of multiple possible outcomes that often depend on judgments about potential actions by third parties. Accordingly, the recorded accrual of approximately $29 million as of March 31, 2023 is based on several factors, considerations, and judgments, and the ultimate resolution of this matter could result in a material loss in excess of the recorded accrual.
On June 24, 2019, Niles Rosen M.D. filed a sealed ex parte qui tam lawsuit against the Company in the United States District Court for the Middle District of Florida, that alleged a violation of the Federal Anti-Kickback Statute and False Claims Act for offering gift cards to patients in exchange for returning the Cologuard screening test (the “Qui Tam Suit”). Dr. Rosen seeks on behalf of the U.S. government and himself an award of civil penalties, treble damages and fees and costs. On February 25, 2020, the Company received a civil investigative demand by the DOJ related to the Company’s gift card program. The Company produced documents in response thereto. On March 25, 2021, the DOJ filed a notice of its election to decline intervention in the Qui Tam Suit. This election does not prevent Dr. Rosen from continuing the Qui Tam Suit. On April 12, 2021, Dr. Rosen filed an amended complaint against the Company, alleging violations of the Federal Anti-Kickback Statute and False Claims Act. The Company first learned of the Qui Tam Suit and the DOJ’s election to decline intervention in July 2021. The Company intends to vigorously defend itself against Dr. Rosen's claims and seek, among other things, the Company’s attorneys’ fees and costs incurred in defending this action. Although the Company denies Dr. Rosen's allegations and believes that it has meritorious defenses to his False Claims Act claims, neither the outcome of the litigation nor can a reasonable estimate or an estimated range of loss associated with the litigation be determined at this time.
Adverse outcomes from the DOS Rule Investigation and the Qui Tam Suit could include the Company being required to pay treble damages, incur civil and criminal penalties, paying attorneys’ fees, entering into a corporate integrity agreement, being excluded from participation in government healthcare programs, including Medicare and Medicaid, and other adverse actions that could materially affect the Company’s business, financial condition, and results of operation.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.1
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS
 3 Months Ended
Mar. 31, 2023
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS [Abstract]  
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS
During February 2015, the Company entered into an agreement with the Wisconsin Economic Development Corporation (“WEDC,” “Original WEDC Agreement”) to earn $9.0 million in refundable tax credits on the condition that the Company expends $26.3 million in capital investments and establishes and maintains 758 full-time positions over a seven-year period.
During December 2021, the Company amended its agreement with the WEDC (“Amended WEDC Agreement”) to earn an additional $18.5 million in refundable tax credits on the condition that the Company expends $350.0 million in capital investments and establishes and maintains 1,300 additional full-time positions over a five-year period. The capital investment credits are earned at a rate of 10% of eligible capital investments up to a maximum of $7.0 million, while the jobs creation credits are earned annually pursuant to the agreement.
The tax credits earned are first applied against the tax liability otherwise due, and if there is no such liability present, the claim for tax credits will be reimbursed in cash to the Company. The maximum amount of the refundable tax credit to be earned for each year is fixed, and the Company earns the credits by meeting certain capital investment and job creation thresholds over the term of the agreement. Should the Company earn and receive the job creation tax credits but not maintain those full-time positions through the end of the agreement, the Company may be required to pay those credits back to the WEDC.
Under the Original WEDC Agreement, the Company recorded the earned tax credits as job creation and capital investments occurred. The tax credits earned from capital investment are being recognized as an offset to depreciation expense over the expected life of the acquired capital assets. The tax credits earned related to job creation were recognized as an offset to operational expenses through December 31, 2020.
As of December 31, 2020, the Company had earned all $9.0 million of the refundable tax credits, and as of December 31, 2022, the Company had received payment of $9.0 million from the WEDC under the Original WEDC Agreement.
Under the Amended WEDC Agreement, the Company records the earned tax credits as job creation and capital investments occurs. The tax credits earned from capital investment are recognized as a reduction to capital expenditures at the time the costs are incurred, and then as an offset to depreciation expense over the expected life of the acquired capital assets. The tax credits earned related to job creation are recognized as an offset to operational expenses in the period in which the credits are earned. The credits recognized will be required to be repaid if the Company does not maintain minimum cumulative job requirements.
As of March 31, 2023, the Company has earned $10.2 million of the refundable tax credits under the Amended WEDC Agreement and received payment of $1.7 million from the WEDC. The unpaid portion is $8.5 million, of which $3.8 million is reported in prepaid expenses and other current assets and $4.7 million is reported in other long-term assets, net in the Company’s condensed consolidated balance sheets reflecting when collection of the refundable tax credits is expected to occur.
During the three months ended March 31, 2023 and 2022, the Company recorded $1.2 million and $1.0 million respectively, as a reduction to operational expenses for the credits earned for job creation.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.1
ACQUISITIONS AND DIVESTITURES
 3 Months Ended
Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
ACQUISITIONS AND DIVESTITURES ACQUISITIONS AND DIVESTITURES
Business Combinations
OmicEra Diagnostics, GmbH
On May 2, 2022, the Company completed the acquisition (the “OmicEra Acquisition”) of all of the outstanding equity interests of OmicEra Diagnostics GmbH. The OmicEra Acquisition provided the Company a state-of-the-art proteomics lab based in Planegg, Germany. OmicEra combines its mass spectrometry-based proteome analysis technology with its in-house proteomics scientific expertise to discover more reliable and valuable protein biomarkers, which will expand the Company’s research and development capabilities.
Refer to the Company’s 2022 Form 10-K for detailed disclosures on the combination, including the fair value of the consideration transferred, purchase price allocation, and goodwill and intangible assets identified in the transaction. During the three months ended March 31, 2023, there were no changes to the purchase price and purchase price allocation. The measurement period remains open pending the completion of valuation procedures related to certain acquired assets and liabilities assumed, primarily in connection with the developed technology intangible asset.
Divestitures
Oncotype DX Genomic Prostate Score Test
On August 2, 2022, pursuant to an asset purchase agreement with MDxHealth SA, the Company completed the sale of the intellectual property and know-how related to the Company’s Oncotype DX Genomic Prostate Score test, which will allow the Company to focus on the highest impact projects core to the Company’s vision.
Refer to the Company’s 2022 Form 10-K for detailed disclosures on the divestiture, including the fair value of the consideration received, carrying value of the intangible asset sold, and terms of the revenue-based contingent consideration included in the asset purchase agreement. As of March 31, 2023, the contingent consideration remains fully constrained.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.1
SEGMENT INFORMATION
 3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Management determined that the Company functions as a single operating segment, and thus reports as a single reportable segment. This operating segment is focused on the development and global commercialization of clinical laboratory services allowing healthcare providers and patients to make individualized treatment decisions. Management assessed the discrete financial information routinely reviewed by the Company's Chief Operating Decision Maker, its President and Chief Executive Officer, to monitor the Company's operating performance and support decisions regarding allocation of resources to its operations. Performance is continuously monitored at the consolidated level to timely identify deviations from expected results.
The following table summarizes total revenue from customers by geographic region. Product revenues are attributed to countries based on ship-to location.
Three Months Ended March 31,
(In thousands)20232022
United States$565,182 $457,011 
Outside of United States37,268 29,560 
Total revenues$602,450 $486,571 
Long-lived assets located in countries outside of the United States are not significant.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES
 3 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The Company recorded income tax expense of $1.7 million for the three months ended March 31, 2023 and a benefit of $2.0 million for the three months ended March 31, 2022. The Company’s income tax expense recorded during the three months ended March 31, 2023 is primarily related to current foreign and state tax expense. A deferred tax liability of $20.1 million and $19.7 million was recorded as of March 31, 2023 and December 31, 2022, respectively, which is included in other long-term liabilities on the Company’s condensed consolidated balance sheet. The Company continues to maintain a full valuation allowance against its deferred tax assets based on management’s determination that it is more likely than not the benefit will not be realized.
The Company had $29.6 million and $28.3 million of unrecognized tax benefits at March 31, 2023 and December 31, 2022, respectively. These amounts have been recorded as a reduction to the Company’s deferred tax asset, if recognized they would not have an impact on the effective tax rate due to the existing valuation allowance. Certain of the Company's unrecognized tax benefits could change due to activities of various tax authorities, including possible settlement of audits, or through normal expiration of various statutes of limitations. The Company does not expect a material change in unrecognized tax benefits in the next twelve months.
As of March 31, 2023, due to the carryforward of unutilized net operating losses and research and development credits, the Company is subject to U.S. federal income tax examinations for the tax years 2000 through 2023, and to state income tax examinations for the tax years 2000 through 2023. No interest or penalties related to income taxes have been accrued or recognized as of March 31, 2023.
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation and Principles of Consolidation Basis of Presentation and Principles of ConsolidationThe accompanying condensed consolidated financial statements, which include the accounts of the Company and those of its wholly owned subsidiaries and variable interest entities, are unaudited and have been prepared on a basis substantially consistent with the Company’s audited financial statements and notes as of and for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K (the “2022 Form 10-K”). All intercompany transactions and balances have been eliminated upon consolidation. These condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted (“GAAP”) in the United States of America (“U.S.”) and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting only of adjustments of a normal and recurring nature) considered necessary for a fair statement of its financial position, operating results and cash flows for the periods presented. The condensed consolidated balance sheet at December 31, 2022 has been derived from audited financial statements, but does not contain all of the footnote disclosures from the 2022 Form 10-K. The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year. The statements should be read in conjunction with the audited financial statements and related notes included in the 2022 Form 10-K.
Use of Estimates
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that affect the Company’s financial statements materially and involve difficult, subjective or complex judgments by management, and actual results could differ from those estimates. These estimates include revenue recognition, valuation of intangible assets and goodwill, and accounting for income taxes among others. The Company’s critical accounting policies and estimates are explained further in the notes to the condensed consolidated financial statements in this Quarterly Report on Form 10-Q and the 2022 Form 10-K.
The spread of the coronavirus (“COVID-19”) and the macroeconomic conditions including inflation and fluctuations in foreign currency exchange rates has affected many segments of the global economy, including the cancer screening and diagnostics industry. The Company expects these matters to have an impact on operations, however, the ultimate impact presents uncertainty and depends on factors beyond the Company’s knowledge or control, including the duration and severity, as well as third-party actions taken. The Company continues to use the best information available to inform its accounting estimates in light of these uncertainties.
Reclassifications
Reclassifications
Certain prior year amounts have been reclassified to conform to the current year presentation in the condensed consolidated financial statements and accompanying notes to the condensed consolidated financial statements.
Recent Accounting Pronouncements Recent Accounting PronouncementsThe Company did not adopt any accounting standards updates (“ASU”) released by the Financial Accounting Standards Board (“FASB”) in the first quarter of 2023. In addition, there are no ASUs not yet adopted that are expected to impact the Company.
Net Loss Per Share
Net Loss Per Share
Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share is the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive as a result of the Company’s losses.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Schedule of potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect
The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period:
March 31,
(In thousands)20232022
Shares issuable upon conversion of convertible notes23,231 20,309 
Shares issuable upon the release of restricted stock awards6,877 6,991 
Shares issuable upon the release of performance share units1,671 963 
Shares issuable upon exercise of stock options1,416 1,790 
Shares issuable in connection with acquisitions— 45 
33,195 30,098 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.1
REVENUE (Tables)
 3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of disaggregation of revenue
The following table presents the Company’s revenues disaggregated by revenue source:
Three Months Ended March 31,
(In thousands)20232022
Screening
Medicare Parts B & C$171,730 $113,755 
Commercial233,033 161,680 
Other38,432 31,087 
Total Screening443,195 306,522 
Precision Oncology
Medicare Parts B & C$47,381 $52,565 
Commercial44,932 46,062 
International37,268 29,560 
Other25,851 24,433 
Total Precision Oncology155,432 152,620 
COVID-19 Testing$3,823 $27,429 
Total$602,450 $486,571 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.1
MARKETABLE SECURITIES (Tables)
 3 Months Ended
Mar. 31, 2023
Cash and Cash Equivalents [Abstract]  
Cash, Cash Equivalents and Investments
The following table sets forth the Company’s cash, cash equivalents, and marketable securities at March 31, 2023 and December 31, 2022:
(In thousands)March 31, 2023December 31, 2022
Cash and cash equivalents
Cash and money market$351,549 $178,168 
Cash equivalents69,816 64,325 
Total cash and cash equivalents421,365 242,493 
Marketable securities
Available-for-sale debt securities$274,694 $384,415 
Equity securities2,588 5,149 
Total marketable securities277,282 389,564 
Total cash, cash equivalents and marketable securities$698,647 $632,057 
Schedule of available-for-sale securities
Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at March 31, 2023, consisted of the following:
(In thousands)Amortized CostGains in Accumulated Other Comprehensive Income (Loss) (1)Losses in Accumulated Other Comprehensive Income (Loss) (1)Estimated Fair Value
Cash equivalents
Commercial paper$68,081 $— $— $68,081 
U.S. government agency securities1,735 — — 1,735 
Total cash equivalents69,816 — — 69,816 
Marketable securities
U.S. government agency securities$147,979 $16 $(909)$147,086 
Corporate bonds97,378 18 (948)96,448 
Asset backed securities31,659 106 (605)31,160 
Total marketable securities277,016 140 (2,462)274,694 
Total available-for-sale securities$346,832 $140 $(2,462)$344,510 
______________
(1)There was no tax impact from the gains and losses in accumulated other comprehensive income (loss) (“AOCI”).
Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at December 31, 2022, consisted of the following:
(In thousands)Amortized CostGains in Accumulated Other Comprehensive Income (Loss) (1) Losses in Accumulated Other Comprehensive Income (Loss) (1)Estimated Fair Value
Cash equivalents
Commercial paper$63,021 $— $— $63,021 
U.S. government agency securities1,304 — — 1,304 
Total cash equivalents64,325 — — 64,325 
Marketable securities
U.S. government agency securities$228,012 $— $(2,789)$225,223 
Corporate bonds116,318 20 (1,667)114,671 
Asset backed securities45,374 2 (855)44,521 
Total marketable securities389,704 22 (5,311)384,415 
Total available-for-sale securities$454,029 $22 $(5,311)$448,740 
______________
(1)There was no tax impact from the gains and losses in AOCI.
Schedule of contractual maturities of available-for-sale investments
The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at March 31, 2023:
Due one year or lessDue after one year through five years
(In thousands)CostFair ValueCostFair Value
Cash equivalents
Commercial paper$68,081 $68,081 $— $— 
U.S. government agency securities1,735 1,735 — — 
Total cash equivalents69,816 69,816 — — 
Marketable securities
U.S. government agency securities$138,322 $137,423 $9,657 $9,663 
Corporate bonds82,071 81,169 15,307 15,279 
Asset backed securities1,191 1,189 30,468 29,971 
Total marketable securities221,584 219,781 55,432 54,913 
Total available-for-sale securities$291,400 $289,597 $55,432 $54,913 
Schedule of gross unrealized losses and fair values of investments in an unrealized loss position
The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of March 31, 2023, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:
Less than one yearOne year or greaterTotal
(In thousands)Fair ValueGross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
Marketable securities
U.S. government agency securities$35,897 $(161)$103,474 $(748)$139,371 $(909)
Corporate bonds16,430 (61)71,885 (887)88,315 (948)
Asset backed securities10,767 (100)18,544 (505)29,311 (605)
Total available-for-sale securities$63,094 $(322)$193,903 $(2,140)$256,997 $(2,462)
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.1
INVENTORY (Tables)
 3 Months Ended
Mar. 31, 2023
Inventory Disclosure [Abstract]  
Schedule of inventory
Inventory consisted of the following:
(In thousands)March 31, 2023December 31, 2022
Raw materials$63,433 $61,207 
Semi-finished and finished goods60,659 57,052 
Total inventory$124,092 $118,259 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY, PLANT AND EQUIPMENT (Tables)
 3 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
Schedule of property, plant and equipment, net
The carrying value and estimated useful lives of property, plant and equipment are as follows:
(In thousands)Estimated Useful LifeMarch 31, 2023December 31, 2022
Property, plant and equipment
Landn/a$4,716 $4,716 
Leasehold and building improvements(1)200,314 200,588 
Land improvements15 years6,613 6,417 
Buildings
30 - 40 years
290,121 288,941 
Computer equipment and computer software3 years148,798 142,896 
Laboratory equipment
3 - 10 years
253,926 246,344 
Furniture and fixtures
3 - 10 years
34,601 34,047 
Assets under constructionn/a79,648 68,398 
Property, plant and equipment, at cost1,018,737 992,347 
Accumulated depreciation(334,163)(307,591)
Property, plant and equipment, net$684,574 $684,756 
______________
(1)Lesser of remaining lease term, building life, or estimated useful life.
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.1
INTANGIBLE ASSETS AND GOODWILL (Tables)
 3 Months Ended
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of net-book value and estimated remaining life and finite lived intangible assets
The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of March 31, 2023:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated Amortization
Net Balance at March 31, 2023
Finite-lived intangible assets
Trade name12.3$104,000 $(22,465)$81,535 
Customer relationships7.84,000 (556)3,444 
Patents and licenses4.111,542 (8,514)3,028 
Acquired developed technology (1)7.5861,644 (266,170)595,474 
Total finite-lived intangible assets981,186 (297,705)683,481 
In-process research and developmentn/a1,250,000 — 1,250,000 
Total intangible assets$2,231,186 $(297,705)$1,933,481 

The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2022:
(In thousands)Weighted Average Remaining Life (Years)CostAccumulated Amortization
Net balance at December 31, 2022
Finite-lived intangible assets
Trade name12.5$104,000 $(20,653)$83,347 
Customer relationships8.04,000 (444)3,556 
Patents and licenses4.211,542 (8,152)3,390 
Acquired developed technology (1)7.8861,474 (245,527)615,947 
Total finite-lived intangible assets981,016 (274,776)706,240 
In-process research and developmentn/a1,250,000 — 1,250,000 
Total intangible assets$2,231,016 $(274,776)$1,956,240 
______________
(1)The gross carrying amount includes an immaterial foreign currency translation adjustment related to the intangible asset acquired as a result of the acquisition of OmicEra Diagnostics GmbH (“OmicEra”), whose functional currency is also its local currency. Intangible asset balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.
Schedule of estimated future amortization expense, intangible assets
As of March 31, 2023, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:
(In thousands)
2023 (remaining nine months)$68,786 
202491,378 
202590,331 
202689,271 
202789,271 
Thereafter254,444 
$683,481 
Schedule of carrying amount of goodwill
The change in the carrying amount of goodwill for the periods ended March 31, 2023 and December 31, 2022 is as follows:
(In thousands)
Balance, January 1, 2022
$2,335,172 
OmicEra acquisition10,809 
PreventionGenetics acquisition adjustment(58)
Effects of changes in foreign currency exchange rates (1)117 
Balance, December 31, 2022
2,346,040 
Effects of changes in foreign currency exchange rates (1)195 
Balance March 31, 2023
$2,346,235 
______________
(1)Represents the impact of foreign currency translation related to the goodwill acquired as a result of the acquisition of OmicEra. Goodwill balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.1
FAIR VALUE MEASUREMENTS (Tables)
 3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Schedule of fair value measurements along with the level within the fair value hierarchy in which the fair value measurements fall
The following table presents the Company’s fair value measurements as of March 31, 2023 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands)Fair Value at March 31, 2023Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Cash, cash equivalents, and restricted cash
Cash and money market$351,549 $351,549 $— $— 
Commercial paper68,081 — 68,081 — 
U.S. government agency securities1,735 — 1,735 — 
Restricted cash297 297 — — 
Marketable securities
U.S. government agency securities$147,086 $— $147,086 $— 
Corporate bonds96,448 — 96,448 — 
Asset backed securities31,160 — 31,160 — 
Equity securities2,588 2,588 — — 
Non-marketable securities$10,190 $— $— $10,190 
Liabilities
Contingent consideration$(297,990)$— $— $(297,990)
Total$411,144 $354,434 $344,510 $(287,800)
The following table presents the Company’s fair value measurements as of December 31, 2022 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands)Fair Value at December 31, 2022Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Cash and cash equivalents
Cash and money market$178,168 $178,168 $— $— 
Commercial paper63,021 — 63,021 — 
U.S. government agency securities1,304 — 1,304 — 
Restricted cash297 297 — — 
Marketable securities
U.S. government agency securities$225,223 $— $225,223 $— 
Corporate bonds114,671 — 114,671 — 
Asset backed securities44,521 — 44,521 — 
Equity securities5,149 5,149 — — 
Non-marketable securities$10,065 $— $— $10,065 
Liabilities
Contingent consideration$(306,927)$— $— $(306,927)
Total$335,492 $183,614 $448,740 $(296,862)
Schedule of fair value of contingent consideration
The following table provides a reconciliation of the beginning and ending balances of contingent consideration:
(In thousands)Contingent Consideration
Beginning balance, January 1, 2023$306,927 
Changes in fair value (1)(8,937)
Ending balance, March 31, 2023
$297,990 
______________
(1)The change in fair value of the contingent consideration liability for the three months ended March 31, 2022 was a reduction of $26.7 million.
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE NOTES (Tables)
 3 Months Ended
Mar. 31, 2023
CONVERTIBLE NOTES [Abstract]  
Schedule of convertible note obligations included in the condensed consolidated balance sheets
Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of March 31, 2023:
Fair Value (1)
(In thousands)Principal AmountUnamortized Debt Discount and Issuance CostsNet Carrying AmountAmountLeveling
2030 Convertible Notes - 2.000%
$572,993 $(4,912)$568,081 $635,489 2
2028 Convertible Notes - 0.375%
949,042 (12,396)936,646 832,784 2
2027 Convertible Notes - 0.375%
563,822 (6,705)557,117 523,526 2
2025 Convertible Notes - 1.000%
249,172 (820)248,352 284,709 2
Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of December 31, 2022:
Fair Value (1)
(In thousands)Principal AmountUnamortized Debt Discount and Issuance CostsNet Carrying AmountAmountLeveling
2028 Convertible Notes - 0.375%
$1,150,000 $(15,775)$1,134,225 $908,500 2
2027 Convertible Notes - 0.375%
747,500 (9,445)738,055 612,950 2
2025 Convertible Notes - 1.000%
315,005 (1,179)313,826 326,808 2
______________
(1)The fair values are based on observable market prices for this debt, which is traded in less active markets and therefore is classified as a Level 2 fair value measurement.
Schedule of allocation of transaction costs related to convertible debt The following table summarizes the original issuance costs at the time of issuance for each set of Notes:
(In thousands)
2030 Convertible Notes$4,970 
2028 Convertible Notes24,453 
2027 Convertible Notes14,285 
2025 Convertible Notes17,646 
Schedule of interest expense
Interest expense on the Notes includes the following:
Three Months Ended March 31,
(In thousands)20232022
Debt issuance costs amortization$1,378 $1,412 
Debt discount amortization31 36 
Gain on settlements of convertible notes(10,324)— 
Coupon interest expense3,354 2,567 
Total interest expense (income) on convertible notes$(5,561)$4,015 
Schedule of effective interest rates related to convertible debt
The following table summarizes the effective interest rates of the Notes:
Three Months Ended March 31,
20232022
2030 Convertible Notes2.12 %— %
2028 Convertible Notes0.64 %0.64 %
2027 Convertible Notes0.67 %0.67 %
2025 Convertible Notes1.18 %1.18 %
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS' EQUITY (Tables)
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Schedule of amounts recognized in accumulated other comprehensive income (loss) (AOCI)
The amount recognized in AOCI for the three months ended March 31, 2023 were as follows:
(In thousands)Cumulative Translation AdjustmentUnrealized Gain (Loss) on Securities (1)Accumulated Other Comprehensive Income (Loss)
Balance at December 31, 2022$53 $(5,289)$(5,236)
Other comprehensive loss before reclassifications550 2,289 2,839 
Amounts reclassified from accumulated other comprehensive loss— 678 678 
Net current period change in accumulated other comprehensive loss550 2,967 3,517 
Balance at March 31, 2023$603 $(2,322)$(1,719)
______________
(1)There was no tax impact from the amounts recognized in AOCI for the three months ended March 31, 2023.
The amounts recognized in AOCI for the three months ended March 31, 2022 were as follows:
(In thousands)Cumulative Translation AdjustmentUnrealized Gain (Loss) on Securities (1)Accumulated Other Comprehensive Income (Loss)
Balance at December 31, 2021$23 $(1,466)$(1,443)
Other comprehensive loss before reclassifications(237)(4,994)(5,231)
Amounts reclassified from accumulated other comprehensive income— 27 27 
Net current period change in accumulated other comprehensive loss(237)(4,967)(5,204)
Balance at March 31, 2022$(214)$(6,433)$(6,647)
______________
(1)There was no tax impact from the amounts recognized in AOCI for the three months ended March 31, 2022.
Schedule of amounts reclassified from accumulated other comprehensive income (loss)
Amounts reclassified from AOCI for the three months ended March 31, 2023 and 2022 were as follows:
Affected Line Item in the
Statements of Operations		Three Months Ended March 31,
Details about AOCI Components (In thousands)20232022
Change in value of available-for-sale investments
Sales and maturities of available-for-sale investmentsInvestment income (loss), net$678 $27 
Total reclassifications$678 $27 
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK-BASED COMPENSATION (Tables)
 3 Months Ended
Mar. 31, 2023
Share-based Payment Arrangement [Abstract]  
Summary of Stock Option Activity Under the Stock Plans
A summary of stock option activity under the Stock Plans is as follows:
Option SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (Years)Aggregate Intrinsic Value (1)
(Aggregate intrinsic value in thousands)
Outstanding, January 1, 20231,517,876 $44.82 4.7
Exercised(88,260)10.93 
Forfeited(13,285)93.78 
Outstanding, March 31, 20231,416,331 $46.48 4.5$42,583 
Vested and expected to vest, March 31, 2023
1,416,331 $46.48 4.5$42,583 
Exercisable, March 31, 20231,351,469 $44.18 4.4$42,439 
______________
(1)The total intrinsic value of options exercised during the three months ended March 31, 2023 and 2022 was $4.8 million and $29.6 million, respectively, determined as of the date of exercise.
Summary of Restricted Stock and Restricted Stock Unit Activity Under the Stock Plans
A summary of restricted stock and restricted stock unit activity during the three months ended March 31, 2023 is as follows:
Restricted SharesWeighted Average Grant Date Fair Value (1)
Outstanding, January 1, 20235,254,709 $89.29 
Granted3,109,184 60.25 
Released (2)(1,279,999)95.01 
Forfeited(207,363)79.15 
Outstanding, March 31, 20236,876,531 $72.87 
______________
(1)The weighted average grant date fair value of the restricted stock units granted during the three months ended March 31, 2022 was $77.31.
(2)The fair value of restricted stock units vested and converted to shares of the Company’s common stock was $121.2 million and $110.8 million during the three months ended March 31, 2023 and 2022, respectively.
Share-based Payment Arrangement, Performance Shares, Activity
A summary of performance share unit activity is as follows:
Performance Share Units (1)Weighted Average Grant Date Fair Value (2)
Outstanding, January 1, 2023967,846 $102.58 
Granted749,459 79.17 
Released (3)(12,284)78.32 
Forfeited(34,007)100.78 
Outstanding, March 31, 20231,671,014 $92.30 
______________
(1)The performance share units listed above assumes attainment of maximum payout rates as set forth in the performance criteria. Applying actual or expected payout rates, the number of outstanding performance share units as of March 31, 2023 was 575,702.
(2)The weighted average grant date fair value of the performance share units granted during the three months ended March 31, 2022 was $92.31.
(3)The fair value of performance share units vested and converted to shares of the Company’s common stock was $1.0 million and $27.2 million for the three months ended March 31, 2023 and 2022, respectively.
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES (Tables)
 3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Supplemental disclosure of cash flow information related to our operating leases Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows:
Three Months Ended March 31,
(In thousands)20232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$9,135$8,097
Operating cash flows from finance leases170211
Finance cash flows from finance leases7451,548
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for new operating lease liabilities (1)$(3,833)$4,259
Right-of-use assets obtained in exchange for new finance lease liabilities318878
Weighted-average remaining lease term - operating leases (in years)7.188.17
Weighted-average remaining lease term - finance leases (in years)3.072.80
Weighted-average discount rate - operating leases6.42 %6.09 %
Weighted-average discount rate - finance leases6.67 %5.32 %
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.23.1
SEGMENT INFORMATION (Tables)
 3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
Revenue from external customers by geographic areas
The following table summarizes total revenue from customers by geographic region. Product revenues are attributed to countries based on ship-to location.
Three Months Ended March 31,
(In thousands)20232022
United States$565,182 $457,011 
Outside of United States37,268 29,560 
Total revenues$602,450 $486,571 
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details) - shares
shares in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Common shares not included in the computation of diluted net loss per share    
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect 33,195 30,098
Shares issuable in connection with acquisitions    
Common shares not included in the computation of diluted net loss per share    
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect 0 45
Shares issuable upon exercise of stock options    
Common shares not included in the computation of diluted net loss per share    
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect 1,416 1,790
Shares issuable upon the release of restricted stock awards    
Common shares not included in the computation of diluted net loss per share    
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect 6,877 6,991
Shares issuable upon the release of performance share units    
Common shares not included in the computation of diluted net loss per share    
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect 1,671 963
Shares issuable upon conversion of convertible notes    
Common shares not included in the computation of diluted net loss per share    
Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect 23,231 20,309
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.23.1
REVENUE - Schedule of Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disaggregation of Revenue [Line Items]    
Revenue recognized $ 602,450 $ 486,571
Screening    
Disaggregation of Revenue [Line Items]    
Revenue recognized 443,195 306,522
Screening | Medicare Parts B & C    
Disaggregation of Revenue [Line Items]    
Revenue recognized 171,730 113,755
Screening | Commercial    
Disaggregation of Revenue [Line Items]    
Revenue recognized 233,033 161,680
Screening | Other    
Disaggregation of Revenue [Line Items]    
Revenue recognized 38,432 31,087
Precision Oncology    
Disaggregation of Revenue [Line Items]    
Revenue recognized 155,432 152,620
Precision Oncology | Medicare Parts B & C    
Disaggregation of Revenue [Line Items]    
Revenue recognized 47,381 52,565
Precision Oncology | Commercial    
Disaggregation of Revenue [Line Items]    
Revenue recognized 44,932 46,062
Precision Oncology | International    
Disaggregation of Revenue [Line Items]    
Revenue recognized 37,268 29,560
Precision Oncology | Other    
Disaggregation of Revenue [Line Items]    
Revenue recognized 25,851 24,433
COVID-19 Testing    
Disaggregation of Revenue [Line Items]    
Revenue recognized $ 3,823 $ 27,429
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.23.1
REVENUE - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Variable consideration    
Disaggregation of Revenue [Line Items]    
Revenue recognized from changes in transaction prices $ 11.7 $ 4.2
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.23.1
MARKETABLE SECURITIES - Schedule of Cash and Cash Equivalents (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Marketable securities      
Cash and money market $ 351,549 $ 178,168  
Cash equivalents 69,816 64,325  
Total cash, cash equivalents and restricted cash 421,365 242,493 $ 189,776
Equity securities 2,588 5,149  
Marketable securities 277,282 389,564  
Total cash, cash equivalents and marketable securities 698,647 632,057  
Marketable securities      
Marketable securities      
Available-for-sale debt securities $ 274,694 $ 384,415  
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.23.1
MARKETABLE SECURITIES - Schedule of Available For Sale Securities (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Available-for-sale securities    
Amortized Cost $ 346,832 $ 454,029
Gains in Accumulated Other Comprehensive Income (Loss) 140 22
Losses in Accumulated Other Comprehensive Income (Loss) (2,462) (5,311)
Estimated Fair Value 344,510 448,740
Cash equivalents    
Available-for-sale securities    
Amortized Cost 69,816 64,325
Gains in Accumulated Other Comprehensive Income (Loss) 0 0
Losses in Accumulated Other Comprehensive Income (Loss) 0 0
Estimated Fair Value 69,816 64,325
Marketable securities    
Available-for-sale securities    
Amortized Cost 277,016 389,704
Gains in Accumulated Other Comprehensive Income (Loss) 140 22
Losses in Accumulated Other Comprehensive Income (Loss) (2,462) (5,311)
Estimated Fair Value 274,694 384,415
Commercial paper | Cash equivalents    
Available-for-sale securities    
Amortized Cost 68,081 63,021
Gains in Accumulated Other Comprehensive Income (Loss) 0 0
Losses in Accumulated Other Comprehensive Income (Loss) 0 0
Estimated Fair Value 68,081 63,021
U.S. government agency securities | Cash equivalents    
Available-for-sale securities    
Amortized Cost 1,735 1,304
Gains in Accumulated Other Comprehensive Income (Loss) 0 0
Losses in Accumulated Other Comprehensive Income (Loss) 0 0
Estimated Fair Value 1,735 1,304
U.S. government agency securities | Marketable securities    
Available-for-sale securities    
Amortized Cost 147,979 228,012
Gains in Accumulated Other Comprehensive Income (Loss) 16 0
Losses in Accumulated Other Comprehensive Income (Loss) (909) (2,789)
Estimated Fair Value 147,086 225,223
Corporate bonds | Marketable securities    
Available-for-sale securities    
Amortized Cost 97,378 116,318
Gains in Accumulated Other Comprehensive Income (Loss) 18 20
Losses in Accumulated Other Comprehensive Income (Loss) (948) (1,667)
Estimated Fair Value 96,448 114,671
Asset backed securities | Marketable securities    
Available-for-sale securities    
Amortized Cost 31,659 45,374
Gains in Accumulated Other Comprehensive Income (Loss) 106 2
Losses in Accumulated Other Comprehensive Income (Loss) (605) (855)
Estimated Fair Value $ 31,160 $ 44,521
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.23.1
MARKETABLE SECURITIES - Schedule of Underlying Maturities of AFS Securities (Details)
$ in Thousands
Mar. 31, 2023
USD ($)
Available-for-sale securities  
Due in one year or less, Cost $ 291,400
Due in one year or less, Fair Value 289,597
Due after one year through five years, Cost 55,432
Due after one year through five years, Fair Value 54,913
Cash equivalents  
Available-for-sale securities  
Due in one year or less, Cost 69,816
Due in one year or less, Fair Value 69,816
Due after one year through five years, Cost 0
Due after one year through five years, Fair Value 0
Cash equivalents | Commercial paper  
Available-for-sale securities  
Due in one year or less, Cost 68,081
Due in one year or less, Fair Value 68,081
Due after one year through five years, Cost 0
Due after one year through five years, Fair Value 0
Cash equivalents | U.S. government agency securities  
Available-for-sale securities  
Due in one year or less, Cost 1,735
Due in one year or less, Fair Value 1,735
Due after one year through five years, Cost 0
Due after one year through five years, Fair Value 0
Marketable securities  
Available-for-sale securities  
Due in one year or less, Cost 221,584
Due in one year or less, Fair Value 219,781
Due after one year through five years, Cost 55,432
Due after one year through five years, Fair Value 54,913
Marketable securities | U.S. government agency securities  
Available-for-sale securities  
Due in one year or less, Cost 138,322
Due in one year or less, Fair Value 137,423
Due after one year through five years, Cost 9,657
Due after one year through five years, Fair Value 9,663
Marketable securities | Corporate bonds  
Available-for-sale securities  
Due in one year or less, Cost 82,071
Due in one year or less, Fair Value 81,169
Due after one year through five years, Cost 15,307
Due after one year through five years, Fair Value 15,279
Marketable securities | Asset backed securities  
Available-for-sale securities  
Due in one year or less, Cost 1,191
Due in one year or less, Fair Value 1,189
Due after one year through five years, Cost 30,468
Due after one year through five years, Fair Value $ 29,971
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.23.1
MARKETABLE SECURITIES - Schedule of Gross Unrealized Losses and Fair Values of Investments in an Unrealized Loss Position (Details)
$ in Thousands
Mar. 31, 2023
USD ($)
Marketable securities  
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months $ 63,094
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months (322)
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer 193,903
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer, accumulated loss (2,140)
Total fair value of available-for-sale securities in a continuous unrealized loss position 256,997
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position (2,462)
Corporate bonds | Marketable securities  
Marketable securities  
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months 16,430
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months (61)
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer 71,885
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer, accumulated loss (887)
Total fair value of available-for-sale securities in a continuous unrealized loss position 88,315
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position (948)
Asset backed securities | Marketable securities  
Marketable securities  
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months 10,767
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months (100)
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer 18,544
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer, accumulated loss (505)
Total fair value of available-for-sale securities in a continuous unrealized loss position 29,311
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position (605)
U.S. government agency securities | Marketable securities  
Marketable securities  
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months 35,897
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months (161)
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer 103,474
Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer, accumulated loss (748)
Total fair value of available-for-sale securities in a continuous unrealized loss position 139,371
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position $ (909)
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.23.1
INVENTORY (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 63,433 $ 61,207
Semi-finished and finished goods 60,659 57,052
Total inventory $ 124,092 $ 118,259
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY, PLANT AND EQUIPMENT - Schedule of Estimated Useful Lives (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Property, plant and equipment    
Property, plant and equipment, at cost $ 1,018,737 $ 992,347
Accumulated depreciation (334,163) (307,591)
Property, plant and equipment, net 684,574 684,756
Land    
Property, plant and equipment    
Property, plant and equipment, at cost 4,716 4,716
Leasehold and building improvements    
Property, plant and equipment    
Property, plant and equipment, at cost $ 200,314 200,588
Land improvements    
Property, plant and equipment    
Estimated Useful Life 15 years  
Property, plant and equipment, at cost $ 6,613 6,417
Buildings    
Property, plant and equipment    
Property, plant and equipment, at cost $ 290,121 288,941
Computer equipment and computer software    
Property, plant and equipment    
Estimated Useful Life 3 years  
Property, plant and equipment, at cost $ 148,798 142,896
Laboratory equipment    
Property, plant and equipment    
Property, plant and equipment, at cost 253,926 246,344
Furniture and fixtures    
Property, plant and equipment    
Property, plant and equipment, at cost 34,601 34,047
Assets under construction    
Property, plant and equipment    
Property, plant and equipment, at cost $ 79,648 $ 68,398
Minimum | Buildings    
Property, plant and equipment    
Estimated Useful Life 30 years  
Minimum | Laboratory equipment    
Property, plant and equipment    
Estimated Useful Life 3 years  
Minimum | Furniture and fixtures    
Property, plant and equipment    
Estimated Useful Life 3 years  
Maximum | Buildings    
Property, plant and equipment    
Estimated Useful Life 40 years  
Maximum | Laboratory equipment    
Property, plant and equipment    
Estimated Useful Life 10 years  
Maximum | Furniture and fixtures    
Property, plant and equipment    
Estimated Useful Life 10 years  
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Property, plant and equipment    
Depreciation $ 26,815 $ 22,993
Assets under construction 79,600  
Buildings    
Property, plant and equipment    
Assets under construction 5,200  
Laboratory equipment    
Property, plant and equipment    
Assets under construction 51,900  
Leasehold and building improvements    
Property, plant and equipment    
Assets under construction 12,400  
Computer software    
Property, plant and equipment    
Assets under construction $ 10,100  
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.23.1
INTANGIBLE ASSETS AND GOODWILL - Schedule of Finite Lived Intangible Assets Net Balances and Weighted Average Useful Lives (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Cost $ 981,186 $ 981,016
Accumulated Amortization (297,705) (274,776)
Intangibles, net 683,481 706,240
In-process research and development 1,250,000 1,250,000
Finite-lived and indefinite-lived intangible assets, gross 2,231,186 2,231,016
Finite-lived and indefinite-lived intangible assets, net $ 1,933,481 $ 1,956,240
Trade name    
Finite-Lived Intangible Assets [Line Items]    
Weighted-average remaining useful life of finite-lived intangible asset (in years) 12 years 3 months 18 days 12 years 6 months
Cost $ 104,000 $ 104,000
Accumulated Amortization (22,465) (20,653)
Intangibles, net $ 81,535 $ 83,347
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Weighted-average remaining useful life of finite-lived intangible asset (in years) 7 years 9 months 18 days 8 years
Cost $ 4,000 $ 4,000
Accumulated Amortization (556) (444)
Intangibles, net $ 3,444 $ 3,556
Patents and licenses    
Finite-Lived Intangible Assets [Line Items]    
Weighted-average remaining useful life of finite-lived intangible asset (in years) 4 years 1 month 6 days 4 years 2 months 12 days
Cost $ 11,542 $ 11,542
Accumulated Amortization (8,514) (8,152)
Intangibles, net $ 3,028 $ 3,390
Acquired developed technology (1)    
Finite-Lived Intangible Assets [Line Items]    
Weighted-average remaining useful life of finite-lived intangible asset (in years) 7 years 6 months 7 years 9 months 18 days
Cost $ 861,644 $ 861,474
Accumulated Amortization (266,170) (245,527)
Intangibles, net $ 595,474 $ 615,947
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.23.1
INTANGIBLE ASSETS AND GOODWILL - Schedule of Future Amortization Expense (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
2023 $ 68,786  
2024 91,378  
2025 90,331  
2026 89,271  
2027 89,271  
Thereafter 254,444  
Intangibles, net $ 683,481 $ 706,240
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.23.1
INTANGIBLE ASSETS AND GOODWILL - Schedule of Changes in Goodwill (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Recognized Goodwill    
Beginning balance $ 2,346,040 $ 2,335,172
Goodwill, foreign currency translation gain (loss) 195 117
Ending balance $ 2,346,235 2,346,040
OmicEra acquisition    
Recognized Goodwill    
OmicEra acquisition   10,809
PreventionGenetics acquisition adjustment    
Recognized Goodwill    
Goodwill, Purchase Accounting Adjustments   $ (58)
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.23.1
INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]      
Gross value of intangible asset $ 981,186,000   $ 981,016,000
Finite-lived intangible assets, accumulated amortization 297,705,000   274,776,000
Intangibles, net 683,481,000   706,240,000
Impairment losses 0 $ 0  
Acquired developed technology (1)      
Finite-Lived Intangible Assets [Line Items]      
Gross value of intangible asset 861,644,000   861,474,000
Finite-lived intangible assets, accumulated amortization 266,170,000   245,527,000
Intangibles, net $ 595,474,000   $ 615,947,000
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.23.1
FAIR VALUE MEASUREMENTS - Schedule of Fair Value (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Fair value measurements    
Equity securities $ 2,588 $ 5,149
Fair Value, Recurring    
Fair value measurements    
Restricted cash 297 297
Equity securities 2,588 5,149
Non-marketable securities 10,190 10,065
Contingent consideration (297,990) (306,927)
Total 411,144 335,492
Fair Value, Recurring | Corporate bonds    
Fair value measurements    
Estimated Fair Value 96,448 114,671
Fair Value, Recurring | U.S. government agency securities    
Fair value measurements    
Estimated Fair Value 147,086 225,223
Fair Value, Recurring | Asset backed securities    
Fair value measurements    
Estimated Fair Value 31,160 44,521
Fair Value, Recurring | Cash and money market    
Fair value measurements    
Cash and cash equivalents, fair value 351,549 178,168
Fair Value, Recurring | Commercial paper    
Fair value measurements    
Cash and cash equivalents, fair value 68,081 63,021
Fair Value, Recurring | U.S. government agency securities    
Fair value measurements    
Cash and cash equivalents, fair value 1,735 1,304
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring    
Fair value measurements    
Restricted cash 297 297
Equity securities 2,588 5,149
Non-marketable securities 0 0
Contingent consideration 0 0
Total 354,434 183,614
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Corporate bonds    
Fair value measurements    
Estimated Fair Value 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | U.S. government agency securities    
Fair value measurements    
Estimated Fair Value 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Asset backed securities    
Fair value measurements    
Estimated Fair Value 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Cash and money market    
Fair value measurements    
Cash and cash equivalents, fair value 351,549 178,168
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Commercial paper    
Fair value measurements    
Cash and cash equivalents, fair value 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | U.S. government agency securities    
Fair value measurements    
Cash and cash equivalents, fair value 0 0
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring    
Fair value measurements    
Restricted cash 0 0
Equity securities 0 0
Non-marketable securities 0 0
Contingent consideration 0 0
Total 344,510 448,740
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Corporate bonds    
Fair value measurements    
Estimated Fair Value 96,448 114,671
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | U.S. government agency securities    
Fair value measurements    
Estimated Fair Value 147,086 225,223
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Asset backed securities    
Fair value measurements    
Estimated Fair Value 31,160 44,521
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Cash and money market    
Fair value measurements    
Cash and cash equivalents, fair value 0 0
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Commercial paper    
Fair value measurements    
Cash and cash equivalents, fair value 68,081 63,021
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | U.S. government agency securities    
Fair value measurements    
Cash and cash equivalents, fair value 1,735 1,304
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring    
Fair value measurements    
Restricted cash 0 0
Equity securities 0 0
Non-marketable securities 10,190 10,065
Contingent consideration (297,990) (306,927)
Total (287,800) (296,862)
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Corporate bonds    
Fair value measurements    
Estimated Fair Value 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | U.S. government agency securities    
Fair value measurements    
Estimated Fair Value 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Asset backed securities    
Fair value measurements    
Estimated Fair Value 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Cash and money market    
Fair value measurements    
Cash and cash equivalents, fair value 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Commercial paper    
Fair value measurements    
Cash and cash equivalents, fair value 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | U.S. government agency securities    
Fair value measurements    
Cash and cash equivalents, fair value $ 0 $ 0
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.23.1
FAIR VALUE MEASUREMENTS - Fair Value of Contingent Consideration (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Fair Value Disclosures [Abstract]    
Beginning balance $ 306,927  
Change in amount of contingent consideration liability (8,937) $ (26,680)
Ending balance $ 297,990  
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.23.1
FAIR VALUE MEASUREMENTS - Narrative (Details)
 3 Months Ended
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Business Combination, Contingent Consideration, Liability $ 297,990,000   $ 306,927,000
Business Combination, Contingent Consideration, Liability 297,990,000   306,927,000
Venture capital investment fund      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Investment owned, at fair value 4,200,000   $ 3,900,000
Committed capital 17,500,000    
Committed capital callable $ 13,300,000    
Product development and other milestone-based payments | Weighted average | Measurement Input, Probability of Success      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Contingent consideration liability, measurement input 0.91   0.91
Product development and other milestone-based payments | Weighted average | Measurement Input, Present-value Factor      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Contingent consideration liability, measurement input 0.061   0.062
Foreign exchange forward      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Derivative, notional amount $ 29,200,000   $ 22,300,000
Derivative, fair value 0   0
Gain (Loss) on derivative instruments, net, pretax 0 $ 0  
Significant Unobservable Inputs (Level 3) | Fair value, nonrecurring      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Investment owned, at fair value 39,400,000   39,800,000
Thrive and Ashion | Fair value      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Business Combination, Contingent Consideration, Liability 297,900,000   306,800,000
Business Combination, Contingent Consideration, Liability 297,900,000   $ 306,800,000
Thrive and Ashion | Revenue and Other Performance-based Payments      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Business Combination, Contingent Consideration, Liability 0    
Business Combination, Contingent Consideration, Liability $ 0    
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.23.1
LONG-TERM DEBT - Narrative (Details) - USD ($)
 1 Months Ended
Jan. 31, 2023
Dec. 31, 2021
Nov. 30, 2021
Mar. 31, 2023
Dec. 31, 2022
Jun. 29, 2022
Long-term debt            
Financing receivable, amount elected to collateralize       $ 50,000,000    
Securitized receivables            
Long-term debt            
Maximum borrowing capacity           $ 150,000,000
Line of credit facility, current borrowing capacity       111,100,000    
Long-term debt       $ 50,000,000    
Line of credit facility, interest rate at period end       6.35%    
Securitized receivables | Minimum            
Long-term debt            
Long-term debt           $ 50,000,000
Revolving loan agreement | Revolving loan agreement | Line of credit            
Long-term debt            
Maximum borrowing capacity     $ 150,000,000      
Minimum market value covenant     150,000,000      
Maximum outstanding cash advances threshold     $ 20,000,000      
Remaining borrowing capacity       $ 145,600,000 $ 147,100,000  
Revolving loan agreement | Revolving loan agreement | Line of credit | Daily bloomberg short-term bank yield index rate            
Long-term debt            
Variable rate     0.60%      
City letter of credit | Revolving loan agreement | Line of credit            
Long-term debt            
Proceeds from lines of credit $ 1,500,000 $ 2,900,000        
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE NOTES - Schedule of Convertible Notes (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
2027 Convertible Notes    
Long-term debt    
Coupon interest rate 0.375% 0.375%
Principal Amount $ 949,042 $ 1,150,000
Unamortized Debt Discount and Issuance Costs (12,396) (15,775)
Net Carrying Amount 936,646 1,134,225
2027 Convertible Notes | Significant Other Observable Inputs (Level 2) | Fair value    
Long-term debt    
Amount $ 832,784 $ 908,500
2028 Convertible Notes    
Long-term debt    
Coupon interest rate 0.375% 0.375%
Principal Amount $ 563,822 $ 747,500
Unamortized Debt Discount and Issuance Costs (6,705) (9,445)
Net Carrying Amount 557,117 738,055
2028 Convertible Notes | Significant Other Observable Inputs (Level 2) | Fair value    
Long-term debt    
Amount $ 523,526 $ 612,950
2030 Convertible Notes    
Long-term debt    
Coupon interest rate 1.00% 1.00%
Principal Amount $ 249,172 $ 315,005
Unamortized Debt Discount and Issuance Costs (820) (1,179)
Net Carrying Amount 248,352 313,826
2030 Convertible Notes | Significant Other Observable Inputs (Level 2) | Fair value    
Long-term debt    
Amount $ 284,709 $ 326,808
Convertible Notes Payable2030    
Long-term debt    
Coupon interest rate 2.00%  
Principal Amount $ 572,993  
Unamortized Debt Discount and Issuance Costs (4,912)  
Net Carrying Amount 568,081  
Convertible Notes Payable2030 | Significant Other Observable Inputs (Level 2) | Fair value    
Long-term debt    
Amount $ 635,489  
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE NOTES - Narrative (Details)
$ / shares in Units, $ in Thousands, shares in Millions
 1 Months Ended 3 Months Ended
Mar. 31, 2023
USD ($)
$ / shares
Mar. 31, 2023
USD ($)
$ / shares
shares
Mar. 31, 2022
USD ($)
Mar. 06, 2023
USD ($)
Mar. 01, 2023
USD ($)
Long-term debt          
Principal amount, convertible note   $ 1      
Repurchase price, as percentage of principal amount, if company undergoes change of control   100      
Market price (in dollars per share) | $ / shares $ 67.81 $ 67.81      
Net proceeds from issuance   $ 137,976 $ 0    
Gain (Loss) on Extinguishment of Debt $ 17,700        
2030 Convertible Notes          
Long-term debt          
Gain (Loss) on Extinguishment of Debt $ 7,400        
2030 Convertible Notes          
Long-term debt          
Conversion rate, number of shares to be issued per $1,000 of principal amount (in shares)   13.26      
Conversion price (in dollars per share) | $ / shares $ 75.43 $ 75.43      
Potential shares issued from convertible instrument (in shares) | shares   3.3      
Effective interest rate (as a percent)   1.18% 1.18%    
Amount of debt extinguished $ 65,800        
Interest expense amortization term   1 year 9 months 18 days      
Convertible Notes Payable2027          
Long-term debt          
Conversion rate, number of shares to be issued per $1,000 of principal amount (in shares)   8.96      
Conversion price (in dollars per share) | $ / shares $ 111.66 $ 111.66      
Potential shares issued from convertible instrument (in shares) | shares   5.0      
Effective interest rate (as a percent)   0.67% 0.67%    
Amount of debt extinguished $ 183,700        
Interest expense amortization term   3 years 11 months 15 days      
2027 Convertible Notes          
Long-term debt          
Conversion rate, number of shares to be issued per $1,000 of principal amount (in shares)   8.21      
Conversion price (in dollars per share) | $ / shares $ 121.84 $ 121.84      
Potential shares issued from convertible instrument (in shares) | shares   7.8      
Effective interest rate (as a percent)   0.64% 0.64%    
Amount of debt extinguished $ 201,000        
Interest expense amortization term   4 years 11 months 1 day      
Convertible Notes Payable2030          
Long-term debt          
Conversion rate, number of shares to be issued per $1,000 of principal amount (in shares)   12.37      
Conversion price (in dollars per share) | $ / shares $ 80.83 $ 80.83      
Potential shares issued from convertible instrument (in shares) | shares   7.1      
Effective interest rate (as a percent)   2.12% 0.00%    
Face amount         $ 500,000
Net proceeds from issuance $ 138,000        
Proceeds from Debt, Net of Issuance Costs $ 133,000        
Interest expense amortization term   6 years 11 months 1 day      
Convertible Notes Payable2030 | 2030 Convertible Notes          
Long-term debt          
Face amount       $ 73,000  
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE NOTES - Schedule of Transaction Costs (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
USD ($)
Convertible Notes Payable2027  
Long-term debt  
Total transaction costs $ 14,285
Convertible Notes Payable2028  
Long-term debt  
Total transaction costs 24,453
Convertible Notes Payable2030  
Long-term debt  
Total transaction costs 4,970
2030 Convertible Notes  
Long-term debt  
Total transaction costs $ 17,646
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE NOTES - Summary of Interest Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Debt Disclosure [Abstract]    
Debt issuance costs amortization $ 1,378 $ 1,412
Debt discount amortization 31 36
Gain on settlements of convertible notes, net (10,324) 0
Coupon interest expense 3,354 2,567
Total interest expense (income) on convertible notes $ (5,561) $ 4,015
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE NOTES - Schedule of Effective Interest Rates Related to Convertible Debt (Details)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
2030 Convertible Notes    
Schedule of Convertible notes [Line Items]    
Effective interest rate (as a percent) 1.18% 1.18%
2028 Convertible Notes    
Schedule of Convertible notes [Line Items]    
Effective interest rate (as a percent) 0.67% 0.67%
2027 Convertible Notes    
Schedule of Convertible notes [Line Items]    
Effective interest rate (as a percent) 0.64% 0.64%
Convertible Notes Payable2030    
Schedule of Convertible notes [Line Items]    
Effective interest rate (as a percent) 2.12% 0.00%
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.23.1
LICENSE AND COLLABORATION AGREEMENTS - Mayo (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Sep. 30, 2020
USD ($)
installment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development expense $ 95,419 $ 102,248  
Licensing agreements | Mayo      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
License agreement fees commitment     $ 6,300
Number of installments | installment     5
Period patent remains in effect 5 years    
Research and development expense $ 1,300 $ 1,400  
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.23.1
LICENSE AND COLLABORATION AGREEMENTS - John Hopkins University (Details) - OmicEra acquisition - Licensing agreements
$ in Millions
Jan. 05, 2021
USD ($)
Sales milestone range one  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Collaboration arrangement, milestones to be paid $ 10.0
Collaborative arrangement sales milestone amount 500.0
Sales milestone range two  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Collaboration arrangement, milestones to be paid 15.0
Collaborative arrangement sales milestone amount 1,000.0
Sales milestone range three  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Collaboration arrangement, milestones to be paid 20.0
Collaborative arrangement sales milestone amount $ 1,500.0
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.23.1
LICENSE AND COLLABORATION AGREEMENTS - Translational Genomics Research Institute (Details) - Tgen - Licensing agreements
$ in Millions
Jan. 31, 2021
USD ($)
Product Revenue Related to MRD Detection, Payment One  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Collaboration arrangement, milestones to be paid $ 10.0
Product Revenue Related to MRD Detection, Payment Two  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Collaboration arrangement, milestones to be paid 35.0
Product Revenue Related to Treatment, Payment One  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Collaboration arrangement, milestones to be paid 100.0
Product Revenue Related to Treatment, Payment Two  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Collaboration arrangement, milestones to be paid $ 250.0
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.23.1
PFIZER PROMOTION AGREEMENT (Details) - Cologuard promotion agreement - Pfizer Inc - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2022
Nov. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Contract termination fee   $ 35.9
Service fee based on incremental gross profits over specified baselines and royalties $ 2.5  
Charges for promotion, sales and marketing $ 38.4  
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS' EQUITY - Narrative (Details) - OmicEra diagnostics acquisition - USD ($)
shares in Millions, $ in Millions
 1 Months Ended
May 31, 2022
May 01, 2022
Subsidiary or Equity Method Investee [Line Items]    
Business acquisition, equity interest issued or issuable (in shares) 0.3  
Fair value of stock issued in acquisition   $ 14.8
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS' EQUITY - Schedule of OCI (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance $ 3,043,162 $ 3,387,636
Other comprehensive loss before reclassifications 2,839 (5,231)
Amounts reclassified from accumulated other comprehensive income 678 27
Net current period change in accumulated other comprehensive loss 3,517 (5,204)
Ending balance 3,057,708 3,258,211
Cumulative Translation Adjustment    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance 53 23
Other comprehensive loss before reclassifications 550 (237)
Amounts reclassified from accumulated other comprehensive income 0 0
Net current period change in accumulated other comprehensive loss 550 (237)
Ending balance 603 (214)
Unrealized Gain (Loss) on Marketable Securities    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (5,289) (1,466)
Other comprehensive loss before reclassifications 2,289 (4,994)
Amounts reclassified from accumulated other comprehensive income 678 27
Net current period change in accumulated other comprehensive loss 2,967 (4,967)
Ending balance (2,322) (6,433)
Accumulated Other Comprehensive Income (Loss)    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (5,236) (1,443)
Ending balance $ (1,719) $ (6,647)
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS' EQUITY - Schedule of Amounts Reclassified from AOCI (Details) - Reclassification out of accumulated other comprehensive income - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Changes in Accumulated Other Comprehensive Income (Loss)    
Total reclassifications $ 678 $ 27
Unrealized Gain (Loss) on Marketable Securities    
Changes in Accumulated Other Comprehensive Income (Loss)    
Investment income (loss), net $ 678 $ 27
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Stock-based compensation    
Stock-based compensation expense $ 49.1 $ 52.4
Proceeds from stock options exercised 1.0 $ 4.3
Stock plans    
Stock-based compensation    
Unrecognized compensation cost $ 503.4  
Weighted average period for recognition of cost 2 years 10 months 24 days  
Employee stock | Employee Stock Purchase Plan2010    
Stock-based compensation    
Purchase of employee stock purchase plan shares (in shares) 0 0
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK-BASED COMPENSATION - Fair Value and Activity (Details) - Stock plans - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Dec. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Shares      
Outstanding at the beginning of the period (in shares)   1,517,876  
Exercised (in shares)   (88,260)  
Forfeited (in shares)   (13,285)  
Outstanding at the end of the period (in shares) 1,517,876 1,416,331  
Vested and expected to vest at end of period (in shares)   1,416,331  
Exercisable at the end of the period (in shares)   1,351,469  
Weighted Average Exercise Price      
Outstanding at the beginning of the period (in dollars per share)   $ 44.82  
Exercised (in dollars per share)   10.93  
Forfeited (in dollars per share)   93.78  
Outstanding at the end of the period (in dollars per share) $ 44.82 46.48  
Vested and expected to vest at end of period (in dollars per share)   46.48  
Exercisable at the end of the period (in dollars per share)   $ 44.18  
Weighted Average Remaining Contractual Term      
Outstanding 4 years 8 months 12 days 4 years 6 months  
Vested and expected to vest at end of period   4 years 6 months  
Exercisable at the end of the period   4 years 4 months 24 days  
Aggregate Intrinsic Value      
Outstanding at the end of the period   $ 42,583  
Vested and expected to vest at end of period   42,583  
Exercisable at the end of the period   42,439  
Total intrinsic value of options exercised   $ 4,800 $ 29,600
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK-BASED COMPENSATION - Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Restricted Shares and RSUs    
Restricted Shares    
Outstanding at the beginning of the period (in shares) 5,254,709  
Granted (in shares) 3,109,184  
Released (in shares) (1,279,999)  
Forfeited (in shares) (207,363)  
Outstanding at the end of the period (in shares) 6,876,531  
Weighted Average Exercise Price    
Outstanding at the beginning of the period (in dollars per share) $ 89.29  
Granted (in dollars per share) 60.25  
Released (in dollars per share) 95.01  
Forfeited (in dollars per share) 79.15  
Outstanding at the end of the period (in dollars per share) $ 72.87  
Fair value of equity instruments other than options vested in period $ 121.2 $ 110.8
Restricted stock units    
Weighted Average Exercise Price    
Granted (in dollars per share)   $ 77.31
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK-BASED COMPENSATION - Share-based Payment Arrangement, Performance Shares, Activity (Details) - Shares issuable upon the release of performance share units - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Stock-based compensation      
Outstanding (in shares) 1,671,014   967,846
Outstanding (in dollars per share) $ 92.30   $ 102.58
Granted (in shares) 749,459    
Granted (in dollars per share) $ 79.17 $ 92.31  
Released (in shares) (12,284)    
Released (in dollars per share) $ 78.32    
Forfeited (in shares) (34,007)    
Forfeited (in dollars per share) $ 100.78    
Number of outstanding performance share units (in shares) 575,702    
Fair value of equity instruments other than options vested in period $ 1.0 $ 27.2  
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES - Supplemental Disclosure of Cash Flow Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows from operating leases $ 9,135 $ 8,097
Operating cash flows from finance leases 170 211
Finance cash flows from finance leases 745 1,548
Non-cash investing and financing activities:    
Right-of-use assets obtained in exchange for new operating lease liabilities (3,833) (4,259)
Right-of-use assets obtained in exchange for new finance lease liabilities $ 318 $ 878
Weighted-average remaining lease term - operating leases (in years) 7 years 2 months 4 days 8 years 2 months 1 day
Weighted-average remaining lease term - finance leases (in years) 3 years 25 days 2 years 9 months 18 days
Weighted-average discount rate - operating leases 6.42% 6.09%
Weighted-average discount rate - finance leases 6.67% 5.32%
Operating Lease, Right-of-Use Asset Modification $ 6,200  
XML 86 R75.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jun. 30, 2022
Mar. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Lessee, Lease, Description [Line Items]        
Operating lease right-of-use assets   $ 156,782 $ 167,003  
Additional amount to be recognized at lease commencement for the lease liability   204,700 210,800  
Operating lease liability, current   30,014 28,366  
Operating lease liability, noncurrent   174,690 182,399  
Finance lease, right-of-use asset   $ 9,500 10,200  
Finance lease, right-of-use asset, statement of financial position, extensible list   Other long-term assets, net    
Finance lease liability   $ 10,000 10,600  
Finance lease liability, current   $ 3,200 $ 3,200  
Finance lease, liability, current, statement of financial position, extensible list   Other current liabilities Other current liabilities  
Finance lease liability, noncurrent   $ 6,800 $ 7,400  
Finance lease, liability, noncurrent, statement of financial position, extensible list   Other long-term liabilities Other long-term liabilities  
DOS Rule Investigation        
Lessee, Lease, Description [Line Items]        
Estimated civil damages       $ 48,200
Civil damages $ 53,800      
Loss Contingency Accrual   $ 29,000    
XML 87 R76.htm IDEA: XBRL DOCUMENT v3.23.1
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS (Details)
$ in Millions
 1 Months Ended 3 Months Ended
Dec. 31, 2021
USD ($)
position
Feb. 28, 2015
USD ($)
position
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2020
USD ($)
Wisconsin economic development tax credit agreement            
Agreements            
Refundable tax credits available, contingent   $ 9.0        
Capital investment expenditures over specified period, requirement to earn the refundable tax credits   $ 26.3        
Full-time positions that must be created over a specified time period to earn the refundable tax credits | position   758        
Period over which the capital investment expenditures must be incurred and the creation of full-time positions must be completed   7 years        
Refundable tax credits earned           $ 9.0
Refundable tax credit received         $ 9.0  
Amended wisconsin economic development tax credit agreement            
Agreements            
Capital investment expenditures over specified period, requirement to earn the refundable tax credits $ 350.0          
Full-time positions that must be created over a specified time period to earn the refundable tax credits | position 1,300          
Period over which the capital investment expenditures must be incurred and the creation of full-time positions must be completed 5 years          
Refundable tax credits earned $ 18.5   $ 10.2      
Credit earning rate 10.00%          
Maximum credits available to earn $ 7.0          
Refundable tax credit received     1.7      
Refundable tax credit receivable     8.5      
Amended wisconsin economic development tax credit agreement | Operating expense            
Agreements            
Amortization of tax credits     1.2 $ 1.0    
Amended wisconsin economic development tax credit agreement | Prepaid expenses and other current assets            
Agreements            
Refundable tax credit receivable     3.8      
Amended wisconsin economic development tax credit agreement | Other long-term assets            
Agreements            
Refundable tax credit receivable     $ 4.7      
XML 88 R77.htm IDEA: XBRL DOCUMENT v3.23.1
SEGMENT INFORMATION (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
USD ($)
segment
Mar. 31, 2022
USD ($)
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue $ 602,450 $ 486,571
Number of operating segments | segment 1  
United States    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue $ 565,182 457,011
Outside of United States    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue $ 37,268 $ 29,560
XML 89 R78.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
Tax expense (benefit) $ 1,657 $ (2,015)  
Deferred tax liabilities, net 20,100   $ 19,700
Unrecognized tax benefits $ 29,600   $ 28,300
XML 90 exas-20230331_htm.xml IDEA: XBRL DOCUMENT 0001124140 2023-01-01 2023-03-31 0001124140 2023-05-08 0001124140 2023-03-31 0001124140 2022-12-31 0001124140 2022-01-01 2022-03-31 0001124140 us-gaap:CommonStockMember 2022-12-31 0001124140 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001124140 us-gaap:RetainedEarningsMember 2022-12-31 0001124140 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001124140 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001124140 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001124140 us-gaap:CommonStockMember 2023-03-31 0001124140 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001124140 us-gaap:RetainedEarningsMember 2023-03-31 0001124140 2022-03-31 0001124140 us-gaap:CommonStockMember 2021-12-31 0001124140 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001124140 us-gaap:RetainedEarningsMember 2021-12-31 0001124140 2021-12-31 0001124140 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001124140 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001124140 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001124140 us-gaap:CommonStockMember 2022-03-31 0001124140 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001124140 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001124140 us-gaap:RetainedEarningsMember 2022-03-31 0001124140 us-gaap:ConvertibleNotesPayableMember 2023-01-01 2023-03-31 0001124140 us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-03-31 0001124140 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0001124140 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001124140 us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0001124140 us-gaap:PerformanceSharesMember 2022-01-01 2022-03-31 0001124140 exas:EmployeeAndNonEmployeesStockOptionMember 2023-01-01 2023-03-31 0001124140 exas:EmployeeAndNonEmployeesStockOptionMember 2022-01-01 2022-03-31 0001124140 exas:SharesIssuedUponAcquisitionMember 2023-01-01 2023-03-31 0001124140 exas:SharesIssuedUponAcquisitionMember 2022-01-01 2022-03-31 0001124140 us-gaap:ProductMember exas:ScreeningMember 2023-01-01 2023-03-31 0001124140 us-gaap:ProductMember exas:ScreeningMember 2022-01-01 2022-03-31 0001124140 us-gaap:ServiceMember exas:ScreeningMember 2023-01-01 2023-03-31 0001124140 us-gaap:ServiceMember exas:ScreeningMember 2022-01-01 2022-03-31 0001124140 us-gaap:ProductAndServiceOtherMember exas:ScreeningMember 2023-01-01 2023-03-31 0001124140 us-gaap:ProductAndServiceOtherMember exas:ScreeningMember 2022-01-01 2022-03-31 0001124140 exas:ScreeningMember 2023-01-01 2023-03-31 0001124140 exas:ScreeningMember 2022-01-01 2022-03-31 0001124140 us-gaap:ProductMember exas:PrecisionOncologyMember 2023-01-01 2023-03-31 0001124140 us-gaap:ProductMember exas:PrecisionOncologyMember 2022-01-01 2022-03-31 0001124140 us-gaap:ServiceMember exas:PrecisionOncologyMember 2023-01-01 2023-03-31 0001124140 us-gaap:ServiceMember exas:PrecisionOncologyMember 2022-01-01 2022-03-31 0001124140 exas:InternationalSalesMember exas:PrecisionOncologyMember 2023-01-01 2023-03-31 0001124140 exas:InternationalSalesMember exas:PrecisionOncologyMember 2022-01-01 2022-03-31 0001124140 us-gaap:ProductAndServiceOtherMember exas:PrecisionOncologyMember 2023-01-01 2023-03-31 0001124140 us-gaap:ProductAndServiceOtherMember exas:PrecisionOncologyMember 2022-01-01 2022-03-31 0001124140 exas:PrecisionOncologyMember 2023-01-01 2023-03-31 0001124140 exas:PrecisionOncologyMember 2022-01-01 2022-03-31 0001124140 exas:COVID19TestingMember 2023-01-01 2023-03-31 0001124140 exas:COVID19TestingMember 2022-01-01 2022-03-31 0001124140 exas:VariablePriceContractMember 2023-01-01 2023-03-31 0001124140 exas:VariablePriceContractMember 2022-01-01 2022-03-31 0001124140 us-gaap:ShortTermInvestmentsMember 2023-03-31 0001124140 us-gaap:ShortTermInvestmentsMember 2022-12-31 0001124140 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember 2023-03-31 0001124140 us-gaap:CashEquivalentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0001124140 us-gaap:CashEquivalentsMember 2023-03-31 0001124140 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0001124140 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateBondSecuritiesMember 2023-03-31 0001124140 us-gaap:ShortTermInvestmentsMember us-gaap:AssetBackedSecuritiesMember 2023-03-31 0001124140 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember 2022-12-31 0001124140 us-gaap:CashEquivalentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001124140 us-gaap:CashEquivalentsMember 2022-12-31 0001124140 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001124140 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001124140 us-gaap:ShortTermInvestmentsMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0001124140 us-gaap:LandMember 2023-03-31 0001124140 us-gaap:LandMember 2022-12-31 0001124140 exas:BuildingsAndLeaseholdImprovementsMember 2023-03-31 0001124140 exas:BuildingsAndLeaseholdImprovementsMember 2022-12-31 0001124140 us-gaap:LandImprovementsMember 2023-01-01 2023-03-31 0001124140 us-gaap:LandImprovementsMember 2023-03-31 0001124140 us-gaap:LandImprovementsMember 2022-12-31 0001124140 srt:MinimumMember us-gaap:BuildingMember 2023-01-01 2023-03-31 0001124140 srt:MaximumMember us-gaap:BuildingMember 2023-01-01 2023-03-31 0001124140 us-gaap:BuildingMember 2023-03-31 0001124140 us-gaap:BuildingMember 2022-12-31 0001124140 exas:OfficeEquipmentAndComputerSoftwareMember 2023-01-01 2023-03-31 0001124140 exas:OfficeEquipmentAndComputerSoftwareMember 2023-03-31 0001124140 exas:OfficeEquipmentAndComputerSoftwareMember 2022-12-31 0001124140 srt:MinimumMember us-gaap:EquipmentMember 2023-01-01 2023-03-31 0001124140 srt:MaximumMember us-gaap:EquipmentMember 2023-01-01 2023-03-31 0001124140 us-gaap:EquipmentMember 2023-03-31 0001124140 us-gaap:EquipmentMember 2022-12-31 0001124140 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2023-01-01 2023-03-31 0001124140 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2023-01-01 2023-03-31 0001124140 us-gaap:FurnitureAndFixturesMember 2023-03-31 0001124140 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001124140 us-gaap:AssetUnderConstructionMember 2023-03-31 0001124140 us-gaap:AssetUnderConstructionMember 2022-12-31 0001124140 us-gaap:ComputerSoftwareIntangibleAssetMember 2023-03-31 0001124140 us-gaap:TradeNamesMember 2023-01-01 2023-03-31 0001124140 us-gaap:TradeNamesMember 2023-03-31 0001124140 us-gaap:CustomerRelationshipsMember 2023-01-01 2023-03-31 0001124140 us-gaap:CustomerRelationshipsMember 2023-03-31 0001124140 us-gaap:PatentsMember 2023-01-01 2023-03-31 0001124140 us-gaap:PatentsMember 2023-03-31 0001124140 us-gaap:DevelopedTechnologyRightsMember 2023-01-01 2023-03-31 0001124140 us-gaap:DevelopedTechnologyRightsMember 2023-03-31 0001124140 us-gaap:TradeNamesMember 2022-01-01 2022-12-31 0001124140 us-gaap:TradeNamesMember 2022-12-31 0001124140 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-12-31 0001124140 us-gaap:CustomerRelationshipsMember 2022-12-31 0001124140 us-gaap:PatentsMember 2022-01-01 2022-12-31 0001124140 us-gaap:PatentsMember 2022-12-31 0001124140 us-gaap:DevelopedTechnologyRightsMember 2022-01-01 2022-12-31 0001124140 us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0001124140 exas:OmicEraMember 2022-01-01 2022-12-31 0001124140 exas:PreventionGeneticsLLCMember 2022-01-01 2022-12-31 0001124140 2022-01-01 2022-12-31 0001124140 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001124140 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001124140 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001124140 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001124140 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001124140 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001124140 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001124140 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001124140 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001124140 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001124140 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001124140 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001124140 us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001124140 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001124140 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001124140 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001124140 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0001124140 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0001124140 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0001124140 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0001124140 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-03-31 0001124140 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-03-31 0001124140 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-03-31 0001124140 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-03-31 0001124140 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-03-31 0001124140 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-03-31 0001124140 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-03-31 0001124140 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-03-31 0001124140 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001124140 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0001124140 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0001124140 exas:ThriveAndAshionMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-03-31 0001124140 exas:ThriveAndAshionMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0001124140 srt:WeightedAverageMember exas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMember exas:MeasurementInputProbabilityOfSuccessMember 2023-03-31 0001124140 srt:WeightedAverageMember exas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMember exas:MeasurementInputProbabilityOfSuccessMember 2022-12-31 0001124140 srt:WeightedAverageMember exas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMember exas:MeasurementInputPresentValueFactorMember 2023-03-31 0001124140 srt:WeightedAverageMember exas:ProductDevelopmentAndOtherMilestoneBasedPaymentsMember exas:MeasurementInputPresentValueFactorMember 2022-12-31 0001124140 exas:ThriveAndAshionMember exas:RevenueAndOtherPerformanceBasedPaymentsMember 2023-03-31 0001124140 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2023-03-31 0001124140 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2022-12-31 0001124140 exas:VentureCapitalInvestmentFundMember 2023-01-01 2023-03-31 0001124140 exas:VentureCapitalInvestmentFundMember 2023-03-31 0001124140 exas:VentureCapitalInvestmentFundMember 2022-12-31 0001124140 us-gaap:ForeignExchangeForwardMember 2023-03-31 0001124140 us-gaap:ForeignExchangeForwardMember 2022-12-31 0001124140 us-gaap:ForeignExchangeForwardMember 2022-01-01 2022-03-31 0001124140 us-gaap:ForeignExchangeForwardMember 2023-01-01 2023-03-31 0001124140 exas:SecuritizedReceivablesMember 2022-06-29 0001124140 srt:MinimumMember exas:SecuritizedReceivablesMember 2022-06-29 0001124140 exas:SecuritizedReceivablesMember 2023-03-31 0001124140 us-gaap:RevolvingCreditFacilityMember exas:RevolvingLoanAgreementMember us-gaap:LineOfCreditMember 2021-11-30 0001124140 us-gaap:RevolvingCreditFacilityMember exas:RevolvingLoanAgreementMember us-gaap:LineOfCreditMember exas:DailyBloombergShortTermBankYieldIndexRateMember 2021-11-01 2021-11-30 0001124140 us-gaap:LetterOfCreditMember exas:RevolvingLoanAgreementMember us-gaap:LineOfCreditMember 2021-12-01 2021-12-31 0001124140 us-gaap:LetterOfCreditMember exas:RevolvingLoanAgreementMember us-gaap:LineOfCreditMember 2023-01-01 2023-01-31 0001124140 us-gaap:RevolvingCreditFacilityMember exas:RevolvingLoanAgreementMember us-gaap:LineOfCreditMember 2023-03-31 0001124140 us-gaap:RevolvingCreditFacilityMember exas:RevolvingLoanAgreementMember us-gaap:LineOfCreditMember 2022-12-31 0001124140 exas:ConvertibleNotesPayable2030Member 2023-03-31 0001124140 exas:ConvertibleNotesPayable2030Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-03-31 0001124140 exas:ConvertibleNotesPayable2028Member 2023-03-31 0001124140 exas:ConvertibleNotesPayable2028Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-03-31 0001124140 exas:ConvertibleNotesPayable2027Member 2023-03-31 0001124140 exas:ConvertibleNotesPayable2027Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-03-31 0001124140 exas:ConvertibleNotesPayable2025Member 2023-03-31 0001124140 exas:ConvertibleNotesPayable2025Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-03-31 0001124140 exas:ConvertibleNotesPayable2028Member 2022-12-31 0001124140 exas:ConvertibleNotesPayable2028Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0001124140 exas:ConvertibleNotesPayable2027Member 2022-12-31 0001124140 exas:ConvertibleNotesPayable2027Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0001124140 exas:ConvertibleNotesPayable2025Member 2022-12-31 0001124140 exas:ConvertibleNotesPayable2025Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0001124140 exas:ConvertibleNotesPayable2030Member 2023-03-01 0001124140 exas:ConvertibleNotesPayable2027Member 2023-03-01 2023-03-31 0001124140 exas:ConvertibleNotesPayable2028Member 2023-03-01 2023-03-31 0001124140 exas:ConvertibleNotesPayable2030Member 2023-03-01 2023-03-31 0001124140 2023-03-01 2023-03-31 0001124140 exas:ConvertibleNotesPayable2030Member exas:ConvertibleNotesPayable2025Member 2023-03-06 0001124140 exas:ConvertibleNotesPayable2025Member 2023-03-01 2023-03-31 0001124140 exas:ConvertibleNotesPayable2025Member 2023-03-01 2023-03-31 0001124140 exas:ConvertibleNotesPayable2025Member 2023-01-01 2023-03-31 0001124140 exas:ConvertibleNotesPayable2027Member 2023-01-01 2023-03-31 0001124140 exas:ConvertibleNotesPayable2028Member 2023-01-01 2023-03-31 0001124140 exas:ConvertibleNotesPayable2030Member 2023-01-01 2023-03-31 0001124140 exas:ConvertibleNotesPayable2030Member 2022-01-01 2022-03-31 0001124140 exas:ConvertibleNotesPayable2028Member 2022-01-01 2022-03-31 0001124140 exas:ConvertibleNotesPayable2027Member 2022-01-01 2022-03-31 0001124140 exas:ConvertibleNotesPayable2025Member 2022-01-01 2022-03-31 0001124140 exas:MAYOFoundationMember us-gaap:LicensingAgreementsMember 2020-09-30 0001124140 exas:MAYOFoundationMember us-gaap:LicensingAgreementsMember 2023-01-01 2023-03-31 0001124140 exas:MAYOFoundationMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-03-31 0001124140 exas:ThriveEarlierDetectionCorporationMember us-gaap:LicensingAgreementsMember exas:SalesMilestoneRangeOneMember 2021-01-05 0001124140 exas:ThriveEarlierDetectionCorporationMember us-gaap:LicensingAgreementsMember exas:SalesMilestoneRangeTwoMember 2021-01-05 0001124140 exas:ThriveEarlierDetectionCorporationMember us-gaap:LicensingAgreementsMember exas:SalesMilestoneRangeThreeMember 2021-01-05 0001124140 exas:ThriveEarlierDetectionCorporationMember us-gaap:LicensingAgreementsMember exas:SalesMilestoneRangeOneMember 2021-01-05 2021-01-05 0001124140 exas:ThriveEarlierDetectionCorporationMember us-gaap:LicensingAgreementsMember exas:SalesMilestoneRangeTwoMember 2021-01-05 2021-01-05 0001124140 exas:ThriveEarlierDetectionCorporationMember us-gaap:LicensingAgreementsMember exas:SalesMilestoneRangeThreeMember 2021-01-05 2021-01-05 0001124140 exas:TgenMember us-gaap:LicensingAgreementsMember exas:ProductRevenueRelatedToMRDDetectionPaymentOneMember 2021-01-31 0001124140 exas:TgenMember us-gaap:LicensingAgreementsMember exas:ProductRevenueRelatedToMRDDetectionPaymentTwoMember 2021-01-31 0001124140 exas:TgenMember us-gaap:LicensingAgreementsMember exas:ProductRevenueRelatedToTreatmentPaymentOneMember 2021-01-31 0001124140 exas:TgenMember us-gaap:LicensingAgreementsMember exas:ProductRevenueRelatedToTreatmentPaymentTwoMember 2021-01-31 0001124140 exas:PfizerIncMember us-gaap:ManufacturedProductOtherMember 2021-11-30 0001124140 exas:PfizerIncMember us-gaap:ManufacturedProductOtherMember 2022-01-01 2022-03-31 0001124140 exas:OmicEraDiagnosticsAcquisitionMember 2022-05-01 2022-05-31 0001124140 exas:OmicEraDiagnosticsAcquisitionMember 2022-05-01 0001124140 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0001124140 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0001124140 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0001124140 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-03-31 0001124140 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0001124140 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-03-31 0001124140 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0001124140 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0001124140 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0001124140 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-03-31 0001124140 us-gaap:AccumulatedTranslationAdjustmentMember 2022-03-31 0001124140 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-03-31 0001124140 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-03-31 0001124140 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-03-31 0001124140 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001124140 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001124140 exas:StockBasedCompensationPlansMember 2023-03-31 0001124140 exas:StockBasedCompensationPlansMember 2023-01-01 2023-03-31 0001124140 exas:StockBasedCompensationPlansMember 2022-12-31 0001124140 exas:StockBasedCompensationPlansMember 2022-12-31 2022-12-31 0001124140 exas:StockBasedCompensationPlansMember 2022-01-01 2022-03-31 0001124140 exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember 2022-12-31 0001124140 exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001124140 exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember 2023-03-31 0001124140 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001124140 exas:RestrictedStockAwardsAndRestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001124140 us-gaap:PerformanceSharesMember 2022-12-31 0001124140 us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0001124140 us-gaap:PerformanceSharesMember 2023-03-31 0001124140 us-gaap:PerformanceSharesMember 2022-01-01 2022-03-31 0001124140 us-gaap:EmployeeStockMember exas:EmployeeStockPurchasePlan2010Member 2022-01-01 2022-03-31 0001124140 us-gaap:EmployeeStockMember exas:EmployeeStockPurchasePlan2010Member 2023-01-01 2023-03-31 0001124140 exas:DOSRuleInvestigationMember 2021-12-31 0001124140 exas:DOSRuleInvestigationMember 2022-04-01 2022-06-30 0001124140 exas:DOSRuleInvestigationMember 2023-03-31 0001124140 exas:WisconsinEconomicDevelopmentTaxCreditAgreementMember 2015-02-28 0001124140 exas:WisconsinEconomicDevelopmentTaxCreditAgreementMember 2015-02-01 2015-02-28 0001124140 exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember 2021-12-31 0001124140 exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember 2021-12-01 2021-12-31 0001124140 exas:WisconsinEconomicDevelopmentTaxCreditAgreementMember 2020-12-31 0001124140 exas:WisconsinEconomicDevelopmentTaxCreditAgreementMember 2022-12-31 0001124140 exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember 2023-03-31 0001124140 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember 2023-03-31 0001124140 us-gaap:OtherNoncurrentAssetsMember exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember 2023-03-31 0001124140 us-gaap:OperatingExpenseMember exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember 2023-01-01 2023-03-31 0001124140 us-gaap:OperatingExpenseMember exas:AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember 2022-01-01 2022-03-31 0001124140 country:US 2023-01-01 2023-03-31 0001124140 country:US 2022-01-01 2022-03-31 0001124140 us-gaap:NonUsMember 2023-01-01 2023-03-31 0001124140 us-gaap:NonUsMember 2022-01-01 2022-03-31 shares iso4217:USD iso4217:USD shares pure exas:installment exas:position exas:segment 2023 Q1 0001124140 false --12-31 http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent 1 10-Q true 2023-03-31 false 001-35092 EXACT SCIENCES CORPORATION DE 02-0478229 5505 Endeavor Lane Madison WI 53719 608 535-8815 Common Stock, $0.01 par value per share EXAS NASDAQ Yes Yes Large Accelerated Filer false false false 180388167 421365000 242493000 277282000 389564000 183371000 158043000 124092000 118259000 85274000 73898000 1091384000 982257000 684574000 684756000 156782000 167003000 2346235000 2346040000 1933481000 1956240000 91872000 90577000 6304328000 6226873000 86713000 74916000 241844000 299216000 30014000 28366000 8783000 10249000 367354000 412747000 2310196000 2186106000 50000000 50000000 344380000 352459000 174690000 182399000 3246620000 3183711000 0.01 0.01 5000000 5000000 0 0 0 0 0 0 0.01 0.01 400000000 400000000 179830145 179830145 177925631 177925631 1799000 1780000 6396805000 6311644000 -1719000 -5236000 -3339177000 -3265026000 3057708000 3043162000 6304328000 6226873000 602450000 486571000 156866000 134705000 95419000 102248000 186964000 232181000 217295000 169770000 22928000 24654000 69000 0 679541000 663558000 -77091000 -176987000 490000 -1487000 4107000 -4478000 4597000 -5965000 -72494000 -182952000 1657000 -2015000 -74151000 -180937000 -0.42 -0.42 -1.04 -1.04 178574000 178574000 174417000 174417000 -74151000 -180937000 2967000 -4967000 550000 -237000 -70634000 -186141000 0.01 177925631 1780000 6311644000 -5236000 -3265026000 3043162000 88228 1000 963000 964000 517215 5000 35072000 35077000 1299071 13000 49126000 49139000 -74151000 -74151000 3517000 3517000 179830145 1799000 6396805000 -1719000 -3339177000 3057708000 0.01 173674067 1738000 6028861000 -1443000 -2641520000 3387636000 485537 5000 4277000 4282000 1391797 14000 52427000 52441000 7 7000 7000 -180937000 -180937000 -5204000 -5204000 175551408 1757000 6085558000 -6647000 -2822457000 3258211000 -74151000 -180937000 26815000 22993000 -284000 -321000 -3009000 -1350000 1261000 -1912000 49139000 52441000 10324000 0 1783000 1700000 -54000 956000 22928000 24654000 69000 0 -8937000 -26680000 6806000 7363000 25434000 -11020000 5827000 7964000 -5982000 -5177000 -4817000 -66048000 13622000 6619000 -1161000 -1215000 -38215000 -173754000 8589000 70267000 121332000 150630000 29360000 33623000 442000 1172000 0 7000 82941000 45561000 964000 4282000 137976000 0 -5344000 -1547000 133596000 2735000 550000 -237000 178872000 -125695000 242790000 315768000 421662000 190073000 10548000 31491000 6442000 5133000 421365000 189776000 297000 297000 421662000 190073000 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exact Sciences Corporation (together with its subsidiaries, “Exact,” or the “Company”) was incorporated in February 1995. Exact is a leading global cancer diagnostics company. It has developed some of the most impactful tests in cancer screening and diagnostics, including Cologuard® and Oncotype DX®. Exact is currently working on the development of additional tests, with the goal of bringing new, innovative cancer tests to patients throughout the world.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements, which include the accounts of the Company and those of its wholly owned subsidiaries and variable interest entities, are unaudited and have been prepared on a basis substantially consistent with the Company’s audited financial statements and notes as of and for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K (the “2022 Form 10-K”). All intercompany transactions and balances have been eliminated upon consolidation. These condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted (“GAAP”) in the United States of America (“U.S.”) and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting only of adjustments of a normal and recurring nature) considered necessary for a fair statement of its financial position, operating results and cash flows for the periods presented. The condensed consolidated balance sheet at December 31, 2022 has been derived from audited financial statements, but does not contain all of the footnote disclosures from the 2022 Form 10-K. The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year. The statements should be read in conjunction with the audited financial statements and related notes included in the 2022 Form 10-K. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that affect the Company’s financial statements materially and involve difficult, subjective or complex judgments by management, and actual results could differ from those estimates. These estimates include revenue recognition, valuation of intangible assets and goodwill, and accounting for income taxes among others. The Company’s critical accounting policies and estimates are explained further in the notes to the condensed consolidated financial statements in this Quarterly Report on Form 10-Q and the 2022 Form 10-K.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of the coronavirus (“COVID-19”) and the macroeconomic conditions including inflation and fluctuations in foreign currency exchange rates has affected many segments of the global economy, including the cancer screening and diagnostics industry. The Company expects these matters to have an impact on operations, however, the ultimate impact presents uncertainty and depends on factors beyond the Company’s knowledge or control, including the duration and severity, as well as third-party actions taken. The Company continues to use the best information available to inform its accounting estimates in light of these uncertainties. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, there were no changes to the Company’s significant accounting policies as described in the Company’s 2022 Form 10-K. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to the current year presentation in the condensed consolidated financial statements and accompanying notes to the condensed consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not adopt any accounting standards updates (“ASU”) released by the Financial Accounting Standards Board (“FASB”) in the first quarter of 2023. In addition, there are no ASUs not yet adopted that are expected to impact the Company. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share is the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive as a result of the Company’s losses.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,231 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,309 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon the release of restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,877 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,991 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon the release of performance share units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable in connection with acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,195 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,098 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> Basis of Presentation and Principles of ConsolidationThe accompanying condensed consolidated financial statements, which include the accounts of the Company and those of its wholly owned subsidiaries and variable interest entities, are unaudited and have been prepared on a basis substantially consistent with the Company’s audited financial statements and notes as of and for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K (the “2022 Form 10-K”). All intercompany transactions and balances have been eliminated upon consolidation. These condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted (“GAAP”) in the United States of America (“U.S.”) and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting only of adjustments of a normal and recurring nature) considered necessary for a fair statement of its financial position, operating results and cash flows for the periods presented. The condensed consolidated balance sheet at December 31, 2022 has been derived from audited financial statements, but does not contain all of the footnote disclosures from the 2022 Form 10-K. The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year. The statements should be read in conjunction with the audited financial statements and related notes included in the 2022 Form 10-K. <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that affect the Company’s financial statements materially and involve difficult, subjective or complex judgments by management, and actual results could differ from those estimates. These estimates include revenue recognition, valuation of intangible assets and goodwill, and accounting for income taxes among others. The Company’s critical accounting policies and estimates are explained further in the notes to the condensed consolidated financial statements in this Quarterly Report on Form 10-Q and the 2022 Form 10-K.</span></div>The spread of the coronavirus (“COVID-19”) and the macroeconomic conditions including inflation and fluctuations in foreign currency exchange rates has affected many segments of the global economy, including the cancer screening and diagnostics industry. The Company expects these matters to have an impact on operations, however, the ultimate impact presents uncertainty and depends on factors beyond the Company’s knowledge or control, including the duration and severity, as well as third-party actions taken. The Company continues to use the best information available to inform its accounting estimates in light of these uncertainties. <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to the current year presentation in the condensed consolidated financial statements and accompanying notes to the condensed consolidated financial statements.</span></div> Recent Accounting PronouncementsThe Company did not adopt any accounting standards updates (“ASU”) released by the Financial Accounting Standards Board (“FASB”) in the first quarter of 2023. In addition, there are no ASUs not yet adopted that are expected to impact the Company. <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share is the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive as a result of the Company’s losses.</span></div> <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,231 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,309 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon the release of restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,877 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,991 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon the release of performance share units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable in connection with acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,195 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,098 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 23231000 20309000 6877000 6991000 1671000 963000 1416000 1790000 0 45000 33195000 30098000 REVENUE <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard, Oncotype®, and COVID-19 tests. The services are completed upon release of a patient’s test result to the ordering healthcare provider. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s revenues disaggregated by revenue source:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;text-indent:18pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Screening</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Parts B &amp; C</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,755 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233,033 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">161,680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,087 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Screening</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">443,195 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">306,522 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precision Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Parts B &amp; C</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,565 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,932 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,433 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Precision Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155,432 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152,620 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 Testing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,823 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,429 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602,450 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,571 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Screening revenue primarily includes laboratory service revenue from Cologuard and PreventionGenetics LLC (“PreventionGenetics”) tests while Precision Oncology revenue includes laboratory service revenue from global Oncotype products and therapy selection products.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. The Company recognized revenue from a change in transaction price of $11.7 million and $4.2 million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s deferred revenue, which is reported in other current liabilities in the Company’s condensed consolidated balance sheets, was not material as of March 31, 2023 and December 31, 2022. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized for the three months ended March 31, 2023 and 2022, respectively, which was included in the deferred revenue balance at the beginning of the period, was not material.</span></div> <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s revenues disaggregated by revenue source:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;text-indent:18pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Screening</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Parts B &amp; C</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,755 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233,033 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">161,680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,087 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Screening</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">443,195 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">306,522 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precision Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Parts B &amp; C</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,565 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,932 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,433 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Precision Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155,432 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152,620 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 Testing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,823 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,429 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602,450 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,571 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 171730000 113755000 233033000 161680000 38432000 31087000 443195000 306522000 47381000 52565000 44932000 46062000 37268000 29560000 25851000 24433000 155432000 152620000 3823000 27429000 602450000 486571000 11700000 4200000 MARKETABLE SECURITIES<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company’s cash, cash equivalents, and marketable securities at March 31, 2023 and December 31, 2022:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">421,365 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">242,493 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,694 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,282 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,564 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698,647 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632,057 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at March 31, 2023, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains in Accumulated Other Comprehensive Income (Loss) (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses in Accumulated Other Comprehensive Income (Loss) (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,016 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,462)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,694 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,832 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,462)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,510 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">There was no tax impact from the gains and losses in accumulated other comprehensive income (loss) (“AOCI”).</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at December 31, 2022, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains in Accumulated Other Comprehensive Income (Loss) (1) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses in Accumulated Other Comprehensive Income (Loss) (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,325 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,325 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,704 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,415 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,029 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,740 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">There was no tax impact from the gains and losses in AOCI.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at March 31, 2023:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due after one year through five years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,663 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,584 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,781 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,432 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,913 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,400 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,597 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,432 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,913 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of March 31, 2023, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;text-indent:18pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less than one year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">One year or greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(748)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,885 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(887)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,094 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,903 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,140)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,997 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,462)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The Company evaluates investments that are in an unrealized loss position for impairment as a result of credit loss. It was determined that no credit losses exist as of March 31, 2023 and December 31, 2022, because the change in market value for those securities in an unrealized loss position has resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers. The gains and losses recorded on available-for-sale debt securities and equity securities are included in investment income, net in the Company’s condensed consolidated statements of operations. The gains and losses recorded were not material for the three months ended March 31, 2023 and 2022. MARKETABLE SECURITIES<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company’s cash, cash equivalents, and marketable securities at March 31, 2023 and December 31, 2022:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">421,365 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">242,493 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,694 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,282 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,564 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698,647 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632,057 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at March 31, 2023, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains in Accumulated Other Comprehensive Income (Loss) (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses in Accumulated Other Comprehensive Income (Loss) (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,016 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,462)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,694 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,832 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,462)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,510 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">There was no tax impact from the gains and losses in accumulated other comprehensive income (loss) (“AOCI”).</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at December 31, 2022, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains in Accumulated Other Comprehensive Income (Loss) (1) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses in Accumulated Other Comprehensive Income (Loss) (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,325 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,325 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,704 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,415 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,029 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,740 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">There was no tax impact from the gains and losses in AOCI.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at March 31, 2023:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due after one year through five years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,663 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,584 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,781 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,432 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,913 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,400 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,597 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,432 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,913 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of March 31, 2023, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;text-indent:18pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less than one year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">One year or greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(748)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,885 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(887)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,094 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,903 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,140)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,997 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,462)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The Company evaluates investments that are in an unrealized loss position for impairment as a result of credit loss. It was determined that no credit losses exist as of March 31, 2023 and December 31, 2022, because the change in market value for those securities in an unrealized loss position has resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers. The gains and losses recorded on available-for-sale debt securities and equity securities are included in investment income, net in the Company’s condensed consolidated statements of operations. The gains and losses recorded were not material for the three months ended March 31, 2023 and 2022. MARKETABLE SECURITIES<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company’s cash, cash equivalents, and marketable securities at March 31, 2023 and December 31, 2022:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">421,365 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">242,493 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,694 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,282 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,564 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698,647 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632,057 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at March 31, 2023, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains in Accumulated Other Comprehensive Income (Loss) (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses in Accumulated Other Comprehensive Income (Loss) (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,016 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,462)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,694 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,832 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,462)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,510 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">There was no tax impact from the gains and losses in accumulated other comprehensive income (loss) (“AOCI”).</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at December 31, 2022, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains in Accumulated Other Comprehensive Income (Loss) (1) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses in Accumulated Other Comprehensive Income (Loss) (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,325 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,325 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,704 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,415 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,029 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,740 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">There was no tax impact from the gains and losses in AOCI.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at March 31, 2023:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due after one year through five years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,663 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,584 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,781 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,432 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,913 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,400 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,597 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,432 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,913 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of March 31, 2023, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;text-indent:18pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less than one year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">One year or greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(748)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,885 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(887)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,094 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,903 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,140)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,997 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,462)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The Company evaluates investments that are in an unrealized loss position for impairment as a result of credit loss. It was determined that no credit losses exist as of March 31, 2023 and December 31, 2022, because the change in market value for those securities in an unrealized loss position has resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers. The gains and losses recorded on available-for-sale debt securities and equity securities are included in investment income, net in the Company’s condensed consolidated statements of operations. The gains and losses recorded were not material for the three months ended March 31, 2023 and 2022. MARKETABLE SECURITIES<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company’s cash, cash equivalents, and marketable securities at March 31, 2023 and December 31, 2022:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">421,365 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">242,493 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,694 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,282 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,564 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698,647 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632,057 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at March 31, 2023, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains in Accumulated Other Comprehensive Income (Loss) (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses in Accumulated Other Comprehensive Income (Loss) (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,016 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,462)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,694 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,832 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,462)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,510 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">There was no tax impact from the gains and losses in accumulated other comprehensive income (loss) (“AOCI”).</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at December 31, 2022, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains in Accumulated Other Comprehensive Income (Loss) (1) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses in Accumulated Other Comprehensive Income (Loss) (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,325 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,325 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,704 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,415 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,029 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,740 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">There was no tax impact from the gains and losses in AOCI.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at March 31, 2023:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due after one year through five years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,663 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,584 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,781 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,432 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,913 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,400 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,597 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,432 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,913 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of March 31, 2023, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;text-indent:18pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less than one year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">One year or greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(748)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,885 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(887)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,094 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,903 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,140)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,997 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,462)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The Company evaluates investments that are in an unrealized loss position for impairment as a result of credit loss. It was determined that no credit losses exist as of March 31, 2023 and December 31, 2022, because the change in market value for those securities in an unrealized loss position has resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers. The gains and losses recorded on available-for-sale debt securities and equity securities are included in investment income, net in the Company’s condensed consolidated statements of operations. The gains and losses recorded were not material for the three months ended March 31, 2023 and 2022. MARKETABLE SECURITIES<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company’s cash, cash equivalents, and marketable securities at March 31, 2023 and December 31, 2022:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">421,365 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">242,493 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,694 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,282 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,564 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698,647 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632,057 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at March 31, 2023, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains in Accumulated Other Comprehensive Income (Loss) (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses in Accumulated Other Comprehensive Income (Loss) (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,016 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,462)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,694 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,832 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,462)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,510 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">There was no tax impact from the gains and losses in accumulated other comprehensive income (loss) (“AOCI”).</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at December 31, 2022, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains in Accumulated Other Comprehensive Income (Loss) (1) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses in Accumulated Other Comprehensive Income (Loss) (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,325 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,325 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,704 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,415 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,029 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,740 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">There was no tax impact from the gains and losses in AOCI.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at March 31, 2023:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due after one year through five years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,663 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,584 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,781 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,432 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,913 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,400 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,597 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,432 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,913 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of March 31, 2023, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;text-indent:18pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less than one year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">One year or greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(748)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,885 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(887)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,094 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,903 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,140)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,997 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,462)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The Company evaluates investments that are in an unrealized loss position for impairment as a result of credit loss. It was determined that no credit losses exist as of March 31, 2023 and December 31, 2022, because the change in market value for those securities in an unrealized loss position has resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers. The gains and losses recorded on available-for-sale debt securities and equity securities are included in investment income, net in the Company’s condensed consolidated statements of operations. The gains and losses recorded were not material for the three months ended March 31, 2023 and 2022. <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company’s cash, cash equivalents, and marketable securities at March 31, 2023 and December 31, 2022:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">421,365 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">242,493 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,694 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,282 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,564 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698,647 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632,057 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 351549000 178168000 69816000 64325000 421365000 242493000 274694000 384415000 2588000 5149000 277282000 389564000 698647000 632057000 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at March 31, 2023, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains in Accumulated Other Comprehensive Income (Loss) (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses in Accumulated Other Comprehensive Income (Loss) (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,016 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,462)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,694 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,832 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,462)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,510 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">There was no tax impact from the gains and losses in accumulated other comprehensive income (loss) (“AOCI”).</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities, including the classification within the condensed consolidated balance sheet at December 31, 2022, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains in Accumulated Other Comprehensive Income (Loss) (1) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses in Accumulated Other Comprehensive Income (Loss) (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,325 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,325 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,521 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,704 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,415 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,029 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,740 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">There was no tax impact from the gains and losses in AOCI.</span></div> 68081000 0 0 68081000 1735000 0 0 1735000 69816000 0 0 69816000 147979000 16000 909000 147086000 97378000 18000 948000 96448000 31659000 106000 605000 31160000 277016000 140000 2462000 274694000 346832000 140000 2462000 344510000 63021000 0 0 63021000 1304000 0 0 1304000 64325000 0 0 64325000 228012000 0 2789000 225223000 116318000 20000 1667000 114671000 45374000 2000 855000 44521000 389704000 22000 5311000 384415000 454029000 22000 5311000 448740000 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at March 31, 2023:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due after one year through five years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,816 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,663 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,584 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,781 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,432 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,913 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,400 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,597 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,432 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,913 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 68081000 68081000 0 0 1735000 1735000 0 0 69816000 69816000 0 0 138322000 137423000 9657000 9663000 82071000 81169000 15307000 15279000 1191000 1189000 30468000 29971000 221584000 219781000 55432000 54913000 291400000 289597000 55432000 54913000 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of March 31, 2023, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;text-indent:18pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less than one year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">One year or greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(748)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,885 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(887)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,544 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total available-for-sale securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,094 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,903 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,140)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,997 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,462)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 35897000 161000 103474000 748000 139371000 909000 16430000 61000 71885000 887000 88315000 948000 10767000 100000 18544000 505000 29311000 605000 63094000 322000 193903000 2140000 256997000 2462000 INVENTORY<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,433 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,207 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Semi-finished and finished goods</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,052 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,092 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,259 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,433 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,207 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Semi-finished and finished goods</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,052 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,092 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,259 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 63433000 61207000 60659000 57052000 124092000 118259000 PROPERTY, PLANT AND EQUIPMENT<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value and estimated useful lives of property, plant and equipment are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,716 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,716 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold and building improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,613 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 - 40 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,798 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,896 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 10 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,926 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 10 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,047 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets under construction</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,648 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, at cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018,737 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992,347 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334,163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,574 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,756 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Lesser of remaining lease term, building life, or estimated useful life.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended March 31, 2023 and 2022 was $26.8 million and $23.0 million, respectively.</span></div>At March 31, 2023, the Company had $79.6 million of assets under construction, which consisted of $51.9 million in laboratory equipment, $12.4 million in leasehold and building improvements, $10.1 million in capitalized costs related to software projects, and $5.2 million related to buildings. Depreciation will begin on these assets once they are placed into service upon completion. <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value and estimated useful lives of property, plant and equipment are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,716 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,716 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold and building improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,613 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 - 40 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,798 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,896 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 10 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,926 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 10 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,047 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets under construction</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,648 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, at cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018,737 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992,347 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334,163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,574 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,756 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Lesser of remaining lease term, building life, or estimated useful life.</span></div> 4716000 4716000 200314000 200588000 P15Y 6613000 6417000 P30Y P40Y 290121000 288941000 P3Y 148798000 142896000 P3Y P10Y 253926000 246344000 P3Y P10Y 34601000 34047000 79648000 68398000 1018737000 992347000 334163000 307591000 684574000 684756000 26800000 23000000 79600000 51900000 12400000 10100000 5200000 INTANGIBLE ASSETS AND GOODWILL<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of March 31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Balance at March 31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,514)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,028 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired developed technology (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861,644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(266,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981,186 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297,705)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683,481 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,231,186 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297,705)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933,481 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net balance at December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,152)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired developed technology (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">861,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(245,527)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">615,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981,016 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274,776)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,240 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,231,016 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274,776)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956,240 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The gross carrying amount includes an immaterial foreign currency translation adjustment related to the intangible asset acquired as a result of the acquisition of OmicEra Diagnostics GmbH (“OmicEra”), whose functional currency is also its local currency. Intangible asset balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,786 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683,481 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s acquired intangible assets are being amortized on a straight-line basis over their estimated useful lives.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amount of goodwill for the periods ended March 31, 2023 and December 31, 2022 is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,335,172 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OmicEra acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,809 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PreventionGenetics acquisition adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effects of changes in foreign currency exchange rates (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,346,040 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effects of changes in foreign currency exchange rates (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance March 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,346,235 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents the impact of foreign currency translation related to the goodwill acquired as a result of the acquisition of OmicEra. Goodwill balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no impairment losses for the three months ended March 31, 2023 and 2022.</span></div> <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of March 31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Balance at March 31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,514)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,028 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired developed technology (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861,644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(266,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981,186 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297,705)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683,481 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,231,186 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297,705)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933,481 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net balance at December 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,152)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired developed technology (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">861,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(245,527)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">615,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981,016 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274,776)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,240 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,231,016 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274,776)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956,240 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The gross carrying amount includes an immaterial foreign currency translation adjustment related to the intangible asset acquired as a result of the acquisition of OmicEra Diagnostics GmbH (“OmicEra”), whose functional currency is also its local currency. Intangible asset balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.</span></div> P12Y3M18D 104000000 22465000 81535000 P7Y9M18D 4000000 556000 3444000 P4Y1M6D 11542000 8514000 3028000 P7Y6M 861644000 266170000 595474000 981186000 297705000 683481000 1250000000 1250000000 2231186000 297705000 1933481000 P12Y6M 104000000 20653000 83347000 P8Y 4000000 444000 3556000 P4Y2M12D 11542000 8152000 3390000 P7Y9M18D 861474000 245527000 615947000 981016000 274776000 706240000 1250000000 1250000000 2231016000 274776000 1956240000 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,786 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683,481 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 68786000 91378000 90331000 89271000 89271000 254444000 683481000 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amount of goodwill for the periods ended March 31, 2023 and December 31, 2022 is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,335,172 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OmicEra acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,809 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PreventionGenetics acquisition adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effects of changes in foreign currency exchange rates (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,346,040 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effects of changes in foreign currency exchange rates (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance March 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,346,235 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents the impact of foreign currency translation related to the goodwill acquired as a result of the acquisition of OmicEra. Goodwill balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income.</span></div> 2335172000 10809000 -58000 117000 2346040000 195000 2346235000 0 0 0 0 FAIR VALUE MEASUREMENTS<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three levels of the fair value hierarchy established are as follows:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Unobservable inputs that reflect the Company’s assumptions about the assumptions that market participants would use in pricing the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s fair value measurements as of March 31, 2023 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,086 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,086 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297,990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297,990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,144 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,434 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,510 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287,800)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s fair value measurements as of December 31, 2022 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306,927)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306,927)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,492 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,614 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,740 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296,862)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in valuation techniques or transfers between fair value measurement levels during the three months ended March 31, 2023. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities are valued using a third-party pricing agency where the valuation is based on observable inputs including pricing for similar assets and other observable market factors. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration Liabilities</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration liabilities as of March 31, 2023 and December 31, 2022 was $298.0 million and $306.9 million, respectively, which was recorded in other long-term liabilities in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of contingent consideration:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance, January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,927 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance, March 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,990 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The change in fair value of the contingent consideration liability for the three months ended March 31, 2022 was a reduction of $26.7 million. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This fair value measurement of contingent consideration is categorized as a Level 3 liability, as the measurement amount is based primarily on significant inputs not observable in the market. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration liabilities recorded from the Company’s acquisitions of Thrive Earlier Detection Corporation (“Thrive”), Ashion Analytics, LLC (“Ashion”), and OmicEra related to regulatory and product development milestones was $297.9 million and $306.8 million as of March 31, 2023 and December 31, 2022, respectively. The Company evaluates the fair value of the expected contingent consideration and the corresponding liabilities related to the regulatory and product development milestones using the probability-weighted scenario based discounted cash flow model, which is consistent with the initial measurement of the expected contingent consideration liabilities. Probabilities of success are applied to each potential scenario and the resulting values are discounted using a present-value factor. The passage of time in addition to changes in projected milestone achievement timing, present-value factor, the degree of achievement, if applicable, and probabilities of success may result in adjustments to the fair value measurement. The fair value of the contingent consideration liability recorded related to regulatory and product development milestones was determined using a weighted average probability of success of 91% as of March 31, 2023 and December 31, 2022, and a weighted average present-value factor of 6.1% and 6.2% as of March 31, 2023 and December 31, 2022, respectively. The projected fiscal year of payment range is from 2024 to 2029. Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration liability related to certain revenue milestones associated with the Biomatrica acquisition was not material as of March 31, 2023 and December 31, 2022. The revenue milestone associated with the Ashion acquisition is not expected to be achieved and therefore no liability has been recorded for this milestone. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Marketable Equity Investments</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and December 31, 2022, the aggregate carrying amounts of the Company’s non-marketable equity securities without readily determinable fair values were $39.4 million and $39.8 million, respectively, which are classified as a component of other long-term assets, net in the Company’s condensed consolidated balance sheets. Since initial recognition of these investments, there have been no upward or downward adjustments made on these investments since initial recognition. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has committed capital to venture capital investment funds (the “Funds”) of $17.5 million, of which $13.3 million remained callable through 2033 as of March 31, 2023. The aggregate carrying amount of the Funds, which are classified as a component of other long-term assets, net in the Company’s condensed consolidated balance sheets, were $4.2 million and $3.9 million as of March 31, 2023 and December 31, 2022, respectively. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into foreign currency forward contracts on the last day of each month to mitigate the impact of adverse movements in foreign exchange rates related to the remeasurement of monetary assets and liabilities and hedge the Company’s foreign currency exchange rate exposure. As of March 31, 2023 and December 31, 2022, the Company had open foreign currency forward contracts with notional amounts of $29.2 million and $22.3 million, respectively. The Company's foreign exchange derivative instruments are classified as Level 2 within the fair value hierarchy as they are valued using inputs that are observable in the market or can be derived principally from or corroborated by observable market data. The fair value of the open foreign currency forward contracts was zero at March 31, 2023 and December 31, 2022, and there were no gains or losses recorded to adjust the fair value of the open foreign currency contract held as of March 31, 2023. The contracts are closed subsequent to each month-end, and the gains and losses recorded from the contracts were not material for the three months ended March 31, 2023 and 2022.</span></div> <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s fair value measurements as of March 31, 2023 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,086 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,086 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297,990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297,990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,144 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,434 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,510 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287,800)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s fair value measurements as of December 31, 2022 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306,927)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306,927)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,492 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,614 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,740 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296,862)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 351549000 351549000 0 0 68081000 0 68081000 0 1735000 0 1735000 0 297000 297000 0 0 147086000 0 147086000 0 96448000 0 96448000 0 31160000 0 31160000 0 2588000 2588000 0 0 10190000 0 0 10190000 297990000 0 0 297990000 411144000 354434000 344510000 -287800000 178168000 178168000 0 0 63021000 0 63021000 0 1304000 0 1304000 0 297000 297000 0 0 225223000 0 225223000 0 114671000 0 114671000 0 44521000 0 44521000 0 5149000 5149000 0 0 10065000 0 0 10065000 306927000 0 0 306927000 335492000 183614000 448740000 -296862000 298000000 306900000 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances of contingent consideration:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance, January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,927 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance, March 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,990 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div>(1)The change in fair value of the contingent consideration liability for the three months ended March 31, 2022 was a reduction of $26.7 million. 306927000 -8937000 297990000 -26700000 297900000 306800000 0.91 0.91 0.061 0.062 0 39400000 39800000 17500000 13300000 4200000 3900000 29200000 22300000 0 0 0 0 0 0 LONG-TERM DEBT<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable Securitization Facility</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2022, the Company, through a wholly-owned special purpose entity, Exact Receivables LLC (“Exact Receivables”) entered into an accounts receivable securitization program (the “Securitization Facility”) with PNC Bank, National Association (“PNC”), with a scheduled maturity date of June 29, 2024. The Securitization Facility provides Exact Receivables with a revolving line-of-credit of up to $150.0 million of borrowing capacity, subject to certain borrowing base requirements, by collateralizing a security interest in the domestic customer accounts receivable of certain wholly-owned subsidiaries of the Company. The amount available under the Securitization Facility fluctuates over time based on the total amount of eligible customer accounts receivable generated by the Company during the normal course of operations. The Securitization Facility requires the Company to maintain minimum borrowings under the facility of $50.0 million. The debt issuance costs incurred related to the Securitization Facility were not material and are being amortized over the life of the Securitization Facility through interest expense within the condensed consolidated statements of operations.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Securitization Facility, the Company also entered into two Receivables Purchase Agreements (“Receivable Purchase Agreements”) on June 29, 2022. The Receivable Purchase Agreements are among the Company and certain wholly-owned subsidiaries of the Company, and between the Company and Exact Receivables. Under the agreements, the wholly-owned subsidiaries sell all of their right, title and interest in their accounts receivables to Exact Receivables. The receivables are used to collateralize borrowings made under the Securitization Facility. The Company retains the responsibility of servicing the accounts receivable balances pledged as collateral under the Securitization Facility and provides a performance guaranty. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the eligible borrowing base under the Securitization Facility was $111.1 million of which the Company elected to collateralize $50.0 million. As of March 31, 2023 and December 31, 2022, the Company had an outstanding balance of $50.0 million, which is recorded to long-term debt on the Company’s condensed consolidated balance sheets. The outstanding balance accrues interest at a rate equal to a daily secured overnight financing rate (“SOFR”) rate plus a SOFR adjustment and an applicable margin. The interest rate was 6.35% at March 31, 2023. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revolving Loan Agreement</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2021, the Company entered into a revolving loan agreement (the “Revolving Loan Agreement”) with PNC. The Revolving Loan Agreement provides the Company with a revolving line of credit of up to $150.0 million (the “Revolver”). The Revolver is collateralized by the Company’s marketable securities held by PNC, which must continue to maintain a minimum market value of $150.0 million. The Revolver is available for general working capital purposes and all other lawful corporate purposes. In addition, the Company may request, in lieu of cash advances, letters of credit with an aggregate stated amount outstanding not to exceed $20.0 million. The availability of advances under the line of credit will be reduced by the stated amount of each letter of credit issued and outstanding.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Revolving Loan Agreement accrue interest at an annual rate equal to the sum of the daily Bloomberg Short-Term Bank Yield Index Rate plus the applicable margin of 0.60%. Loans under the Revolving Loan Agreement may be prepaid at any time without penalty. In October 2022, the Revolving Loan Agreement was amended to extend the maturity date from November 5, 2023 to November 5, 2025. There were no other amendments to the Revolver.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreed to various financial covenants under the Revolving Loan Agreement, and as of March 31, 2023, the Company is in compliance with all covenants.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 and January 2023, PNC issued a letters of credit of $2.9 million and $1.5 million, respectively, which, reduced the amount available for cash advances under the line of credit to $145.6 million and $147.1 million as of March 31, 2023 and December 31, 2022, respectively. As of March 31, 2023 and December 31, 2022, the Company has not drawn funds from, nor are any amounts outstanding under, the Revolving Loan Agreement.</span></div> 150000000 50000000 111100000 50000000 50000000 0.0635 150000000 150000000 20000000 0.0060 2900000 1500000 145600000 147100000 CONVERTIBLE NOTES<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of March 31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.626%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value (1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt Discount and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 Convertible Notes - 2.000%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,993 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,912)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568,081 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635,489 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes - 0.375%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes - 0.375%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563,822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,705)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557,117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523,526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes - 1.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(820)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,709 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of December 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.626%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value (1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt Discount and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes - 0.375%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150,000 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,775)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134,225 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908,500 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes - 0.375%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes - 1.000%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,005 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The fair values are based on observable market prices for this debt, which is traded in less active markets and therefore is classified as a Level 2 fair value measurement. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuances and Settlements</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Company entered into a privately negotiated exchange and purchase agreement with a single holder of certain of the Company’s convertible notes due in 2027 (the “2027 Notes”) and 2028 (the “2028 Notes”). The Company issued the holder $500.0 million aggregate principal amount of 2.0% Convertible Notes due in 2030 (collectively, the “2030 Notes”) in exchange for $183.7 million of aggregate principal of 2027 Notes, $201.0 million of aggregate principal of 2028 Notes, and $138.0 million of cash. The extinguishment resulted in a gain on settlement of convertible notes of $17.7 million, which is included in interest income (expense), net in the condensed consolidated statement of operations for the three months ended March 31, 2023. The gain represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of exchange.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company entered into a privately negotiated exchange agreement with two holders of certain of the Company’s convertible notes due in 2025 (the “2025 Notes”). The Company issued the holder $73.0 million aggregate principal amount of 2030 Notes in exchange for $65.8 million of aggregate principal of 2025 Notes. The extinguishment resulted in a loss on settlement of convertible notes of $7.4 million, which is included in interest income (expense), net in the condensed consolidated statement of operations for the three months ended March 31, 2023. The loss represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of exchange.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds from the issuance of the 2030 Notes were approximately $133.0 million, after deducting commissions and offering expenses payable by the Company.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes will mature on March 1, 2030 and bear interest at a rate of 2.0% per year, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2023.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Conversion Features</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until the six-months immediately preceding the maturity date of the applicable series of the Company’s convertible notes (the “Notes”), each series of Notes is convertible only upon the occurrence of certain events and during certain periods, as set forth in the Indentures filed at the time of the original offerings. On or after the date that is six-months immediately preceding the maturity date of the applicable series of Notes until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert such Notes at any time. The Notes will be convertible into cash, shares of the Company’s common stock (plus, if applicable, cash in lieu of any fractional share), or a combination of cash and shares of the Company’s common stock, at the Company’s election.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company’s intent and policy to settle all conversions through combination settlement. The initial conversion rate is 13.26, 8.96, 8.21, and 12.37 shares of common stock per $1,000 principal amount for the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, respectively, which is equivalent to an initial conversion price of approximately $75.43, $111.66, $121.84, and $80.83 per share of the Company’s common stock for the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, respectively. The 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes are potentially convertible into up to 3.3 million, 5.0 million, 7.8 million, and 7.1 million shares, respectively. The conversion rate is subject to adjustment upon the occurrence of certain specified events as set forth in the Indentures filed at the time of the original offerings but will not be adjusted for accrued and unpaid interest. In addition, holders of the Notes who convert their Notes in connection with a “make-whole fundamental change” (as defined in the Indenture), will, under certain circumstances, be entitled to an increase in the conversion rate.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a “fundamental change” (as defined in the Indentures), holders of the Notes may require the Company to repurchase for cash all or part of their Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the closing price of the Company’s common stock of $67.81 on March 31, 2023, the if-converted values on the Notes do not exceed the principal amount.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness, or the issuance or repurchase of securities by the Company.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ranking of Convertible Notes</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are the Company’s senior unsecured obligations and (i) rank senior in right of payment to all of its future indebtedness that is expressly subordinated in right of payment to the Notes; (ii) rank equal in right of payment to each outstanding series thereof and to all of the Company’s future liabilities that are not so subordinated, unsecured indebtedness; (iii) are effectively junior to all of the Company’s existing and future secured indebtedness and other secured obligations, to the extent of the value of the assets securing that indebtedness and other secured obligations; and (iv) are structurally subordinated to all indebtedness and other liabilities of the Company’s subsidiaries.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuance Costs</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance costs are amortized to interest expense over the term of the Notes. The following table summarizes the original issuance costs at the time of issuance for each set of Notes:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,970 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,453 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,285 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on the Notes includes the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on settlements of convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense (income) on convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,561)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,015 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effective interest rates of the Notes:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.12 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining period over which the unamortized debt discount will be recognized as non-cash interest expense is 1.80, 3.96, 4.92, and 6.92 years for the 2025 Notes, 2027 Notes, 2028 Notes, and 2030 Notes, respectively.</span></div> <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of March 31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.626%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value (1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt Discount and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 Convertible Notes - 2.000%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,993 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,912)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568,081 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635,489 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes - 0.375%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes - 0.375%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563,822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,705)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557,117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523,526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes - 1.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(820)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,709 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible note obligations included in the condensed consolidated balance sheet consisted of the following as of December 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.626%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value (1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt Discount and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes - 0.375%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150,000 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,775)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134,225 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908,500 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes - 0.375%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes - 1.000%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,005 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div>(1)The fair values are based on observable market prices for this debt, which is traded in less active markets and therefore is classified as a Level 2 fair value measurement. 0.02000 572993000 4912000 568081000 635489000 0.00375 949042000 12396000 936646000 832784000 0.00375 563822000 6705000 557117000 523526000 0.01000 249172000 820000 248352000 284709000 0.00375 1150000000 15775000 1134225000 908500000 0.00375 747500000 9445000 738055000 612950000 0.01000 315005000 1179000 313826000 326808000 500000000 0.020 183700000 201000000 138000000 -17700000 73000000 65800000 -7400000 133000000 0.020 13.26 8.96 8.21 12.37 1000 75.43 111.66 121.84 80.83 3300000 5000000 7800000 7100000 100 67.81 The following table summarizes the original issuance costs at the time of issuance for each set of Notes:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,970 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,453 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,285 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 4970000 24453000 14285000 17646000 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on the Notes includes the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on settlements of convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense (income) on convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,561)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,015 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1378000 1412000 31000 36000 10324000 0 3354000 2567000 -5561000 4015000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effective interest rates of the Notes:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.12 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.0212 0 0.0064 0.0064 0.0067 0.0067 0.0118 0.0118 P1Y9M18D P3Y11M15D P4Y11M1D P6Y11M1D LICENSE AND COLLABORATION AGREEMENTS<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company licenses certain technologies that are, or may be, incorporated into its technology under several license agreements, as well as the rights to commercialize certain diagnostic tests through collaboration agreements. Generally, the license agreements require the Company to pay single-digit royalties based on net revenues received using the technologies and may require minimum royalty amounts, milestone payments, or maintenance fees.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mayo</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2009, the Company entered into a license agreement with the Mayo Foundation for Medical Education and Research (“Mayo”). The Company’s license agreement with Mayo was most recently amended and restated in September 2020. Under the license agreement, Mayo granted the Company an exclusive, worldwide license to certain Mayo patents and patent applications, as well as a non-exclusive, worldwide license with regard to certain Mayo know-how. The scope of the license covers any screening, surveillance or diagnostic test or tool for use in connection with any type of cancer, pre-cancer, disease or condition.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The licensed Mayo patents and patent applications contain both method and composition claims that relate to sample processing, analytical testing and data analysis associated with nucleic acid screening for cancers and other diseases. The jurisdictions covered by these patents and patent applications include the U.S., Australia, Canada, the European Union, China, Japan and Korea. Under the license agreement, the Company assumed the obligation and expense of prosecuting and maintaining the licensed Mayo patents and is obligated to make commercially reasonable efforts to bring to market products using the licensed Mayo intellectual property.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Company’s agreement with Mayo, the Company is required to pay Mayo a low-single-digit royalty on the Company’s net sales of current and future products using the licensed Mayo intellectual property each year during the term of the Mayo agreement. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the most recent amendment, the Company agreed to pay Mayo an additional $6.3 million, payable in five equal annual installments through 2024. The annual installments are recorded in research and development expenses in the Company’s condensed consolidated statements of operations. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The license agreement will remain in effect, unless earlier terminated by the parties in accordance with the agreement, until the last of the licensed patents expires in 2039 (or later, if certain licensed patent applications are issued). However, if the Company is still using the licensed Mayo know-how or certain Mayo-provided biological specimens or their derivatives on such expiration date, the term shall continue until the earlier of the date the Company stops using such know-how and materials and the date that is five years after the last licensed patent expires. The license agreement contains customary termination provisions and permits Mayo to terminate the license agreement if the Company sues Mayo or its affiliates, other than any such suit claiming an uncured material breach by Mayo of the license agreement.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to granting the Company a license to the covered Mayo intellectual property, Mayo provides the Company with product development and research and development assistance pursuant to the license agreement and other collaborative arrangements. In September 2020, Mayo also agreed to make available certain personnel to provide such assistance through January 2025. In connection with this collaboration, the Company incurred charges of $1.3 million and $1.4 million for the three months ended March 31, 2023 and 2022, respectively. The charges incurred in connection with this collaboration are recorded in research and development expenses in the Company’s condensed consolidated statements of operations. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Johns Hopkins University </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the acquisition of Thrive, the Company acquired a worldwide exclusive license agreement with Johns Hopkins University (“JHU”) for use of several JHU patents and licensed know-how. The license is designed to enable the Company to leverage JHU proprietary data in the development and commercialization of a blood-based, multi-cancer early detection test. The agreement terms include single-digit sales-based royalties and sales-based milestone payments of $10.0 million, $15.0 million, and $20.0 million upon achieving calendar year licensed product revenue using JHU proprietary data of $0.50 billion, $1.00 billion, and $1.50 billion, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Translational Genomics Research Institute (“TGen”)</span></div>In January 2021, the Company entered into a worldwide exclusive license to the proprietary Targeted Digital Sequencing (“TARDIS”) technology from TGen, an affiliate of City of Hope. Under the agreement, the Company acquired a royalty-free, worldwide exclusive license to proprietary TARDIS patents and know-how. Under the agreement, the Company is obligated to make milestone payments to TGen of $10.0 million and $35.0 million upon achieving cumulative product revenue related to MRD detection and/or treatment totaling $100.0 million and $250.0 million, respectively. These payments are contingent upon achievement of these cumulative revenues on or before December 31, 2030. The Company will record the sales milestones once achievement is deemed probable. 6300000 5 P5Y 1300000 1400000 10000000 15000000 20000000 500000000 1000000000 1500000000 10000000 35000000 100000000 250000000 PFIZER PROMOTION AGREEMENTIn August 2018, the Company entered into a Promotion Agreement (the “Original Promotion Agreement”) with Pfizer Inc. (“Pfizer”), which was amended and restated in October 2020 (the “Restated Promotion Agreement”). The Restated Promotion Agreement extended the relationship between the Company and Pfizer and restructured the manner in which the Company compensates Pfizer for promotion of the Cologuard test through a service fee, and provision of certain other sales and marketing services related to the Cologuard test. The Restated Promotion Agreement included fixed and performance-related fees, some of which retroactively went into effect on April 1, 2020. In November 2021, the Company and Pfizer entered into an <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amendment to the Restated Promotion Agreement (the “November 2021 Amendment”), which provided that after November 30, 2021, Pfizer will no longer promote the Cologuard test to healthcare providers. The November 2021 Amendment provided that the Company pay Pfizer a total of $35.9 million in three installments, which occurred during the second, third, and fourth quarters of 2022. The November 2021 Amendment eliminated the Company's obligation to pay Pfizer royalties or other fees except for certain media fees, advertising fees, and any detail fees owed to Pfizer for promoting the Cologuard test prior to November 30, 2021. The $35.9 million fee incurred as a result of the November 2021 Amendment was recognized in full during the fourth quarter of 2021. All payments to Pfizer are recorded in sales and marketing expenses in the Company’s condensed consolidated statements of operations. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Original Promotion Agreement, the service fee was calculated based on incremental gross profits over specified baselines during the term. Under the Restated Promotion Agreement (and prior to giving effect to the November 2021 Amendment), the service fee provided a fee-for-service model that included certain fixed fees and performance-related bonuses. The performance-related bonuses were contingent upon the achievement of certain annual performance criteria with any applicable expense being recognized ratably upon achievement of the payment becoming probable. The Company incurred a charge of $2.5 million for the service fee during the three months ended March 31, 2022. The Company incurred charges of $38.4 million for promotion, sales and marketing services performed by Pfizer on behalf of the Company during the three months ended March 31, 2022. All services provided by Pfizer under the November 2021 Amendment ended in the third quarter of 2022, and there were no payments made or charges incurred during the three months ended March 31, 2023.</span></div> 35900000 35900000 2500000 38400000 STOCKHOLDERS’ EQUITY<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OmicEra Acquisition Stock Issuance</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company completed its acquisition of OmicEra. In connection with the acquisition, which is further described in Note 16, the Company issued 0.3 million shares of the Company's common stock that had a fair value of $14.8 million.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount recognized in AOCI for the three months ended March 31, 2023 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gain (Loss) on Securities (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,289)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,236)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period change in accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,517 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,322)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,719)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">There was no tax impact from the amounts recognized in AOCI for the three months ended March 31, 2023. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts recognized in AOCI for the three months ended March 31, 2022 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gain (Loss) on Securities (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,466)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,443)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,994)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,231)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period change in accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,967)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,204)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,433)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,647)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">There was no tax impact from the amounts recognized in AOCI for the three months ended March 31, 2022.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reclassified from AOCI for the three months ended March 31, 2023 and 2022 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.970%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the<br/>Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about AOCI Components (In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in value of available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and maturities of available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income (loss), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 300000 14800000 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount recognized in AOCI for the three months ended March 31, 2023 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gain (Loss) on Securities (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,289)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,236)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period change in accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,517 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,322)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,719)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">There was no tax impact from the amounts recognized in AOCI for the three months ended March 31, 2023. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts recognized in AOCI for the three months ended March 31, 2022 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gain (Loss) on Securities (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,466)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,443)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,994)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,231)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period change in accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,967)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,204)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,433)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,647)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">There was no tax impact from the amounts recognized in AOCI for the three months ended March 31, 2022.</span></div> 53000 -5289000 -5236000 550000 2289000 2839000 0 -678000 -678000 550000 2967000 3517000 603000 -2322000 -1719000 23000 -1466000 -1443000 -237000 -4994000 -5231000 0 -27000 -27000 -237000 -4967000 -5204000 -214000 -6433000 -6647000 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reclassified from AOCI for the three months ended March 31, 2023 and 2022 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.970%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the<br/>Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about AOCI Components (In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in value of available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and maturities of available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income (loss), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 678000 27000 -678000 -27000 STOCK-BASED COMPENSATION<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation Plans</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains the following plans for which awards were granted from or had awards outstanding in 2023: the 2010 Omnibus Long-Term Incentive Plan (As Amended and Restated Effective July 27, 2017), the 2019 Omnibus Long-Term Incentive Plan, and the 2010 Employee Stock Purchase Plan (collectively referred to as the “Stock Plans”). </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Company adopted the Equity Award Death, Disability and Retirement Policy (the “Policy”) as further described in Item 9B of the Company’s 2022 Form 10-K. The terms of the Policy will result in the recognition of expense on an accelerated basis for retirement-eligible participants for restricted stock units only. The Policy was considered a modification to outstanding awards with no impact to fair value. The accelerated stock-based compensation expense recorded as a result of the modification was not material for the three months ended March 31, 2023.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records stock-based compensation expense in connection with the amortization of restricted stock and restricted stock unit awards, performance share units, stock purchase rights granted under the Company’s employee stock purchase plan and stock options granted to employees, non-employee consultants and non-employee directors. The Company recorded $49.1 million and $52.4 million in stock-based compensation expense during the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, there was approximately $503.4 million of expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted under all equity compensation plans. The Company expects to recognize that cost over a weighted average period of 2.9 years.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity under the Stock Plans is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Aggregate intrinsic value in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January 1, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416,331 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.48 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, March 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416,331 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.48 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,583 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351,469 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.18 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,439 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The total intrinsic value of options exercised during the three months ended March 31, 2023 and 2022 was $4.8 million and $29.6 million, respectively, determined as of the date of exercise.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received approximately $1.0 million and $4.3 million from stock option exercises during the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock and Restricted Stock Units</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock and restricted stock units is determined on the date of grant using the closing stock price on that day. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock and restricted stock unit activity during the three months ended March 31, 2023 is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,254,709 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.29 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,109,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released (2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,279,999)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207,363)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,876,531 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.87 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The weighted average grant date fair value of the restricted stock units granted during the three months ended March 31, 2022 was $77.31.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The fair value of restricted stock units vested and converted to shares of the Company’s common stock was $121.2 million and $110.8 million during the three months ended March 31, 2023 and 2022, respectively. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued performance-based equity awards to certain employees which vest upon the achievement of certain performance goals, including financial performance targets and operational milestones. In addition, certain of the performance-based equity awards include a market condition. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of performance share unit activity is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance Share Units (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value (2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,846 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.58 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749,459 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released (3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,284)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,007)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,671,014 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.30 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The performance share units listed above assumes attainment of maximum payout rates as set forth in the performance criteria. Applying actual or expected payout rates, the number of outstanding performance share units as of March 31, 2023 was 575,702. </span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The weighted average grant date fair value of the performance share units granted during the three months ended March 31, 2022 was $92.31. </span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The fair value of performance share units vested and converted to shares of the Company’s common stock was $1.0 million and $27.2 million for the three months ended March 31, 2023 and 2022, respectively. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no shares issued under the 2010 Employee Stock Purchase Plan during the three months ended March 31, 2023 and 2022.</span></div> 49100000 52400000 503400000 P2Y10M24D <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity under the Stock Plans is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Aggregate intrinsic value in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January 1, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416,331 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.48 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, March 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416,331 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.48 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,583 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351,469 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.18 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,439 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The total intrinsic value of options exercised during the three months ended March 31, 2023 and 2022 was $4.8 million and $29.6 million, respectively, determined as of the date of exercise.</span></div> 1517876 44.82 P4Y8M12D 88260 10.93 13285 93.78 1416331 46.48 P4Y6M 42583000 1416331 46.48 P4Y6M 42583000 1351469 44.18 P4Y4M24D 42439000 4800000 29600000 1000000 4300000 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock and restricted stock unit activity during the three months ended March 31, 2023 is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,254,709 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.29 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,109,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released (2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,279,999)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207,363)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,876,531 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.87 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The weighted average grant date fair value of the restricted stock units granted during the three months ended March 31, 2022 was $77.31.</span></div>(2)The fair value of restricted stock units vested and converted to shares of the Company’s common stock was $121.2 million and $110.8 million during the three months ended March 31, 2023 and 2022, respectively. 5254709 89.29 3109184 60.25 1279999 95.01 207363 79.15 6876531 72.87 77.31 121200000 110800000 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of performance share unit activity is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance Share Units (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value (2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,846 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.58 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749,459 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released (3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,284)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,007)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,671,014 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.30 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The performance share units listed above assumes attainment of maximum payout rates as set forth in the performance criteria. Applying actual or expected payout rates, the number of outstanding performance share units as of March 31, 2023 was 575,702. </span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The weighted average grant date fair value of the performance share units granted during the three months ended March 31, 2022 was $92.31. </span></div>(3)The fair value of performance share units vested and converted to shares of the Company’s common stock was $1.0 million and $27.2 million for the three months ended March 31, 2023 and 2022, respectively. 967846 102.58 749459 79.17 12284 78.32 34007 100.78 1671014 92.30 575702 92.31 1000000 27200000 0 0 COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,135</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,097</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance cash flows from finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,548</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,833)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,259</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - operating leases (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.17</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - finance leases (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">For the three months ended March 31, 2023, this includes a reduction of $6.2 million on the carrying value of the right-of-use asset held related to a building lease due to a reduction of the expected lease term.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and December 31, 2022, the Company’s right-of-use assets from operating leases are $156.8 million and $167.0 million, respectively, which are reported in operating lease right-of-use assets in the Company’s condensed consolidated balance sheets. As of March 31, 2023, the Company has outstanding operating lease obligations of $204.7 million, of which $30.0 million is reported in operating lease liabilities, current portion and $174.7 million is reported in operating lease liabilities, less current portion in the Company’s condensed consolidated balance sheets. As of December 31, 2022, the Company had outstanding operating lease obligations of $210.8 million, of which $28.4 million is reported in operating lease liabilities, current portion and $182.4 million is reported in operating lease liabilities, less current portion in the Company’s condensed consolidated balance sheets. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and December 31, 2022, the Company’s right-of-use assets from finance leases are $9.5 million and $10.2 million, respectively, which are reported in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc1NzE1ODllZjdlODQ0NzE5YThjZTkyYWJhNjJkNjFhL3NlYzo3NTcxNTg5ZWY3ZTg0NDcxOWE4Y2U5MmFiYTYyZDYxYV83MC9mcmFnOjcxOTY2YzJkNDcwMTQzYTk5ODlmNGRiNjhkNjM0NzdmL3RleHRyZWdpb246NzE5NjZjMmQ0NzAxNDNhOTk4OWY0ZGI2OGQ2MzQ3N2ZfODM5OQ_0fffc5c4-cc9f-4a9c-8e33-0242b3b700b8">other long-term assets</span>, net in the Company’s condensed consolidated balance sheets. As of March 31, 2023, the Company has outstanding finance lease obligations of $10.0 million, of which $3.2 million is reported in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc1NzE1ODllZjdlODQ0NzE5YThjZTkyYWJhNjJkNjFhL3NlYzo3NTcxNTg5ZWY3ZTg0NDcxOWE4Y2U5MmFiYTYyZDYxYV83MC9mcmFnOjcxOTY2YzJkNDcwMTQzYTk5ODlmNGRiNjhkNjM0NzdmL3RleHRyZWdpb246NzE5NjZjMmQ0NzAxNDNhOTk4OWY0ZGI2OGQ2MzQ3N2ZfODM5NA_0606cd01-a8aa-43e7-b858-5dd91e6409f9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc1NzE1ODllZjdlODQ0NzE5YThjZTkyYWJhNjJkNjFhL3NlYzo3NTcxNTg5ZWY3ZTg0NDcxOWE4Y2U5MmFiYTYyZDYxYV83MC9mcmFnOjcxOTY2YzJkNDcwMTQzYTk5ODlmNGRiNjhkNjM0NzdmL3RleHRyZWdpb246NzE5NjZjMmQ0NzAxNDNhOTk4OWY0ZGI2OGQ2MzQ3N2ZfODM5NA_2fc1b6e0-16b1-4bf0-9455-764387477f8e">other current liabilities</span></span> and $6.8 million is reported in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc1NzE1ODllZjdlODQ0NzE5YThjZTkyYWJhNjJkNjFhL3NlYzo3NTcxNTg5ZWY3ZTg0NDcxOWE4Y2U5MmFiYTYyZDYxYV83MC9mcmFnOjcxOTY2YzJkNDcwMTQzYTk5ODlmNGRiNjhkNjM0NzdmL3RleHRyZWdpb246NzE5NjZjMmQ0NzAxNDNhOTk4OWY0ZGI2OGQ2MzQ3N2ZfODM5NQ_107381b1-b509-4092-b741-5a3d2821d88c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc1NzE1ODllZjdlODQ0NzE5YThjZTkyYWJhNjJkNjFhL3NlYzo3NTcxNTg5ZWY3ZTg0NDcxOWE4Y2U5MmFiYTYyZDYxYV83MC9mcmFnOjcxOTY2YzJkNDcwMTQzYTk5ODlmNGRiNjhkNjM0NzdmL3RleHRyZWdpb246NzE5NjZjMmQ0NzAxNDNhOTk4OWY0ZGI2OGQ2MzQ3N2ZfODM5NQ_29d228df-288f-484a-87ef-06222065a838">other long-term liabilities</span></span> in the Company’s condensed consolidated balance sheets. As of December 31, 2022, the Company had outstanding finance lease obligations of $10.6 million, of which $3.2 million is reported in other current liabilities and $7.4 million is reported in other long-term liabilities in the Company’s condensed consolidated balance sheets.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records reserves and accrues costs for certain legal proceedings and regulatory matters to the extent that it determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. While such reserves and accrued costs reflect the Company’s best estimate of the probable loss for such matters, the recorded amounts may differ materially from the actual amount of any such losses. In some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal and regulatory proceedings, which may be exacerbated by various factors, including but not limited to, they may involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; involve a large number of parties, claimants or regulatory bodies; are in the early stages of the proceedings; involve a number of separate proceedings and/or a wide range of potential outcomes; or result in a change of business practices.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Quarterly Report on Form 10-Q, amounts accrued for legal proceedings and regulatory matters were not material except for the amounts accrued related to the Medicare Date of Service Rule Investigation discussed below. However, it is possible that in a particular quarter or annual period the Company’s financial condition, results of operations, cash flow and/or liquidity could be materially adversely affected by an ultimate unfavorable resolution of, or development in, legal and/or regulatory proceedings, including as described below. Except for the proceedings discussed below, the Company believes that the ultimate outcome of any of the regulatory and legal proceedings that are currently pending against it should not have a material adverse effect on financial condition, results of operations, cash flow or liquidity.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently responding to civil investigative demands and administrative subpoenas issued pursuant to the Health Insurance Portability and Accountability Act of 1996 by the United States Department of Justice (“DOJ”) concerning Genomic Health’s compliance with the Medicare Date of Service billing regulations (the “DOS Rule Investigation”). The Company has been cooperating with these inquiries and has produced documents in response thereto. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, as part of ongoing discussions between the DOJ and the Company regarding the DOS Rule Investigation, the DOJ presented an initial estimate of civil damages in the amount of $48.2 million relating to alleged non-compliance with the Medicare Date of Service billing regulations from 2007 to 2020. The initial civil damages estimate did not include potential treble damages, civil or criminal penalties or other remedies that the DOJ could seek against the Company. In December 2021, the DOJ presented a total adjusted demand of $53.8 million for civil damages, which includes a multiplier and penalties. On January 19, 2023, the Company was informed that the DOJ has closed its criminal investigation without taking any action. Based on the Company’s review and analysis of the DOJ presentation, ongoing discussions held with the DOJ, the civil damages estimate, and range of potential exposure, the Company recorded an accrual of approximately $29 million as of March 31, 2023. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, litigation outcomes are difficult to predict, and the estimation of probable losses requires an analysis of multiple possible outcomes that often depend on judgments about potential actions by third parties. Accordingly, the recorded accrual of approximately $29 million as of March 31, 2023 is based on several factors, considerations, and judgments, and the ultimate resolution of this matter could result in a material loss in excess of the recorded accrual.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2019, Niles Rosen M.D. filed a sealed ex parte qui tam lawsuit against the Company in the United States District Court for the Middle District of Florida, that alleged a violation of the Federal Anti-Kickback Statute and False Claims Act for offering gift cards to patients in exchange for returning the Cologuard screening test (the “Qui Tam Suit”). Dr. Rosen seeks on behalf of the U.S. government and himself an award of civil penalties, treble damages and fees and costs. On February 25, 2020, the Company received a civil investigative demand by the DOJ related to the Company’s gift card program. The Company produced documents in response thereto. On March 25, 2021, the DOJ filed a notice of its election to decline intervention in the Qui Tam Suit. This election does not prevent Dr. Rosen from continuing the Qui Tam Suit. On April 12, 2021, Dr. Rosen filed an amended complaint against the Company, alleging violations of the Federal Anti-Kickback Statute and False Claims Act. The Company first learned of the Qui Tam Suit and the DOJ’s election to decline intervention in July 2021. The Company intends to vigorously defend itself against Dr. Rosen's claims and seek, among other things, the Company’s attorneys’ fees and costs incurred in defending this action. Although the Company denies Dr. Rosen's allegations and believes that it has meritorious defenses to his False Claims Act claims, neither the outcome of the litigation nor can a reasonable estimate or an estimated range of loss associated with the litigation be determined at this time. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse outcomes from the DOS Rule Investigation and the Qui Tam Suit could include the Company being required to pay treble damages, incur civil and criminal penalties, paying attorneys’ fees, entering into a corporate integrity agreement, being excluded from participation in government healthcare programs, including Medicare and Medicaid, and other adverse actions that could materially affect the Company’s business, financial condition, and results of operation.</span></div> Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,135</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,097</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance cash flows from finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,548</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,833)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,259</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - operating leases (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.17</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term - finance leases (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 9135000 8097000 170000 211000 745000 1548000 3833000 4259000 318000 878000 P7Y2M4D P8Y2M1D P3Y25D P2Y9M18D 0.0642 0.0609 0.0667 0.0532 6200000 156800000 167000000 204700000 30000000 174700000 210800000 28400000 182400000 9500000 10200000 10000000 3200000 6800000 10600000 3200000 7400000 48200000 53800000 29000000 29000000 WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During February 2015, the Company entered into an agreement with the Wisconsin Economic Development Corporation (“WEDC,” “Original WEDC Agreement”) to earn $9.0 million in refundable tax credits on the condition that the Company expends $26.3 million in capital investments and establishes and maintains 758 full-time positions over a seven-year period. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2021, the Company amended its agreement with the WEDC (“Amended WEDC Agreement”) to earn an additional $18.5 million in refundable tax credits on the condition that the Company expends $350.0 million in capital investments and establishes and maintains 1,300 additional full-time positions over a five-year period. The capital investment credits are earned at a rate of 10% of eligible capital investments up to a maximum of $7.0 million, while the jobs creation credits are earned annually pursuant to the agreement.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax credits earned are first applied against the tax liability otherwise due, and if there is no such liability present, the claim for tax credits will be reimbursed in cash to the Company. The maximum amount of the refundable tax credit to be earned for each year is fixed, and the Company earns the credits by meeting certain capital investment and job creation thresholds over the term of the agreement. Should the Company earn and receive the job creation tax credits but not maintain those full-time positions through the end of the agreement, the Company may be required to pay those credits back to the WEDC.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Original WEDC Agreement, the Company recorded the earned tax credits as job creation and capital investments occurred. The tax credits earned from capital investment are being recognized as an offset to depreciation expense over the expected life of the acquired capital assets. The tax credits earned related to job creation were recognized as an offset to operational expenses through December 31, 2020.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had earned all $9.0 million of the refundable tax credits, and as of December 31, 2022, the Company had received payment of $9.0 million from the WEDC under the Original WEDC Agreement. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended WEDC Agreement, the Company records the earned tax credits as job creation and capital investments occurs. The tax credits earned from capital investment are recognized as a reduction to capital expenditures at the time the costs are incurred, and then as an offset to depreciation expense over the expected life of the acquired capital assets. The tax credits earned related to job creation are recognized as an offset to operational expenses in the period in which the credits are earned. The credits recognized will be required to be repaid if the Company does not maintain minimum cumulative job requirements.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company has earned $10.2 million of the refundable tax credits under the Amended WEDC Agreement and received payment of $1.7 million from the WEDC. The unpaid portion is $8.5 million, of which $3.8 million is reported in prepaid expenses and other current assets and $4.7 million is reported in other long-term assets, net in the Company’s condensed consolidated balance sheets reflecting when collection of the refundable tax credits is expected to occur.</span></div>During the three months ended March 31, 2023 and 2022, the Company recorded $1.2 million and $1.0 million respectively, as a reduction to operational expenses for the credits earned for job creation. 9000000 26300000 758 P7Y 18500000 350000000 1300 P5Y 0.10 7000000 9000000 9000000 10200000 1700000 8500000 3800000 4700000 1200000 1000000 ACQUISITIONS AND DIVESTITURES <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OmicEra Diagnostics, GmbH</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 2, 2022, the Company completed the acquisition (the “OmicEra Acquisition”) of all of the outstanding equity interests of OmicEra Diagnostics GmbH. The OmicEra Acquisition provided the Company a state-of-the-art proteomics lab based in Planegg, Germany. OmicEra combines its mass spectrometry-based proteome analysis technology with its in-house proteomics scientific expertise to discover more reliable and valuable protein biomarkers, which will expand the Company’s research and development capabilities. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the Company’s 2022 Form 10-K for detailed disclosures on the combination, including the fair value of the consideration transferred, purchase price allocation, and goodwill and intangible assets identified in the transaction. During the three months ended March 31, 2023, there were no changes to the purchase price and purchase price allocation. The measurement period remains open pending the completion of valuation procedures related to certain acquired assets and liabilities assumed, primarily in connection with the developed technology intangible asset. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestitures</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncotype DX Genomic Prostate Score Test</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2022, pursuant to an asset purchase agreement with MDxHealth SA, the Company completed the sale of the intellectual property and know-how related to the Company’s Oncotype DX Genomic Prostate Score test, which will allow the Company to focus on the highest impact projects core to the Company’s vision.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the Company’s 2022 Form 10-K for detailed disclosures on the divestiture, including the fair value of the consideration received, carrying value of the intangible asset sold, and terms of the revenue-based contingent consideration included in the asset purchase agreement. As of March 31, 2023, the contingent consideration remains fully constrained.</span></div> SEGMENT INFORMATION<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management determined that the Company functions as a single operating segment, and thus reports as a single reportable segment. This operating segment is focused on the development and global commercialization of clinical laboratory services allowing healthcare providers and patients to make individualized treatment decisions. Management assessed the discrete financial information routinely reviewed by the Company's Chief Operating Decision Maker, its President and Chief Executive Officer, to monitor the Company's operating performance and support decisions regarding allocation of resources to its operations. Performance is continuously monitored at the consolidated level to timely identify deviations from expected results. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total revenue from customers by geographic region. Product revenues are attributed to countries based on ship-to location.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,182 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,011 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602,450 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,571 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets located in countries outside of the United States are not significant.</span></div> <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total revenue from customers by geographic region. Product revenues are attributed to countries based on ship-to location.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,182 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,011 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602,450 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,571 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 565182000 457011000 37268000 29560000 602450000 486571000 INCOME TAXES<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded income tax expense of $1.7 million for the three months ended March 31, 2023 and a benefit of $2.0 million for the three months ended March 31, 2022. The Company’s income tax expense recorded during the three months ended March 31, 2023 is primarily related to current foreign and state tax expense. A deferred tax liability of $20.1 million and $19.7 million was recorded as of March 31, 2023 and December 31, 2022, respectively, which is included in other long-term liabilities on the Company’s condensed consolidated balance sheet. The Company continues to maintain a full valuation allowance against its deferred tax assets based on management’s determination that it is more likely than not the benefit will not be realized.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $29.6 million and $28.3 million of unrecognized tax benefits at March 31, 2023 and December 31, 2022, respectively. These amounts have been recorded as a reduction to the Company’s deferred tax asset, if recognized they would not have an impact on the effective tax rate due to the existing valuation allowance. Certain of the Company's unrecognized tax benefits could change due to activities of various tax authorities, including possible settlement of audits, or through normal expiration of various statutes of limitations. The Company does not expect a material change in unrecognized tax benefits in the next twelve months.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, due to the carryforward of unutilized net operating losses and research and development credits, the Company is subject to U.S. federal income tax examinations for the tax years 2000 through 2023, and to state income tax examinations for the tax years 2000 through 2023. No interest or penalties related to income taxes have been accrued or recognized as of March 31, 2023.</span></div> 1700000 -2000000.0 20100000 19700000 29600000 28300000 EXCEL 91 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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c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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 93 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 94 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 299 348 1 false 99 0 false 7 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.exactsciences.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.exactsciences.com/role/CondensedConsolidatedStatementsofComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 0000010 - Disclosure - REVENUE Sheet http://www.exactsciences.com/role/REVENUE REVENUE Notes 10 false false R11.htm 0000011 - Disclosure - MARKETABLE SECURITIES Sheet http://www.exactsciences.com/role/MARKETABLESECURITIES MARKETABLE SECURITIES Notes 11 false false R12.htm 0000012 - Disclosure - INVENTORY Sheet http://www.exactsciences.com/role/INVENTORY INVENTORY Notes 12 false false R13.htm 0000013 - Disclosure - PROPERTY, PLANT AND EQUIPMENT Sheet http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENT PROPERTY, PLANT AND EQUIPMENT Notes 13 false false R14.htm 0000014 - Disclosure - INTANGIBLE ASSETS AND GOODWILL Sheet http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILL INTANGIBLE ASSETS AND GOODWILL Notes 14 false false R15.htm 0000015 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 15 false false R16.htm 0000016 - Disclosure - LONG-TERM DEBT Sheet http://www.exactsciences.com/role/LONGTERMDEBT LONG-TERM DEBT Notes 16 false false R17.htm 0000017 - Disclosure - CONVERTIBLE NOTES Notes http://www.exactsciences.com/role/CONVERTIBLENOTES CONVERTIBLE NOTES Notes 17 false false R18.htm 0000018 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS Sheet http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTS LICENSE AND COLLABORATION AGREEMENTS Notes 18 false false R19.htm 0000019 - Disclosure - PFIZER PROMOTION AGREEMENT Sheet http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENT PFIZER PROMOTION AGREEMENT Notes 19 false false R20.htm 0000020 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.exactsciences.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY Notes 20 false false R21.htm 0000021 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.exactsciences.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 21 false false R22.htm 0000022 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 22 false false R23.htm 0000023 - Disclosure - WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS Sheet http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITS WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS Notes 23 false false R24.htm 0000024 - Disclosure - ACQUISITIONS AND DIVESTITURES Sheet http://www.exactsciences.com/role/ACQUISITIONSANDDIVESTITURES ACQUISITIONS AND DIVESTITURES Notes 24 false false R25.htm 0000025 - Disclosure - SEGMENT INFORMATION Sheet http://www.exactsciences.com/role/SEGMENTINFORMATION SEGMENT INFORMATION Notes 25 false false R26.htm 0000026 - Disclosure - INCOME TAXES Sheet http://www.exactsciences.com/role/INCOMETAXES INCOME TAXES Notes 26 false false R27.htm 0000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 27 false false R28.htm 0000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 28 false false R29.htm 0000029 - Disclosure - REVENUE (Tables) Sheet http://www.exactsciences.com/role/REVENUETables REVENUE (Tables) Tables http://www.exactsciences.com/role/REVENUE 29 false false R30.htm 0000030 - Disclosure - MARKETABLE SECURITIES (Tables) Sheet http://www.exactsciences.com/role/MARKETABLESECURITIESTables MARKETABLE SECURITIES (Tables) Tables http://www.exactsciences.com/role/MARKETABLESECURITIES 30 false false R31.htm 0000031 - Disclosure - INVENTORY (Tables) Sheet http://www.exactsciences.com/role/INVENTORYTables INVENTORY (Tables) Tables http://www.exactsciences.com/role/INVENTORY 31 false false R32.htm 0000032 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) Sheet http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTTables PROPERTY, PLANT AND EQUIPMENT (Tables) Tables http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENT 32 false false R33.htm 0000033 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables) Sheet http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLTables INTANGIBLE ASSETS AND GOODWILL (Tables) Tables http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILL 33 false false R34.htm 0000034 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTS 34 false false R35.htm 0000035 - Disclosure - CONVERTIBLE NOTES (Tables) Notes http://www.exactsciences.com/role/CONVERTIBLENOTESTables CONVERTIBLE NOTES (Tables) Tables http://www.exactsciences.com/role/CONVERTIBLENOTES 35 false false R36.htm 0000036 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.exactsciences.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.exactsciences.com/role/STOCKHOLDERSEQUITY 36 false false R37.htm 0000037 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables http://www.exactsciences.com/role/STOCKBASEDCOMPENSATION 37 false false R38.htm 0000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIES 38 false false R39.htm 0000039 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://www.exactsciences.com/role/SEGMENTINFORMATIONTables SEGMENT INFORMATION (Tables) Tables http://www.exactsciences.com/role/SEGMENTINFORMATION 39 false false R40.htm 0000040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details) Sheet http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details) Details 40 false false R41.htm 0000041 - Disclosure - REVENUE - Schedule of Disaggregation of Revenue (Details) Sheet http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails REVENUE - Schedule of Disaggregation of Revenue (Details) Details 41 false false R42.htm 0000042 - Disclosure - REVENUE - Narrative (Details) Sheet http://www.exactsciences.com/role/REVENUENarrativeDetails REVENUE - Narrative (Details) Details 42 false false R43.htm 0000043 - Disclosure - MARKETABLE SECURITIES - Schedule of Cash and Cash Equivalents (Details) Sheet http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails MARKETABLE SECURITIES - Schedule of Cash and Cash Equivalents (Details) Details 43 false false R44.htm 0000044 - Disclosure - MARKETABLE SECURITIES - Schedule of Available For Sale Securities (Details) Sheet http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails MARKETABLE SECURITIES - Schedule of Available For Sale Securities (Details) Details 44 false false R45.htm 0000045 - Disclosure - MARKETABLE SECURITIES - Schedule of Underlying Maturities of AFS Securities (Details) Sheet http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails MARKETABLE SECURITIES - Schedule of Underlying Maturities of AFS Securities (Details) Details 45 false false R46.htm 0000046 - Disclosure - MARKETABLE SECURITIES - Schedule of Gross Unrealized Losses and Fair Values of Investments in an Unrealized Loss Position (Details) Sheet http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails MARKETABLE SECURITIES - Schedule of Gross Unrealized Losses and Fair Values of Investments in an Unrealized Loss Position (Details) Details 46 false false R47.htm 0000047 - Disclosure - INVENTORY (Details) Sheet http://www.exactsciences.com/role/INVENTORYDetails INVENTORY (Details) Details http://www.exactsciences.com/role/INVENTORYTables 47 false false R48.htm 0000048 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Estimated Useful Lives (Details) Sheet http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails PROPERTY, PLANT AND EQUIPMENT - Schedule of Estimated Useful Lives (Details) Details 48 false false R49.htm 0000049 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) Sheet http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) Details 49 false false R50.htm 0000050 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Finite Lived Intangible Assets Net Balances and Weighted Average Useful Lives (Details) Sheet http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails INTANGIBLE ASSETS AND GOODWILL - Schedule of Finite Lived Intangible Assets Net Balances and Weighted Average Useful Lives (Details) Details 50 false false R51.htm 0000051 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Future Amortization Expense (Details) Sheet http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails INTANGIBLE ASSETS AND GOODWILL - Schedule of Future Amortization Expense (Details) Details 51 false false R52.htm 0000052 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Changes in Goodwill (Details) Sheet http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails INTANGIBLE ASSETS AND GOODWILL - Schedule of Changes in Goodwill (Details) Details 52 false false R53.htm 0000053 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) Sheet http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) Details 53 false false R54.htm 0000054 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value (Details) Sheet http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails FAIR VALUE MEASUREMENTS - Schedule of Fair Value (Details) Details 54 false false R55.htm 0000055 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Contingent Consideration (Details) Sheet http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSFairValueofContingentConsiderationDetails FAIR VALUE MEASUREMENTS - Fair Value of Contingent Consideration (Details) Details 55 false false R56.htm 0000056 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details) Sheet http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails FAIR VALUE MEASUREMENTS - Narrative (Details) Details 56 false false R57.htm 0000057 - Disclosure - LONG-TERM DEBT - Narrative (Details) Sheet http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails LONG-TERM DEBT - Narrative (Details) Details 57 false false R58.htm 0000058 - Disclosure - CONVERTIBLE NOTES - Schedule of Convertible Notes (Details) Notes http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails CONVERTIBLE NOTES - Schedule of Convertible Notes (Details) Details 58 false false R59.htm 0000059 - Disclosure - CONVERTIBLE NOTES - Narrative (Details) Notes http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails CONVERTIBLE NOTES - Narrative (Details) Details 59 false false R60.htm 0000060 - Disclosure - CONVERTIBLE NOTES - Schedule of Transaction Costs (Details) Notes http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofTransactionCostsDetails CONVERTIBLE NOTES - Schedule of Transaction Costs (Details) Details 60 false false R61.htm 0000061 - Disclosure - CONVERTIBLE NOTES - Summary of Interest Expense (Details) Notes http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofInterestExpenseDetails CONVERTIBLE NOTES - Summary of Interest Expense (Details) Details 61 false false R62.htm 0000062 - Disclosure - CONVERTIBLE NOTES - Schedule of Effective Interest Rates Related to Convertible Debt (Details) Notes http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofEffectiveInterestRatesRelatedtoConvertibleDebtDetails CONVERTIBLE NOTES - Schedule of Effective Interest Rates Related to Convertible Debt (Details) Details 62 false false R63.htm 0000063 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Mayo (Details) Sheet http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails LICENSE AND COLLABORATION AGREEMENTS - Mayo (Details) Details http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTS 63 false false R64.htm 0000064 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - John Hopkins University (Details) Sheet http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnHopkinsUniversityDetails LICENSE AND COLLABORATION AGREEMENTS - John Hopkins University (Details) Details 64 false false R65.htm 0000065 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Translational Genomics Research Institute (Details) Sheet http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTranslationalGenomicsResearchInstituteDetails LICENSE AND COLLABORATION AGREEMENTS - Translational Genomics Research Institute (Details) Details 65 false false R66.htm 0000066 - Disclosure - PFIZER PROMOTION AGREEMENT (Details) Sheet http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails PFIZER PROMOTION AGREEMENT (Details) Details http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENT 66 false false R67.htm 0000067 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details) Sheet http://www.exactsciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails STOCKHOLDERS' EQUITY - Narrative (Details) Details 67 false false R68.htm 0000068 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of OCI (Details) Sheet http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails STOCKHOLDERS' EQUITY - Schedule of OCI (Details) Details 68 false false R69.htm 0000069 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Amounts Reclassified from AOCI (Details) Sheet http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofAmountsReclassifiedfromAOCIDetails STOCKHOLDERS' EQUITY - Schedule of Amounts Reclassified from AOCI (Details) Details 69 false false R70.htm 0000070 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 70 false false R71.htm 0000071 - Disclosure - STOCK-BASED COMPENSATION - Fair Value and Activity (Details) Sheet http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails STOCK-BASED COMPENSATION - Fair Value and Activity (Details) Details 71 false false R72.htm 0000072 - Disclosure - STOCK-BASED COMPENSATION - Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity (Details) Sheet http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementRestrictedStockandRestrictedStockUnitActivityDetails STOCK-BASED COMPENSATION - Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity (Details) Details 72 false false R73.htm 0000073 - Disclosure - STOCK-BASED COMPENSATION - Share-based Payment Arrangement, Performance Shares, Activity (Details) Sheet http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementPerformanceSharesActivityDetails STOCK-BASED COMPENSATION - Share-based Payment Arrangement, Performance Shares, Activity (Details) Details 73 false false R74.htm 0000074 - Disclosure - COMMITMENTS AND CONTINGENCIES - Supplemental Disclosure of Cash Flow Information (Details) Sheet http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails COMMITMENTS AND CONTINGENCIES - Supplemental Disclosure of Cash Flow Information (Details) Details 74 false false R75.htm 0000075 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details) Sheet http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails COMMITMENTS AND CONTINGENCIES - Additional Information (Details) Details 75 false false R76.htm 0000076 - Disclosure - WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS (Details) Sheet http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS (Details) Details http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITS 76 false false R77.htm 0000077 - Disclosure - SEGMENT INFORMATION (Details) Sheet http://www.exactsciences.com/role/SEGMENTINFORMATIONDetails SEGMENT INFORMATION (Details) Details http://www.exactsciences.com/role/SEGMENTINFORMATIONTables 77 false false R78.htm 0000078 - Disclosure - INCOME TAXES (Details) Sheet http://www.exactsciences.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://www.exactsciences.com/role/INCOMETAXES 78 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:NumberOfOperatingSegments - exas-20230331.htm 4 exas-20230331.htm exas-20230331.xsd exas-20230331_cal.xml exas-20230331_def.xml exas-20230331_lab.xml exas-20230331_pre.xml exas-20230331xexx102.htm exas-20230331xexx103.htm exas-20230331xexx311.htm exas-20230331xexx312.htm exas-20230331xexx321.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 97 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "exas-20230331.htm": { "axisCustom": 2, "axisStandard": 30, "baseTaxonomies": { "http://fasb.org/us-gaap/2021-01-31": 886, "http://xbrl.sec.gov/dei/2021q4": 29 }, "contextCount": 299, "dts": { "calculationLink": { "local": [ "exas-20230331_cal.xml" ] }, "definitionLink": { "local": [ "exas-20230331_def.xml" ] }, "inline": { "local": [ "exas-20230331.htm" ] }, "labelLink": { "local": [ "exas-20230331_lab.xml" ] }, "presentationLink": { "local": [ "exas-20230331_pre.xml" ] }, "schema": { "local": [ "exas-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 602, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 6, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 11 }, "keyCustom": 48, "keyStandard": 300, "memberCustom": 42, "memberStandard": 53, "nsprefix": "exas", "nsuri": "http://www.exactsciences.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.exactsciences.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - REVENUE", "menuCat": "Notes", "order": "10", "role": "http://www.exactsciences.com/role/REVENUE", "shortName": "REVENUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - MARKETABLE SECURITIES", "menuCat": "Notes", "order": "11", "role": "http://www.exactsciences.com/role/MARKETABLESECURITIES", "shortName": "MARKETABLE SECURITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - INVENTORY", "menuCat": "Notes", "order": "12", "role": "http://www.exactsciences.com/role/INVENTORY", "shortName": "INVENTORY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - PROPERTY, PLANT AND EQUIPMENT", "menuCat": "Notes", "order": "13", "role": "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENT", "shortName": "PROPERTY, PLANT AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - INTANGIBLE ASSETS AND GOODWILL", "menuCat": "Notes", "order": "14", "role": "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILL", "shortName": "INTANGIBLE ASSETS AND GOODWILL", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - FAIR VALUE MEASUREMENTS", "menuCat": "Notes", "order": "15", "role": "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - LONG-TERM DEBT", "menuCat": "Notes", "order": "16", "role": "http://www.exactsciences.com/role/LONGTERMDEBT", "shortName": "LONG-TERM DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "exas:ConvertibleNotesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - CONVERTIBLE NOTES", "menuCat": "Notes", "order": "17", "role": "http://www.exactsciences.com/role/CONVERTIBLENOTES", "shortName": "CONVERTIBLE NOTES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "exas:ConvertibleNotesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "exas:LicensingAgreementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS", "menuCat": "Notes", "order": "18", "role": "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTS", "shortName": "LICENSE AND COLLABORATION AGREEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "exas:LicensingAgreementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - PFIZER PROMOTION AGREEMENT", "menuCat": "Notes", "order": "19", "role": "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENT", "shortName": "PFIZER PROMOTION AGREEMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - STOCKHOLDERS' EQUITY", "menuCat": "Notes", "order": "20", "role": "http://www.exactsciences.com/role/STOCKHOLDERSEQUITY", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - STOCK-BASED COMPENSATION", "menuCat": "Notes", "order": "21", "role": "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "22", "role": "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "exas:WisconsinEconomicDevelopmentTaxCreditDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS", "menuCat": "Notes", "order": "23", "role": "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITS", "shortName": "WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "exas:WisconsinEconomicDevelopmentTaxCreditDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "exas:BusinessCombinationDivestitureAndAssetAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - ACQUISITIONS AND DIVESTITURES", "menuCat": "Notes", "order": "24", "role": "http://www.exactsciences.com/role/ACQUISITIONSANDDIVESTITURES", "shortName": "ACQUISITIONS AND DIVESTITURES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "exas:BusinessCombinationDivestitureAndAssetAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - SEGMENT INFORMATION", "menuCat": "Notes", "order": "25", "role": "http://www.exactsciences.com/role/SEGMENTINFORMATION", "shortName": "SEGMENT INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "26", "role": "http://www.exactsciences.com/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "27", "role": "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - REVENUE (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.exactsciences.com/role/REVENUETables", "shortName": "REVENUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - MARKETABLE SECURITIES (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.exactsciences.com/role/MARKETABLESECURITIESTables", "shortName": "MARKETABLE SECURITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - INVENTORY (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.exactsciences.com/role/INVENTORYTables", "shortName": "INVENTORY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTTables", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLTables", "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - CONVERTIBLE NOTES (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.exactsciences.com/role/CONVERTIBLENOTESTables", "shortName": "CONVERTIBLE NOTES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "menuCat": "Tables", "order": "36", "role": "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "menuCat": "Tables", "order": "37", "role": "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "menuCat": "Tables", "order": "38", "role": "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - SEGMENT INFORMATION (Tables)", "menuCat": "Tables", "order": "39", "role": "http://www.exactsciences.com/role/SEGMENTINFORMATIONTables", "shortName": "SEGMENT INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details)", "menuCat": "Details", "order": "40", "role": "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - REVENUE - Schedule of Disaggregation of Revenue (Details)", "menuCat": "Details", "order": "41", "role": "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails", "shortName": "REVENUE - Schedule of Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ie58a47177f3742faa87ffa457208658a_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i2b793b30475a4bafb6e0ec582f651626_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - REVENUE - Narrative (Details)", "menuCat": "Details", "order": "42", "role": "http://www.exactsciences.com/role/REVENUENarrativeDetails", "shortName": "REVENUE - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i2b793b30475a4bafb6e0ec582f651626_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - MARKETABLE SECURITIES - Schedule of Cash and Cash Equivalents (Details)", "menuCat": "Details", "order": "43", "role": "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails", "shortName": "MARKETABLE SECURITIES - Schedule of Cash and Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - MARKETABLE SECURITIES - Schedule of Available For Sale Securities (Details)", "menuCat": "Details", "order": "44", "role": "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "shortName": "MARKETABLE SECURITIES - Schedule of Available For Sale Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - MARKETABLE SECURITIES - Schedule of Underlying Maturities of AFS Securities (Details)", "menuCat": "Details", "order": "45", "role": "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails", "shortName": "MARKETABLE SECURITIES - Schedule of Underlying Maturities of AFS Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - MARKETABLE SECURITIES - Schedule of Gross Unrealized Losses and Fair Values of Investments in an Unrealized Loss Position (Details)", "menuCat": "Details", "order": "46", "role": "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails", "shortName": "MARKETABLE SECURITIES - Schedule of Gross Unrealized Losses and Fair Values of Investments in an Unrealized Loss Position (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsAndSupplies", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - INVENTORY (Details)", "menuCat": "Details", "order": "47", "role": "http://www.exactsciences.com/role/INVENTORYDetails", "shortName": "INVENTORY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsAndSupplies", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Schedule of Estimated Useful Lives (Details)", "menuCat": "Details", "order": "48", "role": "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails", "shortName": "PROPERTY, PLANT AND EQUIPMENT - Schedule of Estimated Useful Lives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)", "menuCat": "Details", "order": "49", "role": "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails", "shortName": "PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ConstructionInProgressGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "menuCat": "Statements", "order": "5", "role": "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Finite Lived Intangible Assets Net Balances and Weighted Average Useful Lives (Details)", "menuCat": "Details", "order": "50", "role": "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails", "shortName": "INTANGIBLE ASSETS AND GOODWILL - Schedule of Finite Lived Intangible Assets Net Balances and Weighted Average Useful Lives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Future Amortization Expense (Details)", "menuCat": "Details", "order": "51", "role": "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails", "shortName": "INTANGIBLE ASSETS AND GOODWILL - Schedule of Future Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i79a27481e52e434986525381c6947734_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Changes in Goodwill (Details)", "menuCat": "Details", "order": "52", "role": "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails", "shortName": "INTANGIBLE ASSETS AND GOODWILL - Schedule of Changes in Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i609d9ab87c7d40efa60f4800dac399a8_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)", "menuCat": "Details", "order": "53", "role": "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "shortName": "INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillImpairmentLoss", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value (Details)", "menuCat": "Details", "order": "54", "role": "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails", "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i334dd0638d1d4e7bbb789ac3d1780908_I20230331", "decimals": "-3", "lang": "en-US", "name": "exas:RestrictedCashFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i79a27481e52e434986525381c6947734_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Contingent Consideration (Details)", "menuCat": "Details", "order": "55", "role": "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSFairValueofContingentConsiderationDetails", "shortName": "FAIR VALUE MEASUREMENTS - Fair Value of Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details)", "menuCat": "Details", "order": "56", "role": "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "shortName": "FAIR VALUE MEASUREMENTS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i6a8b550d83e349c7a86fc70a05aea4e8_I20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:InvestmentOwnedAtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "exas:FinancingReceivableAmountElectedToCollateralize", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - LONG-TERM DEBT - Narrative (Details)", "menuCat": "Details", "order": "57", "role": "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails", "shortName": "LONG-TERM DEBT - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "exas:FinancingReceivableAmountElectedToCollateralize", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i14b42f4e4e304239873b3b5d9f1abefd_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - CONVERTIBLE NOTES - Schedule of Convertible Notes (Details)", "menuCat": "Details", "order": "58", "role": "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "shortName": "CONVERTIBLE NOTES - Schedule of Convertible Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i14b42f4e4e304239873b3b5d9f1abefd_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "exas:PrincipalAmountConvertibleNote", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - CONVERTIBLE NOTES - Narrative (Details)", "menuCat": "Details", "order": "59", "role": "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails", "shortName": "CONVERTIBLE NOTES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "exas:PrincipalAmountConvertibleNote", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i98474547bcb448e0b6c805efd8f0fec0_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "menuCat": "Statements", "order": "6", "role": "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i98474547bcb448e0b6c805efd8f0fec0_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i9a1bbb65415641798f4eebb7b7bc5374_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "exas:DebtInstrumentConvertibleTransactionCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - CONVERTIBLE NOTES - Schedule of Transaction Costs (Details)", "menuCat": "Details", "order": "60", "role": "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofTransactionCostsDetails", "shortName": "CONVERTIBLE NOTES - Schedule of Transaction Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i9a1bbb65415641798f4eebb7b7bc5374_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "exas:DebtInstrumentConvertibleTransactionCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "exas:InterestExpenseDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfFinancingCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - CONVERTIBLE NOTES - Summary of Interest Expense (Details)", "menuCat": "Details", "order": "61", "role": "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofInterestExpenseDetails", "shortName": "CONVERTIBLE NOTES - Summary of Interest Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "exas:InterestExpenseDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfFinancingCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "exas:ScheduleOfEffectiveInterestRatesRelatedToConvertibleDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i78f9f0acad7b487baac84e3d1faccb7b_D20230101-20230331", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - CONVERTIBLE NOTES - Schedule of Effective Interest Rates Related to Convertible Debt (Details)", "menuCat": "Details", "order": "62", "role": "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofEffectiveInterestRatesRelatedtoConvertibleDebtDetails", "shortName": "CONVERTIBLE NOTES - Schedule of Effective Interest Rates Related to Convertible Debt (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Mayo (Details)", "menuCat": "Details", "order": "63", "role": "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "shortName": "LICENSE AND COLLABORATION AGREEMENTS - Mayo (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8fbca6f9c04941ed8a3c8e51de230b4f_I20200930", "decimals": "-5", "lang": "en-US", "name": "exas:LicenseAgreementFeesCommitment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i99f518e4df5742d7ba058a7e3627bb99_I20210105", "decimals": "-5", "first": true, "lang": "en-US", "name": "exas:CollaborationArrangementMilestonesToBePaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - John Hopkins University (Details)", "menuCat": "Details", "order": "64", "role": "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnHopkinsUniversityDetails", "shortName": "LICENSE AND COLLABORATION AGREEMENTS - John Hopkins University (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i99f518e4df5742d7ba058a7e3627bb99_I20210105", "decimals": "-5", "first": true, "lang": "en-US", "name": "exas:CollaborationArrangementMilestonesToBePaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i7542bcf1d9414d969cd3bfad07900b26_I20210131", "decimals": "-5", "first": true, "lang": "en-US", "name": "exas:CollaborationArrangementMilestonesToBePaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Translational Genomics Research Institute (Details)", "menuCat": "Details", "order": "65", "role": "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTranslationalGenomicsResearchInstituteDetails", "shortName": "LICENSE AND COLLABORATION AGREEMENTS - Translational Genomics Research Institute (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i7542bcf1d9414d969cd3bfad07900b26_I20210131", "decimals": "-5", "first": true, "lang": "en-US", "name": "exas:CollaborationArrangementMilestonesToBePaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i51e27fe764ed481d885f06b86cac7cf1_I20211130", "decimals": "-5", "first": true, "lang": "en-US", "name": "exas:ContractTerminationFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - PFIZER PROMOTION AGREEMENT (Details)", "menuCat": "Details", "order": "66", "role": "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails", "shortName": "PFIZER PROMOTION AGREEMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i51e27fe764ed481d885f06b86cac7cf1_I20211130", "decimals": "-5", "first": true, "lang": "en-US", "name": "exas:ContractTerminationFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "idda2bb7be3724e83b94e53ca19cf7eae_D20220501-20220531", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)", "menuCat": "Details", "order": "67", "role": "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "shortName": "STOCKHOLDERS' EQUITY - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "idda2bb7be3724e83b94e53ca19cf7eae_D20220501-20220531", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i79a27481e52e434986525381c6947734_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of OCI (Details)", "menuCat": "Details", "order": "68", "role": "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails", "shortName": "STOCKHOLDERS' EQUITY - Schedule of OCI (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ide7ae9ccc069467eabc4469dd95a160d_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Amounts Reclassified from AOCI (Details)", "menuCat": "Details", "order": "69", "role": "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofAmountsReclassifiedfromAOCIDetails", "shortName": "STOCKHOLDERS' EQUITY - Schedule of Amounts Reclassified from AOCI (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ide7ae9ccc069467eabc4469dd95a160d_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)", "menuCat": "Statements", "order": "7", "role": "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i2b72e28cda2640bc9763de0b87a5930c_I20220331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "menuCat": "Details", "order": "70", "role": "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "id602e376daa84f5b93ea59d1b72138ac_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000071 - Disclosure - STOCK-BASED COMPENSATION - Fair Value and Activity (Details)", "menuCat": "Details", "order": "71", "role": "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails", "shortName": "STOCK-BASED COMPENSATION - Fair Value and Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i0fa5a543f18945aaacb591e4cdae8c28_D20230101-20230331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i25a06c8f3b0d40a1ae5533c42a3ff55d_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000072 - Disclosure - STOCK-BASED COMPENSATION - Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity (Details)", "menuCat": "Details", "order": "72", "role": "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementRestrictedStockandRestrictedStockUnitActivityDetails", "shortName": "STOCK-BASED COMPENSATION - Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i25a06c8f3b0d40a1ae5533c42a3ff55d_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i59f18043fbc64c7d9be7aef951ef27da_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000073 - Disclosure - STOCK-BASED COMPENSATION - Share-based Payment Arrangement, Performance Shares, Activity (Details)", "menuCat": "Details", "order": "73", "role": "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementPerformanceSharesActivityDetails", "shortName": "STOCK-BASED COMPENSATION - Share-based Payment Arrangement, Performance Shares, Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i59f18043fbc64c7d9be7aef951ef27da_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000074 - Disclosure - COMMITMENTS AND CONTINGENCIES - Supplemental Disclosure of Cash Flow Information (Details)", "menuCat": "Details", "order": "74", "role": "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - Supplemental Disclosure of Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000075 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)", "menuCat": "Details", "order": "75", "role": "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i72490a1035e74af196bc4d2ba138db72_I20150228", "decimals": "-5", "first": true, "lang": "en-US", "name": "exas:RefundableTaxCreditsAvailableContingentOnCapitalInvestmentsAndCreationOfFullTimePositions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000076 - Disclosure - WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS (Details)", "menuCat": "Details", "order": "76", "role": "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails", "shortName": "WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i72490a1035e74af196bc4d2ba138db72_I20150228", "decimals": "-5", "first": true, "lang": "en-US", "name": "exas:RefundableTaxCreditsAvailableContingentOnCapitalInvestmentsAndCreationOfFullTimePositions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000077 - Disclosure - SEGMENT INFORMATION (Details)", "menuCat": "Details", "order": "77", "role": "http://www.exactsciences.com/role/SEGMENTINFORMATIONDetails", "shortName": "SEGMENT INFORMATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i36d6c80d7f9c4b109e739793987f9894_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000078 - Disclosure - INCOME TAXES (Details)", "menuCat": "Details", "order": "78", "role": "http://www.exactsciences.com/role/INCOMETAXESDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "i8a488a3485c248d1a8c847b835c02d49_I20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DeferredTaxLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "8", "role": "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "9", "role": "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "exas-20230331.htm", "contextRef": "ibd907686c8bb4296b4cf17865a8c284e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 99, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.exactsciences.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r600" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r601" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r598" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r598" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r598" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r598" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r598" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r598" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r598" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r597" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.exactsciences.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "exas_AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended Wisconsin Economic Development Tax Credit Agreement", "label": "Amended Wisconsin Economic Development Tax Credit Agreement [Member]", "terseLabel": "Amended wisconsin economic development tax credit agreement" } } }, "localname": "AmendedWisconsinEconomicDevelopmentTaxCreditAgreementMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "domainItemType" }, "exas_AmortizationDeferredAmortizationOfDeferredFinancingCostsDebtDiscountsPremiumsAndIssuanceCostsOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization (Deferred Amortization) of Deferred Financing Costs, Debt Discounts (Premiums) and Issuance Costs, Other Liabilities", "label": "Amortization (Deferred Amortization) of Deferred Financing Costs, Debt Discounts (Premiums) and Issuance Costs, Other Liabilities", "terseLabel": "Amortization of deferred financing costs, convertible note debt discount and issuance costs, and other liabilities" } } }, "localname": "AmortizationDeferredAmortizationOfDeferredFinancingCostsDebtDiscountsPremiumsAndIssuanceCostsOtherLiabilities", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "exas_AmortizationOfRefundableTaxCredits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amortization of the tax credits, representing a reduction of operating expenses.", "label": "Amortization of Refundable Tax Credits", "terseLabel": "Amortization of tax credits" } } }, "localname": "AmortizationOfRefundableTaxCredits", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "monetaryItemType" }, "exas_BuildingsAndLeaseholdImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to buildings and leasehold improvements.", "label": "Buildings And Leasehold Improvements [Member]", "terseLabel": "Leasehold and building improvements" } } }, "localname": "BuildingsAndLeaseholdImprovementsMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "exas_BusinessCombinationDivestitureAndAssetAcquisitionTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Divestiture, And Asset Acquisition", "label": "Business Combination, Divestiture, And Asset Acquisition [Text Block]", "terseLabel": "ACQUISITIONS AND DIVESTITURES" } } }, "localname": "BusinessCombinationDivestitureAndAssetAcquisitionTextBlock", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/ACQUISITIONSANDDIVESTITURES" ], "xbrltype": "textBlockItemType" }, "exas_CONVERTIBLENOTESAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CONVERTIBLE NOTES", "label": "CONVERTIBLE NOTES [Abstract]", "terseLabel": "CONVERTIBLE NOTES." } } }, "localname": "CONVERTIBLENOTESAbstract", "nsuri": "http://www.exactsciences.com/20230331", "xbrltype": "stringItemType" }, "exas_COVID19TestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "COVID-19 Testing", "label": "COVID-19 Testing [Member]", "terseLabel": "COVID-19 Testing" } } }, "localname": "COVID19TestingMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "exas_CapitalInvestmentExpendituresCreditEarningRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital Investment Expenditures, Credit Earning Rate", "label": "Capital Investment Expenditures, Credit Earning Rate", "terseLabel": "Credit earning rate" } } }, "localname": "CapitalInvestmentExpendituresCreditEarningRate", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "percentItemType" }, "exas_CapitalInvestmentExpendituresMaximumCreditsAvailableToEarn": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Capital Investment Expenditures, Maximum Credits Available To Earn", "label": "Capital Investment Expenditures, Maximum Credits Available To Earn", "terseLabel": "Maximum credits available to earn" } } }, "localname": "CapitalInvestmentExpendituresMaximumCreditsAvailableToEarn", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "monetaryItemType" }, "exas_CapitalInvestmentExpendituresRequirementForRefundableTaxCredits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expenditures in capital investments the Company is required to make over a specified period to earn the refundable tax credits.", "label": "Capital Investment Expenditures, Requirement for Refundable Tax Credits", "terseLabel": "Capital investment expenditures over specified period, requirement to earn the refundable tax credits" } } }, "localname": "CapitalInvestmentExpendituresRequirementForRefundableTaxCredits", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "monetaryItemType" }, "exas_CollaborationArrangementMilestonesToBePaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaboration Arrangement, Milestones To Be Paid", "label": "Collaboration Arrangement, Milestones To Be Paid", "terseLabel": "Collaboration arrangement, milestones to be paid" } } }, "localname": "CollaborationArrangementMilestonesToBePaid", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTranslationalGenomicsResearchInstituteDetails" ], "xbrltype": "monetaryItemType" }, "exas_CollaborativeArrangementMilestoneAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the ranges of sale milestones.", "label": "Collaborative Arrangement Milestone [Axis]", "terseLabel": "Collaborative Arrangement Milestone [Axis]" } } }, "localname": "CollaborativeArrangementMilestoneAxis", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTranslationalGenomicsResearchInstituteDetails" ], "xbrltype": "stringItemType" }, "exas_CollaborativeArrangementMilestoneDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by range of sale milestones pertaining to the collaborative arrangement.", "label": "Collaborative Arrangement Milestone [Domain]", "terseLabel": "Collaborative Arrangement Milestone [Domain]" } } }, "localname": "CollaborativeArrangementMilestoneDomain", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTranslationalGenomicsResearchInstituteDetails" ], "xbrltype": "domainItemType" }, "exas_CollaborativeArrangementsSalesMilestoneAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of net sales of a licensed product considered as a milestone under the collaborative arrangement.", "label": "Collaborative Arrangements Sales Milestone Amount", "terseLabel": "Collaborative arrangement sales milestone amount" } } }, "localname": "CollaborativeArrangementsSalesMilestoneAmount", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnHopkinsUniversityDetails" ], "xbrltype": "monetaryItemType" }, "exas_CompensationExpenseRelatedToIssuanceOfStockOptionsAndRestrictedStockAwardsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents number of stock options and restricted stock awards issued as a compensation expense by an entity during the period.", "label": "Compensation Expense Related to Issuance of Stock Options and Restricted Stock Awards, Shares", "terseLabel": "Compensation expense related to issuance of stock options and restricted stock awards (in shares)" } } }, "localname": "CompensationExpenseRelatedToIssuanceOfStockOptionsAndRestrictedStockAwardsShares", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "exas_CompensationExpenseRelatedToIssuanceOfStockOptionsAndRestrictedStockAwardsValues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents equity impact of the value of stock options and restricted stock awards issued as a compensation expense by an entity during the period.", "label": "Compensation Expense Related to Issuance of Stock Options and Restricted Stock Awards, Values", "terseLabel": "Compensation expense related to issuance of stock options and restricted stock awards" } } }, "localname": "CompensationExpenseRelatedToIssuanceOfStockOptionsAndRestrictedStockAwardsValues", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "exas_ComprehensiveIncomeLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, of comprehensive income (loss).", "label": "Comprehensive Income (loss), Before Tax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeLossBeforeTax", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "exas_ContractTerminationFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract Termination Fee", "label": "Contract Termination Fee", "terseLabel": "Contract termination fee" } } }, "localname": "ContractTerminationFee", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails" ], "xbrltype": "monetaryItemType" }, "exas_ConvertibleNotesPayable2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to convertible notes, maturing on 2025.", "label": "Convertible Notes Payable2025 [Member]", "terseLabel": "2030 Convertible Notes" } } }, "localname": "ConvertibleNotesPayable2025Member", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofEffectiveInterestRatesRelatedtoConvertibleDebtDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofTransactionCostsDetails" ], "xbrltype": "domainItemType" }, "exas_ConvertibleNotesPayable2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to convertible notes, maturing on 2027.", "label": "Convertible Notes Payable2027 [Member]", "terseLabel": "Convertible Notes Payable2027", "verboseLabel": "2028 Convertible Notes" } } }, "localname": "ConvertibleNotesPayable2027Member", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofEffectiveInterestRatesRelatedtoConvertibleDebtDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofTransactionCostsDetails" ], "xbrltype": "domainItemType" }, "exas_ConvertibleNotesPayable2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Notes Payable2028", "label": "Convertible Notes Payable2028 [Member]", "terseLabel": "Convertible Notes Payable2028", "verboseLabel": "2027 Convertible Notes" } } }, "localname": "ConvertibleNotesPayable2028Member", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofEffectiveInterestRatesRelatedtoConvertibleDebtDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofTransactionCostsDetails" ], "xbrltype": "domainItemType" }, "exas_ConvertibleNotesPayable2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Notes Payable2030", "label": "Convertible Notes Payable2030 [Member]", "terseLabel": "Convertible Notes Payable2030" } } }, "localname": "ConvertibleNotesPayable2030Member", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofEffectiveInterestRatesRelatedtoConvertibleDebtDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofTransactionCostsDetails" ], "xbrltype": "domainItemType" }, "exas_ConvertibleNotesPayableGross": { "auth_ref": [], "calculation": { "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails": { "order": 1.0, "parentTag": "us-gaap_ConvertibleNotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount as of balance sheet date of convertible notes payable including debt issuance costs and debt discounts.", "label": "Convertible Notes Payable Gross", "terseLabel": "Principal Amount" } } }, "localname": "ConvertibleNotesPayableGross", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "exas_ConvertibleNotesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of convertible notes.", "label": "Convertible Notes [Text Block]", "terseLabel": "CONVERTIBLE NOTES" } } }, "localname": "ConvertibleNotesTextBlock", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTES" ], "xbrltype": "textBlockItemType" }, "exas_CouponInterestExpense": { "auth_ref": [], "calculation": { "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofInterestExpenseDetails": { "order": 4.0, "parentTag": "exas_InterestExpenseIncomeDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of coupon interest expense.", "label": "Coupon Interest Expense", "terseLabel": "Coupon interest expense" } } }, "localname": "CouponInterestExpense", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "exas_DOSRuleInvestigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DOS Rule Investigation", "label": "DOS Rule Investigation [Member]", "terseLabel": "DOS Rule Investigation" } } }, "localname": "DOSRuleInvestigationMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "exas_DailyBloombergShortTermBankYieldIndexRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Daily Bloomberg Short-Term Bank Yield Index Rate", "label": "Daily Bloomberg Short-Term Bank Yield Index Rate [Member]", "terseLabel": "Daily bloomberg short-term bank yield index rate" } } }, "localname": "DailyBloombergShortTermBankYieldIndexRateMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "exas_DebtConversionConvertedInstrumentPotentialSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Conversion, Converted Instrument, Potential Shares Issued", "label": "Debt Conversion, Converted Instrument, Potential Shares Issued", "terseLabel": "Potential shares issued from convertible instrument (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentPotentialSharesIssued", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails" ], "xbrltype": "sharesItemType" }, "exas_DebtInstrumentAmountSettledInExtinguishment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt instrument, Amount Settled In Extinguishment", "label": "Debt instrument, Amount Settled In Extinguishment", "terseLabel": "Amount of debt extinguished" } } }, "localname": "DebtInstrumentAmountSettledInExtinguishment", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "exas_DebtInstrumentConvertibleTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The transaction costs of the liability and equity component of convertible debt which may be settled upon conversion.", "label": "Debt Instrument Convertible Transaction Costs", "terseLabel": "Total transaction costs" } } }, "localname": "DebtInstrumentConvertibleTransactionCosts", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofTransactionCostsDetails" ], "xbrltype": "monetaryItemType" }, "exas_DebtInstrumentCovenantMaximumOutstandingCashAdvancesThreshold": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Maximum Outstanding Cash Advances Threshold", "label": "Debt Instrument, Covenant, Maximum Outstanding Cash Advances Threshold", "terseLabel": "Maximum outstanding cash advances threshold" } } }, "localname": "DebtInstrumentCovenantMaximumOutstandingCashAdvancesThreshold", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "exas_DebtInstrumentCovenantMinimumMarketValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Minimum Market Value", "label": "Debt Instrument, Covenant, Minimum Market Value", "terseLabel": "Minimum market value covenant" } } }, "localname": "DebtInstrumentCovenantMinimumMarketValue", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "exas_DebtInstrumentRepurchasePriceDueToChangeInControlAsPercentageOfPrincipalAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the price at which the debt may be repurchased, as a percentage of the principal amount if the entity undergoes a change of control.", "label": "Debt Instrument Repurchase Price Due to Change in Control as Percentage of Principal Amount", "terseLabel": "Repurchase price, as percentage of principal amount, if company undergoes change of control" } } }, "localname": "DebtInstrumentRepurchasePriceDueToChangeInControlAsPercentageOfPrincipalAmount", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails" ], "xbrltype": "pureItemType" }, "exas_EmployeeAndNonEmployeesStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize individuals, in addition to their regular compensation and benefits.", "label": "Employee And Non Employees Stock Option [Member]", "terseLabel": "Stock option", "verboseLabel": "Shares issuable upon exercise of stock options" } } }, "localname": "EmployeeAndNonEmployeesStockOptionMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "exas_EmployeeStockPurchasePlan2010Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the 2010 employee stock purchase plan.", "label": "Employee Stock Purchase Plan2010 [Member]", "terseLabel": "Employee Stock Purchase Plan2010" } } }, "localname": "EmployeeStockPurchasePlan2010Member", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "exas_FinancingReceivableAmountElectedToCollateralize": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Amount Elected to Collateralize", "label": "Financing Receivable, Amount Elected to Collateralize", "terseLabel": "Financing receivable, amount elected to collateralize" } } }, "localname": "FinancingReceivableAmountElectedToCollateralize", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "exas_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "auth_ref": [], "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "exas_GainOnSettlementOfConvertibleNotes": { "auth_ref": [], "calculation": { "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofInterestExpenseDetails": { "order": 1.0, "parentTag": "exas_InterestExpenseIncomeDebt", "weight": -1.0 }, "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on Settlement of Convertible Notes", "label": "Gain on Settlement of Convertible Notes", "negatedTerseLabel": "Gain on settlements of convertible notes, net", "terseLabel": "Gain on settlements of convertible notes, net" } } }, "localname": "GainOnSettlementOfConvertibleNotes", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofInterestExpenseDetails", "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "exas_IncreaseDecreaseInAmortizationOfPremiumOnShortTermInvestments": { "auth_ref": [], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying amount of amortization of purchase premium on nonoperating securities.", "label": "Increase (Decrease) in Amortization of Premium on Short Term Investments", "terseLabel": "Accretion (Amortization) of discount (premium) on short-term investments" } } }, "localname": "IncreaseDecreaseInAmortizationOfPremiumOnShortTermInvestments", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "exas_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) in Operating Lease Liabilities", "label": "Increase (Decrease) in Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "exas_InterestExpenseDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the total debt interest expense.", "label": "Interest Expense, Debt [Table Text Block]", "terseLabel": "Schedule of interest expense" } } }, "localname": "InterestExpenseDebtTableTextBlock", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESTables" ], "xbrltype": "textBlockItemType" }, "exas_InterestExpenseIncomeDebt": { "auth_ref": [], "calculation": { "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofInterestExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest Expense (Income), Debt", "label": "Interest Expense (Income), Debt", "totalLabel": "Total interest expense (income) on convertible notes" } } }, "localname": "InterestExpenseIncomeDebt", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "exas_InternationalSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "International Sales", "label": "International Sales [Member]", "terseLabel": "International" } } }, "localname": "InternationalSalesMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "exas_InventoryFinishedAndSemiFinishedGoods": { "auth_ref": [], "calculation": { "http://www.exactsciences.com/role/INVENTORYDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise/goods and merchandise/goods expected to be completed within one year of operating cycle that are expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished and Semi Finished Goods", "terseLabel": "Semi-finished and finished goods" } } }, "localname": "InventoryFinishedAndSemiFinishedGoods", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/INVENTORYDetails" ], "xbrltype": "monetaryItemType" }, "exas_InvestmentCompanyCommittedCapitalAmountCallable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment Company, Committed Capital, Amount Callable", "label": "Investment Company, Committed Capital, Amount Callable", "terseLabel": "Committed capital callable" } } }, "localname": "InvestmentCompanyCommittedCapitalAmountCallable", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "exas_InvestmentIncomeExpenseNonoperating": { "auth_ref": [], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment Income (Expense), Nonoperating", "label": "Investment Income (Expense), Nonoperating", "terseLabel": "Investment income (loss), net" } } }, "localname": "InvestmentIncomeExpenseNonoperating", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "exas_LICENSEAGREEMENTSAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LICENSE AGREEMENTS [Abstract]", "terseLabel": "MAYO LICENSE AGREEMENT" } } }, "localname": "LICENSEAGREEMENTSAbstract", "nsuri": "http://www.exactsciences.com/20230331", "xbrltype": "stringItemType" }, "exas_LicenseAgreementFeesCommitment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License Agreement Fees Commitment", "label": "License Agreement Fees Commitment", "terseLabel": "License agreement fees commitment" } } }, "localname": "LicenseAgreementFeesCommitment", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails" ], "xbrltype": "monetaryItemType" }, "exas_LicenseFeesCommitmentNumberOfInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of annual installments in which the license fee commitment is payable under the terms of the license agreement.", "label": "License Fees Commitment Number of Installments", "terseLabel": "Number of installments" } } }, "localname": "LicenseFeesCommitmentNumberOfInstallments", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails" ], "xbrltype": "integerItemType" }, "exas_LicensingAgreementDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents the entire disclosure related to licensing agreement entered by an entity during the period.", "label": "Licensing Agreement Disclosure [Text Block]", "terseLabel": "LICENSE AND COLLABORATION AGREEMENTS" } } }, "localname": "LicensingAgreementDisclosureTextBlock", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTS" ], "xbrltype": "textBlockItemType" }, "exas_MAYOFoundationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the pertinent information about MAYO Foundation for Medical Education and Research (MAYO).", "label": "M A Y O Foundation [Member]", "terseLabel": "Mayo" } } }, "localname": "MAYOFoundationMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails" ], "xbrltype": "domainItemType" }, "exas_MeasurementInputPresentValueFactorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input, Present-value Factor", "label": "Measurement Input, Present-value Factor [Member]", "terseLabel": "Measurement Input, Present-value Factor" } } }, "localname": "MeasurementInputPresentValueFactorMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "exas_MeasurementInputProbabilityOfSuccessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input, Probability of Success", "label": "Measurement Input, Probability of Success [Member]", "terseLabel": "Measurement Input, Probability of Success" } } }, "localname": "MeasurementInputProbabilityOfSuccessMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "exas_NumberOfFullTimePositionsRequiredToBeCreatedToEarnRefundableTaxCredits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of full-time positions that must be created over a specified time period to earn the refundable tax credits.", "label": "Number of Full-time Positions Required to be Created to Earn Refundable Tax Credits", "terseLabel": "Full-time positions that must be created over a specified time period to earn the refundable tax credits" } } }, "localname": "NumberOfFullTimePositionsRequiredToBeCreatedToEarnRefundableTaxCredits", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "integerItemType" }, "exas_OfficeEquipmentAndComputerSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information relating to office equipment and computer software.", "label": "Office Equipment And Computer Software [Member]", "terseLabel": "Computer equipment and computer software" } } }, "localname": "OfficeEquipmentAndComputerSoftwareMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "exas_OmicEraDiagnosticsAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OmicEra Diagnostics Acquisition", "label": "OmicEra Diagnostics Acquisition [Member]", "terseLabel": "OmicEra diagnostics acquisition" } } }, "localname": "OmicEraDiagnosticsAcquisitionMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "exas_OmicEraMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OmicEra", "label": "OmicEra [Member]", "terseLabel": "OmicEra acquisition" } } }, "localname": "OmicEraMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails" ], "xbrltype": "domainItemType" }, "exas_OperatingLeaseRightOfUseAssetModification": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Lease, Right-of-Use Asset Modification", "label": "Operating Lease, Right-of-Use Asset Modification", "terseLabel": "Operating Lease, Right-of-Use Asset Modification" } } }, "localname": "OperatingLeaseRightOfUseAssetModification", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "exas_PeriodForCapitalInvestmentExpendituresAndCreationOfFullTimePositionsToEarnRefundableTaxCredits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period over which the capital investment expenditures must be incurred and the creation of full-time positions must be completed.", "label": "Period for Capital Investment Expenditures and Creation of Full-time Positions to Earn Refundable Tax Credits", "terseLabel": "Period over which the capital investment expenditures must be incurred and the creation of full-time positions must be completed" } } }, "localname": "PeriodForCapitalInvestmentExpendituresAndCreationOfFullTimePositionsToEarnRefundableTaxCredits", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "durationItemType" }, "exas_PfizerIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member represents information regarding Pfizer Inc.", "label": "Pfizer Inc [Member]", "terseLabel": "Pfizer Inc" } } }, "localname": "PfizerIncMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails" ], "xbrltype": "domainItemType" }, "exas_PrecisionOncologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Precision Oncology", "label": "Precision Oncology [Member]", "terseLabel": "Precision Oncology" } } }, "localname": "PrecisionOncologyMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "exas_PreventionGeneticsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PreventionGenetics LLC", "label": "PreventionGenetics LLC [Member]", "terseLabel": "PreventionGenetics acquisition adjustment" } } }, "localname": "PreventionGeneticsLLCMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "exas_PrincipalAmountConvertibleNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Principal Amount, Convertible Note", "label": "Principal Amount, Convertible Note", "terseLabel": "Principal amount, convertible note" } } }, "localname": "PrincipalAmountConvertibleNote", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "exas_ProductDevelopmentAndOtherMilestoneBasedPaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product Development and Other Milestone-based Payments", "label": "Product Development and Other Milestone-based Payments [Member]", "terseLabel": "Product development and other milestone-based payments" } } }, "localname": "ProductDevelopmentAndOtherMilestoneBasedPaymentsMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "exas_ProductRevenueRelatedToMRDDetectionPaymentOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product Revenue Related to MRD Detection, Payment One", "label": "Product Revenue Related to MRD Detection, Payment One [Member]", "terseLabel": "Product Revenue Related to MRD Detection, Payment One" } } }, "localname": "ProductRevenueRelatedToMRDDetectionPaymentOneMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTranslationalGenomicsResearchInstituteDetails" ], "xbrltype": "domainItemType" }, "exas_ProductRevenueRelatedToMRDDetectionPaymentTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product Revenue Related to MRD Detection, Payment Two", "label": "Product Revenue Related to MRD Detection, Payment Two [Member]", "terseLabel": "Product Revenue Related to MRD Detection, Payment Two" } } }, "localname": "ProductRevenueRelatedToMRDDetectionPaymentTwoMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTranslationalGenomicsResearchInstituteDetails" ], "xbrltype": "domainItemType" }, "exas_ProductRevenueRelatedToTreatmentPaymentOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product Revenue Related to Treatment, Payment One", "label": "Product Revenue Related to Treatment, Payment One [Member]", "terseLabel": "Product Revenue Related to Treatment, Payment One" } } }, "localname": "ProductRevenueRelatedToTreatmentPaymentOneMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTranslationalGenomicsResearchInstituteDetails" ], "xbrltype": "domainItemType" }, "exas_ProductRevenueRelatedToTreatmentPaymentTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product Revenue Related to Treatment, Payment Two", "label": "Product Revenue Related to Treatment, Payment Two [Member]", "terseLabel": "Product Revenue Related to Treatment, Payment Two" } } }, "localname": "ProductRevenueRelatedToTreatmentPaymentTwoMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTranslationalGenomicsResearchInstituteDetails" ], "xbrltype": "domainItemType" }, "exas_PromotionAgreementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "PFIZER PROMOTION AGREEMENT", "terseLabel": "PFIZER PROMOTION AGREEMENT" } } }, "localname": "PromotionAgreementDisclosureAbstract", "nsuri": "http://www.exactsciences.com/20230331", "xbrltype": "stringItemType" }, "exas_RefundableTaxCreditEarnedToDate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of refundable tax credits earned, relating to capital investments and job creation, as of the end of the reporting period.", "label": "Refundable Tax Credit Earned to Date", "terseLabel": "Refundable tax credits earned" } } }, "localname": "RefundableTaxCreditEarnedToDate", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "monetaryItemType" }, "exas_RefundableTaxCreditReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of refundable tax credit receivable as of the end of the reporting period.", "label": "Refundable Tax Credit Receivable", "terseLabel": "Refundable tax credit receivable" } } }, "localname": "RefundableTaxCreditReceivable", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "monetaryItemType" }, "exas_RefundableTaxCreditReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of refundable tax credit received during the reporting period.", "label": "Refundable Tax Credit Received", "terseLabel": "Refundable tax credit received" } } }, "localname": "RefundableTaxCreditReceived", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "monetaryItemType" }, "exas_RefundableTaxCreditsAvailableContingentOnCapitalInvestmentsAndCreationOfFullTimePositions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the refundable tax credits available, that is contingent on the Company expending a specified dollar amount on capital investments and the creation of a specified number of full-time positions.", "label": "Refundable Tax Credits Available Contingent on Capital Investments and Creation of Full-time Positions", "terseLabel": "Refundable tax credits available, contingent" } } }, "localname": "RefundableTaxCreditsAvailableContingentOnCapitalInvestmentsAndCreationOfFullTimePositions", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "monetaryItemType" }, "exas_RestrictedCashFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails": { "order": 5.0, "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restricted Cash, Fair Value Disclosure", "label": "Restricted Cash, Fair Value Disclosure", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashFairValueDisclosure", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "monetaryItemType" }, "exas_RestrictedStockAwardsAndRestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the details relating to the restricted stock awards and restricted stock units (RSUs) as awarded by the entity to their employees as a form of incentive compensation.", "label": "Restricted Stock Awards And Restricted Stock Units R S U [Member]", "terseLabel": "Restricted Shares and RSUs" } } }, "localname": "RestrictedStockAwardsAndRestrictedStockUnitsRSUMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementRestrictedStockandRestrictedStockUnitActivityDetails" ], "xbrltype": "domainItemType" }, "exas_RevenueAndOtherPerformanceBasedPaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue and Other Performance-based Payments", "label": "Revenue and Other Performance-based Payments [Member]", "terseLabel": "Revenue and Other Performance-based Payments" } } }, "localname": "RevenueAndOtherPerformanceBasedPaymentsMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "exas_RevolvingLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving Loan Agreement", "label": "Revolving Loan Agreement [Member]", "terseLabel": "Revolving loan agreement" } } }, "localname": "RevolvingLoanAgreementMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "exas_SalesMilestoneRangeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to the first sales milestone range.", "label": "Sales Milestone Range One [Member]", "terseLabel": "Sales milestone range one" } } }, "localname": "SalesMilestoneRangeOneMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnHopkinsUniversityDetails" ], "xbrltype": "domainItemType" }, "exas_SalesMilestoneRangeThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to the third sales milestone range one.", "label": "Sales Milestone Range Three [Member]", "terseLabel": "Sales milestone range three" } } }, "localname": "SalesMilestoneRangeThreeMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnHopkinsUniversityDetails" ], "xbrltype": "domainItemType" }, "exas_SalesMilestoneRangeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to the second sales milestone range one.", "label": "Sales Milestone Range Two [Member]", "terseLabel": "Sales milestone range two" } } }, "localname": "SalesMilestoneRangeTwoMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnHopkinsUniversityDetails" ], "xbrltype": "domainItemType" }, "exas_ScheduleOfAllocationOfTransactionCostsRelatedToConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Allocation of Transaction Costs Related to Convertible Debt", "label": "Schedule of Allocation of Transaction Costs Related to Convertible Debt [Table Text Block]", "terseLabel": "Schedule of allocation of transaction costs related to convertible debt" } } }, "localname": "ScheduleOfAllocationOfTransactionCostsRelatedToConvertibleDebtTableTextBlock", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESTables" ], "xbrltype": "textBlockItemType" }, "exas_ScheduleOfConvertibleNotesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Convertible notes [Line Items]", "label": "Schedule of Convertible notes [Line Items]", "terseLabel": "Schedule of Convertible notes [Line Items]" } } }, "localname": "ScheduleOfConvertibleNotesLineItems", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofEffectiveInterestRatesRelatedtoConvertibleDebtDetails" ], "xbrltype": "stringItemType" }, "exas_ScheduleOfConvertibleNotesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Table information pertaining to convertible notes.", "label": "Schedule of Convertible notes [Table]", "terseLabel": "Schedule of Convertible notes [Table]" } } }, "localname": "ScheduleOfConvertibleNotesTable", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofEffectiveInterestRatesRelatedtoConvertibleDebtDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofTransactionCostsDetails" ], "xbrltype": "stringItemType" }, "exas_ScheduleOfEffectiveInterestRatesRelatedToConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of effective interest rates related to convertible debt", "label": "Schedule of effective interest rates related to convertible debt [Table Text Block]", "terseLabel": "Schedule of effective interest rates related to convertible debt" } } }, "localname": "ScheduleOfEffectiveInterestRatesRelatedToConvertibleDebtTableTextBlock", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESTables" ], "xbrltype": "textBlockItemType" }, "exas_ScreeningMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Screening", "label": "Screening [Member]", "terseLabel": "Screening" } } }, "localname": "ScreeningMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "exas_SecuritizedReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securitized Receivables", "label": "Securitized Receivables [Member]", "terseLabel": "Securitized receivables" } } }, "localname": "SecuritizedReceivablesMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "exas_ServiceFeeBasedOnIncrementalGrossProfitsOverSpecifiedBaselinesAndRoyalties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents service fee based on incremental gross profits over specified baselines and royalties.", "label": "Service Fee Based on Incremental Gross Profits Over Specified Baselines and Royalties", "terseLabel": "Service fee based on incremental gross profits over specified baselines and royalties" } } }, "localname": "ServiceFeeBasedOnIncrementalGrossProfitsOverSpecifiedBaselinesAndRoyalties", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails" ], "xbrltype": "monetaryItemType" }, "exas_ServiceOrProductTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Service or Product Type", "label": "Service or Product Type [Axis]", "terseLabel": "Service or Product Type [Axis]" } } }, "localname": "ServiceOrProductTypeAxis", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/REVENUENarrativeDetails", "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "exas_ServiceOrProductTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Service or Product Type", "label": "Service or Product Type [Domain]", "terseLabel": "Service or Product Type [Domain]" } } }, "localname": "ServiceOrProductTypeDomain", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/REVENUENarrativeDetails", "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "exas_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "stringItemType" }, "exas_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "stringItemType" }, "exas_SharesIssuedUponAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Issued Upon Acquisition", "label": "Shares Issued Upon Acquisition [Member]", "terseLabel": "Shares issuable in connection with acquisitions" } } }, "localname": "SharesIssuedUponAcquisitionMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "exas_StockBasedCompensationPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Company maintains the 2010 Omnibus Long-Term Incentive Plan (As Amended and Restated Effective July 27, 2017), the 2010 Employee Stock Purchase Plan, the 2015 Inducement Award Plan, the 2016 Inducement Award Plan and the 2000 Stock Option and Incentive Plan (collectively, the \"Stock Plans\").", "label": "Stock Based Compensation Plans [Member]", "terseLabel": "Stock plans" } } }, "localname": "StockBasedCompensationPlansMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "exas_TgenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tgen", "label": "Tgen [Member]", "terseLabel": "Tgen" } } }, "localname": "TgenMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTranslationalGenomicsResearchInstituteDetails" ], "xbrltype": "domainItemType" }, "exas_ThriveAndAshionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Thrive and Ashion", "label": "Thrive and Ashion [Member]", "terseLabel": "Thrive and Ashion" } } }, "localname": "ThriveAndAshionMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "exas_ThriveEarlierDetectionCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Thrive Earlier Detection Corporation", "label": "Thrive Earlier Detection Corporation [Member]", "terseLabel": "OmicEra acquisition" } } }, "localname": "ThriveEarlierDetectionCorporationMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnHopkinsUniversityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "exas_TimePeriodAfterLastLicensedPatentExpiresThatLicenseAgreementRemainsInEffect": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the time period after the last licensed patent expires that the license agreement will remain in effect.", "label": "Time Period After Last Licensed Patent Expires That License Agreement Remains In Effect", "terseLabel": "Period patent remains in effect" } } }, "localname": "TimePeriodAfterLastLicensedPatentExpiresThatLicenseAgreementRemainsInEffect", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails" ], "xbrltype": "durationItemType" }, "exas_VariablePriceContractMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Company estimates the amount of variable consideration using the expected value method, which represents the sum of probability-weighted amounts in a range of possible consideration amounts. When estimating the amount of variable consideration, the Company considers several factors, such as historical collections experience, patient insurance eligibility and payer reimbursement contracts.", "label": "Variable Price Contract [Member]", "terseLabel": "Variable consideration" } } }, "localname": "VariablePriceContractMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/REVENUENarrativeDetails" ], "xbrltype": "domainItemType" }, "exas_VentureCapitalInvestmentFundMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Venture Capital Investment Fund", "label": "Venture Capital Investment Fund [Member]", "terseLabel": "Venture capital investment fund" } } }, "localname": "VentureCapitalInvestmentFundMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "exas_WISCONSINECONOMICDEVELOPMENTTAXCREDITSAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wisconsin Economic Development Tax Credit Disclosure [Abstract]", "label": "WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS [Abstract]", "terseLabel": "WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS" } } }, "localname": "WISCONSINECONOMICDEVELOPMENTTAXCREDITSAbstract", "nsuri": "http://www.exactsciences.com/20230331", "xbrltype": "stringItemType" }, "exas_WisconsinEconomicDevelopmentTaxCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information relating to the agreement with the Wisconsin Economic Development Corporation.", "label": "Wisconsin Economic Development Tax Credit Agreement [Member]", "terseLabel": "Wisconsin economic development tax credit agreement" } } }, "localname": "WisconsinEconomicDevelopmentTaxCreditAgreementMember", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "domainItemType" }, "exas_WisconsinEconomicDevelopmentTaxCreditDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure relating to the Wisconsin Economic Development Tax Credit.", "label": "Wisconsin Economic Development Tax Credit Disclosure [Text Block]", "verboseLabel": "WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS" } } }, "localname": "WisconsinEconomicDevelopmentTaxCreditDisclosureTextBlock", "nsuri": "http://www.exactsciences.com/20230331", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITS" ], "xbrltype": "textBlockItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r253", "r254", "r357", "r374", "r559", "r561" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTranslationalGenomicsResearchInstituteDetails", "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r407", "r513", "r527", "r555", "r556", "r573", "r587", "r595", "r638", "r656", "r657", "r658", "r659", "r660", "r661" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r407", "r513", "r527", "r555", "r556", "r573", "r587", "r595", "r638", "r656", "r657", "r658", "r659", "r660", "r661" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r302", "r514", "r575", "r593", "r639", "r666" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r302", "r514", "r575", "r593", "r639", "r666" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r400", "r407", "r489", "r513", "r527", "r555", "r556", "r573", "r587", "r595", "r638", "r657", "r658", "r659", "r660", "r661" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r400", "r407", "r489", "r513", "r527", "r555", "r556", "r573", "r587", "r595", "r638", "r657", "r658", "r659", "r660", "r661" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r253", "r254", "r357", "r374", "r560", "r561" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTranslationalGenomicsResearchInstituteDetails", "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r303", "r304", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r576", "r594", "r639" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r303", "r304", "r541", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r576", "r594", "r639" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "stringItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r555", "r556", "r656", "r658", "r661" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted average" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r29", "r592" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r228", "r308", "r309", "r558" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r230", "r231", "r232", "r234", "r240", "r241", "r606" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "Unrealized Gain (Loss) on Marketable Securities" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofAmountsReclassifiedfromAOCIDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Changes in Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofAmountsReclassifiedfromAOCIDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r47", "r48", "r49", "r229", "r523", "r532", "r533" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r239", "r240", "r463", "r464", "r465", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofAmountsReclassifiedfromAOCIDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r46", "r49", "r183", "r528", "r529", "r557", "r606", "r607", "r608", "r619", "r620", "r621" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss", "verboseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r45", "r49", "r183", "r240", "r241", "r464", "r465", "r466", "r467", "r468", "r606" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Cumulative Translation Adjustment" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r16" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r408", "r409", "r410", "r619", "r620", "r621", "r646" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r139", "r159", "r163" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r58", "r66", "r198", "r369" ], "calculation": { "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofInterestExpenseDetails": { "order": 3.0, "parentTag": "exas_InterestExpenseIncomeDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Debt discount amortization" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r53", "r369", "r469", "r614" ], "calculation": { "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofInterestExpenseDetails": { "order": 2.0, "parentTag": "exas_InterestExpenseIncomeDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Debt issuance costs amortization" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESSummaryofInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r66", "r102", "r107" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations": { "order": 6.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of acquired intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Common shares not included in the computation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTranslationalGenomicsResearchInstituteDetails", "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails", "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r582", "r623" ], "lang": { "en-us": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset backed securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetUnderConstructionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset in process of being built.", "label": "Asset under Construction [Member]", "terseLabel": "Assets under construction" } } }, "localname": "AssetUnderConstructionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r204", "r214", "r250", "r289", "r293", "r298", "r322", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r436", "r440", "r458", "r592", "r636", "r637", "r654" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r4", "r43", "r250", "r322", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r436", "r440", "r458", "r592", "r636", "r637", "r654" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Long-term Assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r85" ], "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gains in Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r86" ], "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Losses in Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "auth_ref": [ "r89" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "Due after one year through five years, Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r87", "r312", "r522" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "Due after one year through five years, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Due in one year or less, Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r87", "r311", "r521" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Due in one year or less, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r84", "r310", "r329", "r518" ], "calculation": { "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r140", "r161" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementPerformanceSharesActivityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementRestrictedStockandRestrictedStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails", "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r184", "r187" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails", "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Buildings" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r585", "r586" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r169", "r170", "r585", "r586" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": { "auth_ref": [ "r178" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned", "terseLabel": "Fair value of stock issued in acquisition" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Business acquisition, equity interest issued or issuable (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r431", "r613" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in amount of contingent consideration liability", "verboseLabel": "Remeasurement of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSFairValueofContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r175", "r176", "r430" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Business Combination, Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSFairValueofContingentConsiderationDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r175", "r177" ], "calculation": { "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails": { "order": 4.0, "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "negatedLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Contingent consideration liability, measurement input" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_Cash": { "auth_ref": [ "r26", "r534", "r535", "r592" ], "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash and money market" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r0", "r26", "r68" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets", "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "verboseLabel": "Cash and cash equivalents, fair value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "terseLabel": "MARKETABLE SECURITIES" } } }, "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r26" ], "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-term Investments", "totalLabel": "Total cash, cash equivalents and marketable securities" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r63", "r68", "r72" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "terseLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r63", "r197" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r26" ], "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities", "verboseLabel": "Non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails", "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r432", "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "verboseLabel": "PFIZER PROMOTION AGREEMENT" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "verboseLabel": "Agreements" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTranslationalGenomicsResearchInstituteDetails", "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails", "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r39", "r118", "r208", "r218" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 14)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r117", "r121", "r343", "r344", "r542" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r619", "r620", "r646" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r130" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15", "r592" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.01 par value Authorized\u2014400,000,000; shares issued and outstanding\u2014179,830,145 and 177,925,631 shares at March\u00a031, 2023 and December\u00a031, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r588", "r631", "r632" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Computer software" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r181", "r562" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation and Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r113" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "terseLabel": "Assets under construction" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerBasisOfPricingAxis": { "auth_ref": [ "r578", "r639" ], "lang": { "en-us": { "role": { "documentation": "Information by basis of pricing for contract representing right to consideration in exchange for good or service transferred to customer.", "label": "Contract with Customer, Basis of Pricing [Axis]", "terseLabel": "Contract with Customer, Basis of Pricing [Axis]" } } }, "localname": "ContractWithCustomerBasisOfPricingAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/REVENUENarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerBasisOfPricingDomain": { "auth_ref": [ "r578", "r639" ], "lang": { "en-us": { "role": { "documentation": "Basis of pricing for contract with customer. Includes, but is not limited to, fixed-price and time-and-materials contracts.", "label": "Contract with Customer, Basis of Pricing [Domain]", "terseLabel": "Contract with Customer, Basis of Pricing [Domain]" } } }, "localname": "ContractWithCustomerBasisOfPricingDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/REVENUENarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": { "auth_ref": [ "r574" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.", "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price", "terseLabel": "Revenue recognized from changes in transaction prices" } } }, "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/REVENUENarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt, Fair Value Disclosures", "terseLabel": "Amount" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Schedule of convertible note obligations included in the condensed consolidated balance sheets" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r37" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Noncurrent", "terseLabel": "Convertible notes, net" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r13", "r206", "r215", "r223" ], "calculation": { "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable", "totalLabel": "Net Carrying Amount" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r11", "r205", "r213", "r223" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]", "verboseLabel": "Shares issuable upon conversion of convertible notes" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r55", "r250", "r322", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r458", "r636" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of sales (exclusive of amortization of acquired intangible assets)" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r54" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r11", "r12", "r13", "r205", "r206", "r213", "r255", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r470", "r568", "r569", "r570", "r571", "r572", "r616" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofEffectiveInterestRatesRelatedtoConvertibleDebtDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofTransactionCostsDetails", "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r125", "r356" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "verboseLabel": "Conversion price (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r36", "r131", "r132", "r134", "r356" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion rate, number of shares to be issued per $1,000 of principal amount (in shares)" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period", "terseLabel": "Interest expense amortization term" } } }, "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r199", "r201", "r354", "r470", "r569", "r570" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r35", "r199", "r366" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Effective interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofEffectiveInterestRatesRelatedtoConvertibleDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r35", "r355" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "netLabel": "Coupon interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Long-term debt" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofTransactionCostsDetails", "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r37", "r255", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r470", "r568", "r569", "r570", "r571", "r572", "r616" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofEffectiveInterestRatesRelatedtoConvertibleDebtDetails", "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofTransactionCostsDetails", "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r37", "r131", "r133", "r134", "r135", "r198", "r199", "r201", "r212", "r255", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r470", "r568", "r569", "r570", "r571", "r572", "r616" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails", "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r200", "r360", "r371", "r569", "r570" ], "calculation": { "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails": { "order": 2.0, "parentTag": "us-gaap_ConvertibleNotesPayable", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedTerseLabel": "Unamortized Debt Discount and Issuance Costs" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss": { "auth_ref": [ "r329" ], "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss", "totalLabel": "Amortized Cost" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r318", "r333", "r567" ], "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r318", "r333" ], "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "negatedTerseLabel": "Debt securities, available-for-sale, continuous unrealized loss position, 12 months of longer, accumulated loss" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r318", "r333", "r567" ], "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r318", "r333" ], "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "negatedLabel": "Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": { "auth_ref": [ "r629" ], "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest", "terseLabel": "Estimated Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent": { "auth_ref": [ "r629" ], "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails": { "order": 2.0, "parentTag": "us-gaap_MarketableSecuritiesCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current", "terseLabel": "Available-for-sale debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r316", "r330", "r567" ], "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position", "totalLabel": "Total fair value of available-for-sale securities in a continuous unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r317", "r331" ], "calculation": { "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss", "negatedTotalLabel": "Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "auth_ref": [ "r315", "r567", "r630" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]", "terseLabel": "Schedule of gross unrealized losses and fair values of investments in an unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r66", "r167", "r418", "r423", "r424", "r618" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred tax expense (benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r166", "r642" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities, net" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r66", "r112" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "auth_ref": [ "r457" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.", "label": "Derivative, Fair Value, Net", "terseLabel": "Derivative, fair value" } } }, "localname": "DerivativeFairValueOfDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r185", "r186", "r188", "r190", "r561" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r644", "r645" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Acquired developed technology (1)" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/REVENUENarrativeDetails", "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r397", "r575", "r576", "r577", "r578", "r579", "r580", "r581" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/REVENUENarrativeDetails", "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r639" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of disaggregation of revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/REVENUETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r585", "r586" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r242", "r261", "r262", "r263", "r264", "r265", "r269", "r271", "r273", "r274", "r275", "r277", "r444", "r445", "r519", "r524", "r564" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "verboseLabel": "Net loss per share\u2014basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r242", "r261", "r262", "r263", "r264", "r265", "r271", "r273", "r274", "r275", "r277", "r444", "r445", "r519", "r524", "r564" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "verboseLabel": "Net loss per share\u2014diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r74", "r75" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r461" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effects of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period for recognition of cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r160" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee stock" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Laboratory equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r130", "r225", "r239", "r240", "r241", "r256", "r257", "r258", "r260", "r266", "r268", "r278", "r323", "r387", "r408", "r409", "r410", "r419", "r420", "r443", "r463", "r464", "r465", "r466", "r467", "r468", "r528", "r529", "r530", "r557" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofAmountsReclassifiedfromAOCIDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r455" ], "calculation": { "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails": { "order": 3.0, "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": 1.0 }, "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails": { "order": 1.0, "parentTag": "us-gaap_MarketableSecuritiesCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r525", "r627" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedTerseLabel": "Unrealized loss on equity investments" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r362", "r457", "r569", "r570" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAxis": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.", "label": "Extinguishment of Debt [Axis]", "terseLabel": "Extinguishment of Debt [Axis]" } } }, "localname": "ExtinguishmentOfDebtAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ExtinguishmentOfDebtTypeDomain": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Type of debt extinguished.", "label": "Extinguishment of Debt, Type [Domain]", "terseLabel": "Extinguishment of Debt, Type [Domain]" } } }, "localname": "ExtinguishmentOfDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair value measurements" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r193", "r446", "r447", "r453" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r191", "r192" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of fair value measurements along with the level within the fair value hierarchy in which the fair value measurements fall" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r191", "r195", "r196" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r362", "r401", "r402", "r403", "r404", "r405", "r406", "r447", "r486", "r487", "r488", "r569", "r570", "r582", "r583", "r584" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r191", "r194", "r362", "r569", "r570" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r446", "r447", "r449", "r450", "r454" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r362", "r569", "r570" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r362", "r401", "r406", "r447", "r486", "r582", "r583", "r584" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted\u00a0Prices in\u00a0Active Markets for Identical\u00a0Assets (Level\u00a01)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r362", "r401", "r406", "r447", "r487", "r569", "r570", "r582", "r583", "r584" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level\u00a02)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r362", "r401", "r402", "r403", "r404", "r405", "r406", "r447", "r488", "r569", "r570", "r582", "r583", "r584" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level\u00a03)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r362", "r401", "r402", "r403", "r404", "r405", "r406", "r486", "r487", "r488", "r569", "r570", "r582", "r583", "r584" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "auth_ref": [ "r446", "r447", "r449", "r450", "r451", "r454" ], "lang": { "en-us": { "role": { "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.", "label": "Fair Value, Nonrecurring [Member]", "terseLabel": "Fair value, nonrecurring" } } }, "localname": "FairValueMeasurementsNonrecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r452", "r454" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetAssetLiability": { "auth_ref": [], "calculation": { "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset after deduction of liability.", "label": "Fair Value, Net Asset (Liability)", "totalLabel": "Total" } } }, "localname": "FairValueNetAssetLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r475", "r478" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows from finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r472", "r482" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Finance lease liability" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r472" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease liability, current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance lease, liability, current, statement of financial position, extensible list" } } }, "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r472" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance lease liability, noncurrent" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance lease, liability, noncurrent, statement of financial position, extensible list" } } }, "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r474", "r478" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Finance cash flows from finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r471" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Finance lease, right-of-use asset" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance lease, right-of-use asset, statement of financial position, extensible list" } } }, "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r481", "r591" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r480", "r591" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term - finance leases (in years)" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r313", "r314", "r324", "r325", "r326", "r327", "r328", "r332", "r334", "r335", "r370", "r385", "r442", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r567", "r624", "r625", "r626", "r667", "r668", "r669", "r670", "r671", "r672", "r673" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Weighted-average remaining useful life of finite-lived intangible asset (in years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r339" ], "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization", "terseLabel": "Finite-lived intangible assets, accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r108" ], "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r108" ], "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r108" ], "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r108" ], "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r337", "r338", "r339", "r340", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r106", "r516" ], "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Cost", "verboseLabel": "Gross value of intangible asset" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r103", "r105" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r106", "r515" ], "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails_1": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 }, "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangibles, net", "totalLabel": "Intangibles, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign exchange forward" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r185" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "terseLabel": "Gain (Loss) on derivative instruments, net, pretax" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r66" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of property, plant and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r66", "r126", "r127" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Gain (Loss) on Extinguishment of Debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r56" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r91", "r93", "r517", "r592" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r94" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "OmicEra acquisition" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "INTANGIBLE ASSETS AND GOODWILL" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILL" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Goodwill, foreign currency translation gain (loss)" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r66", "r92", "r95", "r99" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Impairment losses" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r97", "r168" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Goodwill, Purchase Accounting Adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Recognized Goodwill" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r66", "r111", "r115" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment, Long-Lived Asset, Held-for-Use", "terseLabel": "Impairment of long-lived assets" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r51", "r202", "r209", "r220", "r289", "r292", "r297", "r300", "r520", "r566" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net loss before tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r585", "r586" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r341", "r342" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r251", "r414", "r416", "r417", "r421", "r425", "r427", "r428", "r429" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r252", "r267", "r268", "r288", "r413", "r422", "r426", "r526" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax benefit (expense)", "terseLabel": "Tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations", "http://www.exactsciences.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r65" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r65" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r65" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory, net" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r65" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "terseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r65" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r109" ], "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 }, "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails_1": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "In-process research and development" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Finite-lived and indefinite-lived intangible assets, gross" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r101", "r104" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Finite-lived and indefinite-lived intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r211" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "verboseLabel": "Interest income (expense), net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r244", "r247", "r248" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORY" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INVENTORY" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r1", "r42", "r592" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.exactsciences.com/role/INVENTORYDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Total inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets", "http://www.exactsciences.com/role/INVENTORYDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r41" ], "calculation": { "http://www.exactsciences.com/role/INVENTORYDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Inventory, Raw Materials and Supplies, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INVENTORYDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentCompanyCommittedCapital": { "auth_ref": [ "r221" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of funds committed to investment company from investors.", "label": "Investment Company, Committed Capital", "terseLabel": "Committed capital" } } }, "localname": "InvestmentCompanyCommittedCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNonoperating": { "auth_ref": [ "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.", "label": "Investment Income, Nonoperating", "terseLabel": "Investment income (loss), net" } } }, "localname": "InvestmentIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofAmountsReclassifiedfromAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedAtFairValue": { "auth_ref": [ "r222", "r536", "r537" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.", "label": "Investment Owned, at Fair Value", "terseLabel": "Investment owned, at fair value" } } }, "localname": "InvestmentOwnedAtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, All Other Investments [Abstract]" } } }, "localname": "InvestmentsAllOtherInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Schedule of contractual maturities of available-for-sale investments" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LandImprovementsMember": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to real estate held.", "label": "Land Improvements [Member]", "terseLabel": "Land improvements" } } }, "localname": "LandImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r640" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails", "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails", "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "City letter of credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r31", "r250", "r322", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r437", "r440", "r441", "r458", "r565", "r636", "r654", "r655" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r207", "r217", "r592", "r617", "r628", "r647" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r34", "r250", "r322", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r437", "r440", "r441", "r458", "r592", "r636", "r654", "r655" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing agreements" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTranslationalGenomicsResearchInstituteDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Line of credit facility, current borrowing capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Line of credit facility, interest rate at period end" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Remaining borrowing capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r39", "r118" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Estimated Litigation Liability", "terseLabel": "Estimated civil damages" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "LONG-TERM DEBT" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBT" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r37" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Loans Payable, Noncurrent", "terseLabel": "Long-term debt" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r37", "r123" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r118" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Loss Contingency Accrual" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r118", "r119", "r120" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Civil damages" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails", "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ManufacturedProductOtherMember": { "auth_ref": [ "r640" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by labor or machinery, classified as other.", "label": "Manufactured Product, Other [Member]", "terseLabel": "Cologuard promotion agreement" } } }, "localname": "ManufacturedProductOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r2", "r32" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities", "totalLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Marketable Securities [Line Items]", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in marketable security.", "label": "Marketable Securities [Table]", "terseLabel": "Marketable Securities [Table]" } } }, "localname": "MarketableSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketingExpense": { "auth_ref": [ "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.", "label": "Marketing Expense", "terseLabel": "Charges for promotion, sales and marketing" } } }, "localname": "MarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Cash and money market" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r246" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r246" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r63", "r64", "r67" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r52", "r67", "r210", "r219", "r227", "r235", "r237", "r241", "r250", "r259", "r261", "r262", "r263", "r264", "r267", "r268", "r272", "r289", "r292", "r297", "r300", "r322", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r445", "r458", "r566", "r636" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "exas_ComprehensiveIncomeLossBeforeTax", "weight": 1.0 }, "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations", "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Outside of United States" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "auth_ref": [ "r69", "r70", "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "terseLabel": "Property, plant and equipment acquired but not paid" } } }, "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r57" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r622" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": { "auth_ref": [ "r49" ], "calculation": { "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "OCI, before Reclassifications, before Tax, Attributable to Parent", "terseLabel": "Other comprehensive loss before reclassifications" } } }, "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenseMember": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.", "label": "Operating Expense [Member]", "terseLabel": "Operating expense" } } }, "localname": "OperatingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r289", "r292", "r297", "r300", "r566" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r652" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Non-cash lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r472" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Additional amount to be recognized at lease commencement for the lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r472" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current portion", "verboseLabel": "Operating lease liability, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails", "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r472" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, less current portion", "verboseLabel": "Operating lease liability, noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails", "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r476", "r478" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r471" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails", "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r481", "r591" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r480", "r591" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term - operating leases (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets, net" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r44", "r47", "r459", "r460", "r462" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 3.0, "parentTag": "exas_ComprehensiveIncomeLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": { "auth_ref": [ "r179", "r180", "r182" ], "calculation": { "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent", "totalLabel": "Net current period change in accumulated other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract]", "verboseLabel": "Other comprehensive loss, net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r179", "r180", "r182", "r236", "r238" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "verboseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r230", "r233", "r319" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "exas_ComprehensiveIncomeLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax", "terseLabel": "Unrealized gain (loss) on available-for-sale investments" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r6", "r7", "r33", "r592" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other long-term assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents and licenses" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r609", "r610" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedTerseLabel": "Other investing activities" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r83" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherInvestments": { "auth_ref": [ "r60" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investments classified as other.", "label": "Payments to Acquire Other Investments", "negatedTerseLabel": "Investments in privately held companies" } } }, "localname": "PaymentsToAcquireOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r59" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Shares issuable upon the release of performance share units", "verboseLabel": "Performance share units" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementPerformanceSharesActivityDetails", "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r140", "r161" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at fair value measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESScheduleofConvertibleNotesDetails", "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r14", "r372" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r14", "r372" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r14", "r592" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.01 par value Authorized\u20145,000,000; shares issued and outstanding\u2014no shares at March\u00a031, 2023 and December\u00a031, 2022" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r3", "r24", "r25" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r603" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r62" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Net proceeds from issuance" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails", "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r243" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Proceeds from Debt, Net of Issuance Costs" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r61", "r162" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from exercise of common stock options" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r62", "r616" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Proceeds from lines of credit" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r611", "r612" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other financing activities" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Maturities and sales of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r61", "r162" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock options exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r640" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]", "terseLabel": "Other" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Medicare Parts B & C" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r227", "r235", "r237", "r245", "r250", "r259", "r267", "r268", "r289", "r292", "r297", "r300", "r322", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r435", "r438", "r439", "r445", "r458", "r520", "r566", "r589", "r590", "r608", "r636" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r634", "r651", "r653" ], "calculation": { "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "negatedLabel": "Accumulated depreciation" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r605", "r635", "r653" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r604", "r633", "r650" ], "calculation": { "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "terseLabel": "Property, plant and equipment, at cost" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r27", "r114" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r116", "r543", "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY, PLANT AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r10", "r114" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r10", "r113" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": { "auth_ref": [ "r49" ], "calculation": { "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent", "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive income" } } }, "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r49", "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedTerseLabel": "Total reclassifications" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofAmountsReclassifiedfromAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofAmountsReclassifiedfromAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofAmountsReclassifiedfromAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of accumulated other comprehensive income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofAmountsReclassifiedfromAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Schedule of amounts reclassified from accumulated other comprehensive income (loss)" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "auth_ref": [ "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r165", "r224", "r662" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "verboseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r615", "r663", "r665" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash \u2014 included in prepaid expenses and other current assets as of March\u00a031, 2023, and other long-term assets, net as of March\u00a031, 2022" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Shares issuable upon the release of restricted stock awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementRestrictedStockandRestrictedStockUnitActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r17", "r136", "r216", "r411", "r531", "r533", "r592" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r225", "r256", "r257", "r258", "r260", "r266", "r268", "r323", "r408", "r409", "r410", "r419", "r420", "r443", "r528", "r530" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit\u200b" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r286", "r287", "r291", "r295", "r296", "r302", "r303", "r306", "r396", "r397", "r514" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue recognized", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations", "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails", "http://www.exactsciences.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/REVENUE" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Revenue from external customers by geographic areas" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SEGMENTINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving loan agreement" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r479", "r591" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new finance lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r479", "r591" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "negatedTerseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESSupplementalDisclosureofCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r49", "r648", "r649" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of amounts recognized in accumulated other comprehensive income (loss) (AOCI)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Available-for-sale securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of available-for-sale securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "terseLabel": "Schedule of fair value of contingent consideration" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Cash, Cash Equivalents and Investments" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Supplemental disclosure of cash flow information related to our operating leases" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/COMMITMENTSANDCONTINGENCIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r643" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTranslationalGenomicsResearchInstituteDetails", "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails", "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r103", "r105", "r515" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r103", "r105" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of net-book value and estimated remaining life and finite lived intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r98", "r100" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofChangesinGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r98", "r100" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of carrying amount of goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r8", "r21", "r22", "r23" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INVENTORYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r27", "r114" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails", "http://www.exactsciences.com/role/PROPERTYPLANTANDEQUIPMENTScheduleofEstimatedUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r140", "r161" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementPerformanceSharesActivityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementRestrictedStockandRestrictedStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r143", "r154", "r156" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity Under the Stock Plans" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock and Restricted Stock Unit Activity Under the Stock Plans" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.", "label": "Schedule of Subsidiary or Equity Method Investee [Table]", "terseLabel": "Schedule of Subsidiary or Equity Method Investee [Table]" } } }, "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of estimated future amortization expense, intangible assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecurityOwnedNotReadilyMarketableFairValue": { "auth_ref": [ "r203" ], "calculation": { "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails": { "order": 6.0, "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of the not readily marketable security or category which has been determined by management based upon fair value methods, including pricing of similar securities and valuation techniques and is included in the schedule of financial condition or the balance sheet.", "label": "Security Owned Not Readily Marketable, Fair Value", "terseLabel": "Non-marketable securities" } } }, "localname": "SecurityOwnedNotReadilyMarketableFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r283", "r284", "r285", "r289", "r290", "r294", "r298", "r299", "r300", "r301", "r302", "r305", "r306", "r307" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "SEGMENT INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SEGMENTINFORMATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]" } } }, "localname": "SegmentReportingRevenueReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SEGMENTINFORMATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Commercial" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/REVENUEScheduleofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r65" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementPerformanceSharesActivityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementRestrictedStockandRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementPerformanceSharesActivityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementRestrictedStockandRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementPerformanceSharesActivityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementRestrictedStockandRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementPerformanceSharesActivityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementRestrictedStockandRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding at the end of the period (in shares)", "periodStartLabel": "Outstanding at the beginning of the period (in shares)", "terseLabel": "Outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementPerformanceSharesActivityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementRestrictedStockandRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementRestrictedStockandRestrictedStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding at the end of the period (in dollars per share)", "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)", "terseLabel": "Outstanding (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementPerformanceSharesActivityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementRestrictedStockandRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Released (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementPerformanceSharesActivityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementRestrictedStockandRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r155" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Fair value of equity instruments other than options vested in period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementPerformanceSharesActivityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementRestrictedStockandRestrictedStockUnitActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Released (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementPerformanceSharesActivityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementRestrictedStockandRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementPerformanceSharesActivityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementRestrictedStockandRestrictedStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r144", "r146" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "terseLabel": "Number of outstanding performance share units (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementPerformanceSharesActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at the end of the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at the end of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r155" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Total intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r161" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding at the end of the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r145", "r161" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at the end of the period (in shares)", "periodStartLabel": "Outstanding at the beginning of the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at the end of the period (in dollars per share)", "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementRestrictedStockandRestrictedStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest at end of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r156" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest at end of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest at end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r138", "r141" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementPerformanceSharesActivityDetails", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONSharebasedPaymentArrangementRestrictedStockandRestrictedStockUnitActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.", "label": "Share-based Payment Arrangement, Performance Shares, Activity [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Performance Shares, Activity" } } }, "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Market price (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CONVERTIBLENOTESNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r161" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable at the end of the period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable at the end of the period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest at end of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r538", "r539", "r540", "r596" ], "lang": { "en-us": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-term Investments [Member]", "terseLabel": "Marketable securities" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofCashandCashEquivalentsDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r40", "r130", "r225", "r239", "r240", "r241", "r256", "r257", "r258", "r260", "r266", "r268", "r278", "r323", "r387", "r408", "r409", "r410", "r419", "r420", "r443", "r463", "r464", "r465", "r466", "r467", "r468", "r528", "r529", "r530", "r557" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofAmountsReclassifiedfromAOCIDetails", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r256", "r257", "r258", "r278", "r514" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "terseLabel": "Issuance of common stock to fund the Company's 401(k) match (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r14", "r15", "r130", "r136" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Purchase of employee stock purchase plan shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r14", "r15", "r130", "r136", "r148" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Exercise of common stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.exactsciences.com/role/STOCKBASEDCOMPENSATIONFairValueandActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Value, Employee Benefit Plan", "terseLabel": "Issuance of common stock to fund the Company's 401(k) match" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r40", "r130", "r136" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of common stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r18", "r19", "r82", "r592", "r617", "r628", "r647" ], "calculation": { "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets", "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYScheduleofOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r137", "r249", "r373", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r386", "r387" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITY" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedTerseLabel": "Other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityOtherShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of increase (decrease) in shares of stock classified as other.", "label": "Stockholders' Equity, Other Shares", "terseLabel": "Other (in shares)" } } }, "localname": "StockholdersEquityOtherShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary or Equity Method Investee [Line Items]", "terseLabel": "Subsidiary or Equity Method Investee [Line Items]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade name" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofFiniteLivedIntangibleAssetsNetBalancesandWeightedAverageUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r313", "r314", "r370", "r385", "r442", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r624", "r625", "r626", "r667", "r668", "r669", "r670", "r671", "r672", "r673" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r643" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSJohnHopkinsUniversityDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSMayoDetails", "http://www.exactsciences.com/role/LICENSEANDCOLLABORATIONAGREEMENTSTranslationalGenomicsResearchInstituteDetails", "http://www.exactsciences.com/role/PFIZERPROMOTIONAGREEMENTDetails", "http://www.exactsciences.com/role/WISCONSINECONOMICDEVELOPMENTTAXCREDITSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r563", "r582", "r664" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government agency securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofAvailableForSaleSecuritiesDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofGrossUnrealizedLossesandFairValuesofInvestmentsinanUnrealizedLossPositionDetails", "http://www.exactsciences.com/role/MARKETABLESECURITIESScheduleofUnderlyingMaturitiesofAFSSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r412", "r415" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r76", "r77", "r78", "r279", "r280", "r281", "r282" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/LONGTERMDEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r270", "r275" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares outstanding\u2014diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r269", "r275" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding\u2014basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.exactsciences.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "820", "Subparagraph": "(c)", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=35710923&loc=d3e45360-110995", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=25866437&loc=d3e10491-115837", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r597": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r598": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r599": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r601": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r602": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 98 0001124140-23-000044-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001124140-23-000044-xbrl.zip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�H&#X[7VG^=_>?!FE^_*/5_&=+['4:IXW- M ][<:1XV-ANL>?%A:>2'$!84;"0R48E\: 1!V@GXU5O)0V*4*Y6[03)U5=N* M50M\5Z!7@=Y3@)ZG/ GOHN3$<.&"M=121Q/ H*"6ZP+TZ!CT: 5Z*P-Z>![T MM @*2R,1B48A'CQ%3E".B&5)&DX$D3D45.>$OA#0>PU1HD+U#:V!+QHL/%CI MK2)%JZ'MY6W='.WJ7_W8:9UT*H"["\ MB75['4A01B#8)HJX) DY*@/\A4/@ M#JN86Y&QJSI,/4<,J&+;EZ6O5&S[8+9=T$M@6V22N53+NX!X)!I9H -$2?(D M\!"M_G_LO6E38TF2+OQ79,R=]U:9$53L2U6_F%$)F4--2^1"5@[Y!8L51 J) MT5(D_/KK<8X$VM@%"#AMUMDT2&>)<']\"??'(ZCMTAW=OO(2O ^9G&5BOM5P M)L;4@+NJ*._.2_O+LTT0R9NZT_YRL:4[:6J(2!6#+0SKQDM5&KM;YXW=O7U. M$@V2$I2PS1T76"!M-4$^R."D54H4,1A>9726,G[FE.DI*O$JC5XR#T4^2*%3 M\V<,Z#QV.Y4NWTV7\;0N8QH49PG\%F$=XD029 *QR'.9YW:'F)1?62^8>.@? M56WMD^KCNTY!\CO-[U"E3%Y$RJ1 MG(+ITK\*N_D,;R3BPRQU5I9(9 (7B&> M"$?&6(^\%]+A)*+,TTW8*A.SSDF50WDU>KRP'$JEQT_KF8STV)GHI?0$"4XQ MX@%39!S#*)$@J-01LRA6UNFJD+/C+ZNDRF-JX6ZG7Y!P3I4Q_])L^\YQ_#7G M6YXDP7++D[MAE3.#'0V=07ZBXNRNJ@)8Q.(LM[UXXAQ5#UX8?KJNO6.[T)&< M@:^LQ\*LQQQ6$!8(A+#<(*X#S_EXCBSE$C$OG1QEO: 7'Z>P?!+VU*T19?Q([C];\* KWM0KFD4;&_N!)LF4 M"4AY"[&BE!BYQ DR.A)#M;98Z#LVBR[Q!)(;V%LO)@Y'9$;;;"\[S=_JI]\WOT*4][G5./I^N+/Y M]W'CJ,[JYW"?W;\/^=__H#G98T/7VGC>(O#?6C]W)_# M.[4:W[8@LIS?FN@QQRG$A"SL%.(I9G_<>^0ECT+BR#BGH'!K+Z%)YSFTY#\K MU'E&U"'4$ZFH(HXX;J2VP5LC*&/,86\MO2%Y=6_4N:'$K4*CVZ'13!Z+>4$U M#@8)*QWB"FODK$[("^Z3#9*GM/ :MU<-2&^A^*XB*'\6['T@1WGE\3T%QLYI M6V21VV0I1I9*@K@+#!DE Q)2L>!H2"[W/^$UN21%=\\/HA5Z+!X]F/,RAQ)_28\="X#)G).R 9+4/<.L"1!.C!@F)* M.*. M;#@E,5IAA2I ],'UTHOIXWI^$*W0XQ%2]H9+P4Q06A@.]ALB 4DU#]0R'61Z MM.19A1YW0H\9%RPQ$RDE&,*VW @J)4/6&HQR\5+ /$_B=15ZO,$L6#7>Y>E! M]($37BH0?0H0'>LZ:&Q^$CN[G_:Q]%H29A$W.B+.;,Z">8RPHHEBD30([LHZ M62,/9F1]+7%LA1Z/D05C !^6L)04MT$;[[WTA@>,O=@77S ]FJP LC;WN%L MEVZS5[NNB^%>GL=U<#'F/'X>O>2(?'"(.M,RC@*5$'">'3%+P#U-6*:Z$\'9EG:T9>;=MOM=I>K7-C['- M/QL'^RPXKZU-B,5,34.3S6U*#L'5).R&PI[PE76^9NCL-MMVN':K[U4J6VWU MPK>ZOKL!SMS7G_7=O?/ZT4;N3E-)A(131(1@!]IM!;*,1=A[4$YA@_$DK:S+ M.=M>RPO8RRM;> %%-J;(P*S6BL.QRY_UZ.Q^-E:W MF0GZZ)[8_!F@OQ#\Z_5*]L >SW\W/3AAH$@;!]U84!UFC6IU>H/NTK1P[KP; M*LS1 ?^^N7':^/;I=&_M;I\U-EM']#'=\OGO[7=;C2];M8W&9NW=SK__O?'GSN>-W>V=1FWCP^>MK?I68_?+ M3 Q/0=V7&/*G;KY,28?6X&$N!1CY(3RZ(,)UKK(&(T\49I-P,L89)H#EW>= M8[CS6:U52#9@/V_ @!\VB+=7V:[8;5VN 9,?V# *6U3SIM-,] MZ>3>U)#CE$ZMV>]=?N\,@IX 05 O@AFRK=$=:G:D.AGL>K73"/&/+3M?BW 5 M?NS @A_#]ODF1*SG\>*90M,>M#L]"&;A-GG\6O\0PN*#PUK1W.KRH^1-O;S# M6NU#;.>[M\Y6BSO,/@0 [/\.FMU8_'FT&O $)_"66=-;$87F0;-?ZW;.;*N? M5\/9'KPQW*@=X=?P>B 9^3H^ DJ'VJ!7M/;"Y2;6, -[7KK1_8[!(A\/CH?7 M/JC#Q35.X/99]_+3E#_7[,D) M?+I8D4E@L$4RY-K+%R_>C0>V&V9N]:/=.46'G=-R$<']/8FC1OK1UWU.UN2' M 8WW\++94UZM@4W_)S8!5[+"P<9-@4_^5;_3:16;.LB)F8(UK1W+#&_Q2 64 MG)4W]/DZW=7:23>BT<^A";O>*ZX.7PW-_,V[^'A#J>5T3>66_9-.K[C$[]U, M-0%K==FI_Y^3-FFH=/CR*];U.JU!_^JOS/3"/I-R4C*U0&/_'G8O^Z@/P/7H M1OL#V00/^[MMG=JSWLIODQ $^#.\N&1P]VO?_5:XE-*CO7J)CB'ZH9G[O3"O M^5/P.'9IGJ5VV,VN]G_<'$PH\$ *Q@K0CG?92P=$^-=O=DYP\FPB.-^L;?W/ MQKO=VI=WVUN-=UM?P!/]_''HAR[]HYW-&"+\%[_O*U;0< J#'\.@\NYH8!-[KU4V& %"II25701G" $]>WP"&G_2[?C8ZQ5VUK9MZZPXGRKL:O:=\[5 'FWYMUX3GJ37ZX!8 M9A$M+&M[X%L1++'US7!IM M;7!K7\N'A^6)W9&9[I0MP-.@V>^"#C5[EG\*9 MC%&]\=HI[6()3APM>U+VNKM8U!KP\A1M.NUM[! P=;NHM;@R[X&K"= M7]OP1?C;(>C6:NTOF[ +P;>%OEX'0Y$US'--J@:,T@#T_R:O4[4_GMEZ$YGP<=/,T M\'X9*< *]&?]]/)O&WQG:X.?ST,$0,HSBT6#6(-,"3G1.2GN50=,Z= MB_"T9ULEZ?.;1 M:Z_57N#V;O1@];O]T1N-!51E.#5'1?/[3FT;:&@H77M8Q/]S!PY&G9RW,AF/ MN>$D!FV9UU&0$"G#CJ?][1RR86_V" @D J+M MT(OM"V' ;T\8SAH'^SQJH\'%0RED/F+*!7*6..0CBY%Z(17%*^L)@NY9:0 T M!]6W[?:@H%V_7/"+_"5L(R^]DWF?LMVR/*0;RIQ-=Y0L*ORD^$]L=4X*VS)T M [*3,M<@^ NGWX\[_;T+5S]#74;YTM=9J[U$U-Z=YTF5939EE4Y>G9)C<164 M$,QCKP;+V6IF+PP,&'AI_0N'L# S7)%K<];4*2#+C)\8Z[: &*#5FE$;:\_ ME6,*%YX6[!&8]N*"%#-3^P5_'M25\"%CZ_]%7&?908*[)/8QDS!(;^GV86-=0>\0Q/DB@!I;K-'2#][^>"GB&!!GMME?CIK0&\ OG\17Y=!'F@3 M>/?Q4AMJ.?,)'W1#'W0JWWWIE;] >-^^]*?S6A>G$2. NW##QP\>\A]&4?[5 M4@PR5\6_! 0^URR4MQX^FRC?]CL39Z[3H9"S781<8*K<0BR5,:@=XE^ M[@7/\\*@4774Z(AMHQTV+[?I3J.@WEP@=/Z5-4[WB9&""!91E 3 V&&)K+8: M16Z(=]% ?&1S$>O5@5 AWW?9?0\13E"2>$DX9])JYIA2*6\XN-V>WS1_H-K] MA>Q^KGXC+@J/*4&1VHBXY1$Y1BCB$L1!8V)UHGGW9ZD]+G9_5/_6+PB5CSL% MH7*<)%3.2,.&U6^43M6]%69Z!"07R#+GQ'46E9XQ>EK^ HV_.H?@P_Q7Y^1' M=G:^MIOY(+S9/WN9<5]IN8JPS/_OH#D\B(!-@3\5E0,3/H(?YECM6$'!197! M5=455R[8J&[CK__Z.BK;N*@,@"<8%4'!GR=R[A=^Z629PNCN(,S@C#0/VJ5A MCV7N?:I2J55<^R"6%P=_IMN,_6R[BR.4H3!/NRWC!59VM$ZVYEJ=3D!%@=-J M[7C0ZC>'Q0I%G :7C/VANN6SFF'*XF*)LN-[>4(RD:HN\M#EA<"4TY$R0RI15LOKAV\^_J-AH+.Z]DL)XI;@*V$#JDR 63(J6D724 M3R0 .Y_V95+:I]R2;P0KPVBD+@V\F6>7.R]>F\<;!OJ*%2\Y0I M;@CBRG!D%+'(Z2BDT7EP''I!P/6-?6ME9"2 @9'8(TZ)1T8F^"?D*BZ3O,=%:@)?)PAWM3)2!QW! MM0%4L)PGXTB*"21$\IA84*(2AF<0AIV-_4S[[T2(2-JD$;?*(\VT0U0X9:E/ M"IS.+ S7HL(U_7;+&,'O@KST6G987O(AMCO'3=^[["?(Y_O-_J ?+R+47?C0 M*$1]>#_A4T?Y\TLW;R[%S#T=EREMD]6B5&AT]%,41>?$ OSO?W5. MXGB=X%7U@9<9C6%A&$KPP=6;WF?B78KGG$A17&8F;GR"N16$J& I.&(4'"0PQ8*C3*R&9.240@A%N8?@ MC\V+_B7,L4PE"]5L^@.A&VR_3E!U Z7RU M.T4 B1NCA,,XY>X 8E@0X& *JDA2-/)*U)Y#U,Z_[A,1P-0+GVF30=28QDA# M6(A$I.#])0^6 6?P63SZ))Z)>T(JD7@&D=C9W=KW M7 M8=8644 Q"0Z:1S96[V+O@0&$MS>,(J+A1).8<0_;&_)A\M%@ZHP<95\:P MJCP/*>MNZ/D=52_F0\S"X2JK M^B\\JWPQ'R=N79P,R.^;RL=':K']_]3'?H["'2++D["'DUR$/W^-0B(QJ M$:Z*^)>.2X361^0[H+[?C_YLUBG\[<,G6M_\=+:W^V=S[_R E(K]Z;Q!]_CW MH^\SY#N@OL?U#]OP_;]^P'5/&YM_'=8__'6TL_EWH=B-S3K[?G1XW#ANI/H1 M/,O&OA"2BX)+Q% (Y'/Q@:&$(I.DCC2SD)L9+A$PP929((,5CA//'3'*."V= ME]P#,D]SB7Q\O_U]ZW/MX^>=^LXDA&2) M@*G#3BAG7! J6L*L2D54O3$X&/3Z@%E$7QM4?X0XMU,\RT45;.V7_/EAA+S3 MA>@YYS#F?/ B;B[.X#\F6(EN;;OMUR[BZ_)WH\^M#ID7,PW"5<0'.[[?&971 M33S(Y]&'KGF0$IVO^R2$VOWRQ@6Q22Q3-+W#Y@E ?O\TQO9D[ Y/-WROT8-V MP;DMJCJ+WB/;;L/?X+DO.25'W\U=EQ#+YWK1T35RY<')Q4-U1O6FK<[!H.!( MR/P%HTH_6P,A^Z=9LHJ4R="+^M:B<6Q8/EB6)Y:6IRR]SMU^15EV^?W>N L^ M>\-;K-FPXR)*4"]*-_6['#@UU[;2\ M6BZ9* JLL['=..DV6[6RT @7)8V-SC\7I913&:&Q_9B4XW9M3IKL*H!XD_P, MM.)GJ/@9*GZ&BI]AT?P,-[LCSQQ6S ?$BU;AD5F\U@2.>R(3]JFV,;K.M)=S MT:]5LK05C2\77V5X=6C>AN:L""7;G5JK U''R$N(9MRDYH[HD8M3IN#NFO^'D("J%)7D,7!-@M8B80D.K+=>0116 MYEL(N;8A.B-9OM?N93_/^_@R*L"?/AS;W-T(?J3"M49JDG!B@+X-$RKVAQ5R)HAL[-8?? MR(_3FZ9A&3^MO][A* /^()T \OVM6^<*N/]2;A] _)]9 M.'?:VY>B^2%+YL=2,'= +K^,Q/+/D51NM,/GD36M3,3\C/?V>?UT'U-+O< 2 M)9WK& VGR$1%48JPB=[AP*)86:=KXH8CS%&GW;A2CB/##0UX] I9O&[DH74?ON+ZAWRMO?.=;Y\A7CG@.QO[VDDB08:0DI8C+C5'QFN---@E M'E+@+LR<%3H="!68$.'R4"JCF3=*"H43T2DI/7W\^F5WY]U__]?.OS>W/G\9 MQ@6UK4]?MW?W[C' X>:;3SXL!O6@VAKFO>&.<1<5@"+$PA"/12;=LV<2Y^O' MSG'3;W5M;6.LN[D0Y=IV+_.+^/@"CZJW"]:I(0)/'VNVBKKJ@A-GLJ-[N!17 M,)-,-("/DDS-'H2^W9(0%F2QVW2E04N,!TBV<>CNB)&[(VYR=_[,G6RQUQO;\!*N1C,\>]O% M<^YT"P& 6&)$Z_>E>+[RKR_#27IRK /'>U\S;KQE E'A);A(6B#'*$'864 % MQR0S./>1S3*;3+K=I3A,^3C_MU=TV><_%TI:Q+Z'M@B.;;-;^\>V!G>.[@Q) MF+LDE>:$2Y6,UMSI9%V4./E0MC@7,O9 T9J6K+_STV[T2C*"2J3FB]0!W_=. M@,-E&.+P/XA' B*%P?5VT63:%&Z%R+7P?&UV".S(ZWX!;4?O#G/16I'@V_## MZD; RYT"7K/\=^-AGI3U3\QU.KE2XY=_=WJ]7V>,^6-Z>?XPAD$K[J2Q1RR> M<.(!R^?+3U><=K]EWR]WUCJ',[\LPDF ^'+JD-6L(+UU/EHGC9[Q_;P@UB>A M=.;QF.24%M4C1=3B70-W;>;=](:53:APM>HR*@ MM'D28*O5.>W]/J/AZ_\JIB!?%@!U(3A!!9/122_^/OKAC]#LG;3LV>_-=O'$ MQ9?^F%S$7&HT-?*Y6-+RSY=%-&NX+*3),Y@OATT/_[Q6_&EJ$'7Y-Z'7I!%7 M_AFOD7O^3;"K;WK=-Z][6$+6)#&/\+!,\Y?SL(^ULI3=ZK+%F.^AF($D9]'_ M_U?8RF4QV,08\_$BE59,3S2_7-]D]PIE^64[9Y Z [A$&+-FPP6XYMUP?K.5 M6WUTSC*4M3K+M!#O+CL:QEJ0:QOA:- KNJS>\-I\;7=C,;@PU#[D(Z;2]=^3N,ML,19_^.@FT?NH>&K>!]C2G\,+6J_M_K/O7-/&[N?.,1AS>\0<]5WO_+& MYL9IG6Z=[IUOGX^^ _<:?*=?)5R??M]L'>Z=OS]JG.^1QN8!WSN&]]C\D9\= MUS^GYPB.N&(F/8<<6PHLIY3 MI%C GEOF9, KZ^*J;-9CR3XH?>V..E A6(5@=WOO7^X"84DZ[DA@R47.4W1. M@*X0QBSG6A)\-83E]"?\=!LLNTV&M *Z6P$=G@8ZK0T5D2ODE4@ = (CK;!' MQLID(V744P5 MTKU;$GEC-M=P5P%[.@7LJ_C/W MWJILJ%UF@-H93G,9SVJT]PK>I];HRC01O=LZS[4! MRP>&=\!"9J-C!%-E@^069\>/"6]9LDD1(M1-XV1FPM<=W_RSV,G/TQM9_GK7 M_MSH][M--RC.:'8['VVWF/!88>+M,;$Y&^-BPCV-X/5!H)LQD>>IG-0B8Y*, M/! 9M0!,G,/Q><<@]QKX>2P/K]+FV_)R$YT)YD2*U'%"E0D\&N>2=T3G^L2G MT^;*_5F8JL]$>2($08EWB'##$7>2($LB108+:R1.L/%I99W.C?(J97\URGZO M4J!*V9=;V6=B'8&Q(\%[I+T$NVX]0TX0BA3!BC%#G2&Y VI5LV52]ON>1K[0 MH*8DH>^-!2^Y;S,S6-NQ ]W.%:'/8QQ/W@HFYRSZZX/)A4!2S/9H,@L'[1>$\1C4Q $.0 -B5E2%ME M([,@DX:OK!=]-?2/!9WV+5&JNU+Z!09"5^1Z%Z']E9;?1Y,[_]D'F8'J\ M4&>!&:$''?:_:+Q<_$'/-1UC%^CXL=,MYC=4(/DPD&R\FPUV-+@[1.2);E%$ M^"=*Y)2&G[3&QE/BDUSHB<^RU/M4<+ < =*BX:#*(B\,*V9")AI\LC) C*18 M;E_%$MED%8AA,-0EF6P>!D17C5056E1H\?A'315:+ ]:S-;7A:1%]!@QJB7B M(I\^!>.1=12QV<%)LV@#581BCI4'HP*_"8G[@ .U9=_)+:Q*U3KW,%,P MIW4N@BV@RC(4/,FAI5)(1V80CCAR0@R.UJ^L2[S@WKD'JL;+:#FIP/'-@N-= MVE6D9EX31YCDD4ME=6(ZX/J\'1I.(,FD:*)>)*^$L:!T. M4?#L>3+M*QA=+AB=R4HP03@+02*.)<"H%9EYV7O$&,?:>&-3TBOK9%61Q34W M/UR#'I2Q^*U(>LTAO!S> 66H*L@ )]@!T3/2 ^Y/_.KW%?(:YW[N1B/C%40_?RZY=\ &^-MIA MP5\2.>Z+8O)]40];T0Z_5=[8BG:XHAVN:(>7BW:85+3#%9O=H]=.*)RW@Z85W_]O5T9Q>>??-[Z_OFI]/&9ITVZ%]'W^&:>^>' M1_7S[_"_X:AQ]'F"=KBQ^177=_?V;63!"9.0U%XA;C-/BZ$82:]CQ%@&V+LR M7531#E<(]KH0[$Y\G$'D6F)A$[;%>@NVC69 MBRP:C*R,$7%)*'*>)*2)TXYQ[J6B^62.RQ? QUG!7 5SCP)S.EA'20)?@!J> M K8B!JFB4M)%3EFH8&ZY8&ZFCHM8PKP#7&,JB1+FC+8*J1@8)5A0[V4!?T^2Q5PL7(M).WR]9N(*DSC!DH]2(4VN05=J@ M$()F*0:%<5A9YZL0S5<:_SHUWE.>A'=138;"P7KC>#FF-GJ$=4<(DX _2TL(&(2:X%]9@HD4FU'LR14RGX\BKX MXX5 E8(_M8+/#EJB+!%E/3(^@H(G%9"#WZ&4N":16$^"6#(%KUB(*Q;B94X9 M/>*Y3\5'_'1H.<1-DD@S3I"54E+)(Q;<%2=(>E* M\%X1*3&M2(F7LR*[XMT8@UJ(@U*V+- MBECSNKZ62$0*%/XUW%-O#$!E96<40G.<$):V(0X M#AP9XT0N7G!>\,2,L"OKP%@*C)U$3C-P1QU6R$F 4YQB B^5ZN1I1E+)'Y+1 M7!8DG: HKKB&*Z[AAW RKLVR#$^R"D_0#B]@/-WUU38[@_Y.&J/%NBHM7/## M[L*3_-D"J'V9L-F*__7Y[/NW<.(HESL?_FKM[-9%_:AUU-C]W&QL?F[N';4. MX5G%S@>(NC_D:^V=[WS[G.J[![QQND^U(U@GBD1@ 8)P 9XD; DB5E"[P[BC82CPU]EZ%HF M*K*^SO0:Q=L^WP"NE(R9I1]Z.W? ;2 M3+U&C'XI#_NZZ4A''Q@J'"W#K87Q,%[WT2XHW=2AZ\NB;TPI^ESP]F_X4VV[ M'X^S_04D^I?K_K9^R9.=>>9D+MEL =+T$Z*U);V0>O>64 M;&:3=*-LO@#ZW,W8M\U6KV9=9] O35AV<3KM0EB>@ESW%A^])U/H\@G=;4>Q MWN)]W]BRT7DZ^68I9]]=U#K_8UN#8CB%_0?T.#M["%Q0U+.M_.=_8DG]?+]R MY]MV@"QHX1]R_>H9KWC&-\;Q] 7DOE=$5<>V/R+V?ASMN&T5W\,Z+YX2C&^Y MQML7"S=L&J_]DCLJ?EVMM>-M2.;OO)0/IMA8.C&]_5')O%=<[M..NW2"8,XX MYD1B%[B@7%.K=?24NT!]Q'1NTNZZ?OA+T2Q3?CQOGGT[K'[;HWN[6Z=[Q)S9]LM&@[X_@N<[W MC@[P]\T_#QN;A\>-;]NL\6&/Y:&->[O?#^N[?S:_;X:YK7!>!1N59"@X8W.. M+R 3'4?22&=RFX?P>&5=*OW07KCE(_RI$.B5(I V-"@+V&)?(>4-X20JRR-=1#/N\O$/ M+366[';ZMK4@^M0%QDJ/>8VJS+PJ,U^8$0J 7-%X[[$T7*IHG>=-W_$TYBL>=U*7#E#HQ$(.Z$15X2 R=(&<6OR",X8-94+ M<9JK$O4*72MTG>?B4J"XV^C)X[;1Z;GJ=!U<>@Z$Q X M'QW.3*0*!XJXU@)I)A**4KF$I0_)V06R\SPON$[46EZ6R%U6Q,TKF;MY0/QZ M42$P6SE9".2-\]&E6KE5N>6CX\05([8)^W6XUX];/+C9[/E6IS?HQIV4#]!C MNU?LP.=8U Z^Z_3ZO2^'H/5_VEX,'^U98@T#%LY))UX:V2'-L4*>>9'D00HP'5.?7$&J*GJPR_[.Z\ M^V_TY\:7KHWWWKR41T72AMLN?*.&Y^L M%\J#6T]EB%@E=E,)Y#/I3-$Q@ HYK8V+M:[05*Q':[]CZZ[L!VSXH]*Y=U)",V=$[R)N3?E2TS MM8V\W;7-:/N'JS7 >NN:K?S[CU2I*? ?= M@I0N %"!2UA6RA<5>^;/?%8]]B@%/;#ZHU?6"+_OP"83C/Y[K99%N@][WAM] M87CGTV8K9^)Z@U9_6/\WJL@O-!@^'']FA8YY]K4MJ/)B*Z>GX2F<[35+%>A> MO!&*X(@TLXMS8K-KTH2GZH\^U ./MJ@Y[!5BD7UP>)YVZZQ\OM$CP2L#+O:: MX!QE,:\==\*%RYQ%;%R'1FK7[!_F3H-AEP%\*-EFMRQV*2\^_N#%[9$K ,N/ M ];H7?,2= L=Z\']A\LS7+B)IRD;'/JY> $R[9NW;O UNZ@!S=+ ^@%R&,[EI%C(6K##A:0\',[4I09^J1.KP\^>C#"WJ6.3*PO7_3]W"+OOY5./ MA=UBVL/> %/ML[Y?NM'C4CP4XMLU-\JWYF^?'YSN.Y.24C0B&K*W[7A$3AE8 M?B_ -65>2):YULS:[.B.&NANJ]DI9>XN4O!0DJY*"A8K!6Q?$QLL9Q:Q9#GB MF4/+.<)1A-U@2=I@"OHLNC;+EW(A! M&B>],HJ:HCW\%F ZB@:^Q.X_31_G*U.C4Q0S0#1;V+?BF'?\[SFIT>CT]R(\ MW*CKLW R=DI[5&GA/"W8R\[)O:-)9 ML1!FQ#(TFOA*$49/>@_E(_;R32\>#G3!]LMGZOR3+UB<,B=P'&[.?<8O,W:.I0IG_AZ#M\V4$1B9T D#& M_PY >19M]XUI07UW^[Q^NL\\5I@[C\ YL(C+X!%L(D.,",M<8#&$M+).U\QT MNJZ6UZQW8\?XF,T8PC2G917[2:=7[,COA5* O;GL>_W/R<3NM_#9I<\'@ M#B\N&=S]VG>_E2%.Z?%8#(JG"#EP*23A]P*V\J?@<>S2/$L-/". L?^X^9Q% M0;!;]'\#(+[+"%BT+=@YYS;/)H+SLPY;_[/Q;K?VY=WV5N/=UI?:NYW/'W<^ M#S/P2_[H .BQL%NPX"$[M3EOTBY.]0HS^K[9AE _IXDN^VOO[+(NP7O^\K5M M!Z$)K_3K/+B8>Q9RX]G&]+&-%-(%0GPBGGNBG+'),D.3#8Y"X+',9R&UH3\[ M)7_QA#(-6W$GS'9)Q/WLCQTO@BBT7$@4,! 1*S+@E$C6'E'(I)EB2QKO<'Q<3ZQ !,PGO>KV>'^CR42QPYJ:LW> M:R$6X6(-5UP=U<.^M(>EXBXL*$_+K; DO:>W(P(H#5ZM,(D+(2]YH>OP;90M MV1AF2[9^QJYOYN-\<$9N,\7YS:S,YYA+/G(J.H=-.8]J)?X92_G$!Z) MUN1%K-;&P4$W'D#L4MN&M6FV>^#)_ETP2HQQ$+ZF/J;BBK\W^W W?QOFULL% M:EXL4$FYT;PC,\YRT4)4S_AVGO$MS /=N:PA6JW]9=M%9=?PY.VY1WV^P#E< M5YY(%E4MO>G^-8EI9$H&:S5/PAD6K3"!.$4)T]:7G-6$3AY*;C?>SR0]YJ8Z M-BZ/H?X\FZFA+@YDAHF0,2EH#(Y=[-[N!!*_S%3)L/MB0]1I7>SLAF-XMJ/O M1Y]^-HY:S<;Y#]PXVB#U;XVCO:,MT?CVUX\9JNO-'^=[YS]$@WX_;M#&<6-S MB^Y\VV8[NY]H??,K/$>C6=_]0?:./Z?ZG*$!0H=DF(^(!P/_*"J1%4HAI16E M)N8QKWQEG:P*HE:UDDO4E5W10E2T$!-E%A]CMT"6A2 ;?41<&\4WP_!F%/<5 M85\%:'<#M-G1@I9IS:E!P7&-N(T<&6$ULD:S%#C#@IF5=<[7-'U]8+8@UW!I M]7[^28UW1A/G-<:16T>MX9A$)@F3$7,\Y'_)"HXN-7V.=\W%D \.C9F&N"_3F+. +"?2N'DTT-]*[5[G=]2%? M/JC<[O4&,6P6%<-EU5R9X1\_Y+[8Y2JF6Q04SAO(CJ6C%'N%DI06<1X=,C89 M)"@@8B[5D["EZUJO4HD?/K]HB3A'7KFBWR/X>:"RWST*ZMT0!HT@H+?=+E&B M"H86AP0SP5 4P0>5 DHJ2L0#!G_(*868!4'"0E.684T>2+);)JHB82 +Q&#TRQGJDDF8! M^Z0)IKF.A!.Y"IN_6#+/5\*%_,;9CE\SG_$5#O?]T+*J37D9(#E+).^DL R< M:L$CAE!;:E+BPF/Q7M2U:V\-$R8 MJ5M1P@<>/$<20Z#-F:=(.RQ0),QY&I6QV.>Z%;&0NI4'.BIOP!EY)0['8CC' M9D:C+=#3N.A6*YK5;A>=/?N,A9[T4B\" M2I8U?7:SXW7+K-IKHQ1^:BB9R:I9G8CQDB 2(P2\##MD%/S0 F\G8,6<9R(-$>90XXE01I /5R)N0,*>8 M6^(6E;%[,F?H+12FC04+2UJ8=O/HVRJ;]XS9O#$!JM)VBP7:G3G-LDD2:92/ MR&IJ$0\1PD_%X*>8/ Z.D<2+M!T39)5+\]13J)\Y+%U,8=OC(,[20?]]"]\> MOCPO%(B7/B%89?X>!81G,G^:@48HYA%)P2/N:$":!X$ FJ,A%-O(64':1!9< M&/?2 ?@NUUC@*[\(O%G6K.'5H%*E!Q\';V;2@YJ$()5Q2(8(T;6.'&DJ(-AV MUF',:!*!Y_0@7X:BN\J)JIRHYTLM+@;H)E.'I,H=+A#=9G*'@5)KC#9(D1$)TTG,#5J\41.]UM MYEY/UF->#+\N1D/?91CT RD79J="+RCDO21<*.;DWN?HYZT-A:X?U+< M10WFGME K#/&1.]*!MR1$-%*B)9:B&CCTSZWG"BC/4K::,25DTC+ ':<>CG10Q9'!]^V[G^ 'LJ&]/,^#OI_N1$Z(D8<@'+Q /)"!'O$0 @(P9'K4V8F6=K,TR MF]X;7CWE27@7,R,6:%ZPEEKJ: *9$-1R?6=XK23@OA) &QO[4F(GD_)(84[* MN25:<(%"("EZ:B7UN4QT;;8NXD("$BQ\;6+^Z@@ >P]P_B81=^T.WORC(^7\ MR/8Z9D$SN4& M%_N[T0Y3ORDVO!I(70ZD_MDXV!?$$!S!TG@>*"".2\A%*A$52D<(W60(?GI8 M.BT<;_/O1!H90EC6.MGGC:.]\[_SO'W#_ MT\:']\V=S1]\^CAP[_@K:1S]W:QO'A[7-S^=P3/2^M$!;'D.GBL@*#R4[*-D_&9ZT5 AZ%P2=G2E*&-74.41Y M+D]5TB K D=:&J6BPT(%MK*NS1I]*>CYUD;*%$I1#91Y=-_31TFDUD8+87AP MS BA4Y#..X5!@"D'GT(-K3@EXFQ(1XG,[*](&+><5#?2W*L2DJ1RK%:.%;.89U46'%KL4/2\8!X(>V>0I4FA MHBF,.!5Q#L",6,.+FLU4I:GNKO+5Y./*H9H#EA=B4?E4B\;*QAQ*(.R)HTX( MI&)F\B8V(D-81(P2&B)V/FFULDZQ6F5RMLBX&HF\M!#QJCVJL5G)E3NU8(B8 M<:>\B,;@2!#61$+8Q2.X4TXCY:AF+A%GG%A95V:-O,(4U5*[4,L_&'A^D_Q4 MG_S;*ULSF>Q)):V3CMP$:HWES'F;J)0!4_SX!(Q5V=JS0>R M"T!75$/+\TY+2C5T.NH:LL.NH;)?N.@>GNQ(SGV05S0@'Y0EBW?NF+P%!]$5 MP.YR@ZHB9^GZE^M'/UCCTWXP4F#'%:*: M$L0](\@8D1 .W 8KK+FINW))F^O M% G<@ROD%;=::LTQC]YC*S1/$@-"Y>*8J7NM+QMFS5^,FU_N%@P+)9;]/!@ZVVS7XO%)JW,6X9%.#YO^L#"' MM<')D%3(^L-F_*?0]&P)1U\:NW[MH /8L5IKMGUKD,UW+37;\(>F;4U\K ]K M&,'<9CGJP!\*88'/P*+ '3OMV%NK;0/B@0O0+Q@"1_<:&N";7JF\/SQQ#7;K M1^QG8"PO-DTRNN\7LWMFP6^4NFE?^^ M_(IU$-T/^E=_989=XIF$*)>J3RS0V+^'W-C?;>O4GO56 M?IM4%="3X<4E@[M?^^ZWTI^4'L_C+)X"[$JG%,??!_! W?PI>!R[-,]2 X0& MZ_X?3244$=K$I*+F7!%CM8^&6FZ==Y<#$W3!-22!<( M\8EX[HERQB;+#$TVY&*$=/T\E$7PS9^8I=KF27.ZM_ MVKZ(*-BCWO^$H^Y97B)6*-P]$3(Q*4W+@B'N2!::&R-K-CCGJ7"HWX.CJ6 MYSC]_F&;[NQ^$COP/'6ZE:L\?M8WWQ_M?/C^H_'MK]9,A<=YH[EWWFKM[/[Y M8^]H3X#3*?:.M\[W=G.5Q]9I_5N=?S_^1/:._Y[+'F<$31A<2N2(]HA'@9$) M."#EN=:.)P@?V,JZD6I5\]EA%,O)?E1QQU7<<8]9(7<_#*TJY%X!?LY4R)G M@_-1(*P=0=QH@K2A$CD([!-Q%K-@5]8)IFMBP;.-7P9Y'%MRV*N8XYZ(.2YA MC86@@0K.-7EJD?]^TQQST1?LYACL-6!*>P0C%D_)0L(:?! M_XS.)6^$S3,35]85-ZMS$VY#VY&6+ZFW)?A35V2QK&*-.[Q.4Y>D$_U M]DCCG@@HYY#&&>$9I5BCJ$5$(!$,Z1 =DM(:(T+DV.!<-[M*YU#Q5HQQ2PL/ MK]J;>IN,<4\&$C/>5**2"R8]8DJ&S((DD7/$(<]"4#32P#$%;TJOL=GB^E?" M&+?LWE1%%U>Y4A5=W%,"Y3RZ.$]#-$D))*QG )2Y"RE)C+35CBN?%,5\99WQ M58QGX\Z*+6YI$>)5>U-OD"WNR1!B]@S0@'3)A$-.8L.2^Y5\&XJ&Q,1I"8J JV MHHM[Q1@[CRZ.*JVES8SF2B+.&466"X.P%T0X3Y./+@]"D(JL8O+@"5/+PD94 MT<4M4ZU;11;Y"?Q?8S8\.(+.+8 M_FP>#XYK)_:L,^C7NC;W2=M>K1?[V=OL']::[6EJAYKO-OOP!G:MMG%RTCK+ M?!*@8P/;JG6ZM?@S$X]D?HNQ2ZX6UV@7;FR^;>?UC?T0HY1XLJ;^2 F^2.* _PD?=!)\Y2X(<%XCH-BW J:RR2+ KV725QY\\O- M$E=>!6?/P5SYL$.DBF!PJ:$-HNW&^5=XGVU6W]TZW:6:?J.HY46.BWRF.Y->1NK'TIP/SC %X7Q+CVL67;U_.F/3^? M$IBY;O;KX9\[5CLI)P*ASL=$.!A>JR66U'"540+"MAL08MXI6UZ][8(Y<[.( M#$J-+JG!1FMY,ZGIH_8T#GL=MYLZYQ?7=#[.Q^_5G?W3NO'_TX M;WS:)XI0S8U&2;KL*UN#;"Y"TDI3';4F/,D[LX PG-OKP.^@(0_ M$Q1YRP3 MP5@55;A'N5LE (\E !P@GLI D-%$(6Z2048EB; C426O*>S=RGJ[,X/OLX _ M=&N'%+<%/68!_%G7:]=!X6WB_=J,@9@S7.!*UM@K,'7]7Z[[VQSRS3(2N)', M$Z\LL_'YA?!?A^<>C\OA"'[;<;-?N& ;[?"NV(.#V/;-V-ML]GRKTQMTEX6G MD=7?#57N"#ZS"PIW#M?:]* >G\[W=G\(N"^HW.=FX^@0[E&'>X?C:97+S], MA:L?YV?;^-G8;!SN[/[@.UGE\JD8J&S]_!-KT._C*@?O56>-TWWE22#.,V12 MKN@"QQF92!6"4%,J*0V1>G98A 14Q5%Z; /7 + A5R80;2F$[%S):<[&=SOU M^O9N?:NQ^Z6VT=BLO=MI[&XW/FPUWFUO?9G)9TPHP/QY#C?>?_)YA24N$!4" M#H%[)[)+(*A,2;GB(C>Q2CZ3SOP[-QB^1)[QQZ9I]8_%B[6O^" AQVJ)=BB6K-= M^C]9BPM^]#+]-#?IE+^4+2L($2K_3\F5VLS$\\U\%I@/%0OUJ.4,UP1]ZG5P M<@WY\$WO7-&P5C2L2TK#:EXFX>ANX5W72^]Z:]*[O@O%Z%)4:=_NE7_9SD4, MG0%<(O063#9[3T+5Y9.+VY:LW^)]W]BRT8J9=VQ!LG=8.['PZ#GK:X_A5?L7 MHU_"J)[H&-P(<%9&=4B%5U%K-:UKM@J'X_='[9Y8T'8\Y/K/\HP+[6ZF:U0L MN2SNE$.,V@>7'C'XK-W.\6B\$?RE-1GO+;"_\<$]C4NWGC-U[?=MX51WKX9= MMG+UZ4/1^T388X>B;#K>OI#=(B$Q//7LW>[0DKW,J'M87[Y%OG_[^["^^_=1 M8W?KY][YI[.=W<]-^._ASK>_FCN;?S7KNY\A&M_^.5-?OOMWZ_NWK9^-;W62 M$^*-S6W1^)#_"^]VO,WS=QH?ZF=[1^_G$MND*&W@EB'"B4,\Q(0THQA9:W"N M-G0^Y8JA5<+$G&1XA2 5@CP 03SE27@7)2>&"Q>LI98ZF@!3!+5*4@YSRQ-2(@3$9;#(.&,0YBI$$368![RRKE>QF>5R6$@8\2*):*[V MT\I!E?$A7MH"'>YY /1R^Z*?P(DI!^O% H"V<^@>>_TA$.VT_ST,]\XJU+D# MZLRCD,&2<,431LSF,P<;&'(&4T0$,Y1$%F0(*^M$S18!5AKUPHQZI5&/H5&S MG:98.>N$0E%0E:L>.3)2"F2EQHD*#B H5]8IF>T<>)@5?]%T(.(]JPS]VFVW?/+&MRVBB IK; \T%$[/=J'9?Y)LJ#W_C3'^:6KN)DN WWG#J%&S\ ON58 MX"JE_N92ZE)*$"DP4M%ZQ&''D5&*(48M=BHE(JA866>KFK&;290KH*F YGECA0IG ME@-G9B()2KD)PB4$(4/F"542.1D,BBDP+K4.7,65=;Y*YTP3?+P#OM?H'$ZD M#<==PV6).5YKXN-9G*;QY$AUC'$?M-J9=S#(N1?..X0%Q8@+3)$A+""<,"-> M824L!J^(W)#UJ)3L=7@,E9(M0,EF7 */O3/.6!1E9(A'[Y%-L&_8!JFHQ Q\ MAI5U/6VC4P$'O J_O2Q] MBMP9O[*NUBZM]TS[[1(<#;YHY:$NDP%J'RR5'#MOE&0A8J>5%89A7R@/K93G MV95GQBAC8UV,)B("YAEQ220R19P>-&RB%,YI!T9Y;);W7.5Y"^=]MS7*DW4\ M#S7)CQ0KO&BXN;^M'O?L*[!YU*K_W8U^O8E_%H"S"Y\_^GJ^3[T*1%.-7* . MXNP@D.9"(4*4C8KQ3' !?C$C59]#%_ZSPH]'QH^[>"T5?CPC?LRX M+5%$F;CV2.),FVR90A:0 U$9.2/2$F)$Q@\\6P?P1O'C3>92ICVT)VQHOL6, MZ%>/KPORSZX)$2MT?3"Z;L]Z9\3!QMG$$>$R>V=:(.<"02F?F)N$<20%NLI9 M&H7[#?I\\>A:HF<5>CPN>LSX9LX:QBSU^<@GTZOSA+07%@F'<6!.ID@A MMA-K[,&QW6M!C\DQPS-S%)[X :L)PD\W ^_]G68SY4F^S0LZSU[-UKHQ#$HL M[:2[C1%[8)GIQ1BQ^-/VIB+@J6*X>B?J07,?;KR7GK&T<;\)GZS_KY M#[JSZ_'.QC[16#%L#+*".\0UQLAQ95' (MC ;(Q>91?LFKE?G9+LU=MNMQ@3 M/3$!MCM3$%X[C*TP3E-O:V[0;(7+D^@ 7R]^/R%U^6H7P>UD(=Q"1ZT;[ ]D$#_N[;9W:L][*;Y,H#! \O+C,/"77OONM9F6D M]'A 6#P%J'RG6TC"[\6@HOPI>!R[-,]2 T0&H/R/6XPA6EDOIFYD9;6\UWFU]J;W;^?QQY_/&[O9.8^D?O='I MP\4 C&#!09Q[ #WP4\' 7,!7Z?0W;:OVI0^_."[WY/9.S+*\YR]?VW80FO!* MO\Z#B_EC/6X:_3,U^H0ED?,ZHBCQ]+ ;\ *^1M'!2W+")Z-8J+O M52,M-Z./.WZWX9L=FAK=)G((+3:]$?8]#K9=PQ3PTA T>52;H)ATT5,X$M'S%0B$ @E MV'2IKIG3/#D-=[5V>MCTAX7Z=^-)IQ@LWFS/4&K, Y+A#(;9J>,C0^;'#9FS MK>%8\PA?7JM="7(32%8[M/"Y0;_7!UG-CS/]8!T'MJVP&;V[1HZ/ V%W;*!^ M@C!DO2.(&&PQH!=-CN29*'QM-B]_*<>PW:7P+M&F MOQMTNT7RM=K[>7O_2>QC*W(W*47<;+':GEC]_'YCVRP#0Z;5_)S'63$+?HOG6,"<42DCQJQ)W R$6A M$/8Z4&)(L,)D8N+K\.).0M.*O=Z,Y"S"WMW">0>3%Q[+Y#V. U>9O)L&]Y[N M?-KGWABLL0(\IY%:2V!&MW_ZQ^ ML)^$"8Z[@ C!#.(UZE&F@$8*TZ@(IRHF#KNOU_ARF+U'%IG*[-TH-1PP(WH0 M&Z0BU)?NHIR5YD=MC?W$4@ (%"P1X $(R_>O?S*P% #>)LFQ1;,R!R^R48V-_G8\H<6W-@AAC#]_BJX]H-[VKHCW_W(!Z>33P/&F!]R,#'0 ML^H%(VZ"! :-+;8\X+7(#X(Q"%YK2]CZ=HZVELC#.D S^6)>)!%(Q5]_FDVG M=O>O/UEQ'(>#T#/#T,=<>!]T).ZZIN5X3N &(\O"3<]!]!9&FF<3DRK*A:"5 MMTS/R/C\83R3;:"Y/?!+;H!IZKA^'=>_]DZO/P6C*!@,_+')O2$'KA\#UX?V MV(S&3@P7 (M! A/7;W.O/ZA;W4EV*=E/#SY90VL81I9MLC%CIN?"Q1I@ M\'(01;[-AY[EQ_Z2^O^3[Y@3AW8PY)9I#P,;1%%LF;XW&)BCH>>.1Z #QF.N M[D)EKZT#-Z7_/)C3>ZTXZFS_&R42)DZ.QF%LA9%GNH,8;/^QZYB!$\0F' 1" M#XVXS4),G-P2W^\DT@;^>OW)MD9PF0-K!0/+!WGOP^Z./-L<,#=R0%^,QN.P MDTC-'7/\R''&46PZXS%HYV./F>,1CTUKZ#B.A?G6[AKM?+-,>JAPRKWIZ=_# M1N_T]!M$(\SM^I,W&(X<'YB712Z0H@-\Z?-H8#J#T0 OJCBV.>GIPWV-I'1Z M^AV._BOHZ:[OC_TP&)B<#US3BVU'P/QP:Q3YW+6' ^[MIJ=OU*'VPFG7:4VW MIP\7M*8PP)0 ;IM@SH&E,?0M5)B8:47^P'<&C-LV0[33'>(EFV^T;[O#=J@K MV1 J^>V_@^)?:]+SZ>!O3/>W74/;*; $)$(*AL&N MI!!C85A4'.FRQ)!4#N*.%PCL#DH0+GU6Y"'GJ!V)WQ=\4J5LGA<+8RIV!2L4 M1'T45H7 GVQN)'.08L@2,"%\#D1CS*[R0I205/,PGW)D)A@]H,]P:!R$30G* M0I9=$,<%?H%7+%0HD4VPGO$',NX=N%$25Q#"(!QRH2EL)D*\,M$SPNF55!#$_B6/A!- M3C!.B\/+:7J%$U1TA;L2IBR9BO.9YAF?,YA*Q*9LPFESF@_& M2(D]8\8SEI)\AN]G>&$G\*5\YAFL X@HPWE<\50N%>:0%_()\4F521[!@9[I M5T1).:MPYK@X^!QN"CD< [F>Q!1\:&X:2/]P43_/C!3D".PU 07@7L]8(5,V M<*$,3Q//O!XBR".: H:.Y(7#60&G!R8-;8(F9W4\S=?5+RHYO IW=(G=_P6O M8\9U I2B*6V6(Y]CV9%D9!B39E56*2V1&;+/#OPXJ$K<>.1TO$N!-ON/4(H> MZ)V,-#."]'I=P?EPW.XWI!1@->H+T+\,VS)?]Y89D,CTUD+U&OB0V$&)$N+L MV9Q&J25E/7JCJ!6_/D'>1;(XE#-^"\(1]M]X4P$['XN^J\*Z)02AJD2=).!I M?MTW_IU?\RM>]%".HY164D?(=CQAHLP0)ET8_Q&[@#3 L@Q%W PFG$=KI6VL M:]90$:)RUIXD'=ICF8$"JE&O[O*N*#%-_E,E\- "'J[22 @Q+6A9!%,N.?X% M,CB4 @?OGE0*T>8E!._$&EI1W]O#R4>PY#2?81D=K+%7"[I_M7FN)>MJ\<5* M&*$,BR2H]_&H?63-8U_:\[9? CY*.%YEM.'XC5Z#NCSE_:$JG>OI(3VM4AD- MA.0@#078)1"%8N(3D&0EW=GE!>TKDMT%(Q&AJ4_NKL%I;Y'2[W:4S6-\C**@ MJ5 E96,[,:*?BQT%%@R3JR15[8TG3-PR'-X>2?TD@BLL*>>%^*JL@ED.5Q-< MX66)W#RKBK)BJ$X)=OXWAVOK OBVK HR%%Z!O)'F'PUX$!+*B_KH("05P_;] M(7(!#O$NHVN5:D5+XQ E_IR('7[W1U6B<#:>(J,ZUK/#LS_H+_O9/_%TX;HC ML/:7/,NG22AGT[!IIC,P?7!:UPG,NJ2F4>"4"I17*7L=? T]$50C;$.5A116SXE+&L\.B?E1_ MYGG?V)R:MK^D>5@51'VP025'GJQ%!0>E2\G M7P^L/YV/,$XX/#W_F)Z\?W?]\?/QXO3EQ\^GA^_L#^]?I&?G:?+QG-Z9G'[] M\/5D^N$J>OF7%_W[C_2CDUX%GW/[=/KNR\?SWZ<0,,0,A1N=3[A>!UEYC>+&#+#',L:X1SX1RDS)^:6^BQM,1V:A"F9(-E[#8;"L.5W3GT&4HWRCRV97-K*=\=@. MPC@<>J$W&##?]5D0ALYPZ-KN,'1ESSA/]8P;NM8-_ 2JXW-R!$UX%BX.Q7:] MS2L06W\A5DO'7[?AK[/#XP7P%T@X/AZ9@^&(F1[0L.FS,$$7@*;COG&6&7\P4/%!S;3]=8EOUZC! M9'BB:(DTB1POWS#-4>%-X-+57)*T+!'D;=!PC3F[)-44AA0KZ!N_,WPV7^]5 M+?A5PJ^%9@6C+LI$6VP-/I'WT[J;CW"!M&2!9\2ZUHN%GC#:5@UB_@5,I:K@ MO:5;4SF*,F&MH>D,ZOL,E)$O-""HC[MP:1A:#@NCV/7#V O'HX#;8Q:/0W_L M!#P([ TI&,,;F/- S.U@_ERB*74,>EL&_0*_'WRRHP"N.=\W+8Z=FX/8QQ2" ML1D%$7.9-1KZMO_D-V<5KKG.!=^47_HX-=*#$F]/I/P@OP*N2+5VI7U'9)2B MUQ2]"63N2+=C3VN?DNTD%%?+-I7DF#*8^!:8 \T M@U&L?*ZBB3 (8++5O,'5XI!*84J<39^M M]O2L1A+6478'?7<#]-VH@[[KH.\ZZ+L.^NZ^H>^^-9.BN7AT%B3Q8E_T1;0O MJXP;CH>W(9J8ITD*P[\!NS$S3OJ'?2.&#]#=47*&?_ OI(UQ Y1 L!JG1LJN MRRJ9K_.D* _CDB,LOF2Y\8)'=&\?P-&9_YN$EXCJ3>^#FXMNZ1>@J<&\1/@:??7XVAQ3!] P MG6"L.&28JX'Z,(RM'-5P)XO0:DPQJ7DE_/)BD6D^ =,\ E6MX%Q\CKD-3>?Z M:]BE<]BEM[!%M4O]L.C++48G5(FJ1\ O6!JK!;WKO^T;$U#ABXPB!N1-AZGS M-":U^QI?JQVZVF'06_*2T7,QEW]0:@;Y%%[PH""G@C,@+;^4BATV5F@MQ=MB4G!INV@PFU#!#!Q4N#4K!M^.46D8/R@/Q)V!GT> M''-0D$Q@7G G(?G#R'/T,F?-8OKF(>'4DL:C4<[)ID(K"1]KG!UY.*6X4$31 M'@IF?# K8 -M1\VX\;B8,YSF5&!SD\L5DQS6\5)/T#]!+BOR+^]._^T3B)," MWI9R5F0\4H,VEZ(U71FGHF.]S?;^48$)ABL'>[H5R<-K7;#;53+)B[PJX8<1 MC]$XA+,C0I>[H+?LOTJ5@(+30=:AF#_"\I"W%_1MBA&OHT'0PG-8W:*4GRRQ M!;KC,+)(689B&N)(DU([Q Y2])5-+EJ\ A(<_:P MW27,B')SZ'VEN'_QA2O"2JP:ZVD3N=!67)HRMVI+/T.7(])5G<+%&V$@=#+6 M&5U+"4VL+'.XYO$+[9QK#!WP.LT,:')_%;"%SU\CKRQZVBV9Y#^ MA-\#$R%P.BC;LYR2B9"K)@5%J"=P):$L[!U]Q&)TYS3Y\/E-^@$^/W70_74R.#D\^;J2(>^\_O+Q\/3SZ>>_IA\/+]+3 MPXG[P?DC.7WYU\7'PQ.7W%]?+Z]/OI[&)U^/K9/))X^%/K.' S-TX/]X0]\V M?=^.S'ADV;'/7!9']G)BMS=RPI$369PQQ^-1Q"+/92$;.:.!Q2QK] 2$>\AF M2.5%!<;)^^.WS\].WQZ?&D?PW[.3X^?&X=%?1W^>O3HY.CTWS@_^SWC^YNCP M^/SMQF;,FVVCFR>S-'D^L**1/1HZ ^:-W7' 8EAD,/:" 8ML:_Q88,%EZD>M M2%OVH*U$DY0F?0*%=%9+Y/IBU;QB*&8Q&MP"(PFYCINM\H3>'QT^[TE#0MD8 M9T4RH1L$OS0.U'MT/A&\'S6[W6(XSWM+ !8:JL@C5#\WYY<$52U+\2/O'YV?90/; 9%MNF/'-SWFA:8_X&/3&0VC M('1>_/Q"/$U'42@]28JM V7X] M;:.&AIA!#(-?HZJXQB(QGOUT] $:\/4GSQX,[-#Q3)>[GNG%KF^._0'#2&_L M#X%@1BY[\AL&9C-S 6K,LHXJ:Q\>9[J&U"+7)!NJ^U3Y!O'V7:=!HL:G=,,# M^=L;U$#412-Q?X,XWN6B=GD0CD&]&/ A]WPO\!$+W.%#-HI&PZ$;W)3SNTDI M/"*_XWF.::7=1;R.64[/#[Y^\N+(&D=6: Y"-!8=%IA^$*#9"%?Q>#0<#?D0 M 6C78%\*N_^A%+Q[H9M.P?LN=!5:GT#2#AULJ#N"(P&ZBGPSB >1&3)F.6C) MQPR[0 S60>VM$-;W5_/<$8*!6O8(E%!O[ U]SFUO.'3&8V;[?!"3APJH27BH M5LCJ>ZEYMR&OGTT'Q$SJ3P$#AG>X9_IC%\AKA,AS0$P@MB)FC^P0_C^*K9YK MK;%)&S?5'17".Y%+IQ ^C$)X>O ICD8C/D!H*R\>FIX;6B:S03\4Y?:96&D;SJ,8,AX)^86&(4L:=FMF_PWRB+G]C=+3U$\LF,?FU79V+IHR!RXM$9#TQW[(XL'<0S6)<). MK8B4?^ I\S294(KRNNNJFHF&Q%/V)9E6TUU+>KZ1)G91>T[$#)==JT+<=!K/ M>N*Y=#Y9 \<=1SXBB@/)>%' S,!FL6/0@^!B6[0=ZB4)Q5!X,]Y M@$4VX@I8*V6H5!_+P)36&3]8')VEDO,%OV +"Z2!4.8&B&2R!K3N(8#$A@VR32 _19Y M'504W\Y1$O>$XO0V&,Y:&PF?#_2AXGLY@]GA582SC9,O/*H3P[75!#\OQ7SE M#(.%,>6<*B\5_L^:VXKRS?.@)JSY!2S^(D\CJ?O0=B(2EIQS34S&6X$ML#P- M&3^G#"]%N8WQ&YNH\&&4J@Z_SN&4UNEA,"V=&<.S:&4V;:>&1*I9R92@X?7; M,85)'A9Z-!XC=[S#[&=:P888W8:Z-0DK@Q36/!!6M@^+TD?67&!Y*'*9!'&O M84^1N;:&W JNLUC"?)+!4B-\*\-,R[CDMWBGZ!&R<7R.?L+5@PFC9,C6="R)* V52E:1-[663I1_68Z2H M-M2J7LHJRJH2Q.EN+K[ B4;6P/<#=QQZWLAC$?.L.&"@O8S8<#PD5XW5N?B^ M@_ES?FF?3#X-A]Q!=YD9V:"5>($3F^.1$YB#B#F^,_"';!#<$+_==GW)HB6V MEHS6@/7J5& 0T J[9!=Z\C"I(XCBH3N*@)A&S+6B\6 8CEP>VA:W;X+AW$1/ M;^2\.EK:D GP!3TO[L@>^V//=$?#R/0L'IN!PR+3B;VQ;SG^.+B1EG2*)-U; MU4WWV98.8_LK4^M;>GT$9=TE7=[+';WY!MQV0R]=@/#OJ-*)V.H9WC 3#>G# M)Z5-^/=+:9RHM&>MLF;[=-^O6>V-U[W,Z9>0:/ O ;?0U+UKJTRZB>3GC5?5 M!D2MH](_9RQ1]DF= ZYJ!+2FC%A3:%"$U;02)9>TL*(.4SQB6+Y;=6.2)[L3 MI) ?.@$#N]P/1Y[CV6QL!?_,CR?-?R MS!'WQR8;,>VO:'16CL.M%4#:=PBZ^5MTT*]L^+QO8BI M4SRVQQ-?#TZ_OH/U'+DGZ*:-;6^$_1K-X3#$=HU18#(66V8X&G/+'V#N+S9- M7=,KO$U1+3U$2.TJ(UFL&Z/N%I/^OO2!'W44*!93J^/S ] MWW)-?S@>FX/Q*!Z$B(45L">_W9C4<,<>$CZ+?<["D/.QY04CQ[=\+V86#UG( M'?B?C@R^6V8IUC]$X[%KVR/?C$+7-;W!B)ECASEF/.#^R/>HJS)VD%C-#UQ* M/&BW"9A)/4TKA75UDNHM(5L"[]I6PAM:C(_\:& -N#<( F9;PX%MV>YPZ(WB MR.KHY7O1R^7U*="+'[CAB)I$43ZI&YECYEE@UKIQS"UK%&(/;N_&Z^2&MA*" M.+Z]?ZG"P2>4U N"34U5T>QV'0E+D)5EA98.6HL= LP-"##C#@&F0X#I$& Z M!)AO0(#9O[+U#867-Q92-M"I,6K,L6/'_*(TA,F]#@H-E:'5,(".2NZB)T4A M']N1!;,;61YS;.9QYH9.R-C 8BYWUY81;U28#J9HY'V5Z75=>N_M4^J.OF(? M+L9";S0$W7K T @?CTP6<&;:8&W%4>@/HU&$1OA-;IU=E>5![#-KR .+1Y%G M!:$?66,W]MV!&SM#/@@DN+&MP(T[(OA.1&"=OOX4VL.ABW9VX [!U KXV!Q; M(VJR&D;Q( J&8X9$<%..-^+RH I[Q1&#EJ,<\''3X=]?H]3N M""KRC1 .PSV'$;X([3SQ^^_I&O+YS>>3 MP]/+9+$Y?GER? M.&_BD_,#F,_QIT$X] /;#YZ_?';\]1E7RK7%P>F@<'O]U]/;\ M^/S=&U T[X#<<.,$]I,%%'$:#>K7F0(-[@0I9_D(; M19OG+U.Q.<-M(_J1.1SP+RH4!,TRTTW4Y):B))'>5*)DQ;\AJ*0%@=7KS!*5 M9JV34QHA@%:GZ;*$6Q1WN@"[H0"JHMSQ/,NDYU977TM:Q^%K!EW>\YT(_X$N MU89Z]S>Y2[,PGR]FW#C\/]U#[561DP0WWH8H!<]AQ?NYUIMNUH-J4I7S^G)M M%I1@<3]27YV&E1>H%[ L"[B;P=4C7\6>8),9F"KYI M)E=)N8H5N'].O_N\>:*:NW>]>506#C:4%*TKVK]>%G9&F:^F3:3<-V[(1-OX!G678!'+@KZ#^P_!3'<)KMU>.GRC M-\+?<&FZ(GK]PK/L''WGV5GD>)MZ'\R@Y_0K__?K:_?#Y MS26.O8;Z7 MB[/SU]>GYP?>Z_22<"*/ M3U^04F)JTRBWY*#M,2.1=RH6Z:6 M@J)5UG6ETA':OQ>?D74F'Y#HY"L#4>DA7HUUQ[:F(4:&09H'!*0[A4/#.)YT MI1.,/"PT";$5#0LP;HMMC4O1V[$4]S"^JPT,C!9R(;1G#9@/]]6475+3^ 2^ MK_ EN#WHWI5[%M+]"^9@8R=1S%-G9G%;(9S^G#? ?T6#.RG P=R'/:?^O]B" MCFL@>KGW_U4:SR\2#G:_WJ1#^59XYZ5HLEV"]L%+,H9H!>*)HR\\K"A9^PS; M8^%/<45YADC=2^^HCP#^H.EETL IJQGU)M=K;71QK:T=W';L%@1WFS"7"'Y' M=W#N&Z\:PR:E8F*!DRZGI""X>3L')<63)]T!*!^M%V'S(5;Y5=+LSJDS3"2< M\K*I\GVE^ANA$[R F1Q] 5;*6/H<]-H1C'H]#BKF,M2^_'(571\(]S)6>DQ*NF M:'U_)>[ &A*I0\K2&$4IR/T332O(:N1*>$4])>;J(5'SP>;S(@DJY0_ 6F_J M55WW_[I(9B9\I5T2*YK;;_\M9Z>RI0J0@B:F=;%9R7]5?SP#*39+V>+7)*/5 MTD//V@> >5E7Z*,#P2L3(^@XQ-=UQE'?$EE'\P+^-U)OEE_WZ:M_S:/5[T9V MW_?]C5];??N.WPW=FC@Y( ZDIO]YXCZI MD]$BO!=^M0R;F$^-=Y>?^BL_=69?\,>KJ3?+="=([KZ9?WR3%6$)WD<_XXGP M,Q[5?D8L2M7LM\-6KEETRN,55GO()3\])BR%"H:(RG^V%OG-9"(ETCR?(?'/ MR")/(@/7].Q1T06J#;?8FMNL]R?;-F<7MD&8C0DHU5EDRAEB,40Y= ,"& M$=A%5C1"GT=@6SX?N?[(=_TQ?#+VO9MR']TMEA)F0^,4WB?S"V4M'7V1+MT# M:4>?LR^W2X5S'Z^3@]<3Y,/U@?/K]S3@\_IA]A M;BO9X4U+E]^(C$"#&COS42<-. M&GX_:3@.N!L[UCAV B\('!9$@0-B,'98%%B>?5,2<"<-]TP:6LO2D+G>R/%= MUV1 P*8W\CTS&,5C<^0/8V9Y(\X<_\EOWF#4LVS[D4C#G;7FF/[G46G&9]4< M7>#HB?YV)7EI_1M-+F>W/5Q[#3QN>>B,/8L-000.?"\>#!F'_S< &1GQ ??' M<:<=/BIYN%C5#AUF#?P(!:#C6Z;G<<=D0-X&%A/?G/\WF"XJ:SJ(3C]KB[! MQZ3Q.7^;N^).^13=7;&G=\7I\U6M MT ^N-/)'YF<7=')A_%HR",[ M,./1&.7LB)O!<,#-D8'3/WL@'DK.DSO^+4LR:Y0O- M!.W5+$"6WI!P_A&$N88^P M"):M]-396M:Q8PW'SXRTYF]&6KM]>?3QW0UD!#/#G\ M"]YU/W$_?+U(SLX_7)^^/TU/ MOAZ EO?BDKRQYY?NZ>03'P2V/[1 'QLZ(]-S1R,S*O=#S I&?LR]Y1**X]/G9R='QOG!_QV]O4/EVXVO M>T0U&BN0@ E1)"'7ZLX@N^'T?ZOC:["128[$A'[G&8^3^;[ O_UP3CG]?/DI MC&,6CP-N1D/L%\^&@3FV!K$)YA!SH]@9#"QG/0I_W0A(5L!M@@4Q6BB2S C$ MMN]*#M]JGP,YH/8/?W5T<0-=?/WPR6G%XQ ;1(5F8(T'I@T\R$"D MCNU1 -K^U@91MZ0+1\"[+$,9K!$@6KA$-X/1U%27E V\EB;JB\1[AWF"-!,8 ME@)VHO'.OG$ 1"00=I:[D^Y&OV.@T3%SO?$ *'DX*83KRF3/RQC8?.-QS/1\N)F?@CNUPZ'NCD>O=U+^N.\_U MYUEW ;%.SM\YH,KY$0.)ST:(G\C@CAK[)@L<=-[90QONIYA%8'?:_K9+ZIJ5 MM?A@FR!"B A4[\/65TYO"=Y4P-$D90N99+E;0!,\*K][MX"6@-0ZJRRJEWW% M& &7-*"NJ#A?E)[+!LM81]Z29=*=IHMHKG="ZL$/J3F:J/=_C)W-FEN/?2\?0N:_R^H&=" GI(+R\PJ) MD_.#Q>G!)SBPX=!U7'/H#AVP\?R!&<2Q;P[YR!Z.XM@>C#FZ)/O#_1/[W9&N M'"DVFO/@X**!S4Q@$MOT1F%@^C[V<@D=EX\#-W(&>*3COKNURVW5V%T2=5(J M4;= M"VDZ LI1O0BW_TK><8BU6"1Y58IE5?.+O*"OFO!BL[PL$P%=,Y^G7/7P(^<> M_)#,!M&8.\-H*"&,)H7&1E%O0%V]FHNWILDTF2M\E*;$U@TX!:()G,P4]JA M;ZA<19)M6:]$&\N _8WY-4^OE*FQ]S!Q6V#0&@1"V&U@ %VS(A)\4\T3 !7"VEF6)@JQ"()'RJ7!]@TC]8W37*,"(^V!V<=2HN:&K5B_@#=YGH5A M4:'N5"PUHUV_]5W(\7M0NFO=2\AQ?!\A1X_"^%W0<0^#CC^F3036;^QQ0.IX MSJ>&TX18TPH)1HZJLE0Z\8%"&(=-K2.(&&),=/?R-P()'&KH0X;6FS;?!H2O5N&^\YT8- $B0=ADU@Q?CQ#14H'HT M"&-^PFSSI83$!'.O3("WS+0^K0N*VP^R.ODA]'ZAYFHB5/94=)=X> M/=<=))J=)MIHRNHG.ZO^WWBC>'M]H[P0QH/Y9YY?(L/=(L=D;['AS[=QF2!! M8C54V@56M%Q\*A??X#0D1FD]3CG+\%M@C+>B48 8RQD=*-N[0:P'(5G#MN^Z MHHG6E%A!6#SMY^VC-<]K0J\'\MH#D1>7%0*]G=B,K@:#&H'4J*F2"4H6<^"T M(L@+R0&B*9?Z(5Y%I9@62-\7&W=$,2V^6'N<=><%[*PPD[BX9%:689$$7$CL M"@'*C5D*A]U3MX;B:V'7"V.29,0'C'8+.DN7/&6QHF,S@&_4%R&W90ALUA4*T+,;] M[!L':>O^$3^C>$'ST]@ S@,UA)"&8Q;.RR7 ]QMOOQI(%RFFIA'LU9&3C@)_ MMFEEC2+0:US]0$QYB4\1W8D^X4I-% G%F[F_#US(L&="N8[4&BN7J^RA/Q'G MCMM#-%[+$2Z D^L%:FQ>R1>UDT:J,,]6]T :]?"C7HTMW&NUX5GA)KJ/Y3NP ME $/JFAB&C^K=0Y-$E'M.Y/Z5J.-4\L+J,@+], %,*QF:$$B#8AG\G=N%2TB MO9LG].0*)64P:Y0O!AZ/>& ;8HKH#V463)O M@(1#O$16(L>E('62S+4)F%/0#$6$EWX M?(NDO!3S4]U_4(%.BK":HIU!^-;J,HH21-8&^L4!9^A*# 4"-_;)PAVKKX]& MJC]N(U['19[V\<:KJ+27V*#76*\@;K%=(*?I9=CT2OJ"4VG+_J>!D*0\JF0954:(^ M1'M FL^V Z& ES @F1)B."4^%R;@#1M9!ZMH=<@4GV'/4,2C!%7P^C!("F*O M%.YJ0\9CF8ARP097I2&MQ,9)EPN0V--GY(.?HI:K;O!)!0204EL]G,U_L.T MD "VU,.F>& &5D(Q5#&EO)C %G]ER[([Q!. 30+-EPM=_D:JV<0.,F("]]7U MMJ.BHD"XN-&;B=>@8AOJ((#QZ63-BW0T$-Y#+GE4\86-+^,Z^F()@7:*.5R\ MB&PNW]FXJ:4.(2:.=S7P;@(_);=.I--.:&\0V9R:0\"+>P:86CPKU0\50P K M%'@#D%!9F7<>""N@,3)N?I6*AA-LAKS,4GF58#Z0X>@A*9SR]V+RPK]2 M.W0JZF64",* /0#*DQNM&US,44Z6RVV0Q VFNW@TQI1W:G,L,<3V"Z8UQ@P[ M58CL/K=415P48.6PH&IQ1?P395;GE7L-G6JI)6T=N/TE-'+6[ITUE2R\O M&/6.I.CA#&UK(&6D$E9(8A=-+O"IAB,-&(;$+G$-6XB@+]#41'Y/SD3;C^E(=KR)ZCQH-WE[PE MXY1_2<0=2>?;]IA.DZBM7RVW5@OS L[R*BE D"G7UO.SOXX/3=O7_BTX9KCY MDE#M+(;BY804D:_5YHE\VQ-JB(NUV5ZH75!2&BK@<]&8M2#NF*-%@VERHI.9 M?$#8A:V'4/5.= M;RE@+6]:M/ FLA7H!!6%3+0&(N^_8D&XAK&;3B@[[X1Z5V16(TB/5#30Y,A3 MJ^1<<"W%+V"[C4LP%#!"@/TQT]I85 DLL>@IA"HSD/0$[078BPRG)YQ=XFL\ M<.1D[/7"I7]?2&7M(H#?77%=X\N_7("N+&(2QAG-/=&:=6V1M%F)+!#I=-)J M\1OXL?%"ZN)"4GQ77[ERHRFOWE(W/W&?!B4H<4)F"+?WLF.D;'E&^L8',$O( M75$5PDG#*GR+B#R0L94R5&XSS MIZ[I:KFTV$)1;KYQQ=BEL9*87@%$0(->( MHT,$%7KZ#F=QG5 ^O^)+X9I3B2%E[1&ECX4HO$ ME)@4Q5,@)BVO;&0QV3*I?E@F>>$IXF)1 MF6OTHM(&?2,]IF8E7/OF((+T2+ONSY3"8=]'"H<_ZJK&?Z8$CGU.*)!Q[SV( M@6UEO*,O>!6_1244+<_G>3&3!VD\G><3*2A58WF\?)(H804Y]Z2&24.LA#-6 MH@95N?P): ^- $(CXM1(E265-4%9FW(6D?M:="L$#2&ZPHLJ4K8YS&N2@:Z MAKUPE2PH)X&R]>I^W*54BR@PE^L6P:"G4I]AX:%<&5$H)-="R9 .8+1!\X)N MES6-%5'SBL2-S^30O3I"C6$8TBZQC@U'@ L$[170?H3C0TY!3 GO.-U(4>0N M@H(GG$9YD:XKJ[B=Q 0!=[O@\K,]Q89I=*6/DP).\S]"&<*]%7FB>&;A!4;Q MI"Z;]XMT9WM<93@J11T6-TR5FJE+Y.2&8D?7=Z+^(O'C+ MIN[:2_'RU5OZ0(M\ZKPJ71?T#8E^,!-^L;UAWVO1$"MJP__&6N..-.Z--#!$ MDZK0LW#KX>V6ZV"//76Q4QAQBG[>5NZ::7Z4AXNR;E%]L=] <=T>P!T:2LRD(*(Z",./HR+QC,U!L[ MSWK"89U="*T.-4\VPV;3*9>%5" &NI.XMY.8,E)=@>,F!3H8YSDZ3$IU+>-W MO__Y[LA\+@YFEEP1;C9&)U;\_%0?)?*NZ*CTO2P#-FFNE>H@S?-(Z@ M]W95R_W'?NSP4U-%.SE&P:F67)R8$M?HGMU8RY5@[(>)7">9RCA%7[LICQ&> MHECF7#*GNLE/GA\=MF[Q:0[\6Z4,P^@E-7Y'_S:);^&WEC$67@_Q1H_P@U-M M;_?,0VXEEZXH?NYI!L74&#< M-U52-RE%'@J&22.MA'&T%5<2?FUK<8'']ZRP$Q+5^D M$65Y9I;3_)(7F"L)!KI(^F_\L"D=%&1S#[ M.6Y"_;'V2VVI%-Y? D*Q$J=L@KDAC:07F:ZB"GP5EY!B)KQTTH WXP+^$Z'] MCB>=9%>L1*]6.<_SU!3IE(>G!YJH2OB')JKZ?60CTH'([!5\A;B&YK!WL.=T MP$@^F/)&EQ&-*S+!ICFZ$8"F@B2G]!F,XI5E#H;%7)6+K*<;.$1YT?6-=Q0( MDQDH*E)%I/P"-1D"#BBJB7$03>'2I/2:YH7XXK!>&4SEH)I4L"C'LKV>+*YJ M;J,1\)!-><.A1>D8&%6#@4PQ#?1BXBI;6[NZD/8^]HVSU;<-3ST3&ATF::B4* &7QJ\P;HX/ MH,)>N[1#PK''?!*>2O\XF@X%O\#T+Z#("2^F.#]T%V'^(_^"KG?%%Z]>XC^% MWTXQB/2RTZ\GZ#9J_CQ;^;DA(N&A(G&0Z?L>;T$>Q&L-=A'3I1I>_AYE&Q!O M?A<-;DB%Z3=;%BOA9G3YFRX]O8PU#W)<1!W/3QY2Z^S!EJ8SK$;-P7)MEK&" M&$T*D9U.N@R)-*V> +DAM!7=Z5-Y':C@0".8+Q+N+KFJGIUCU@\928CO4XIT M^ITI[ULME>$CM%1>%7+#R/D#-]&B;;+L,]=I@FH'13E*F3%% M<>R)]'DG( EAF%+42"!%D;\ERS$]B"2F% ":I"A'@U+4T^=CE5==-37AAJ$O1!>9%?9\U2"]+C$<\MN4"]AC(L0852 M?C@%Z\:P) DN"8&GI]Z78":JU$1:DQ7Y6HW)+DVJ#9M"-@IRKH2CH>QN2KQJ M%X3A+35EG^'::KVLL8]UYG<]@Z,OYP43;Z:\85XNW5CS:IH7PGV=4L!!J)TH M(II76'U)@;*78<[8##NZ-*ZC'N$B)2J1;,F1B=>MCG2)-&89R^YA:CK#,$D2 M8J%67%#RV:)'"8ZS$G\AL&9D#9+:Y/!UY85UNV%YH0L>MPHO?58+W[[J%% F55[(T:-]U MH_><7 @D]PH,V:+X1/&;LDS4I;6^:&A2.M^JL1UI'2_FTUF:+[BH&7W.,A:Q MGO$'PR52J2/.P3BJBGS&6:,/5*^IH>BQ,%.!;JL(/31)4(E,[$G!5?&ERA23 MUT:T?JH-F]JWMC2?0O<0C!CEE&.=4RW0&F\/[--REL.ZH7ZP;6$[C\RV>)7, MQ/W[IAG..JS#68_0CW-&A:<;HG.J7$2@$(251-.0/Y'YA.WJ0A%8%_@!$A14 M?X_*:A11%+C*0 -5VE7&>:1Q 92O7Q?,D7(\7\C*4GJ\J<>!B313!7FZ.%2_ M6_IK4/L3P)PT!]*"P0KY#VA4Z+6=E;4\T$Y.' M1^N21)1S%#*#@9@AJQ /J(\2[/W;/$RXZ+>A_?3:?_02K.4B1QT"Y8H^QM)X MNYCBDJHI>3IHW5<$"P1[FM%290\/?_ /FOF:2- I?NO\@[9#P9+) M-&.Q)3&&?RX0EB,#6S556>!X7C)U@NRH&I$&=UNDV(BL&I57>=T4BBK-YL7A M01V%DL/J9*DV/6CJ@8/-=8XZ1R:>/8MQO>):37'KA<\VJ90@J\2GH1X3)(*&4ZGI:N6@5SDTF&:(+T-#V0$!5P*=SKIR(!#2W+-Z& M]C^$@XR^6Q)GXSX*-/2/"@E5SU<'UL4D")8 %:9CU28)_SY6.0YJ F#L!11? M7)J$.^Z/_H&ME%(,VQ>4MF%*V!Z949A("(!K1FM7Q:IRWW@+.:&\H/1=."_< M?:74J58E*GJ.MT'$<=O4=:;IBB0DU5K#QQE(JPD!3H1%E0C-6+DB%20E2M\" M<4ED>)^::>*T862$.,-BZS=UDLS;LX,WFB@(PV&M; _$5&E3*'5$WPO228F9 M).)M8NJ$6X^Z*\$<5&$#PJ>5K;,E$+K&XNE$[;>+VC=K)*WQD*+V/= Q?^P94M9JW)@"OJHXG"1 MN88A/C$K#&C0'@KKM!D-E/E22C W;@R1X415XUG>'$F,(7HI-E(ZZB=%Z <% M*JAW_=4[E\MN( 2/K.]2'EYDM+UXS2GQWV[016/%HR,/L<+@VL1! ME,G\;P%]]U8"HHEHNDROE&%2T=U([CX!<(9@9(0!$R4EHGSH!9#LAV=@WXI* M*&2L+-E"H9[KYQ6PE\K1H_M.Z;4J4"V=LR)\W722M@HMR1&T'#T@/3@D"UWF M4RC )[ L*)&;WBXU _*D2EY?&2IE D!.8[+_8!LAWW-M=]V M8J^D5#EK2)6C):GRJBE5SE&J/$(I^UZU7A!Z2*UL*[E*F7Q8D*3!.>4FU"B[ MR]+5F))S4Z@+ZGY7,2.EB@F<1(K(!@NC@<]1)ECT*WQ[TSP'Y0O#!G&:7PO\ M<:D#8C)'A29/HQLP*'HIUFY1F!B3[UJ=A'H-;:R*TVWWW&"B/(G;2FJL. MJ21ER6XDT "5MJ.L20K_JD@QN@F6S&KU.XV"GF2R/^OOBW6#U-S6O$!EGE(+ M.1?K!0A%UM1XRQA(S%0C/ DK#T]+! 5T)Y>(#"O2F0C-1N&_2N09BD!=4 4D M]58&$?ZRAE^0C_-(/TP3G55S?!'-1]82*5MC,\.E2>\ERMGM MK*3O8[ [#][\#_8U(_SILHK228DG=5/X&4@$A="U907*L MH- QO>H ^69;IA>Y20\_1B)5JGA&7)4M)@9?1& +_H'^G8TYKN M*AA=1'G=!]-,S-I48.S4^V&!F6@@QR2HN0 :5X$RPHN@92/^?I'4F.,E".8H MOZ8&D@:F6-_B8UWQ,S""L+K$/I'BBW2-*YC?*&=]K]+.I(V+TJ,A-*3'C064:1U6-ZT^\ M*N78QO4KLTSCO)DAH6"E&U]&ZM M&6QY]?N+).5-3'T\:]&$@6=UU%'&,-:,C;:UZGFA&LVMM+"@9[\BCHJD1119APF3R!.19K3-0N40U7)TH=F"$\4+9["G*U^PL)R MOV!8>$5NJ&DE+C!,K0B3^6H5[2]NW_6,0.!)+E4Q+ 7/442*.:E<,D3:T-WT MQ(6-7C31+B3E@A$7\#-R>4FMOH6IN0UN8#]UTTTD29?)PZ:DBD(;<:OA,11P MR 6\IT%@H)_<9*W6$5F5BMW3U6.]53C;W7P:<&"$,U6'JC!*;%+CK5G)?U5_ M/ ,E:Y:RQ:])1@NEAYZUQUN#XT'T(;ZNPSU]2X1\Y@7\;Z3>++_NTU?_FD>K MWPW&_8'G;_S:ZMMW_&[@;G[IMB>W3=:V^T.[F^QWFJSCWFK8?Q&)"3(#2D:N M^)\G[I.E0H!?+<,F3E#CW>6G]F#EM\[L"_[ZV4HL=P7MAACDOF7G^%9-UL\) MH?@D)X3BHS9"L98C.^SEFD5C.NN>+)D$SX'(/Q47=2([GDL$Y[*UYF\F&RE. M$>C(PG1>;->91 8N\=EC(1-+Y9_<8FMNL]Z?;-N<;MMVWK;G9 #N(GX"#7%@ MRCF&(0=[\]D=]^3'R:R;E4G:DI7BT6UTL&DS-M'2?6VB93R&K?QE>0OO;?G- M91?XQKU:M^>Y?4?<=M]K!^#HC1UWHJ/CCHYW6[=K#?N#CHX[.G[D=&R[P_YH M/^EX9VTKIO]Y5!K5:C3U3JK5TLHWJNG.;KNWEG7WD(8'@[ZW(PVOIY7O*F]_ M]D-R^L/ND/;[D)S^^.&.Z*[6]6.2]\M5E-_#D+X5C:[9NT="H^[.-+J>3AY2 MM_Z;'Y$SVOD^[L[H!Y_14\?M#__Y$.?S,^CUY]A,\'NH\C<])XTR&0UWX8BB MO,+8.IEE/ZO-?K^;L]^,/;2>(< SO X\HP//V,M4=U'7(TM.DZQ1:"83EE7Y M3IVTK/'I&LG*,DEY#7I4WF[A>LVP""/!'F&12&!G66L"E+Y>*>1KV2E^!7]: MENTT']SX4YT5/Z<4QZE(<>1UBF,[4Y^F&.F2'=D,E8K7" 1#%I,3\&S/ /E[ MC;BT89%C&4F:UD 8JB"PUVB.(%J!P Y$7-7,J%X&-/^$ZMEEG;ZL3W96U[JF M /!^CDL6+>JF)*IR_AL.KME%;JF5FNB5%2 62 1;5LYE2U!1!]WJV=(G=L.B M!P0%D,C@P6(%6V.!?U*ST3SBID:<;[^X@;VKJK-Q]F^^O#H[/3QZ8\S@LE0( M)')ER&Y'V23%M_P!.Y4)B/03U<2+,#P(;A@[OXB*MOE&"EUJ^K(;@6XC_:6! M\= 0]2ZA;&"&[Z<4D%C0J#EZ_>*GX5D,+($EBO.1==0%2+X9Z@ MS_VL%-DJ]PZK0AW[+<6":$>P_+G3TTS4Z#-(&RFJUT1K[6=U';;%'?1^BU0J@U))$J M714=['+$SKYH%;(J[%@B(X16D$]0>1+6J"R ,J8:4R.D0N3'2!9UF96LL6K< MA$K6*Q2@^IK!9:^(3*.L@L^JPP(<&H&84-&TJK#:&]#%9H&2 *;4I>VR7)PP M)*] VY[6N$+Z:E W&(L0H!(O,"H\[0EQ#/3\1;1]Q)8X*17(%3R9!E51??.( MZS3EE@BK=T7L7R%P;R.!%U,/!!L4$0IU$]!\6>L1@^EW4J,,!>O4:TJ2FU8H M82J2DF>B5TQ]I%% M"\Y;2W.!Y8[*;*,_$.<$;[2)#.JC(G _20?UB\LR#Q/B=T)EFB,(O[A+=Y'7 M785J5_3Y""?;5:AV%:IW7O*CJ5!=UJ7W:1,?4\GJGN_CHZEAW>=][(I:5[LK M+UD 76UK5TMUMW7[SKZ64G5DW)'QK=<]1Y>F@$KJ:7"%+5\ MRH'H%/W=%?V'5%"Z([K=$>TJ[;LC^L%'9#TDP-#/H.:?B:Y&K;RR;W+O_-S: MB777<%&G0'9'U!V1/")JX^8\>[AC^AET?<*S62_Y]P[EQNI "NYO?_:;]^W! M\+O@%.RR18\9S*-CE9^'55QO9UVF8Y6.57Y"5G&235UV]XR:FLB%I!8\EZ+@J0E9?M8>NJL7BU#=YQPW3OI22Y]4J$(4#I M9\RI][,JYM8O;%1W8XWI[W^^.S*?+S]%+ [3*/(TI?FJ:9;S*EI066Y=IPPO M/>0AI_+;&A%'S^F:VN[JRMUL0W5J72I=;@B;";"!>%LFQ8::ZKH4NNXT#D<# MZ\=G,LXCL2%J.((\R"8YUM*V=Z9<*2*^^8CO7%B,O;1;/T:,%UI>=$501!F0 MK0!JVY7J_BWVL2O5[4IU][BHI"L/Z\K# M?O/' M4.BRQ7^T M@55^_]&3UU[%T*N+IT_JYJ]R%3K+RN:G??S\COCFC?CVCW>[E+ MYN\*=Q]*G-PQI[;3(?=7XG='](./R'I("*6?0=,_4SEA]^?@^;EUE-U;;'=J MY(^VQN[J4NZ.Z,<=T0,B*/T,FOZK(H]Y65(?2R/F'0CGG8BTTQ_W_HBZ:,N> M'Y'UD$?T,ZCX J'AQG*-!TR86U\5V25PW,OF[#?W^X-OQ&+_QNUY'#E,'8/\ MM QB6[O7G'<$ M*5]R:O:[GR7JY9:9WEB=;NC"=.K4O+TR?4W3Z.7NR:W?MZNVX8-(I&'6\VPT MI%[VX_17%KKF]3AI.=5IDN44 )@753BO"AQ>]J[6O<-#^B5UGN9&#I2=LIF< MFWR-:I9]E(IP M?X[U3'Q&_["?_5,U(!=G)UMFSR^2(C+^4[%B+CIGB^K]5@MPC(N(&O[VX=RJ M##_FUQ(.E9K,5P7LG4%M!*=37H1-?((D@PV>4I3=F//P(@-^F%#;^<]<=;Z6 M9?=;*1:F1O0(;P^P7_R4P2(XR1,>!8NC!AV MF;:[,0:N)1=-I !#';%DA0E;-_H0 +VHY3]4=7=/ZK) M=B !'4A !Q+0@03\+?:Q PGH0 (ZD("_MTOJL3N=;'OWN&577MW1\=[1L>/L MC)/>T7%'Q_M&QT]MIS^\:Q2@PPCX=HR )>=NETZX>]GY[FU#NV2U'WQ&PZ[9 MW]Z?T5-[U+M.>_.Z'98,'VWZ^7](PJ%,-*> M\DE7,G1WMV$'+;7W9[0[Y&!W1C]:Y(_Z3J?B=^A?CX)8O0X28-^/R+:Z,]KW M,WHZW,6MTZGY=\"!V9;6VVG[=Z@^[Q3)O3^BSI^_YT?TU.K;G:[_7<$![EWN M=T6=75'G-SIA1G=UO'=ESQV'_ 09[3'V%QZ2POJ5KY5RHF3JYX75.*)7^-!^5JK/H1%L#,J_GF1U;*71Y(0W6' M[?+=YO^]*.H:M DW@X*S2Y-ZN/_*TFNV*)_\JUWOFV1J\"&<[/:UWPI>(8Z_ MV](%Y40\S O*L/D5:)47^"N8#MN;N1@7!8__Y\G_2T:#D3T8^SP>\;'GC6R? MC4/N.RQ@0R<:VNS3",P-JJW.8^,YO!!V%ZP+]MNZ\]T.A[&W\!B80@M1$-B).L0,;+66V>;LPJ6L3$( MD2"Y2E)X[@KK_R=B=A&?4N$_XD#@Y-[UW_:-0SYCQ9P (N#1/RKX><@U-,3A MV1\*%P+?$E<%>3TC7H9%$@A\B--\S@W;TV_.DQ4GM>(A+IX!/AE12*$ PDL*X8FG%U3[EU1QV(HM$ CB"/TSP M$'#3$I 4 M]BZYZ/?L26MR ^MD-YJ),A%!+U+6UKD5\#S>&!X<)G*-CDUMPVR7$3X;BN61'UC*":-X!;DC15@\ :-(H &K+UFQV+YN_B416!R$XI+,. H;A0-3 M=I@;^X(,\:A@+![59#O,C0YSH\/;&W]O;^]C]N?[X M&['"_R8AC8Z,'S49H_5YQV33CHX[.MZ;=3]U=LG+ZA WNI*\O21C;_20/4:[ M,[I5KLMP9Y"J[HQ^]!E9#YGM_C/DZG9U>?5]UVKL3++ZJQ;Y$D_#T4_YN>ZPKJ MOO_F[+D L.\,4?XX2DX[#NDXY-M<84/_KNZ%CD,Z#OD).,0;W=6WL\^%V8^I M1O5@FL,Z14]G:CX>_J=*"JJAF[-LDN"6LK+D\X76R/ ];MB?E+,=% MPF;HNE?$;E(5FB]?O:7NUUBD=U!-*OA+32@1G=6Q/#:AVL$\CG'P8+$TB7C] M)/3FRT%4M29]+C %\*.S:1(>%#^ M\M$Q$$I2J%KC-,\F9IILOE@K@W9;6EXJ%FTSSE1?Y;L]+ MADGJ*8<70 ?\]K7+-?L2$H:8"#."*DFI(CDE1L0*9+@SIEA$'NKJW[\),5)M M/&T>'"VLT7B:YF7YSYZ1\?E#4F(?RZ]O=W@]XYH;%RS"*@XW@)ZREY[:592OG\^./$+2=_D>P!+]$@E3DWHNRJL%#I^HBN9A M58" Y64?#F5UA;=>S/HIX!APW,L3X"#6YXOFR_\F?#+GA;@A!9=(CYI@E(>5 MV>)PV_/#(_O%VU4\KU=G]-ARS<0;WC?PQKH)WX$K-( %\AF!5L TX)::IUQ= M8&&>D7:._)#EH.((OM8]>+4XN+Y(8(J;-)V5'5BF^B48BS7O])1]+U^)F!*; M!HV+?'J+8>?H]86?P]A6^RPBX#UX9 =1M3HZG/X6U W_1Z!N;)0<>RPFB)CG M[(L1\(S'R;R6% ^LV-4S4_1&,D+GR7V;C&!ZO4CLSC)![B &'&:7Y=2W=)X7$8)#W)2;O"/ MF0#]PH=I5-!;YGF!_EZX8H2:@WI@"]*K<0G!G957DPMC5@6P\:A3#"G#]4H!;_BB-LE0OUXN06+EC:K@K2+-=#A#60O214F 3WNOG-/70 7O,T)82X-J(8O)+3 M/8Y+C6"):3XC#9[V PX8=]N8%ZA.4I?P98@Q%EWA,2BM'Z>R BU&@P6X]SBM M#$@-ITA#":.YN3?D.D42Z0E"0:OV"K8XFS?A[I?,;-1>+RCY8K[.9H$=0'^: M\, VR*\^2W7*;6+J:8BULHKC)$QPE3#K&(2Q("&IW#3H#S4F-B?_E=BA#%C3 MF,/^7VD%2J2%PYR7GH@0ZJF;DY;0'UI(^J^Q%=#HE0!)3-D<:6!AH_ -S85R M"@^?YE=\&H )!10PT <,^\*FXC=L CJM= \99^$\ES^6=IF:%FJV(>+9S3'% M!S:$.#\$08%V[WIR%'._RR*)2DM"LF9.$8R>FF0(D(_)B9OO@EF[PWZPZ79']!TUK*E\A[F MCU!5W*+18@(1 );&""Z09@C MH44"XXP7A..X9@DP*#,F<,UFQBQ/!&W/@[849J&Q-!EHI;EO<.&4QN7CTD[F"IHF(; MQE]B<;PZ-NW-=F_,^$&],7M]&R!E%RPIN69:5"*DR@[L"2S"Y#T:5*#Y =?V M\/-958 L,RB#DD] CC63AY_ M+1!ZA19:JPWX4$TK2$Q"S '[I1%J(%-D3N$=A:6#C.?X%^BT(9"94)*5-$%_ MI@S]PC0CGC*AJ2;3F?#/ZK@QJ6LT:;5+UWA>98@Z+:9UK #F ML4J,)G!#R; MJWMPOM!,22H3 N@*O8FD<5RE-9:N4$[KC=8*V8HY@#I$>)%PE.JD^LGK$[&H M@8J"NK9ZRC'@#2]6X,:@\D_4UI(,0>C=*4?/];[RTXYFXG/2D?'_&D=+.O)) MK92\U4K)?BYZJQ"Y^9YA,Z"%+PDR![##+YYC+RDY2'95ALY^,!Q1( ME)HO6 M6Q=+XSFCT5*\PMBD\^TK56W/7L>[E7W.28.6K-,06!L7*U#"R[F0O5_H)B/V M:DD[VE T.PNTIT'R1+5B:8)<-M%T%C=Q'GP&009JB[RXT9L,S2GY_%> M*/*K)$*UL^D#*EG,Q>3!\@?I.0/Q";H#85,7"=D>#3&"8O "-@"#/RBA\;F" M@PD!>NI9:_'P?N##!;QMFM!.U+LRUV+/F"]F8LI)!J^KY*X)79RB5V"*SRLA MA\CZ;+Q@4C!8C52>A5@41 @2.:3XKB!:>CC/E*F32'\*' $ZER50.SHC8"[T M#;V_^'M$?TF^O4!K_6\*3SZR^[[_F$"T'Q?BM[-OB-]^!_C]X+5=-R[9:@!^ MH]=A'V&^]VBG'A.J]WYMF[,+[_R=H:=I0S [B=3RJA3.D=HOSE [;-LQ'?QI M!W^Z6[6Z.[Y[=\$'K^/J2+@CX=^>VB/W#H@+'8;O/5Y.T@\A#?PK&6W_Q@OJ MYX8F&CL=6NR^GU$=V>TPI'Z@A*E#6]]7!?Z;(^'8KKLS^79P13\:K>0AD6.[ M/MXKZ>/CKH]WEPB^=X&B74_L;)L3::^6?&.L]D;GV X%.^W2TF8^"Q;U8>+V M,BI"UOIV?6WJ2GXQ94VWJOSJ1PK*4T,\@_93E#9;4?(F51)BW@K&[I_#5D\J M5D04YCS+PIQBGI1-O#K9>K-VVQ26EOGZ%MTJZJN23-HIW.5J)W1,F39*1E'H M*8Q"*=XZ#4K$//A")/YA ML#T,"XP\J^G<5%RYM.TT6W@7AN57$KW;/[S=B>PGE]V;8#G>8OP_2*7A?N[W MUCD_OXU'YI,LUD%CS+B$R+Y7C/% OA@0ZD!)FG;SG+QYG9. MTZ\2B2HH.63^"F8@S53YQ"^.OYR_1 D=[90<6-^52%"ZX*F EV>9FIJU-$#? MN-\MWH!)<.LM%HE\M]OF\?)B;A)HM]WFVAC4 ^^ZS[9")U;[O)_,=V_"[L4: M/\1C%#A:C;K)R;)+*;^K$N($TA,,#79I) G%':_49"-KT*5:EA6CDK=U@ E( MDD!GFQ[F7W@1)@(40A2QY3-5MK252VCY>34715 XQ\%REF.=-;UN:R1PP:UV M\?9R9?,6>BO3^^8]6(\PLVW)^TGK.Z;3G<@L4&=16.!J)O#CPYY2&5A;3PK>:E)6I9:^0G+V(0>QNH>>_2L M- [K%R)W'F0L70#1XL O=/;^K4J]/C?/;U"MI[! M<6:\X$$!)L"BSLPFIY5 _4/-H+Y',S[)@17G9*.$U'M=9+S*>[M1DT?9L@PK M@B<@$"_R-)+68-L&6Y6:J)# ]S"94:MPBS[ FIU2%QKBJ^'C\?+OQNW?47FJ M3.JE!&(QF5\&F/6IP0;9!.8^P9SB.A&Y+MMR^M8_D##T9$_;DW4M_*_>%!1& MO]ACMP%FB'"*:UXAS$6YLAYHD);=F-36A\;J(7'1X#W5?! YJ%5SUQ.(@"BT MA:Z]ZTFW#W=^G8BJQR%Q/%SVC-2/X MNDUN*P<\'/3'MSLJN3AQ\=9#BV(;4J<)+$\<#LDT^ F577-6U"!*5!VH\MYI M>2"1C 7\IJ<="26?)B;+LHIN3"Q6+<#P+\K&^+)>;C87!;8VCL89?"-&"C@( MJXP<%UGS9T)5D@G_C6K #RR5.UWP *=? MI0*\ #:)"IBOL+-X557\(Z2&\= VE ;\^//L# M=H27JC"O9\"#DQPYH]9O2F&#:@Q9>$B(FQ 4U!3.90JJ"BC6L"K<,;&M)&E0 MF<[1XR\V<9:C%[(NE];09Z(F&FYRP7Q+A5!^+3,W%64)QJ['JP=K/IXTX ]* M+!/$^DK0L_.B[ D3(*KA%W 5GZM(*&'RW[AH4*C$,F';,):F87"34E*0+)R4 MKEA1._11NJ.=PQHFY:I5A@7+&PR1.>+1-!=_%I-X+$+IO M+$^$O063TPQ82E9^>4%EJ@4QIA 5NZZQ0SE;#5/[]X)RYEH=RMG/'=S>&R_- M<_2!(_#2@8CRH6HJO;S2%[SC]%KL\:K$K6]*DT%":^6=;@(0FUM=_*U0D,6@3O!^1-M>9'/+R+"7BQ!2!+Y2*)PO6P<*=SB1< B(P"$B(EHI< MD'8NDP9V-'ID6)E"'P0ZDPD[] R/0.NIL.%)*5P_B&1$*CFBHJ*,@=I%PW&Z""R$]-(*I5&NNL #2['&FTR @ L- M%@X&)U.#PX1)$593-#T)&4TH?IJ,Q/&CK4;?T++(XH"=QW7J): >58E=!BNC MH)W1&$X2L!]GG28"I2+AC8FB60-72H3A,Y@E$_BHA'U!*Y-@AGU@_SEJT&J" M".X1)0ACIQW@99,>Q"K%+PC!I$$;>5$SS[X"@V\5&XA)S]8X?$,E*YOLV)25 M>G]ZL)'2"8 /?C_OKM:)E]R[$CREEB[K5&]E;MYZ60W0Q.7W[58ROQ]WWQN. MRF3KYBOR#/X.;XA3[ F=ON5>8W8:?+?R.MI+C*R#DB8"]04UORWL09ZR5Z**UPTE^Q8NLUKP0>08NJ4Q+_21K M)*F8A"#3(T";="%Q<5I)+#*D+G,($? 6P^7H@64SQ$P,6'9)@9A)EIICEM/8 Q)C6D#FA33%6@@Y+02T1CB),EER#!P3;2P@X6W=W M"=%IVW:3LHY[9!)VXGS1$+U-@)Z>P/I9PEN4^#Q-&D20RCSCS8<;*,4P,9A! M4E[PYED8$S@;@L4M#>6,(72V!+'"GTU=:RU9F+W X5==:Y/FOC@ARLGV0$A:IOW?N'#WLKN&$4EL2!" *0L+V(<01PH=9UZ_.D M$UD*-A.+). QN[2MELK;!#S2-KZ M\..*\,X)+:QOO*3,]C95XH *L[#&K%P10FM.H;7Y&F,1?](PDB71BYA3R948 M%]:V/'EX!\*[MMG' $DU$7%8&9^OX2"7?@G+Q0!_O.5&OJ9(F'YAL%@.[BVW:%,(J71?XQU5 ML&N@H.NLB8FJN% X'7A"U()RX(W&_/XS1Q=1L1GC5X*2LG N(/3$#&7N+4?5 M@ HGUFV/7%6 'B?@-*!<%*]]XZ"! 2J<*0W)H88P,2M"H)+7[IF53 D!;%AH M_Q7%S+"-C7;B-$1;G%8H^;7YOW;2SXR+_)H36G7 0U:57/+JTMH(/U=XY MI_/*0@67K)9#3DA9GR-N6SC]3*'! R&6H 8"4?-286:301$ATF$AH3@;M4G7 M:XE8.Z-$DT-2,,6M0AJ+:N&D)S6'6ZE,6UUH]4P6&U(CWL(/YBR3";D-R%Y9 M*B:H'X/QP+=?A=.ZL92RH6\QHYSB .C=EJD%<'SY%-XKO=TK,Z9.&"U,?HE" M30EL@F_J\'?3-'LNT]-TJ5GDPFY 31RS=FE@=5DL UAP^7;?%PMD[0(&2]HQUFDQWFS:/@9X\R> MU95#_]01XSVY(M[+M%LALX"IK['^$F5:P4+95B>AY#:^I&$I^VN*K5%4E9.2 M"DNR9"F?KN"F+&!51513,)OF*.MXLN[5ZY36^)' 3PZGBK M^T!^'[CAVOJJK+);*MX"O;%AQ-<[5@_?U.]D9'E%7E(G%HKLU/X!I83-6#E7 M>5:=K@RY,1&N$/#QL,]S]LX/5)(A1Y*BCX%::J M1A@E>(3*9)VWR[-(_8D.@QSYY(HR]ZF+6:*2!*3[H2@2ZJR&?I@:T_F49-/&MM/Z)1O_@7L1#)A N /3@X5HL%UF MVH.G_)_BG_#(M$HGQ'JK[6O@S(Z40#L0W&O[KD>CJWY3S7J%YH_KB@7A/*AF MY,,!<=#<^7O8*X*,%RGLPHNWT6?0N^7N"1>!WOI^(ZJV\9%6#Q61=-L3WV/_ ME[*:8F'Q5YG!+/+*&^GSK=8F 6\EY>.<6Z<0DP-!W 12\M6/ Z-)7A#0_[=8 MK7S9QN^;WGJ>B7 !GN.6^(/)WAX]1W.'A6#. M5^(^$-&:Z;3**)2C+XB=6*_7H!J5^B-#SI*(L(M-@?,KJ=LB+W!IU-$E 0G& M"FV]"M9J9N&@!SC%TG#<>RP=YV%2RCMMP@J:E]Z>^CCVU$%QDQF_G.G1=$0U M;#IY?Z>*J R4RRW5@LQ;+ :HDZ?_(RHOMG1I)[JC]S<;!^EV09A,0V8VMD0" M?L3HX247.# K#_2:BL;-$]V2=_)3FHWV_:0G^UUZ\L]@;#Z,[OL*Y(F0(,?' MAFF(,I+C^MKZP9:"Y^R_I6#WC3^IFNU57;9CIB&0H6PPS MV0YIN;JK3J/$)L5P88%B-%NT[MQ:#Z*J,4JQE>//69+*0CK2H@J$W<*I@ZZ: MUH 7334.FU#+FD9E025(%0EIB2IIAK0ZRCJE$*WTI33':10:?F-)*K*P<7R[ MXLS=:ZN^E:$'CX"A#_H4-<( )7K@'Z':^9[+2@@N2AX+-DLB3(U#?9. ZK*K MI,@%JTG3A%J@8@"B1MS#=!"9\R 8;44E7.K:N:Y"@\J?*? HO6-@W&&+.)UF M+W+V%[GJI2W4RK5=?E4N0LTW".,"_Z*.:FT'!EEYM #D9Y)5LQ$[5J**!G:X1UKS64];\6O*19KV2ENW<;)7,)P:Z M_4A4:5G]_^U=:U/B2AK^*ZGS9?64!)* ,EHU50[JKG/.JCLX4_-M*T CJ0V$ MS47E_/I]+]VY0$!T16#255MG'6B23J>[GZ??V].+X)0$KQ!#B>A<.+_8H[G5 M/I<6FKJ8TD&$ 0F>E'GRQ0!U-<3IA0JZN(M/NY^1Z+>%+- -[:B>Q4;/?A!KV!Z MD[Y6$Q<#1X#!C3E3*@W=&F0/C'0*:P'(2J&3K!0H-N_'[!7.6O NQGJGH8>)43Y;@\ZFAML\O'3YBCUB",9UJC\%&1(RNGQ MLC5-!;I)&]\CVTLQ]H\[I_H1CT)RN]#]\_V+\N3-ESJ[& MM7*BR_6!-6-SJ7=IA.E\9*0RT^;&AV-X5*;5VW&R2>>7:S:>I2KX])0UMXN= ;FD?$#6>W,^()AX5AD)3--XD-U4'D^ M"">>:UQ@!F.L7(%93X%'.0@GZ4XI_DT5YKCB $B^'=AUH MKR(=.Y)"L^V;C>U7%]<=,BJR&#V&>W79Z(BU=[+'LK/'>IAP;1QZ(JI:XZ'@ M._E&._)-XJU,:>JNE$T\J8PG]!XR<-QY8686"&F20]&CB]/ M'9AE96[2*%X9?)D&LZK(S-2<&RFO2>*[X6(XZ" H^>U:@:@4W9JO:3O4+>!%1Z*$W8W/E+ MJJ//*%0I_W <#!_/%-613YM5.X9>C'%CAHF\-("VQXF9!3_K7 @M$<:T%^0I M+8B54P0D/R2F2,SC5V$(V1=?F"EX*!12#SE">DT'VT(L'CH"8%O%>$Y:H=+/J6U<D+)4NQ27YPAW($W$LW'&^ M,# :2CXI,\U7X.^AF!F7&(L=QWP>3^^0NXHTPIX98-RKMYJK(3&E_5"6H M%Z+N.)H^\/F$"2=)7BZ7:1CH#S2?WL%S> -ES^R,/)&WS=WRI4SC'QYF%>&7 MF8*5NL_"2"CC2'KRI$-P&$B+0LG+YK@_@RQOY*X64V7]F!\23!5-5IL&*HF( MSKL@XO'F*UK"$_9K,&IH:SCEV-W9*_:RK<-DH?_B>03S/C[;>@EQ9JD+M9NC@ MJ9&9;QJ)4_7'&>S+4]^=G7H3Z@7]:.Y5XKXY)WU+P\1?9VO;;/#ZEC+;\L[R M:Y,/9T5!7OZN99Z<6$N_;9AO_:[E++_GJE^N[&O3;%C'>]+9IGG2/-F3OK;- M=G-?)D';M*RW774;?;6/6VM=E02LY=HM$1N?T\@^6R ['R,%WGX) F@/DEL_ M&4MN*"YM#C.?.-Q6)3)^BB]R;\#=XOJ4/D8;P1T%('W3[(S%(?%'A\;RB M-$(:#523J?!(="\[/#EP_1EUN=S0,X.!+]YL5]J4P:&QZQ:1U1V4 M%I%1'$^CTWK]Z>G)A'Z:#\%C_3SLC[Q'$=7%X,$-ZP,W=NN693>M9J..'?X$ M)_(6;&>-YK'=;M9=5$MLG9S\)9YKSK\=,WZ&B>"85HG59-/[^\KI\\%6"][> MO>=X9)S+>@6RO'U,Z4>=K$@PFBPRBI&K_:608+(A\K69IFL#[W9?35!\%QG%JSW;;L_Y-N[2S;L=#.8S4<29JLAFG]KFD3IPYE5IR_1:K*RCG*&QT9%\+%!-P++U)5@M@< M%'M2FNDN\+W^3+.8=[=U-/(T!J:K4VTB8]=MS60TD]%--9/9-R:3&6X<14,R M%F)K%E+&0NR&U3 NQU,_F EA=..@_Q_C+@'ZAYKB=S[T\""G=<;B7=)%Q38> M6Y9EK31H_MPG7O9QFZ9&RBHUU4BYSTCII$CI:*0L0\J;8%)+@?("CN4HI$#> M##&).,24S^C2!?+5G218]]]N,D!J?-3XJ/&QPDTU/NXO/CJ6BERT=$XI[NA9 MJ@4!7Q)&B6GQK%*LNNZ8<^=B*AV^XQR MF1)-[4:CTGE0&DTUFE:^Z7L78=YRR*/U81O:2V1B>\Z]K(Z_TC^-,E7P?R5N M"!_Z,X/+#J-B35K*GR5:4(:SVR>E[RBO:TP"U7B-__(U# Z=H6@9F5XL\Z*D M9 +#$LT4AE3K#84DXBX<4TB (;X&0O4 MMHO!/U+'>FC6 H[T."S)E&3Y1>X8/9U0[N"!KC-<97ONDOAO$?9P+< M78SO!] M [6Q&-I1VFP!VA5> Y1YP6 Y7!])O$9I CXO%@624S-L)QB/O2BB MHG-EV.Y%I?!^^?QV>-<0IB&L9#>KDV[4YYGXR@W_+:+P@G!E3(+5'Q29AB L4 M?[I"$'S]D=@AU=_EBGV[('S8G-N?WBA\Z/SV64L![TQ?MB %O(497:YEV+W^ M^\WY_?=OE]T]5#',V\*1QX0"#MQA=IJ>XS9E[N6CN:ITQLC%8BM JOIN@H=U M$C\,F6#!;7K"D,J[P(@\N$U/C%Q_:/1F="&:5$J:%P6,D@G\B*[G)O$H".'I M!GNHH-@PG>.WJ=.Y[!J=VV]WM]_.[Z]O;]9(*+9:NV%G>%\/,/\0BGY7L3.408S,J6TL0AKR-+4&?D"701 8?"K'AFY.5SSU8G@W M_;6&SIOTO:GK+Q^P;8Q2F4E-X[7&:XW7:^/U5S$7#&U^ -8890A^E08+: 1?"\&S <-!/._W@V1"WJM=!O0U MG23K6/ V9[-[!S/C#GDK=L8QT5KNF*CW@L$,_F\4C_W/_P-02P,$% @ MRHBI5BVA[NC&%@ $OX !$ !E>&%S+3(P,C,P,S,Q+GAS9.U=6W/;N))^ MGU^!]OBHSVRZ)7D9+(O4Q )2:A0A(8@'7M^_39 4J0$ MDB I.>$9*@^Q+NP+^FLT&HV+?OOG\\I&3\3EE#D?3L[?G)T@XIC,HL[BP\GC MM-]Z=_+/CS_]]-M_M5J_WXZ'J,M,?T4<#W5<@CUBH6_46Z+/%N%?T=QE*_29 MN5_I$VZU/DJB#EN_N'2Q]-#%V<7E[K?N#89_[R\NSEM7;]_/6F]GQ&J]OS+/ M6V=X9IY=O[TZ-]]=_K*XF9U=$S*[GK>NK\RWK;?G)FGA\^O+%KF\/K^ZO+Z> M7YB69/K,;[BY)"N,H&$.OWGF'TZ6GK>^.3W]]NW;FV^7;YB[.+TX.SL__?U^ M.)&/GH3/VM3YNO7T\\RUH^ABPI MYNHT^/($8<]SZAGV,^D_IRUQ-DYZ)UPHX!N$-F8D]ZK'B> M1PU4J$Z)[7'QKA7S>//,K9/3XAKXO+7 >%U!BR1EH$GX27EM$KY[_O[]^]-G MX8SI>J0ZEGR^)5ZVSB_*BG#JF]+LLC=)3R M/2^H1GHO+FB$B$"T_JJ,0$[,-POV=&HRW_'<%^G.FBZ01A*]D9*'^"3\;+VFSIP%'\!'PFUN(M\9DWD4897A(J6# MRC\WV#5=9FMZ\^G:96OB>I3PY% C&2Q=,O]P(@:<5A1#_[#Q[ UH$CVB"-CN M .+K4R A]C!N240K?/##"0<8;!+8ILX-7[ND;,.!A,,H)H'^CV^_B>VR[0<2 MT[?_'LVWR+QL\X&$.K1"ZP7U%+Y'U/IPTF&0)S_@!6@G/G\<#S3ICI0=4T6L M(^:Q5A_/Y+]SU(KSZQ:2E$B0_G:Z2[##RN?$,IR/\O6NKX?$X2,YA#M.4IAN MV[JI9.&'D3ESC>Q8Q %B>,&932TQR;C%ML@=)DM"/%[2^EIV6E@N (L)V)-L M< EYHB13%')% =LC9 D;/V 7FK:DH'^@0-01 MZ#P@#CP4EQ&F=8'K0[G <;S.B<"8+_LV^W;HP+YAJX7Y7:6 #OR1%- @,">/ M]_?M\1>C/QG-Q-!V,[AZ,X: SZ$U* 5F0I1;$]V*N2KEI M,^Z[1" :,$9&'R58HY@WBI@W",!Q[U-O]-@KA5!$HX/@_&P7@I"R0?8%C_MW M;]J^'?8FO0[8=UJV.Z0RT%K^?-?R,1L4\VD0#H,1>-[4&'\I9?R82FOQBUV+ M;V@;9.6'L?'0&T^_/ Q%T!YU>__[.'BX!S.4LGHV%RT*E[LH1+Q^09(; G9H MPZ]!R R$)>\&T/_;DTEO.@$[W!E&]_-@."S9([+Y:-%YJ_:1B!L*V$E\(H8- M@J??'HP_M8>/O7NPZ^.X)[RSW#B1SD$+R=4N)((/DHQ0DE.#L!@:H[MI;WS? M[=V6BUM;A%K+_[IK>4'>$O1(,&B0P3L&#)7CJ0@#(V-:,C]2B+6&O]XU?((% MDCP:9'N8\/1&DQZ$W8XQ'+9OC7%[.C!&[;MQKT(0TG/3HO-.Z18!3SDR;'%% M,=L& ?;0'_Q?;PQIS;VQ9=IR&586$RT\RJPZ8(4VO&)4&@3*9&IT_OTO8]CM MC2]"#TW#] Q) QHCP,*@LM%,ID M6S)J24XHR:I!<$"S[P=3&9SE:" +;+U1Z6I@'A\M,,JX'W2ZO4^]H2$GQ=/V[YUQKSLH.?079*G%3)G!;QBCB#-*L$; M&X7,&P1@NP/Q?3(0047TB^[@4V\R'4QAME8.M3P^6JB4Z7R2F^Q?27X-0F?2 MNQ.^.1CUC?%]A7%()==BH1)C:KU&- MRQ"D@_>MNE>A>'6NA4"J/!^)0"Z2@M'/H>@F^4)8.1,7@EF^3=@<+(H7"Y%_0R]+Z@U*+*>(/ M&[D(!",A&<6BCSZAX/3H6,2U7ZBSN,=>:"9 KS]Y3>2,9!:*1E'UTB21.>TT7BW/5 JV>#-( W>QI9<["=]SS M^D(>$4YO#:"ESH)"]MV&(R1WXOJFMG6$.#+1QOCB3F?'HQ#A M'$_7)36 8K>QR2^B4&7]TE'@M&6Y*-#1";;*X07XZB%5ZEJ M9\/;[*B=O$MK+^!R&6GQ4NK2VY=T-1ZFW4WGB5R6.4_B-W-@WCIB7K4Z5'GN M6D!3MH+N[G;?R8UC24B*.N(,1MJK2VJ9:5%4:LUI*!Y[9GK?F;K8X0 ,R.DP M7FVS4GGN.DQ_54IFNIZ9D(2DJ"/. @E_M<+NBUB.]PBTS-NCIE66MQ9CI7J5 MBG$@)5BD#^0TNDB5W==Z\SDQ182+[#3&,$"-B2V63#V6&+JZ9.8=MI]7DZWU MD)0KN_*CP$:/V%FD)BA4!7EL:PP7VC32C;1W<][C%U8IPR[#6.L 2GFKR/V? M8GL0"#GBFF;^_V%+YU]L_94Z_-&A\I?4O9=7 3I7DA9YI?95$'DA%85B42SW MZ QI$,FD*= 2VW?$82MJ0M3F!+OF/;C> M],FY:NDXL38Z@\. E\I2"Z!ZDUHZ@,D<'/@?8=RQ>7O%?,>#\=T3HDU M=]FJ_0KP%A"EA5T]@:V'/92+DH*1D(S:C?8(Y5:)_:.RGJ4.X>OT"^/3KJPX M1N;%CM47%H>(LJCQW+;2%+Z#?7C466P@-T:25PS,,/!\P"_B M@% ;.H.SD+_T";,$SZ6F_&E19GX%"^Y\ O-/[_#><7"5M"ZEU.%R7$IJUY+J MH5 _E%#P%Q0K%/P8KO0\Y4.AYR]'ARR'_@-QY\Q=B;W \C'^?9U/*U[K:$J] M;Q]'2Z@3/,P;[E YER=-_/7:EG;#=@Q _#O) T>:LNI&J<-*UKJ14CS,O^)) MK#+%2B0ID[_DC!*:'-UG&\2V9=&@AO9ZCI(K0^L2*1<;YKM$+*[QP!?[-9U"WCJ1U0GR@L<]MR5>\1N+K3!U M!O"=8'1RFMFFZ=*E3Z3M6&V^!-;YK7.X_D]L^Q(%/:(OJ2>RJ\U=* K$$C=C'G?M^TI79'H)A2>::E7E*@W)@4\ ML.-%7\V"H[$?3DRI1RD3KY@#0<]]J6;D,3$)?1(?E3%4DJIZ8RTR>[VVR@+- MK9AW=]A*[,23<#V :)X?*PH0UB%N?(9!4!R:<7KP1^P'Z)(G8K.U>&J#4WOA M$DF7W^1JO.I@!1'NXM@6K.Y,B.?9(N3UGD4?]BE?BB]S0V9A'F4:_3W=O0., MF+.SR36SR1E/U[5Q#RZS?-,++UH-=TE.V53$8#FF!84UPR'Y?EZ>3QU\/#E0 M/P)L;?-/\$,PQZ1K;03PJ&+SV%_-*>2"H10H8 M3=FD/_/D#>I3\NS=VC N9]JA .4K>H4722D4S(A)17)N.":SV>)%%[,R'J^# MDT^(^P1^UB=$)DP&#"F0P085:GFQ(43<.>35!LQ")FMHB-AO(1Z%R2T1:?28 MO6#;DS^QF0'L(47L,;Z];F*>?=./\&>QX)B\_Z0]!U__0K#;9[Z;:;B]>-8U MJ<9 \+8J4*D5U2,J547:(N3>$(Y0P[!:Y4VB\)_3[!8JQ ?#IRU[ST$RPUR0UL?-&1N?@\O3E^'[FRLY2TN M,#,#M0)(F+^'-U3W^V#JU(IK3&/*W$G^EV14AKZV])Y;MD3EQW.[TWYM&G?7'1 MO0FPA5<=S#RQG"IWQ4-@65%_)29-HF@D])8/R?1J2/&,VC1WKO:=M:AKN3). M37)/G$]W3YP7+'4'4E*F$+L-Z+6D_.CWK8FJ_@,F9&,46DR6$JREQ M5[?8^?J%$ML:P/3J672L_#&Q-)LZ#)?QFO; ,=F*A-73$4PAHR0LI^):@+:V M ^;#G/Y%7-!<4WW=?:P.J.U.>*&S"94NSBZN-'F;GK .[5,G/&P6#/LOQGSB MFR;AFM)0&0YU:'&'"1U8<( M$5(W1 M11U:)+,O)[R>(2@VYWIG]O-U:$UFD+@\JQA=8L(ZM,]84;/GXB[%"P>2/FKR MP@OJA4CKT,:@P@X@Z1*S MDZ)KXDF*NDZ=LS.4ZZJIS76=.N;.?HL=K3.1U)'5%\YXIAAZX6:.'15W("&+ M%RGE@OWV66 YA^3!7J:<#6V'%O2C-T3?M[\8?2:BE'Y<2G^V#OX>G1P04V$: MI#Q]DK$3I:H/Q-8# MOF1V_A[^/;C6=/P*SF#T,) 1MTL\$M;=W#5S"_AX8?(ZN'U<&Q&!"3LO\&=% M/8@TX6&",([C0-4"-9:"?&J*?:'="652U.H,:Y*U1CMTY,CS$&W:!"PNSLXU M\ZQ"I'7H!06W6T^_L8-LVT[PJ4/K1=]U/.:^B(UX?$DLR#@F9$6CM^)GJ[(3 MFH+4->WOJ9F5FG&)ZU/X>/*HV^=5B5D=?*!K3,:^38(P3A<%AKD\BCJT*"R! M%*J3U$GOPTT0@M]C_PXSD4A0;==0E(.1LKT@$$996VHGQMY\ M:QH5;WUJB[Q=("[W-HE\?;!:NY#A%]CO6IB\'OTMM1XC=^SG3?]RB.HZ"4S9 M7JX]B99/4P< @\VDT,5R>V/^2>@I@_F:4ZKOO[;8'[^UU9C/J4EZ$,7D;$4T M!88,WR/NA,T]B/P:URE.7PS=M,5TR\4V-"/O=&0Y/C7MLQFUL?MQ=U,CW_-VA'Q6=?")[*-@ M0^K(@UL\>^PI0/JC=Z@^N (2R9& 8U"3#X<=[:GQ;)(Z8';K4RH< W(XU-4(^QXS^DS$ M@6%BM:'I>$&"L^WRH&&PM2LF?53=M*UK:S':']W"E(*^*.J*@;V+$KGV)UZ67EX\%/M7BH7%IXO9YQW>53TH\:Y.?O ) MWD%\4F)7'\#0W%Q?@+(.+4P[U=A^IMFERLSG#W/3E07=P>'A&G;5)%)W$#6O M@06):]G:K:G!1F$NHLD#IME;_&%S+3(P,C,P,S,Q7V-A;"YX;6SM?5ES6T>2[GO_"EW/ZRVK]L71[@E* MHMR*D45=2K*GGQ"U9(DG# (:'%#+_/J;=4"*.PD25>"A9ARR1((@3F;E5[E5 M5N;?__WKX?3)9UCTW7SVZT_L9_K3$YC%>>IF'W_]Z?OBVZCP?+)YQR?=/QV__>NG]7\3P;N:<>SK\]/M; M^^ZJ-^+'LJ?_^?OK=_$ #CWI9OW2SV)Y0-_]T@\OOIY'OQS6_%:ZGES[CO(= M.7D;*2\1QHE@/W_MTT__^-N3)ZOE6,RGL _Y2?GWP_ZK.UA _O4G_.B>%*E3L2+IW];XU*>G9$<_C4?3895>X_?'GUW(:\$!?%T" M_L9JW4Y(F,[CN3=-B]3FBY/?G/H T^'5R5%//GK_:;+3]_C1SX\6"]PD$P5& MY)@CL5)[(@U88KE@Q%)FK F0/>?G%ZTPUB-G@Z"S[\,@[>-/1ZES]A2FR_[D ME;*^N%G8L=#_[4HR5HMZ?YZ>^_Y@9Y;*/[O_=83;=XH?VN\LG_O%XALJBC_\ M] @FW KIE**$J0!$YIR)M=02D(*KJ(RC43;A=2WRSJ_!&6CM+.*3^2+! K7? M3T^^0-%5QXIP1:M?Q$N8.[\-C]_QM#\Z/!P^DW1+.#SY_:(5:V%D.6\MF14F MD*--0?.[7_P%2Q^F\ [BT:);=O"=96U=:<8\*\Z 5D3&@,Y M$)I 0@NBO-:9-5*7-U"U#C#$HP-&-3E40\:KV6=\]GSQ#0F9R&QS\"P1+ZT@ MTB5-K+:&:,I-@B!L;F1,SE*QCN3EHY/\O=>YFJ3?+N"3[]+NUT_%04/[M;<\ M@,5Y#FGPD2<+)&>>T69)1X(1CDBO1%H$P"L0=PZN%"/#A>UI5(-+J\[ M'[KI.=.5"=XC#H[@";HN$S+IMP-JWP%BT9$ZZQ M*8J,3IN1N#.%H$12!L&FD"5+35B\AJ Q.= ;(N(B\FN(H+J#]-9_*U;YA!9F M$UB#ZCE);I&"B#L[,X=VF0N;7$[:MD'\U?2,R5NNC(8* J@&AKU/L, EF'U\ M#;Z'$T:_G=!DJ>&2^4"X1)LMN\D\2$$=/:!$F>I(!J_9"DP*8QI H?+M%0( M(3+@ZJ;AHU=I+EQ+:QAXDGU&EQ0]7H)B8R0B=X(';P.+K4*&B\2,R5O:$ E7 MQ D;+7TUA#^?'Q[.9V>H"-HKXU'G6JW02W.>DT S)3Z!X,E8X40;E_DB)6/R MCBI+?Z-%KV?R4NH*[W[Z%D/65[/G_E.W]-,SQ$UHS%I39TD&#H4N]-(?@&YBQUZ?XZBLP>.>*G1L>2BJ$IAB>$A),9B M )6;0.EVVL:4R*R,GLJ":9',G'AI909ID2OGB;1*E]J73(SUD27K+7>B=1:S M=OKRS7P6C\,>,#I3SRFA1J'X= S$QV!(TDH#\S)+I;>2P3RE:4QN^7V1<%OV M\IX2J(?P^>SC>U@% M,BQ(;40;K7<+86/RRFNAHJ8L6I[G:2TE958@CR&BHJ)HZ8WA),5,4X@^:=\F M*W M^3Q]Z:;3"1RUL M(QVV7Y9L+W_H86!L$G+*%E(BIAP52Z?* 5)(1%&7T>5F&4R;NK4;R1J3PUL! M /5$4+%X<>EG'XN?M>+O#2QWO\;I4;E'\QVOE.D /@7"'$=E:D6I)_% E/$2 M3:YSQK8YH%J'NC&YOQ4P4ET@%:L?YXC?Y;>W4S];[LQ2279]*E>J\.N7W:S< M3[D*USMY"8MS6:Q/"XC=2D2SM',X1S__OX=O)TP*].ZX)H :DL@D$KKU=$AO M,:%2]MRV<:?;\S8F][P"3$<&ALHNW$FPD7R6R2A&T!EUI7;*D0 ZD)AL3"HK M@-0FY!]YV>Y&T+G_$M?SA4XKA,]F'9740EA*M-460TLAB?-<$4.]EBSYJ',; M:5])SCI2UX]'ZILO>8L\#NJ<*\YOC$[&9=0W,9>37JLCL39[XLL-$B^ICK[- M(>IME-4\Q+&&.@G4$&85,LE\(@Z0TR15P# $(E=M:C"O/<09S;'&YJBX(9%U MIX5O6567F8^" 6Y?KDVY7:F(Q3"#@!-.*+2T3+1)6=V&Z]$<;-3'P89BJ%J" MUBT/ATNWLW+3O$2E,(L%G]EIE4*Y:VL8)3)&20+/2!_5UM.L2M54LVJT:X@: M4Y#7%""U!',!*7]_>G'A7N/W]3LMO%OBWP/U\WR<[<"?GB=J@Y8+UWQ\V]X+ MZ_!4J0G#\WD_R/WX+AO:BBBY$8* MI\:".?19PA26MXFH72.C#%Y'QM)_K(2 MN>]BU_,W8(H_^H@8WF*'AG98483KL M9EV_+&;X,WP',]?!.IX)" RL)&6:>,DE82:F'(V74K1IS'(+86/*^E;%2DV! M5"QJ[@$_IG06>H'&;SH?,M(G)"D5A$;HDA!+20 @28YF1W(0E(? &+-M$AXW MDC6FY&Y5A-031KWD_IGCA;U\\:1MPHWG.:1R[!H%:C94;]8[@8%YEIY'+EVC MLN:;Z1I3(K@J0BJ*HQI$WL#R](K&Q!KC:6*,V%"NU7()Q KN"!->6Y55BHW. M(\^1L?D9_\DGO42!KG(*1^@)G@:SSR#/%\=W4][[K]#O?D5]CMCJ9G[Q[15" M8DC:XV\B6HI#B<*"!?3+B=4!@H?2;$F49&9I-0&X0@)734;#',MM;JLU9&I, M<>']\7BYL& <**A8NG),Z+$R>H8N2>Z6$VV2RUD#,4&B2LJ4DP FD'*9RE,9 M;*9M^.79!UNN+;T6S0^4:&6+F7Y\M9I9+H M\J.7KYFG/IDVA1%;\_8VJ*L^8U>=951104DN%[EE3ACG)NY)PB"&:U!<-4I' M74',F#3T6+!Y;6'V/66X!3_&2=#)!DFX*EC/2@]@QZ?)-L70Y7]Q6=A5KIR[D0*7.W(FH24Q0W+Q/R:7DHKXUXT@DX1*"OGCD/G"!,[/3,2@[BZ[''[W ;VMI5#%L%^LUN1M#E=G#P?[!<#(&1]'W!R^G\R^-',3OG[Y%Q_!JCBH5 MS9?Y3_B MXOYYPX_[=FW#TC*J]GJZ*8$C(B;S\=7K\#9Z*4C@G*/(0/#D,%3 M39(&@*1X -$F?[T^C1O?TO??AE5_/]^)_W74+>"J26H3"AZ,BA@L2<%+X*Q) ML*L6I R,X<*K-JIS+?+NZ((] ^IU7=^"D,U^;*0 M]&TO7TFF8L@[&$U\TKF,(XAH$D0D5!@!T07(JDU.\HA T&*X;#3U>G\8[WB?X,8%51X+5 M$88QRUG5>@;^Y]="^>PXFN[CD?"\'%IP:4B@R7,-6HI&TS[N2.@=;R;\4%AK M(I7K<7W Y @Z)R.?'<>Z*= 9Z250J:Y977I+%"O=.B M=)IZ :M_5Z H@V(' 0491/:9"!M$J7!%)\881] 6!48]<.G;-+FXD:S'$.!L M"JBV.Y+#R^.NB&YP?E MRU>SG<,R;G$O7_,KW[O2LHFEWB@0FFCERH@V+4@ Z5%!61:RT5XW N&6&'P$ M051M-(\1.O5NVYZ>,6!\N)?/.5RGWA;UP20C@814:(O*$Z<4)TY$6FZ$9-6H M+>AZ]#V&(*PV+!M(;ENW+ZWPO$PG)HR7TL@JBBH>OU$#OP"GOGAD.&P% "M>H12$![Y%$1D<$A+\"2($$K_P)!! M60ZL3?'>U?2,Z3+WEL!203#50++JOW6:N'SY^4UW>H!^HALG7@:,SQ(&;9$B M;3%%$KPV)'DO:30Z,MGF%&@]^NYXW_N'L%L-)%<-56=[%$\X30(C%>0OE$OI M@G$2@F'$T92%%TF9BW?K*F'G+!7K(,3\6&KFWD*H>:_J0ORZ$V-QX_M]B-!] M'N82,1=I9"D35'W#4%E'G#>9)&V3%^"MSFT.OM:A;AW8V!],L527VI9;8>7 M'*.4$B:R)I(*1ZR,I?ERBB",5IXVZJ]0JQ66^[$447VQ;8RHXYO*EX!^SHU_ MNX##[N@0 \,#?+D,5#M[-!=M0J6:;$E=$)HP*R? + M&F.S3ASK$KD6YK;8[>5AC&(=&=;19,7;+]7-R^445GKVS#3(80KD)#/-J(Z\ M7/1"HB!I5*])$'3\4F(6O,AI+75U^[/6PL/9G9'HSF*I?*7XV1JO21$A]+ MQQ,;D"JAK5/-6H7>3-I:T/G!$NIUY57SKDGNEL-A3Y2>9VI#F591^CO02+R3 M@4"FCF/\821K5-[_G8:U@&%_+&#<4P(5C]M6OM5U_469<:C&@B5"E""!8NSI M2F,FRRB4GDHT-&J5< MA:V'E!TN&UY15Z_+H[[[Z&=XAYAB4I\6%BB4Y;T@H MQ\M,)I^ 1<5I&Q6S/HTU+^^=!")[>:C:Z#_,4BEKCS KHQO*,+,KBSE*\5B/ M;UOU7QH&GNU]&IJJ33C+*EI."9<"-81WO@0OE @:D_-,1 :-KLRT9&L,?5 : MH_FF2X$/"Y,FUU;/W.L8 O"KEB^K[#G&XH05^J2%C-:N= V(S$9EF=2-VDG< MD=!'4&W=$IVU1=D$;V6 ^&B'-65<9_>,$F;$O5 M %L7B!I#AY$'Q-$F(JK72Q"9+O^7^K?/?@I#74J_7'1QBQ<,E 9-HV1>66,L#R=X#CTD(9MI< M1-DNGUOT(!7/5D10A)8.L3)FA6C4&"E3K44P7*E&H\+OZT$^\)C+\>+]BC9Q M+4#P$+= 4V2!*Y>(5KR,>HR6.*$381D@ZLC!VC;;_KZW0!]X N>C!^FF(&@- MTJNN4@.U&!T80YB",D;#1.)X<$2%8)0W(D6QU:O*][P1O[7)GX\>I)N"H-ZU MD8'%O7R6[;W91@L\81 8TYD3L$/RW +Q:"3(4!BJ?(KJ]LBZ[;&RF;6YF ME:>/+<:JBXA+K?CONMY5\R4W,*694EKK3*CPC$C.4%T;5->!1P^>)Q<:C7B^ M"[X?/KAICXY*,JJ&FZO:&JZ:"R\G&/J ,TP3[C7ZG$X9$K3@)(%R)@5!:6I3 M,'P#42UN0D^XP/T9+"<9.2;2&$F\2IQ0B=+T"OT':),&N(J:,6G,6NA8YU;S MG:10L:@B+,_TB_^,[DAA]^5\4?J$G,[6B7%Q5&*SU>BKDS60*3KP*I-2W%\Z M?&<2G#!$X)9UV@]U HU*+C8@>TQ:MQ7"MB?7ED<>PY'R%1?<9/**"IF)-M$3 MR;@KHPMP>4SQ/)("9]O0CBM^&4LT4M]::/K MQ0-X>ALS]C#^\P0$5RQ)35).95P#303W-WIZ'"P'W,S"M>H6=!]ZQV3(QX3T M.E[WG=!0K^OB!>HNT![CT6$1,J3?%K@LYWMNGNQ*#O-U&/$LVC)B M%JC.63#=YIRD"OECJD_X$6%^?ZP\M*=^!2/0^UEZZ;O%$*OV\WPFNBDU;N?? M_7;>=ZO[\(T<^^H4;BD.:+NR6PD;KJ9G$H*(R2A+O/8&=U@RQ%H%)'JO4A2. M\D;'!?>AMJV#O^K3?C0_ZJ]^.N._XSL.^KU%:0D'BPFGP7,T=P2<+H>C$M>N M3&Q3/"4=**ZJ;G,069>/QQ,05,#PW;S\II#8TKG/;3R\AKY_?^"_\S*QVDLT MKIH$-+-$9H6>G=>*1*&TE58QSQY")=R5CS&E'!\9K#>"Q)9@?37E9]RZE0-I MD^)6!2($Q2@E:UQ-"Y(PK@,O=?MNQV=#Q;HB9^VN<:7KWY8_?-^[W]?VV0#;CT M&=7B]9NIJQ11G\RN^_8&EA,--$>&[@^56I9.28%8[A5Q1FOIM%8RM8GVSE*Q M84O XP]ZV6"B(J MKTTBW)5:,894.1HH28%C&&N5=*;-1>?;*!N3$=H8)DW$T=X@O-W?>[N[__Y? M;U_OO'F_\^;%[O_[\.KM[ZB%3_.DN_VR.RSV[$,/^6A:QB9L4B6RX1.K&9N: MG%.Q\:O5[?786@7N5\VQ%Y&JH;VRSMY><[O.#MQ!W_S; /<"4]*"B<\ M,3H:(G7T))3&<%$%IYDVWC6Z9]&>MPI=8.Y#X?%9UWK+SPSG.KJ$JJ2T;&.2 MH69A0#2+P@9MG=!MTG!;8&Y,5G]D.^F*;C:C@EK-3DKW6O?U6+)2T1P,FF3E M16F$P(E+PI+(-!A&;:#CVCWU]LW6:EQ^S(W3 %_;B-71+?GMU;/7NSOOWNV^ M?X<^RF][>R_^?/7Z]:F+4@*0)0RCK"Z.>T5/]IF?EB4II]I_#O#!P.4S+/Q' MJ./+;9O$BIF&!US;:HF,2S1]K\B7;CJ=6 O,!F\(\&(%,I>;> M".^=;G0!;!WJ-@]]SS]CJ.BXO ;969V-C!ABA3+2S?HR>U00KE+2T@C'0YM: MWO7H&Y/?5!U3E\/CZB*KYKSY(YHSZI M0"EO4W5X=UI'Y68TQUEC66X#>6&_* M8E *WBE%+TY:K+:=[D;IN$XOF\.KJ2!_N&3:Y,(Y_RC3:4CD8TVH75S?K:;4 MP*,616T09C #9>MW)_Z^GI<:;8[X&QC;7T7,6XK^0$N^6#12)665D3&D@14QI D M0X#$94J\S4:[2_)C7(:_.I JBF@L1OYH>;2 L^'E\>B[YN=@MSUXR\;X3NM0 MR<#> B:(-MIQ)9GPK$W;N =+=UZQ_F]PK=]_@>EG M.+ZHE4../ I'(#M'9%'+(: #;Z7&5X>K%6VN(&Q&]Y@,;D7!C'1>*5]*75F>36RJC"U@\CKB=W3&9Z-/"[ MCR@?$'4OYT>+B8S&1R$IX2 U4LAPAUB12L?4RF54N+NS M,#<&WG!UXWI""VWQPE'#4,CVG5K!2L+461)Q2 @QF$AE +U.3[B,F: K$(BETI4" MW>B\BAGB&##YG>!U<*C_I^'P?N)LGYYYN?-J_X^=UQ]V?]_=>?=A?W>X;'4F M(7'2=VN#1,Q='U$MY;(1;[62*R;>-\]D+_Q$4'W$B#I&D@4I6FEL9KHKD. M6K(@=*,T\KH4CBI14@=#M_5MK"*LJH,M+L\$.-VS:,RG\_YH 1/O,#YA5)/D M,QISCW(/05.BJ'/2F)0AM<'2VB2.*NW1!DQMQ%5O*.E5LX.$,MYY[0D+-A&I M.27>!D"T]92%&TPLK$0JL'AV5'?S:#OG\\/0S<;EF35 M4^8CHA:_ZKLTC'PN;L.*3@9%,%8^0@6DJ M;_.[UWO4J+(&=;'18*VK::!C+?AM[\L,TIOY[KTSBJD+^-@FDDL/81_O.]-W_L[K\OE0=O M]MZ?&Z\\GWV&Q;+D+9"AC2X=W_TAU:+\#?FK-3CZPK/>^F\%%&A<:.)<>F)9 MH,7;E218F@GE6KDP5'*U*<6[AJ"-[-8UG[DJ93T,V]WX6U#XW;<9O'< M1R=<5C)!]5-*Y<.KQX6'IM \MK'K&1M2IC ME/9F[V"YG$)!^=XEAV#B(U>.*XX>(/J"TJA8$$P)HX8Z]!:MM6DM#FY_UATM M5QN54E&@YRQ7Y:6N-\;JS$%<.0 NS8BZV<=!C4T4^OR@2Q>#@'2@164$(T$, M#@(+@HLSX\^S6<7^)T(GH$;&DBV7*$K)J", M&=9EAIKS"EF40JUE1Z[\^#%4F[6R')NO9WOW\MW[O>?_\<^]UR]V]]^5CK3O M_W6:8]A[_FH#KW+-3Z[F3-Z'DTH)DKWE 2R>SP\_+> 9=Q]/H;/N2F ;\N& M1UPOEXLN' UIM??SMWY(TT=*)==.$RI"&1&.L:_GG)/$(@*"&US5-I7NFU*^ MJ87:ASCU?=_E+@YR?XF;N^/SB[>PZ.;I.R%7KEWFSF4A#7'.RK(],5QC M-A".FTIBX.8$M!E$O3GMH_";'P3$%\WAEG%0ST^L>OE[^"[^$??_O_ M4$L#!!0 ( ,J(J58[6E85DX( )H'!@ 5 97AA&UL[+U9=UM)#(8 M#?_^,_\W]O-/.$RC/!A^^OO/OW]\!>[G__4?__(O__[_ /S?9^_?_/1BE,[/ M<#C]Z?D8PQ3S3W\.II]_^F?&R1\_E?'H[*=_CL9_#+X&@/^8_:/GHR_?QH-/ MGZ<_"2;D[;\=_RW0_[P0'+3R$53$#%XG#BS$Q*S2/#GY_W[Z6V06,=H"5B<% MBB>$P*T$E)9K:6T1*<\^]'0P_.-O]9<8)O@3+6XXF7W[]Y\_3Z=?_O;++W_^ M^>>__17'I_\V&G_Z13 F?YG_],^7/_[7G9__4\Y^FGOO?YG][=6/3@:+?I ^ MEO_R?W][\R%]QK, @^%D&H;I^@'T^#R]^HA?+OZ2?G0R^-MD]N_?C%*8 MSM3SX!)^6OH3]3N8_QC4/P(N0/)_^VN2?_Z/?_GIIPO)A7$:CT[Q/9:?+K_\ M_?WKNT@'P^DO>7#VR^7/_!).3PGQ[!.FW[[@WW^>#,Z^G.+\SSZ/L2Q%/U]R M!:4KG'^MG_;+UI@^$Y!Q.H\(]*\]5G0<82SD^G'2*^^]F= MXAV=A4&7 K[ST1V@G7T0G.%9Q'&74+_[W!LXYR!O(ZP?B7^%-)VD >VV./FW M-#K[98;Q^6B8:=V8Z8O)Z'20ZR;[84J_UEUW,BH?IJ/TQ^?1::8]^^5_GP^F MWQY>"3UK G7_9?+BC?_731YS8V'$H,%P4#>E-_3MY;,J_EZ6B']-D3XB__S3 M(/_]YP%+,GK/,XO:JAQ5B,%'IK7,#H/&<++) ^M:YZL]':7OGG]:-^31%8-. M0\33V9^>G$_@4PA?3JX^G,2#K^G+R8EW/L:2%0163S#,"#[K"#(:^KU(Y7BY MR[_)G,\E3.*,@9>/("8*_@N>3B?S/ZD*IG.37V[J_[H/1^= MG8TN('[X',8X.3Z?5DNI&I\GC@OC"VI:N'47%I\SQD"V0A9A$D]9-2'-?:CZ M9TA3E8X:Z>,N5_BV7+F[ZA,EL]&"%9#*,'I3HH4@BH9LE(K9!N]";K2C+CX; M#Y476\K^+AM$)VQX/9F<8WYQ/B9ZOL/Q8)0O6#O[R^,O5?Z3EW^1E3Z@H_]$ M:506G880"R'624(TL4#)R2E3.$9CVK%E+:Q/@$WM='>7;;(1V_X13L]Q,6!+ M[T8*3(-ULT.<.8(>)7A=9:,M9T7W2;;E4)\DUSK2W%VJJ:8;VTOR[$;?$)_A MD/0T?7<:AB5?]4M\CZ?5*?XXJFNH=Y7'Y>;[<33,[W$R'0_2S'.F MOSBJ(IMR7> M9:39$T;.MO;)22ZQ1.$+.)4M*!8]>">J%\USBBE@<*9G1EX@^\'(-DJ\RTC; MTNQ;M*4K(QS/0D'P*H%R!-=%(2#%X)3UD:78YIIK3:"'2<$^M':79*[[>XWC MZ6<0TA$96-"#*S-#>F]L)XD43;0R(([TJTOU-_BE(0Q M.L,WH\GD! 5F9:2C\U($/X:]WH_%,_%,RN^+Y-,13_#AZ1_0=3D^"-%F8 M(N@LK)0F_2V=CB:8__[S='R.UW\X&D[QK^G+T]D#__[S!#^=W=D] MM^##!;WJ3C4:UL2:H[\&DQ/%&'>N;C]FR@[F7,V5KL#<+UMS"]F)VJ*X$ZN97YV"DG%L+JTGI8EK]Y#Q.V M5]^HE>Q[(T9T9*!H1"B1]*;02W"%L ;GG I<*Q_:Q$M[),1W";*[Y\,Z(F_ M@QOFUV\S6_M$TR)\5!)TCF0A2:T@2HZT8BP9@Q).M7%7[T#IWYWH0$7+<[DV MD&^#9+^CG&="#*?OPB"_'CX/7P;3<'H)K@:9LM<&."^EFE &(I,H2DG2TQ+!B&)J5H6K MEQX>0Z!$!Y)>FI+W[[_<$@SYU']L53[SX????CMZ_Y_' MKSZ\_O7MZU>OGQ^]_7CT_/GQ[V\_OG[[Z[OC-Z^?OW[YX2U.Z^79N\N+^Q=U MB:>33>IHMGI>5P4UW2WZ5F6-LXJ3;< YMT(%)B-3QEI?@L=D20HG6SUYRZ-C M.!WDP>GYE':F#YC.QR0]G+S\*YV>TP)>T9M1WX+SZ2P=X;C,Z3L'<7U[8X(7 M2J,$+D,"I>K5;$SDB+L@ AV#7NLVA3E=K6#K0W@['$=GH_/A]$1YQIBNI0%D M3M(OO&X(4@%+=%($:YEO%&WJ!'[_._5.^'OGO.]=]0T\BUIEG<]/\;ALN9R+ M.SGK9 Z))9#.T6JTY^!6G:ZCK_OPO>#Q#BFP+[?P6R[\ MV;?%'S"[?3+2*K+K!"!/%E1.&AR+%HPUVAHAO?:-G*]VB]I9!&"'5.UV]^^, M,BTN%A8B>QO.\-(E6@5?TU#$0PAW$Y78&TJL1-4M];D+WM$YEDH2$DI1]+ZF MFB+&>0'#A5.ZH,ZN3;1\-WQ[(.CQ:.FVCAH[I-DLS_XB7>4BQ?GW+Z2A]-_G M@\E,69>7,TDI$62P8)6GI;L0:H!9@4Y>&9>$2[(\=+.QVJ/VQ6_:5#6C9G+M MT-&9H9OGKA\-\]O1X-&!<]'PZ\XG@[(,7P[FN+D7?A6G<1+<"$DI:-,P%@FJEK:MV*6 M""X;I7DL#"5OE&!Q#ZP#8T9W*EC:7:#[J-G[E_]X^?;WE_.KB5%Y,9B$3Y_& M^&EF>(_*>_R*P_-M F7K/J*KV-A62[L5#M-TJBMK"F?T4NN@O?).Y>PY^MH7 M(I^L^[#MWO;O/_QX_N'7-ZI,<72\]E;UC-%N%#V$>L$:D3-#F(UG;4(R#R'; MWOJ9?=Z%?SBNF(@245*%6B2;.-X;P"V_SVQ4R[=M9S:JJM!3&F)/"[N7(UT=":8 M##G2 :\, ?3&SJRGGT+F,!GRNC0UJU#1:S8&3^X!.L&AS?NA O?<)NPIN=*>_ M4==R[/P6;@&H2_MQ%5B+8PMKJ'D748(.M?&0?K<098^:SDFRD*V$>@L BJ5$ M\,C[SR@B$Y:\/FGW4L-+[N7[5_ Z$NQX%# MDP1,1:5 NLQ!94&VHG:$T$H,QDC.V8)Q*X]#]TN,YQY5OXYT&T2?+X'-2X$< M0QW)>+"VADL8G63>:#J &&9'/H.,9B55KQ]KO FCOT.]0]7<#BMN+-<6:?47 MZ[H$@Z58IZ0ED]"0I8*FQL3( 61,QUI8G .+;;+B;\(X!"5O+M>N+>_7PRF. MA^&B.OA#.+T*8PMA=$'K($7'JCM@P8MD@,6HHU BY")7LKZ7/>$QZ[$[T;7( M![E8ZO5*9V6\\PX *(L+MH!#3N>0S)J\/,R05):,*;3!M*ELN0_58Z9"YU+O ML5+V,E;]-HS'H69";!_;O_-1':6X\T%DJ;S!R(JW M'$^6?6CCF+PW1 .O2?U>ZVH+&G#:!N!1HLITW)?4:^SP35#$ >G MM2#]HJL B?EYF*;/OW\YRO]%/S-KA#6Z1/+\OH4J#5:L%D(2 MU%[1H>\<@22M9T8JX)Q^435UP=.>"9G'D#G*VCWAZ>8(;,.LSL2^ZQR!^UZ5 M9V$RF!R7RO.:&%-O$5+!B-HEL$$Z4*E:%#%XT&2?B!A8<:F-F[T:OKV\:UV+ M#BOL8%NJI4D?M8=07MJWJ^!L6O"X*M+=%#ZVT/;:A-I"5;ND5HZ,8Y(:,"57 M(QJ9?)U@0)82;5&ZL+"KG6F'M8W[Q*AU--3U+=,_PGA0-^.9S39'?.D;UX.> M::P9!!)!J2@@+WX4![#*K .,.-Q+6VLF!"W MB2A[S'@4A65GDX88C:7=I;B+,> L:<5"EEF*S5.7]R[CL86"UY'@4L5V?Q_\ MV]'[__/RX]&S-R\_O'Q._^;CZYX,][F M<5W=*W>VY%MWSRBB$FATLLXH="4H:ZSSR+3,-EM^LLV#M[/I?POC/W V'N:Z M\O'Z6B80U[DEIH<4:\L,&\ [KNHM3< 8DK&J3?O4>V%M[<>0($]2B"*P$, R M1Z86+PC>.UJIR_1?X-+K-@71]>G]FZ#=Z?F.S[&N-!OFH@( 2DZT,CCGI0Z..I2O!.S2V=*N/!JD3+S!.;[20 M^DJG;97%J]&XYG=<%ZFF-#['/$L P&*U%)T" MD4,B%Q]=O-URJ:MXSS:P#XED_>FO0>>.B[[MU_!??7T[.!$AF%A<@<0\NQS. MD)F'Z*1&;I#N9'^7%KH+4^;VN3G,'SZ/QM./.#Y[/?R*%XD3DQ/+ MC4S)U6Y#.9'1-9L^FQ(DF9UQTAH=5BJWV60WC(9&FD6;N=#G#.L0C MS:("R$XSP-$D;FW M15GCVF0_]TV-!W)#^F;&.G)OP(A%1M&\CRXR:VK#U,PR>5W):'"*O"Y!1A$S M!9G*J0DCEF/JWTCM2G.W*\VZ$?O2"_R^@Y"W[W2NS]MF@F3KFUSD;52S%DHNEI5 M)B3PDCPJ)1 #BQE3HTC>6C#;WD8?G=&;/?@?S,]'D^FRJ\UG6$9C/#H]'?U9 M=Q?ZI\_'F >S67PG6?/(@Z4SQM>:="(!!*?IM'$84D$?P^TN\;W<5V^]L/XW M[W;L7>^&NU].-(CJWE[0K>5>CZ;]=4QH?Q^.,9S6]?Y*6KI85VT.@Q-,@6-*NJ!$2:K-E48G\ ^9OOWKM\6 GPT745^PZT5DB01>"(OU%-BC&/8AT[ '#3:(8M^/^N)2- L6#+FT(%..H!3W$!6YMN22))=H M%]=<[8!DO08?]H5'ZVMD7\(2KP9#LE\'X?3U<$+/JQ]YT6HKY5($#S4=,=6Q M3&2])BE ).6U%1&Y:!.56 )H9V4I7>M]U+W\&UAGLQ8!!SFPA()S09[9F.]YVW3-')K:/KK57+$%=25JAI;"@N:MDP,'(UHU)Q_ M(9R]RI]<2U_W%[EO(.P68QF6)W5*;S0JY2$90294E#4U@B>PEGL=5:YI/$\Y MEW8;+G0D]KUIZ//[D)Y^6HOO?PO32]MK5(Y>?>@AJ7:-9_>37;NI,&[WG-=, MZQ*1Z:)53#8F[XM#B3)[^1ASKKDWG:[[2!( V].B&Y M4(J1O%&;C%[S;>_+<8[3:X74GHZ#X?$0_Q/#^+N4RQ..*MDL$Z2@#"BG+7@4 MLO;T%,8IKZ5J,V%^>^S[GDJS#@$F-76L&K,!A?]%71F'PQJ !M MKL,]K8"0'8<8HI>1"ZU=&[-@.]P_.-F)1GO(@5V&_JA,<4S@/WX>C\X_?7XU M^#I;Q^3[ERL4YF*=@>JYK+76-9=71@11@E6&:Q=&Y=OCPO>$N#^VV&9ZWE%2K2HAA)P+ M8*@]966=IU*C_2%9[8UTT<0V5'RT2;7;4*MKC>Q+4NW2NU2GG3)(Y'>L;MD\ M!G A,D"=F.>)RZC:% L^QEC56II?-5:UC@;Z#42L@NQ'K&IM':X>D=A$ 3W' MJKA2@0<)">N8"UY':Y;L0695K!+(G&ES,?)88E6-F+&.W'N+525OLI$L 8L: M:Y=7VAD=MY!<,HQ+'JUO$[A\!+&J=?2U4JQJ'6'W&ZMBDJ-Q5H-B1H%"4ED= M"@A&B"R+-\HW\OH?2ZQJ"RYT)/8&6\*R!'NG92DE"Y"H7>6I!1^LAY15)*LI M)XMM3HA'6+:UC7W9A?P;W,ETFDBXREI^E&UM5+:U%DU:UL%LHN-]+]M2U=3+ M*D$1=7\V3M5!@(X. %L3'H7GO$T2S_[S=<.RK;VAZSJJ[:ULRT05H?95M--+Q2V=8ZZMEEV9:S7)@ZN9(L2 ]*L A1)0:! M%J"U8T+K-BT]GTC9UC;,:J+$_LNVDM)9.P$B<$G;N%00D7NP)7.A,*..;=K2 M''+9UG8;5E?JZKEL2Q?'?'0=(^PG0;>M8&^/ M[S16"L4C9F*S%MZI+%"Y*$K6/+F'QG=VCK7EQ$]K2F$1);"B&"CE'/A"[QJ7 MWFIEK="-DGN;3OR\_QJMSDL?#,]'YY/%@^@E13&1\6L;#,.M>FR?K"YA?X;.'?;+6Z^J./Q MF]'P$QF&@LQ*1@X&L$3253E8"#QZ\'4P._J@L+2Y;^AV'3_HVXF&>V^>N^YJ M;K^,J=#BK!9@'?+:2LQ 5(:!Q!R-YL*A\(^ OC\VXQ[TWWLR\>(EG2@T.C.; M@0LRC%2F4\05D2#*J'-@-D2_B[[0B]$^'2IVH*T&1>U\U;$U,@MVO/9I]L0IAMI[TL]Q+*\ E8\5XP\J#B;DX-%0>1>@HYZ[/*6G[DJ&V4H[8639KV:MY Q_O.6V,Q.%\2 M%&4=*)<$.&_H6-T'4=U?:> B)D22&6VO! *P(G M/ 0F%-@2DM,Q)J^P">\..05D+8VOE0*RCKI:]$NY)Z\ OW" MTA]ZT28\_$0R(+?A5Q,E]M0,^&(@O(DN21_!\5CJD@N$("5DK8U/QFCEVH2[ M]JWTOHVSV8G<^VT.O0JR'P7W:^MP];+J3130;\$]6L>0G =@M?I%,2$A:H\0 MK9W$B M:&?;.%"/I-QZ+W_\[N7[C__Y[LW1VX]';U^\_/]^ M?_WNMY=O/UYGL;Z<3 =G-8CS^P3+^>F;P=>M&@)O^<2NLHR[7/BMK.&H(DO< M%U%,4CQ8YS$9EK0RY/"R;$^V?/9V6\.[\8ALK>FW=_0&3,DHKZTBOE2F7L=] M&(OHG=/ %+W)JF0+P?!,OVCN6&#>N#:-.1[&MNW&N/0)WS*X5TN 2:2E$^OK"6<4W&";X M?O#I\_2X$/"+NXS9#/@;0? 7^&6,Y-C.]#7,E[TP9]^>>$6FAA<1!'($A;YV M<4!&IXX5046IN&[3F;>'Q3T=SNZ($ T,R V7N.+BBDTR\^P@<72@X3VW_P?,Z'&I>$ M!+K7XCIBZUA[OY&DSL[/YI?,PI@0"FU6.3!0-D=PGD?@DOE2)',\KI2.O)+^ MOGMT?_;@5L(?=2&Y#J^89D#"7S>!2 S)^ 0\U3B!()G'% J4E+((6BB%':KP MYJ,?H0HWEER?-R;/OM7$EMEF@T0LGT4!HV4$9;! M+3W(+)4$MG_T;0I^5P! MW$$:3:V4T^=]1 4XCTVN +%IPL<*('>3^=&Y@E#0Y6F?:Y(A<8]BC"\9-533J1+X=6ILU&>/DV?G@- ^&GVI" M[NQ&\_/H-+\^^S(>?<6;"2O1.\^"=:"]0E J.%HEL\""2,Z[$(2[=7E]-]=C MG0<>CL*;B;G12[\ %=-*,<0,4@2RI5UVM.R

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end